論文

• Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study
  Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025年03月27日
  英語, 研究論文（学術雑誌）
• Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study.
  Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma
  International journal of clinical oncology, 2025年03月27日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUNDS: Standard treatments for locally advanced oropharyngeal cancer (OPC) include surgery and chemoradiotherapy (CRT). While surgery offers good tumor control, it often results in significant postoperative functional impairments. Conversely, intravenous chemoradiotherapy (IV-CRT) is less effective in controlling primary tumors in T4 OPC cases and offers limited options for salvage surgery after recurrence. RADPLAT, a treatment involving intra-arterial cisplatin combined with radiotherapy, has demonstrated favorable results for other cancers and may offer an alternative treatment for OPC. METHODS: This retrospective study compared the efficacy and safety of RADPLAT and IV-CRT in the patients with T4 OPC treated at Hokkaido University Hospital between 2003 and 2022. The primary endpoint was local recurrence-free survival (LRFS), and the secondary endpoint was overall survival (OS). RESULTS: Fifty-six patients were included, with 29 in the RADPLAT group and 27 in the IV-CRT group. The RADPLAT group showed significantly better LRFS (2-year LRFS: 82.3%) and OS (5-year OS: 73.8%) compared to the IV-CRT group (2y-LRFS: 66.0%, 5y-OS: 45.7%). Multivariate analysis identified RADPLAT as an independent favorable prognostic factor for both LRFS and OS. There was no significant difference in the incidence of adverse events between the two groups, although grade 3 or higher mucositis was more common in the RADPLAT group. Swallowing function and tracheostomy rates were similar between the groups. CONCLUSION: RADPLAT provides superior local control and survival outcomes compared to IV-CRT for T4 OPC, with comparable safety and functional preservation. These findings suggest that RADPLAT may be a promising alternative to IV-CRT for cases with T4 OPC.
• Dual-type deep learning-based image reconstruction for advanced denoising and super-resolution processing in head and neck T2-weighted imaging.
  Noriyuki Fujima, Yukie Shimizu, Yohei Ikebe, Hiroyuki Kameda, Taisuke Harada, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
  Japanese journal of radiology, 2025年03月05日, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To assess the utility of dual-type deep learning (DL)-based image reconstruction with DL-based image denoising and super-resolution processing by comparing images reconstructed with the conventional method in head and neck fat-suppressed (Fs) T2-weighted imaging (T2WI). MATERIALS AND METHODS: We retrospectively analyzed the cases of 43 patients who underwent head/neck Fs-T2WI for the assessment of their head and neck lesions. All patients underwent two sets of Fs-T2WI scans with conventional- and DL-based reconstruction. The Fs-T2WI with DL-based reconstruction was acquired based on a 30% reduction of its spatial resolution in both the x- and y-axes with a shortened scan time. Qualitative and quantitative assessments were performed with both the conventional method- and DL-based reconstructions. For the qualitative assessment, we visually evaluated the overall image quality, visibility of anatomical structures, degree of artifact(s), lesion conspicuity, and lesion edge sharpness based on five-point grading. In the quantitative assessment, we measured the signal-to-noise ratio (SNR) of the lesion and the contrast-to-noise ratio (CNR) between the lesion and the adjacent or nearest muscle. RESULTS: In the qualitative analysis, significant differences were observed between the Fs-T2WI with the conventional- and DL-based reconstruction in all of the evaluation items except the degree of the artifact(s) (p < 0.001). In the quantitative analysis, significant differences were observed in the SNR between the Fs-T2WI with conventional- (21.4 ± 14.7) and DL-based reconstructions (26.2 ± 13.5) (p < 0.001). In the CNR assessment, the CNR between the lesion and adjacent or nearest muscle in the DL-based Fs-T2WI (16.8 ± 11.6) was significantly higher than that in the conventional Fs-T2WI (14.2 ± 12.9) (p < 0.001). CONCLUSION: Dual-type DL-based image reconstruction by an effective denoising and super-resolution process successfully provided high image quality in head and neck Fs-T2WI with a shortened scan time compared to the conventional imaging method.
• Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis.
  Hirotaka Shinomiya, Kazuto Matsuura, Rikiya Onimaru, Akira Ohkoshi, Yuki Saito, Hiroyuki Tachibana, Kiyoto Shiga, Tsutomu Ueda, Yukinori Asada, Hirokazu Uemura, Takeshi Beppu, Akira Seto, Ryuji Yasumatsu, Mitsuhiko Nakahira, Go Omura, Takahiro Asakage, Shujiro Minami, Takashi Fujii, Yuji Hirayama, Daisuke Yoshida, Kenichi Nakamura, Keita Sasaki, Junki Mizusawa, Haruhiko Fukuda, Akihiro Homma
  International journal of clinical oncology, 30, 3, 489, 496, 2025年03月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: JCOG1212 is a dose-finding and efficacy confirmatory study of concurrent superselective intra-arterial infusion of cisplatin and radiotherapy (RADPLAT) for locally advanced primary squamous cell carcinoma of the maxillary sinus (cT4a,bN0M0). In this study, we report the results of the final analysis of the efficacy confirmation phase for the T4a cohort with 5-year follow-up data to evaluate the late adverse events and long-term efficacy. METHODS: Based on the results of the dose-finding phase, the efficacy confirmation phase consisted of seven weekly intra-arterial infusions of cisplatin 100 mg/m2 combined with radiotherapy (70 Gy). The 5-year prognosis and late adverse events were evaluated. RESULTS: Between April 2014 and August 2018, 64 patients were included in the analysis (one ineligible patient was excluded); 31 patients were treated with three-dimensional conformal radiation therapy (3D-CRT) and 33 with intensity modulated radiation therapy (IMRT). The 5-year overall survival, event-free survival, and local event-free survival was 71.9, 54.7, and 57.5%, respectively. In terms of late adverse events, grade 3 or higher non-hematologic toxicity was observed in 42.9% of 63 patients (retinopathy: 12, cataract: 10, osteonecrosis of mandible: 4, etc.). Grade 3 and 4 cataracts of affected side appeared in 22.6% (7/31) of the 3D-CRT group compared to 3.1% (1/32) in the IMRT group. Twenty-one patients had died, with 15 from the primary disease, 5 from other causes, and 1 from treatment-related cause. CONCLUSION: The prognosis of RADPLAT was favorable after 5-year follow-up with acceptable late adverse events and low proportion of treatment related death.
• Motion analysis for objective evaluation of psychomotor skills in Endoscopic Sinus Surgery
  K Miyaji, M Suzuki, R Watanabe, T Suzuki, K Matoba, A Nakazono, Y Nakamaru, K Ebina, T Abe, D Hinder, A J Psaltis, P J Wormald, A Homma, A Konno
  Rhinology Journal, Stichting Nase, 2024年12月01日
  研究論文（学術雑誌）, Background: This study aims to digitalize surgical maneuvers in ESS using a motion capture system under standardized conditionsprovided by 3D printed-sinus models. Methodology: Forty-seven otolaryngologists performed ESS on 3D printed modelsmanufactured from computed tomography (CT) images of actual patients. Participants were classified to 3 groups according tothe objective structured technical skills assessment score. All surgical maneuverers performed during ESS were captured by amotion capture system. The path length, velocity, acceleration, and jerk were calculated for each surgical instrument and comparedamong the groups. Principle Component Analysis (PCA) was utilized to identify which metrics reflected surgical skill level. Inaddition, ten registrars repeated the surgical dissection. Their motion metrics were also compared between first training and therepeated training and then subjected to the PCA. Results: Several metrics such as the angular acceleration and jerk of the cuttingforceps were identified by PCA as possible indicators distinguishing the different skill levels for the ESS maneuvers. PCA analysis inthe repetitive training also found the angular metrics of the upturned-cutting forceps correlating to their skill improvement.Conclusions: Combined with the validated 3D-printed sinus models, the motion capture system provided the objective evaluationof the surgical performances of ESS.
• Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.
  Kazuki Yokoyama, Koichiro Wasano, Keita Sasaki, Ryunosuke Machida, Mitsuhiko Nakahira, Koji Kitamura, Tomofumi Sakagami, Naohiro Takeshita, Akira Ohkoshi, Motoyuki Suzuki, Ichiro Tateya, Yohei Morishita, Mariko Sekimizu, Masahiro Nakayama, Taiji Koyama, Hirofumi Shibata, Satoru Miyamaru, Naomi Kiyota, Nobuhiro Hanai, Akihiro Homma
  Japanese journal of clinical oncology, 54, 10, 1115, 1122, 2024年10月03日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan. METHODS: From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied. RESULTS: The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens' first-month costs were 612 851-849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000-800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN. CONCLUSION: First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.
• 上顎洞癌に対するシスプラチンの超選択的動注と放射線同時併用療法(JCOG1212) T4aコホートの最終結果(Superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for maxillary sinus cancer(JCOG1212): Final results of the T4a cohort)　　　　　　　　　　　　　　　
  立花 弘之, 松浦 一登, 鬼丸 力也, 大越 明, 四宮 弘隆, 齊藤 祐毅, 志賀 清人, 中平 光彦, 吉本 世一, 朝蔭 孝宏, 関田 哲也, 佐々木 啓太, 水澤 純基, 福田 治彦, 本間 明宏
  日本癌治療学会学術集会抄録集, 62回, FR1, 3, (一社)日本癌治療学会, 2024年10月
  英語
• Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
  Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Hirokazu Uemura, Kiyoto Shiga, Mitsuhiko Nakahira, Takahiro Asakage, Yuki Saito, Keita Sasaki, Ryo Kitabayashi, Satoshi Ishikura, Yasumasa Nishimura, Makoto Tahara
  Oral oncology, 157, 106976, 106976, 2024年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND AND PURPOSE: Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative chemoradiotherapy. We aimed to elucidate factors associated with hypothyroidism by analyzing the JCOG1008 data. MATERIALS AND METHODS: In 2012-2018, 261 patients from 28 institutions were enrolled in JCOG1008. Thyroid function tests were conducted to assess hypothyroidism, including free thyroxine (FT4) and thyroid-stimulating hormone assays. Hypothyroidism was defined as Grade 2 or higher in CTCAE v4.0. Various clinical and dosimetric parameters were analyzed. In radiotherapy, there were no dose constraints for the thyroid. Multivariable analysis was conducted on these variables to identify predictive factors for hypothyroidism. RESULTS: The analysis included 162 patients (57 with 3D-CRT and 105 with IMRT), with a median follow-up of 4.7 years (0.3-9.3 years). Among these, 27 (16.7 %) developed hypothyroidism within 2 years after radiotherapy. In a multivariable analysis, the weekly cisplatin [OR=7.700 (CI: 1.632-36.343, p = 0.010)] and baseline FT4 [OR=0.009 (CI: <0.001-0.313, p = 0.010)] were significantly associated with hypothyroidism in the IMRT group. Regarding dosimetric characteristics, V60Gy [OR=1.069 (CI: 0.999-1.143, p = 0.054)] was potentially associated with the development of hypothyroidism. CONCLUSION: The study revealed that the incidence of hypothyroidism within 2 years after postoperative chemoradiotherapy for high-risk HNC was 16.7 % based on analytical results from prospective clinical trials.
• [ANL Secondary Publication] 平均赤血球容積高値は頭頸部癌に食道癌を併発するリスク因子である
  対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 127, 9, 1027, 1029, (一社)日本耳鼻咽喉科頭頸部外科学会, 2024年09月
  日本語
• 鼻副鼻腔粘膜悪性黒色腫におけるTRIM27の検討　　　　　　　　　　　　　　　
  木村 将吾, 中丸 裕爾, 鈴木 正宣, 中薗 彬, 本間 あや, 渡邉 良亮, 加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 本間 明宏, 渡部 昌, 近藤 豪, 畠山 鎮次
  日本鼻科学会会誌, 63, 3, 336, 336, (一社)日本鼻科学会, 2024年09月
  日本語
• Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.
  Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
  Cancer medicine, 13, 18, e70235, 2024年09月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non-inferior to 3-weekly cisplatin (100 mg/m2) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS). METHODS: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5-fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log-rank test. RESULTS: The total incidence of AKI was lower in the weekly arm than in the 3-weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3-weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m2 vs. 239.2 mg/m2; p = 0.94), but lower in the 3-weekly arm for those who developed AKI (median, 276.3 mg/m2 vs. 297.4 mg/m2; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3-weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21). CONCLUSIONS: In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3-weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.
• Evaluation of Semicircular Canal Function in Relapsing Polychondritis Patients with Dizziness and Sensorineural Hearing Loss Using Video Head Impulse Test.
  Kimiko Hoshino, Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Hideaki Takeda, Yuji Nakamaru, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2024年08月26日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: To evaluate semicircular canal function using video head impulse test (vHIT) in relapsing polychondritis (RP) patients presenting with dizziness and sensorineural hearing loss. STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Three patients with RP underwent vHIT and hearing tests. INTERVENTION: Diagnostic. MAIN OUTCOME MEASURES: The gain in vestibulo-ocular reflex (VOR) and the presence of catch-up saccade were examined, and the correlation between semicircular canal dysfunction and hearing loss was investigated. RESULTS: Of the six ears, five exhibited semicircular canal dysfunction. Among these, one ear showed dysfunction in two semicircular canals, while the remaining four ears demonstrated dysfunction in all three semicircular canals. Sensorineural hearing loss, ranging from moderate to profound, was detected by pure-tone audiometry in all six ears. Furthermore, a significant correlation was observed between VOR gain in the horizontal semicircular canal (HSC) and hearing level. CONCLUSIONS: This study demonstrated semicircular canal dysfunction in RP patients presenting with dizziness and hearing loss using vHIT. Moreover, a significant correlation was found between HSC dysfunction and the severity of hearing loss. While inner ear involvement is a key clinical symptom included in the diagnostic criteria for RP, there have been few reports evaluating vestibular dysfunction, and this is the first report on the evaluation of several cases using vHIT. Accurate assessment of vestibular function by vHIT may facilitate early diagnosis and intervention in RP, potentially improving patient outcomes.
• A Case of Cochlear Implantation in a Deaf Patient With Eosinophilic Otitis Media in Whom Post-implantation Hearing Threshold Improved After Introduction of Dupilumab.
  Atsushi Fukuda, Kimiko Hoshino, Shinya Morita, Keishi Fujiwara, Akihiro Homma
  Cureus, 16, 7, e65059, 2024年07月, ［国際誌］
  英語, 研究論文（学術雑誌）, Eosinophilic otitis media (EOM) is a rare, intractable, and chronic form of otitis media. The associated hearing loss often progresses to deafness, necessitating cochlear implantation (CI). EOM is associated with type 2 inflammatory conditions such as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Dupilumab, a monoclonal antibody targeting the IL4Rα subunit, has shown efficacy in mitigating type 2 inflammatory diseases, including asthma and CRSwNP. Recent studies also suggest its effectiveness in treating EOM. We report a unique case of CI for EOM, in which the post-implant hearing threshold improved after the introduction of dupilumab. The patient was a 63-year-old man with a history of asthma and multiple nasal polypectomies. Eosinophils were detected in otorrhea samples from both ears, leading to an EOM diagnosis four years prior. Despite local corticosteroid therapy, his hearing gradually deteriorated. One month ago, he experienced sudden bilateral deafness and was referred to our hospital. The right tympanic membrane had a pinhole perforation but no otorrhea. CT showed a small amount of soft tissue density in the right middle ear, while the left side displayed cochlear osteolysis with soft tissue density. A right CI and myringoplasty were performed one and a half months after his visit. The cochleostomy revealed no perilymph leakage, confirming that the scala tympani was filled with granulation tissue. The electrode was inserted successfully despite the granulation, and all electrodes were placed correctly. Six months after CI, his hearing threshold with the cochlear implant remained poor at 67.5 dB. However, upon starting dupilumab therapy seven months postoperatively, his hearing threshold with the cochlear implant rapidly improved to 31.3 dB. Intraoperative findings suggested that the scala tympani was filled with granulation tissue, indicating significant cochlear inflammation due to EOM. The subsequent hearing improvement after introducing dupilumab may be attributed to the reduction or disappearance of granulation in the cochlea, allowing for effective electrical stimulation from the electrodes to the spiral ganglion. This case suggests the potential for improved postoperative hearing outcomes in CI for EOM when inflammation is effectively controlled with dupilumab.
• Evaluation of quality of life for patients with resolved facial nerve palsy.
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Kimiko Hoshino, Makoto Kobayashi, Yuji Nakamaru, Yasushi Furuta, Akihiro Homma
  Auris, nasus, larynx, 51, 3, 456, 459, 2024年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The quality of life (QOL) for patients with resolved facial nerve palsy has not been evaluated adequately. The objective of this study is to investigate QOL for patients with resolved facial nerve palsy. METHODS: Forty-seven patients with resolved facial nerve palsy were included and the patients' QOL was evaluated using the Facial Clinimetric Evaluation Scale (FaCE Scale). RESULTS: Twenty-two of the 47 patients (46.8%) with resolved facial nerve palsy showed impaired QOL, especially in terms of facial comfort and eye comfort. In 10 cases followed-up after the condition was judged to be resolved, the median scores for the FaCE scale at the time the condition was judged to be resolved and at the last visit were 65.5 and 72, respectively. The mean durations from the onset of the palsy to diagnosis of cure and to the last visit were 2.4 ± 1.6 and 4.3 ± 2.2 months, respectively. There was a significant improvement in QOL after the condition was judged to be resolved. CONCLUSION: There were discrepancies between QOL and facial movement as evaluated by physicians in patients in whom facial nerve palsy was resolved as in patients with non-cured facial nerve palsy. Patients' QOL continued to improve even after physicians judged the condition to be resolved and this result indicated that there were cases where improvement in QOL was delayed in comparison to improvement in facial movement.
• Evaluation of Semicircular Canal Function Using Video Head Impulse Test in Patients With Peripheral Vestibular Disorders Without Nystagmus.
  Keishi Fujiwara, Shinya Morita, Kimiko Hoshino, Atsushi Fukuda, Hideaki Takeda, Yuji Nakamaru, Akihiro Homma
  Cureus, 16, 6, e62786, 2024年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, Objectives This study aims to evaluate semicircular canal function using video head impulse test (vHIT) in patients with peripheral vestibular disorders without nystagmus. Methods Patients who underwent vHIT were enrolled in this study, and the proportion of abnormal findings on vHIT in patients without nystagmus was investigated. In addition, the results of vestibular testing were investigated in cases in which both vHIT and caloric testing were performed in patients without nystagmus. Results Forty-six patients (23.4%) of 197 patients who had no abnormal findings on the nystagmus tests, including the gaze nystagmus test, positional nystagmus test, and positioning nystagmus test, showed dysfunction in at least one semicircular canal on vHIT. The most frequent diagnosis was vestibular schwannoma (14/46, 30.4%), and cases with bilateral vestibular dysfunction were also included (12/46, 26.1%). A disorganized pattern of catch-up saccade was observed more frequently in patients with subjective symptoms of dizziness/vertigo compared to those without subjective symptoms. Although the sensitivity of vHIT was low compared to caloric testing, vHIT could detect isolated vertical canal dysfunction not detected by caloric testing. Conclusions vHIT is considered to be a useful test for patients without nystagmus, as vHIT could detect abnormalities in approximately one-quarter of patients without nystagmus. vHIT is considered to be one of the first tests to be performed following nystagmus testing, including the gaze nystagmus test, the positional nystagmus test, and the positioning nystagmus test. On the other hand, there are some cases in which vHIT shows no abnormality while caloric testing shows canal paresis. It is necessary to perform vHIT, bearing in mind that there are abnormalities that cannot be detected by vHIT alone.
• Pre- and post-operative semicircular canal function evaluated by video head impulse test in patients with vestibular schwannoma.
  Keishi Fujiwara, Shinya Morita, Hiroaki Motegi, Shigeru Yamaguchi, Yukitomo Ishi, Kimiko Hoshino, Atsushi Fukuda, Makoto Kobayashi, Yuji Nakamaru, Miki Fujimura, Akihiro Homma
  Auris, nasus, larynx, 51, 3, 542, 547, 2024年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: To evaluate pre- and post-operative semicircular canal function in patients with vestibular schwannoma (VS) by the video Head Impulse Test (vHIT). METHODS: Nineteen patients with VS who underwent surgery were enrolled in this study. The gain in vestibulo-ocular reflex (VOR) and the degree of scatter in catch-up saccades were examined pre- and post-operatively for the semicircular canals in VS patients. RESULTS: Ten of 19 cases (52.6 %) with VS were defined as demonstrating both superior vestibular nerve (SVN) and inferior vestibular nerve (IVN) impairment from the results of pre-operative vHIT. Hearing level and subjective vestibular symptoms showed significant correlations with pre-operative semicircular canal function. Compared to pre-operative vHIT results, VOR gains within 1 month after surgery were significantly reduced in all three canals; however, significant differences had disappeared in the anterior and posterior semicircular canals at 6 months after surgery. Cases of unknown origin had a significantly greater reduction in posterior semicircular canal function after surgery compared with those with disease of IVN origin. CONCLUSIONS: As vHIT could evaluate pre-operative vestibular nerve impairment, post-operative VOR gain reduction and the degree of vestibular compensation, semicircular canal function evaluated by vHIT provides a good deal of useful information regarding VS patients undergoing surgery compared to caloric testing, and vHIT should be performed pre- and post-operatively for patients with VS.
• Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
  Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
  Oral oncology, 154, 106868, 106868, 2024年05月30日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: Acute kidney injury (AKI) represents a major toxicity associated with cisplatin. We developed a risk prediction model for cisplatin-induced AKI in patients with postoperative high-risk head and neck cancer who received chemoradiotherapy during a randomized phase II/III trial, JCOG1008. MATERIALS AND METHODS: Two hundred and fifty-one patients received radiotherapy with weekly cisplatin at 40 mg/m2 (weekly arm) or 3-weekly cisplatin at 100 mg/m2 (3-weekly arm). AKI was defined using the AKI Network classification/staging system as increased serum creatinine of ≥0.3 mg/dL or a ≥1.5-fold increase from baseline 30 days after completing chemoradiotherapy. The Akaike information criterion was used to explore the optimal model by combining explanatory variables at registration. RESULTS: Among the 251 patients (210 men and 41 women (median age; 62 years)), 94 (37.5 %) developed cisplatin-induced AKI. The optimal cisplatin-induced AKI risk prediction model comprised four factors, including a primary site of hypopharynx/larynx (vs. oral cavity/oropharynx), 3-weekly arm (vs. weekly arm), serum albumin of ≤3.5 g/dL (vs. >3.5 g/dL) and creatinine clearance (CCr) of <90 mL/min (vs. ≥90 mL/min). The incidence of cisplatin-induced AKI rose with cumulative count of the four factors. When the cumulative count was ≥2, the positive predictive value for cisplatin-induced AKI was 50.3 %. CONCLUSIONS: We developed a risk prediction model for cisplatin-induced AKI in patients with head and neck cancer who received postoperative chemoradiotherapy using primary site, cisplatin administration method, serum albumin, and CCr. Patients with risk factors unrelated to the cisplatin administration method should adopt a weekly cisplatin regimen.
• Validity of endoscopic ossiculoplasty immediately after its introduction for ossicular chain disruption.
  Atsushi Fukuda, Shinya Morita, Kimiko Hoshino, Keishi Fujiwara, Yuji Nakamaru, Akihiro Homma
  BMC surgery, 24, 1, 149, 149, 2024年05月14日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Transcanal endoscopic ear surgery (TEES) reportedly requires a long learning curve and may be associated with more complications and longer operative times than microscopic ear surgery (MES). In this study, we aimed to examine the usefulness and validity of TEES for ossicular chain disruption in the early stages of its introduction in our institution. METHODS: TEES was performed on 11 ears (10 with congenital ossicular chain discontinuity and 1 with traumatic ossicular chain dislocation), and MES was performed with a retroauricular incision on 18 ears (6 with congenital ossicular chain discontinuity and 12 with traumatic ossicular chain dislocation) in a tertiary referral center. Postoperative hearing results, operative times, and postoperative hospital length of stay were retrospectively reviewed. The Mann-Whitney U test and Fisher's exact test was performed to compare variables between the TEES and MES groups. Pre- and postoperative air- and bone-conduction thresholds and the air-bone gap of each group were compared using the Wilcoxon signed-rank test. The Mann-Whitney U test and Wilcoxon signed-rank was performed to compare the pre- and postoperative air-bone gaps between the diagnoses. RESULTS: No significant differences in the postoperative air-conduction thresholds, bone-conduction thresholds, air-bone gaps, or incidence of air-bone gap ≤ 20 dB were observed between the TEES and MES groups. The air-conduction thresholds and air-bone gaps of the TEES group significantly improved postoperatively. The air-conduction thresholds and air-bone gaps of the MES group also significantly improved postoperatively. No significant difference was observed in the operative times between the groups (TEES group: median, 80 min; MES group: median, 85.5 min). The TEES group had a significantly shorter postoperative hospital stay (median, 2 days) than the MES group (median, 7.5 days). CONCLUSIONS: TEES was considered appropriate for the treatment of ossicular chain disruption, even immediately after its introduction at our institution. For expert microscopic ear surgeons, ossicular chain disruption may be considered a suitable indication for the introduction of TEES.
• 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) T4aN0M0の最終解析結果　　　　　　　　　　　　　　　
  齊藤 祐毅, 松浦 一登, 鬼丸 力也, 別府 武, 三谷 浩樹, 田中 薫, 南 修司郎, 藤井 隆, 平山 裕次, 本間 明宏
  頭頸部癌, 50, 2, 133, 133, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• 高齢者局所進行頭頸部癌に対する化学放射線療法の適応について JCOG頭頸部がんグループアンケート調査　　　　　　　　　　　　　　　
  安田 耕一, 清田 尚臣, 松浦 一登, 斎藤 哲, 今村 善宣, 田中 薫, 全田 貞幹, 古平 毅, 花井 信広, 岡野 晋, 酒井 昭博, 伊藤 薫樹, 山村 悠大, 本間 明宏
  頭頸部癌, 50, 2, 194, 194, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• 早期声門癌に対する強度変調放射線治療の初期経験　　　　　　　　　　　　　　　
  服部 敬寛, 安田 耕一, 湊川 英樹, 打浪 雄介, 木下 留美子, 浜田 誠二郎, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏
  頭頸部癌, 50, 2, 206, 206, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• 遠隔転移のない頭頸部粘膜悪性黒色腫を対象とした根治治療に関する観察研究(RESUME試験)　　　　　　　　　　　　　　　
  茂木 厚, 野村 基雄, 清田 尚臣, 清水 康, 秋元 哲夫, 向川 卓志, 藤井 隆, 対馬 那由多, 志賀 清人, 小山 泰司, 川北 大介, 大越 明, 中平 光彦, 花井 信広, 室野 重之, 上田 勉, 三谷 浩樹, 本間 明宏
  頭頸部癌, 50, 2, 192, 192, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• 頭頸部アルミノックス治療における複合現実を用いた治療計画の3次元可視化の試み　　　　　　　　　　　　　　　
  鈴木 崇祥, 足利 雄一, 若林 侑輝, 鈴木 正宣, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
  頭頸部癌, 50, 2, 189, 189, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) T4aN0M0の最終解析結果　　　　　　　　　　　　　　　
  齊藤 祐毅, 松浦 一登, 鬼丸 力也, 別府 武, 三谷 浩樹, 田中 薫, 南 修司郎, 藤井 隆, 平山 裕次, 本間 明宏
  頭頸部癌, 50, 2, 133, 133, (一社)日本頭頸部癌学会, 2024年05月
  日本語
• SlicerPIT: software development and implementation for planning and image-guided therapy in photoimmunotherapy.
  Takayoshi Suzuki, Satoshi Kano, Masanobu Suzuki, Seijiro Hamada, Hiroshi Idogawa, Nayuta Tsushima, Yuichi Ashikaga, Yuki Wakabayashi, Takeshi Soyama, Yasuhiro Hida, Akihiro Homma
  International journal of clinical oncology, 2024年04月23日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Photoimmunotherapy is a treatment modality that induces targeted cell death by binding a molecular-targeted drug activated by infrared light to the tumor cells and subsequently illuminating the lesion with infrared light. For deep lesions, a needle catheter is used to puncture the tumor, and an illumination fiber (cylindrical diffuser) is inserted into the catheter lumen for internal illumination. However, it can be challenging to place the cylindrical diffusers in an appropriate position as the deep lesions cannot be often confirmed accurately during surgery. MATERIALS AND METHODS: We have developed "SlicerPIT", a planning simulation software for photoimmunotherapy. SlicerPIT allows users to place the cylindrical diffuser with its illumination range on preoperative images in 2D and 3D and export the planning data to external image-guided surgical navigation systems. We performed seven cycles of photoimmunotherapy with SlicerPIT in three patients with recurrent head and neck cancer. RESULTS: Preoperative planning for photoimmunotherapy was conducted using SlicerPIT, which could be imported into the navigation system. During the operation, we punctured the needle catheters along with the treatment plan on the navigation screen. Subsequently, intraoperative CT imaging was performed and overlaid with the preoperative treatment plan to confirm the alignment of the cylindrical diffusers as planned, followed by infrared light illumination. Postoperative imaging showed necrosis and shrinkage of the entire tumor in all cycles. CONCLUSION: SlicerPIT allows for detailed preoperative treatment planning and accurate puncture. It may be a valuable tool to improve the accuracy of photoimmunotherapy for deep lesions and improve patient outcomes.
• Stage I/II舌癌における潜在的リンパ節転移の予測式の確立
  野島 雄介, 鬼島 菜摘, 佐野 大佑, 西川 大輔, 後藤 聖也, 土田 宏大, 加納 里志, 有泉 陽介, 森下 洋平, 桑原 達, 向川 卓志, 志賀 清人, 朝蔭 孝宏, 松浦 一登, 折舘 伸彦, 本間 明宏, 林 隆一, 花井 信広
  日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 539, 539, (一社)日本耳鼻咽喉科頭頸部外科学会, 2024年04月
  日本語
• 鼻副鼻腔粘膜悪性黒色腫の遺伝子変異を次世代シークエンサーにより解析する
  対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 井戸川 寛志, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 540, 540, (一社)日本耳鼻咽喉科頭頸部外科学会, 2024年04月
  日本語
• 治療計画ARナビゲーション・ニードルベンダーを用いた頭頸部アルミノックス治療の1例
  鈴木 崇祥, 足利 雄一, 若林 侑輝, 鈴木 正宣, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 599, 599, (一社)日本耳鼻咽喉科頭頸部外科学会, 2024年04月
  日本語
• 真珠腫性中耳炎半規管瘻孔症例におけるvideo Head Impulse Testを用いた半規管機能評価
  藤原 圭志, 森田 真也, 干野 季美子, 福田 篤, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 127, 4, 617, 617, (一社)日本耳鼻咽喉科頭頸部外科学会, 2024年04月
  日本語
• 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) 有効性検証(T4aN0M0)の結果　　　　　　　　　　　　　　　
  本間 明宏, 三上 剛史, 松浦 一登, 鬼丸 力也, 吉田 大介, 四宮 弘隆, 大越 明, 林 隆一, 齊藤 祐毅, 立花 弘之, 水澤 純基, 中村 健一, 福田 治彦
  日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 182, 182, (一社)日本インターベンショナルラジオロジー学会, 2024年04月
  日本語
• Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.
  Naomi Kiyota, Makoto Tahara, Akihiro Homma
  Japanese journal of clinical oncology, 2024年03月07日, ［国際誌］
  英語, 研究論文（学術雑誌）, Surgery remains a foundation of treatment for locally advanced squamous cell carcinoma of the head and neck. For postoperative patients at high risk of recurrence, however, surgery by itself is not enough, and improvement in survival requires postoperative treatment. Unlike the case with most other malignancies, the standard postoperative treatment for locally advanced squamous cell carcinoma of the head and neck patients with high-risk factors for recurrence is radiotherapy or chemoradiotherapy with cisplatin. However, chemoradiotherapy with cisplatin at a dose of 100 mg/m2 once every 3 weeks has raised discussion over insufficient cisplatin delivery due to high-dose-related toxicity. As a possible solution, a recent randomized trial of the JCOG1008 has proved the non-inferiority of postoperative chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 to 3-weekly cisplatin in terms of overall survival. Here, this review article focuses on current evidence and future perspectives of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.
• Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
  Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama
  Radiation oncology journal, 42, 1, 74, 82, 2024年03月, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival. RESULTS: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541). CONCLUSION: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.
• Improved image quality in contrast-enhanced 3D-T1 weighted sequence by compressed sensing-based deep-learning reconstruction for the evaluation of head and neck.
  Noriyuki Fujima, Junichi Nakagawa, Yohei Ikebe, Hiroyuki Kameda, Taisuke Harada, Yukie Shimizu, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
  Magnetic resonance imaging, 108, 111, 115, 2024年02月09日, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To assess the utility of deep learning (DL)-based image reconstruction with the combination of compressed sensing (CS) denoising cycle by comparing images reconstructed by conventional CS-based method without DL in fat-suppressed (Fs)-contrast enhanced (CE) three-dimensional (3D) T1-weighted images (T1WIs) of the head and neck. MATERIALS AND METHODS: We retrospectively analyzed the cases of 39 patients who had undergone head and neck Fs-CE 3D T1WI applying reconstructions based on conventional CS and CS augmented by DL, respectively. In the qualitative assessment, we evaluated overall image quality, visualization of anatomical structures, degree of artifacts, lesion conspicuity, and lesion edge sharpness based on a five-point system. In the quantitative assessment, we calculated the signal-to-noise ratios (SNRs) of the lesion and the posterior neck muscle and the contrast-to-noise ratio (CNR) between the lesion and the adjacent muscle. RESULTS: For all items of the qualitative analysis, significantly higher scores were awarded to images with DL-based reconstruction (p < 0.001). In the quantitative analysis, DL-based reconstruction resulted in significantly higher values for both the SNR of lesions (p < 0.001) and posterior neck muscles (p < 0.001). Significantly higher CNRs were also observed in images with DL-based reconstruction (p < 0.001). CONCLUSION: DL-based image reconstruction integrating into the CS-based denoising cycle offered superior image quality compared to the conventional CS method. This technique will be useful for the assessment of patients with head and neck disease.
• 両側頸動脈小体腫瘍に対して放射線治療を施行した1例　　　　　　　　　　　　　　　
  西川 昇, 安田 耕一, 藤田 祥博, 檜垣 朔, 志藤 元泰, 宮崎 智彦, 高橋 周平, 青山 英史, 加納 里志, 本間 明宏
  Japanese Journal of Radiology, 42, Suppl., 8, 8, (公社)日本医学放射線学会, 2024年02月
  日本語
• Diagnosis of skull-base invasion by nasopharyngeal tumors on CT with a deep-learning approach.
  Junichi Nakagawa, Noriyuki Fujima, Kenji Hirata, Taisuke Harada, Naoto Wakabayashi, Yuki Takano, Akihiro Homma, Satoshi Kano, Kazuyuki Minowa, Kohsuke Kudo
  Japanese journal of radiology, 2024年01月27日, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To develop a convolutional neural network (CNN) model to diagnose skull-base invasion by nasopharyngeal malignancies in CT images and evaluate the model's diagnostic performance. MATERIALS AND METHODS: We divided 100 malignant nasopharyngeal tumor lesions into a training (n = 70) and a test (n = 30) dataset. Two head/neck radiologists reviewed CT and MRI images and determined the positive/negative skull-base invasion status of each case (training dataset: 29 invasion-positive and 41 invasion-negative; test dataset: 13 invasion-positive and 17 invasion-negative). Preprocessing involved extracting continuous slices of the nasopharynx and clivus. The preprocessed training dataset was used for transfer learning with Residual Neural Networks 50 to create a diagnostic CNN model, which was then tested on the preprocessed test dataset to determine the invasion status and model performance. Original CT images from the test dataset were reviewed by a radiologist with extensive head/neck imaging experience (senior reader: SR) and another less-experienced radiologist (junior reader: JR). Gradient-weighted class activation maps (Grad-CAMs) were created to visualize the explainability of the invasion status classification. RESULTS: The CNN model's diagnostic accuracy was 0.973, significantly higher than those of the two radiologists (SR: 0.838; JR: 0.595). Receiver operating characteristic curve analysis gave an area under the curve of 0.953 for the CNN model (versus 0.832 and 0.617 for SR and JR; both p < 0.05). The Grad-CAMs suggested that the invasion-negative cases were present predominantly in bone marrow, while the invasion-positive cases exhibited osteosclerosis and nasopharyngeal masses. CONCLUSIONS: This CNN technique would be useful for CT-based diagnosis of skull-base invasion by nasopharyngeal malignancies.
• Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.
  Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki, Hajime Higaki, Jun Taguchi, Yasushi Shimizu, Tomohiro Sakashita, Akihiro Homma, Hidefumi Aoyama
  Discover. Oncology, 15, 1, 18, 18, 2024年01月25日, ［国際誌］
  英語
• Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group.
  Koichi Yasuda, Naomi Kiyota, Kazuto Matsuura, Satoshi Saito, Yoshitaka Honma, Yoshinori Imamura, Kaoru Tanaka, Sadamoto Zenda, Takuma Onoe, Takeshi Kodaira, Satoshi Kobayashi, Hidefumi Aoyama, Nobuhiro Hanai, Akihiro Homma
  Frontiers in oncology, 14, 1441056, 1441056, 2024年, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Chemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications. METHODS: In April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions. RESULTS: The major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65-74 years with PS 0-1 and 65-74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50. DISCUSSION: In Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients.
• Analysis of salivary duct carcinoma at 13 facilities in northern Japan
  Satoshi Kano, Nayuta Tsushima, Takayoshi Suzuki, Hiroshi Idogawa, Seijiro Hamada, Akira Ohkoshi, Takahiro Kusaka, Daisuke Matsushita, Kosuke Murayama, Ryosuke Sato, Yuya Miyakura, Satoshi Kubota, Satoshi Toyoma, Ai Tagawa, Shino Godo, Hiroki Tomizawa, Akina Shirotori, Akihiro Homma
  Toukeibu Gan, 50, 3, 246, 253, Japan Society for Head and Neck Cancer, 2024年
  研究論文（学術雑誌）
• 顔面神経麻痺治癒例におけるQOLの評価
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 43, 211, 213, 日本顔面神経学会, 2024年01月
  日本語
• Neutrophil Extracellular Trap Formation and Deoxyribonuclease I Activity in Patients with Otitis Media with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
  Shinya Morita, Yuji Nakamaru, Atsushi Fukuda, Keishi Fujiwara, Masanobu Suzuki, Kimiko Hoshino, Aya Honma, Akira Nakazono, Akihiro Homma
  International archives of allergy and immunology, 185, 8, 810, 819, 2024年, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: No previous studies have evaluated the levels of neutrophil extracellular trap (NET) remnants or the importance of deoxyribonuclease (DNase) I activity based on the disease activity of otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV). The aim of this study was to explore the formation of NETs in the middle ear of patients with OMAAV during the onset and remission phases of the disease, with a particular focus on the relationships between the quantifiable levels of NET remnants and DNase I activity. METHODS: OMAAV patients were eligible for inclusion. Patients with otitis media with effusion (OME) were examined as controls. The levels of cell-free deoxyribonucleic acid (DNA), citrullinated-histone H3 (cit-H3)-DNA complex, and myeloperoxidase (MPO)-DNA complex were quantified using an enzyme-linked immunosorbent assay. DNase I activity was measured using a fluorometric method. RESULTS: The quantifiable levels of cell-free DNA, cit-H3-DNA complex, and MPO-DNA complex in the middle ear lavage of patients with OMAAV at onset were significantly higher than those in patients with OMAAV at remission and in patients with OME. DNase I activity in the patients with OMAAV at onset was significantly lower than those in patients with OMAAV at remission and OME and was negatively correlated with the level of MPO-DNA complex. CONCLUSIONS: This study suggests that NET remnants and DNase I activity may be potentially useful biomarkers for the diagnosis and disease activity of OMAAV.
• Clinical outcomes for olfactory neuroblastoma.
  Akira Nakazono, Hiroaki Motegi, Masanobu Suzuki, Yuji Nakamaru, Shigeru Yamaguchi, Yukitomo Ishi, Satoshi Kano, Nayuta Tsushima, Aya Honma, Takayoshi Suzuki, Shogo Kimura, Seijiro Hamada, Jun Taguchi, Yasushi Shimizu, Takashi Mori, Koichi Yasuda, Hidefumi Aoyama, Ichiro Kinoshita, Miki Fujimura, Akihiro Homma
  Frontiers in oncology, 14, 1329572, 1329572, 2024年, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB. METHODS: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data. RESULTS: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS. CONCLUSION: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.
• Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan.
  Koichi Yasuda, Yusuke Uchinami, Satoshi Kano, Jun Taguchi, Daisuke Kawakita, Megumi Kitayama, Kentaro Nishioka, Takashi Mori, Fuki Koizumi, Yuri Fujii, Yasushi Shimizu, Keiji Kobashi, Seiichi Yoshimoto, Ken-Ichi Nibu, Akihiro Homma, Hidefumi Aoyama
  International journal of clinical oncology, 2023年12月29日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Whether concurrent chemotherapy with radiotherapy (CRT) is effective for elderly patients with head and neck cancer is a controversial topic. This study aimed to analyze the effectiveness of CRT vs. radiation therapy (RT) among elderly patients in Japan. METHODS: Data from the Head and Neck Cancer Registry of Japan were extracted and analyzed. Patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx who received definitive CRT or RT between 2011 and 2014 were included. RESULTS: CRT was administered to 78% of the 1057 patients aged ≥ 70 years and 67% of the 555 patients aged ≥ 75 years. For the patients aged ≥ 75 years, the overall survival (OS) rate was significantly better in the CRT group than in the RT group (P < 0.05), while the progression-free survival (PFS) rate was not significantly different (P > 0.05). The add-on effect of CRT was significantly poor in elderly patients (P < 0.05), and it was not a significant factor in the multivariate analysis for patients aged ≥ 75 years. After propensity score matching, there were no significant differences in the OS and PFS rates between the patients aged ≥ 70 years and those aged ≥ 75 years (all, P > 0.05). CONCLUSION: Although aggressive CRT is administered to elderly patients in Japan, its effectiveness is uncertain. Further prospective randomized trials are needed to verify whether CRT is superior to RT alone for elderly patients.
• Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.
  Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki, Hajime Higaki, Jun Taguchi, Yasushi Shimizu, Tomohiro Sakashita, Akihiro Homma, Hidefumi Aoyama
  Discover. Oncology, 14, 1, 226, 226, 2023年12月08日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Tri-weekly cisplatin and radiotherapy (CDDP + RT) is a standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) but is sometimes challenging to complete in older patients. Weekly CDDP + RT has shown mild toxicity compared to tri-weekly CDDP + RT for LA-HNSCC and is a promising option for older adults. We aimed to report the treatment outcomes and prognostic factors in patients with LA-HNSCC treated with weekly CDDP + RT. METHODS: We analyzed patients aged ≥ 70 years who started weekly CDDP + RT for LA-HNSCC between July 2006 and October 2022. LA-HNSCC includes cancer in the oropharynx, hypopharynx, or larynx with a clinical stage of 3 or 4 without distant metastases based on the Union for International Cancer Control staging system 8th edition. The radiation dose of 70 Gy was delivered in 35 fractions by 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy. The primary endpoint was the 3-year overall survival (OS), and the secondary endpoints were the 3-year progression-free survival (PFS) and 3-year cause-specific survival (CSS). The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used to evaluate statistical significance. A Cox proportional hazards model was used for the multivariate analysis of prognostic factors. RESULTS: The median age of the 49 patients was 72 (range: 70-78) years. The median CDDP dose was 200 (40-280) mg/ m2, and 47 patients completed scheduled radiotherapy. Forty-eight patients (98.0%) had a performance status of ≥ 1 at the initial visit. The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8-90.7), 68.3% (95% CI 51.8-81.2), and 85.0% (95% CI 68.7-93.4), respectively. In the multivariate analysis, the cumulative CDDP dose (< 200 or ≥ 200 mg/m2) was a significant factor for OS (hazard ratio: 0.29 [95% CI 0.08-0.97], p = 0.044). There was one case of early mortality. Grade 3 or higher late adverse events were observed in four patients (8.2%). CONCLUSIONS: Weekly CDDP + RT in older patients led to good survival outcomes with an acceptable rate of adverse events. CDDP should be administered at a dose of at least 200 mg/m2 in older patients. Trial registration Retrospectively registered.
• Improvement of image quality in diffusion-weighted imaging with model-based deep learning reconstruction for evaluations of the head and neck.
  Noriyuki Fujima, Junichi Nakagawa, Hiroyuki Kameda, Yohei Ikebe, Taisuke Harada, Yukie Shimizu, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Jihun Kwon, Masami Yoneyama, Kohsuke Kudo
  Magma (New York, N.Y.), 2023年11月21日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: To investigate the utility of deep learning (DL)-based image reconstruction using a model-based approach in head and neck diffusion-weighted imaging (DWI). MATERIALS AND METHODS: We retrospectively analyzed the cases of 41 patients who underwent head/neck DWI. The DWI in 25 patients demonstrated an untreated lesion. We performed qualitative and quantitative assessments in the DWI analyses with both deep learning (DL)- and conventional parallel imaging (PI)-based reconstructions. For the qualitative assessment, we visually evaluated the overall image quality, soft tissue conspicuity, degree of artifact(s), and lesion conspicuity based on a five-point system. In the quantitative assessment, we measured the signal-to-noise ratio (SNR) of the bilateral parotid glands, submandibular gland, the posterior muscle, and the lesion. We then calculated the contrast-to-noise ratio (CNR) between the lesion and the adjacent muscle. RESULTS: Significant differences were observed in the qualitative analysis between the DWI with PI-based and DL-based reconstructions for all of the evaluation items (p < 0.001). In the quantitative analysis, significant differences in the SNR and CNR between the DWI with PI-based and DL-based reconstructions were observed for all of the evaluation items (p = 0.002 ~ p < 0.001). DISCUSSION: DL-based image reconstruction with the model-based technique effectively provided sufficient image quality in head/neck DWI.
• Extent of thyroidectomy and paratracheal lymph node dissection in total pharyngolaryngectomy for pyriform sinus cancer, and recurrence, survival, and postoperative hypoparathyroidism: A multicenter retrospective study.
  Yosuke Ariizumi, Nobuhiro Hanai, Takahiro Asakage, Akira Seto, Toshifumi Tomioka, Junji Miyabe, Hisashi Kessoku, Takashi Mukaigawa, Go Omura, Masanori Teshima, Daisuke Nishikawa, Yuki Saito, Yukinori Asada, Takuo Fujisawa, Takuma Makino, Hiroshi Nishino, Daisuke Sano, Mitsuhiko Nakahira, Kunihiko Tokashiki, Hirokazu Uemura, Tsutomu Ueda, Akihiro Sakai, Muneyuki Masuda, Takahiro Tsujikawa, Yusuke Hiei, Naoki Nishio, Hidetoshi Matsui, Naomi Kiyota, Akihiro Homma
  Head & neck, 2023年11月13日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Total pharyngolaryngectomy (TPL) is standard treatment for hypopharyngeal cancer. However, extensive thyroidectomy and paratracheal nodal dissection (PTND) can cause hypoparathyroidism. We sought to determine the optimum extent of resection. METHODS: We analyzed the clinicopathological information of 161 pyriform sinus cancer patients undergoing TPL from 25 Japanese institutions. Rates of recurrence and risk factors for hypoparathyroidism, as well as incidence of pathological contralateral level VI nodal metastasis and stomal recurrence, were investigated. RESULTS: The extent of thyroidectomy and nodal dissection were not independent risk factors for recurrence. Incidences of contralateral level VI nodal involvement and stomal recurrence were 1.8% and 1.2%, respectively. Patients undergoing hemithyroidectomy/ipsilateral PTND did not develop stomal recurrence and had the lowest incidence of hypoparathyroidism. Prognosis in patients without tracheostomy prior to hemithyroidectomy/ipsilateral PTND was comparable to that with more extensive resections. CONCLUSIONS: Hemithyroidectomy/ipsilateral PTND may be sufficient for pyriform sinus cancer cases without tracheostomy.
• Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
  Yasuhiro Dekura, Koichi Yasuda, Hideki Minatogawa, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takashi Mori, Kentaro Nishioka, Keiji Kobashi, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
  Journal of radiation research, 2023年11月10日, ［国際誌］
  英語, 研究論文（学術雑誌）, The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.
• Comparative study of physiological FDG uptake in small structures between silicon photomultiplier-based PET and conventional PET.
  Shiro Watanabe, Kenji Hirata, Keiichi Magota, Junki Takenaka, Naoto Wakabayashi, Daiki Shinyama, Koichi Yasuda, Akihiro Homma, Kohsuke Kudo
  Annals of nuclear medicine, 2023年11月09日, ［国内誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Silicon photomultiplier-based positron emission tomography/computed tomography (SiPM-PET/CT) has the superior spatial resolution to conventional PET/CT (cPET/CT). This head-to-head comparison study compared the images of physiological 18F-fluorodeoxyglucose (FDG) accumulation in small-volume structures between SiPM-PET/CT and cPET/CT in patients scanned with both modalities, and we investigated whether the thresholds that are reported to be useful for differentiating physiological accumulations from malignant lesions can also be applied to SiPM-PET/CT. METHODS: We enrolled 21 consecutive patients with head and neck malignancies who underwent whole-body FDG-PET/CT for initial staging or a follow-up evaluation (October 2020 to March 2022). After being injected with FDG, all patients underwent PET acquisition on both Vereos PET-CT and Gemini TF64 PET-CT systems (both Philips Healthcare) in random order. For each patient, the maximum standardized uptake value (SUVmax) was measured in the pituitary gland, esophagogastric junction (EGJ), adrenal glands, lumbar enlargement of the spinal cord, and epididymis. We measured the liver SUVmean and the blood pool SUVmean to calculate the target-to-liver ratio (TLR) and the target-to-blood ratio (TBR), respectively. Between-groups differences in each variable were examined by a paired t-test. We also investigated whether there were cases of target uptake greater than the reported threshold for distinguishing pathological from physiological accumulations. RESULTS: Data were available for 19 patients. Ten patients were in Group 1, i.e., the patients who underwent SiPM-PET first, and the remaining nine patients who underwent cPET first were in Group 2. In the SiPM-PET results, the SUVmax of all targets was significantly higher than that obtained by cPET in all patients, and this tendency was also observed when the patients were divided into Groups 1/2. The TLRs of all targets were significantly higher in SiPM-PET than in cPET in all patients, and SiPM-PET also showed significantly higher TBRs for all targets except the EGJ (p = 0.052). CONCLUSIONS: The physiological uptake in the small structures studied herein showed high accumulation on SiPM-PET. Our results also suggest that the thresholds reported for cPET to distinguish pathological accumulations likely lead to false-positive findings in SIPM-PET evaluations.
• Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
  Tomoya Yokota, Sadamoto Zenda, Takeshi Kodaira, Naomi Kiyota, Yasushi Fujimoto, Koichiro Wasano, Ryo Takahashi, Takashi Mizowaki, Akihiro Homma, Keita Sasaki, Ryunosuke Machida, Yuta Sekino, Haruhiko Fukuda
  BMC cancer, 23, 1, 1068, 1068, 2023年11月06日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Chemoradiotherapy (CRT) with concurrent cisplatin is the standard of care as a nonsurgical definitive treatment for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, CRT is associated with increased severe late adverse events, including swallowing dysfunction, xerostomia, ototoxicity, and hypothyroidism. Few strategies aimed at less invasive CRT without compromising treatment outcomes have been successful. The purpose of this study is to confirm the non-inferiority of reduced dose prophylactic radiation with 40 Gy compared to standard dose prophylactic radiation with 56 Gy in terms of the time to treatment failure (TTF) among patients with clinical stage III-IVB LA-SCCHN. METHODS: This study is a multicenter, two-arm, open-label, randomized phase III trial. Patients with LA-SCCHN excluding p16 positive oropharynx cancer are randomized to the standard arm or experimental arm. A total dose of 70 Gy for tumors with concurrent cisplatin at 100 mg/m2 are administered in both arms. For prophylactic field, patients in the standard arm receive a total dose of 56 Gy in 35 fractions for 7 weeks using simultaneous integrated boost (SIB56) and those in the experimental arm receive 40 Gy in 20 fractions using two-step methods for 4 weeks (2-step40). A total of 400 patients will be enrolled from 52 Japanese institutions within 5 years. The primary endpoint is TTF, and the secondary endpoints are overall survival, complete response rate, progression-free survival, locoregional relapse-free survival, acute and late adverse events, quality of life score, and swallowing function score. DISCUSSION: If the experimental arm is non-inferior to the standard arm in terms of TTF and superior on the safety endpoints, the 2-step40 procedure is the more useful treatment than SIB56 for definitive CRT. TRIAL REGISTRATION: This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031210100 ( https://jrct.niph.go.jp/latest-detail/jRCTs031210100 ). Date of Registration: May 2021.
• 鼓室型グロムス腫瘍の3例　　　　　　　　　　　　　　　
  小林 諒, 森田 真也, 福田 篤, 干野 季美子, 藤原 圭志, 中丸 裕爾, 本間 明宏
  日本耳科学会総会・学術講演会抄録集, 33回, 296, 296, (一社)日本耳科学会, 2023年11月
  日本語
• 当科における耳小骨離断に対する経外耳道的内視鏡下耳科手術の成績　　　　　　　　　　　　　　　
  福田 篤, 森田 真也, 干野 季美子, 小林 諒, 藤原 圭志, 中丸 裕爾, 本間 明宏
  日本耳科学会総会・学術講演会抄録集, 33回, 390, 390, (一社)日本耳科学会, 2023年11月
  日本語
• Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
  Nayuta Tsushima, Satoshi Kano, Kanako C. Hatanaka, Takayoshi Suzuki, Seijiro Hamada, Hiroshi Idogawa, Yuji Nakamaru, Masanobu Suzuki, Yutaka Hatanaka, Akihiro Homma
  Auris Nasus Larynx, Elsevier BV, 2023年11月
  研究論文（学術雑誌）
• 高悪性度唾液腺癌に対する術前診断モデルの開発　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 浜田 誠二郎, 本間 明宏
  日本癌治療学会学術集会抄録集, 61回, O30, 1, (一社)日本癌治療学会, 2023年10月
  英語
• vHIT、VEMPを用いて手術による前庭機能改善を評価し得た小脳橋角部を占拠する錐体斜台部巨大軟骨肉腫の1例
  武田 英明, 藤原 圭志, 藤原 由有希, 本間 明宏
  Equilibrium Research, 82, 5, 447, 447, (一社)日本めまい平衡医学会, 2023年10月
  日本語
• 錐体尖コレステリン肉芽腫における術前後の定量的平衡機能評価
  藤原 圭志, 藤原 由有希, 本間 明宏
  Equilibrium Research, 82, 5, 503, 503, (一社)日本めまい平衡医学会, 2023年10月
  日本語
• Quantitative Evaluations of Vestibular Function in Patients With Petrous Apex Cholesterol Granulomas Treated With an Endoscopic Transsphenoidal Approach: A Report of Two Cases.
  Yuuki Fujiwara, Keishi Fujiwara, Hiroaki Motegi, Yukitomo Ishi, Shinya Morita, Kimiko Hoshino, Atsushi Fukuda, Yuji Nakamaru, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 44, 8, 809, 812, 2023年09月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: We report two cases of petrous apex cholesterol granuloma (PACG) treated with an endoscopic transsphenoidal approach. Vestibular functions of the two patients were evaluated quantitatively by video Head Impulse Test (vHIT) and/or vestibular evoked myogenic potentials (VEMPs). PATIENTS: Two patients with PACG who experienced episodes of dizziness are presented. INTERVENTION: An endoscopic transsphenoidal approach to PACG. MAIN OUTCOME MEASURE: The preoperative and postoperative vestibular functions as evaluated by vHIT and VEMP. RESULTS: Two cases of PACG were treated by a transsphenoidal approach. The internal auditory canal was compressed by the PACG in both cases. The patients both experienced episodes of dizziness before surgery and preoperative vestibular testing including vHIT and VEMP indicated dysfunction of vestibular nerves. After surgery, their symptoms were completely resolved, and the vestibular testing results were improved. CONCLUSIONS: This article is noteworthy for being the first to publish quantitative vestibular function testing for patients with PACG with vestibular dysfunction. PACG may show various symptoms, with dizziness being one of the most common symptoms. In cases in which the internal auditory canal is compressed by the PACG, vestibular functions should be evaluated by vHIT and VEMP. In the present cases, dizziness was found to be resolved by surgery to release the compression on internal auditory canal. Based on the present cases, the transsphenoidal approach is considered to be both safe and effective.
• Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer.
  Akihiro Homma, Mizuo Ando, Nobuhiro Hanai, Hiroyuki Harada, Yoshitaka Honma, Tomonori Kanda, Satoshi Kano, Daisuke Kawakita, Naomi Kiyota, Yoshiyuki Kizawa, Masahiro Nakagawa, Takenori Ogawa, Hirotaka Shinomiya, Takeshi Shinozaki, Motoyuki Suzuki, Tetsuya Tsuji, Koichi Yasuda, Sadamoto Zenda, Takeshi Kodaira, Tadaaki Kirita, Ken-Ichi Nibu
  Auris, nasus, larynx, 2023年07月21日, ［国際誌］
  英語, 研究論文（学術雑誌）, The aim of the "Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2022 Update" is to review the latest evidence regarding head and neck cancer and to present the current standard approaches for diagnosis and treatment. These evidence-based recommendations were created with the consensus of the Guideline Committee, which is composed of otorhinolaryngologists and head and neck surgeons, together with radiologists, radiation oncologists, medical oncologists, plastic surgeons, dentists, palliative care physicians, and rehabilitation physicians. These guidelines were created by the Clinical Practice Guideline Committee of the Japan Society for Head and Neck Cancer based on the "Head and Neck Cancer Treatment Guidelines 2018 Edition," and the revised draft was compiled after evaluation by the Assessment Committee and public comments. The 'Clinical questions and recommendations' section consists of 13 categories, and 59 clinical questions are described in total. Here we describe 6 clinical questions specific to other sets of guidelines with recommendations and comments.
• Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study.
  Satoshi Takeuchi, Kenji Hirata, Keiichi Magota, Shiro Watanabe, Rika Moku, Akihiko Shiiya, Jun Taguchi, Shin Ariga, Tomohiro Goda, Yoshihito Ohhara, Takurou Noguchi, Yasushi Shimizu, Ichiro Kinoshita, Rio Honma, Yasushi Tsuji, Akihiro Homma, Hirotoshi Dosaka-Akita
  EJNMMI research, 13, 1, 69, 69, 2023年07月17日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Lenvatinib is widely used to treat unresectable and advanced thyroid carcinomas. We aimed to determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) performed 1 week after lenvatinib treatment initiation could predict treatment outcomes. RESULTS: This was a prospective, nonrandomised, multicentre study. Patients with pathologically confirmed differentiated thyroid carcinoma (DTC) and lesions refractory to radioiodine treatment were eligible for inclusion. Patients were treated with 24 mg lenvatinib as the initial dose and underwent PET/CT examination 1 week after treatment initiation. Contrast-enhanced CT was scheduled at least 4 weeks later as the gold standard for evaluation. The primary endpoint was to evaluate the discrimination power of maximum standardised uptake value (SUVmax) obtained by PET/CT compared to that obtained by contrast-enhanced CT. Evaluation was performed using the area under the receiver operating characteristic (ROC-AUC) curve. Twenty-one patients were included in this analysis. Receiver operating characteristic (ROC) curve analysis yielded an AUC of 0.714 for SUVmax after 1 week of lenvatinib treatment. The best cut-off value for the treatment response for SUVmax was 15.211. The sensitivity and specificity of this cut-off value were 0.583 and 0.857, respectively. The median progression-free survival was 26.3 months in patients with an under-cut-off value and 19.7 months in patients with an over-cut-off value (P = 0.078). CONCLUSIONS: The therapeutic effects of lenvatinib were detected earlier than those of CT because of decreased FDG uptake on PET/CT. PET/CT examination 1 week after the initiation of lenvatinib treatment may predict treatment outcomes in patients with DTC. TRIAL REGISTRATION: This trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (number UMIN000022592) on 6 June, 2016.
• Utility of Color Doppler Ultrasonography in Monitoring of a Free Jejunal Flap
  Taku Maeda, Kosuke Ishikawa, Yoichiro Oda, Satoshi Kano, Nayuta Tsushima, Tomohiro Sakashita, Akihiro Homma, Yuhei Yamamoto, Emi Funayama
  The Laryngoscope, Wiley, 2023年06月29日
  研究論文（学術雑誌）
• Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy.
  Nayuta Tsushima, Satoshi Kano, Koichi Yasuda, Takayoshi Suzuki, Seijiro Hamada, Yuji Nakamaru, Masanobu Suzuki, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
  International journal of clinical oncology, 28, 9, 1218, 1226, 2023年06月17日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The standard of care for sinonasal mucosal melanoma is surgery and postoperative radiotherapy (PORT). Our treatment strategy comprises endoscopic resection and PORT. We performed combined endoscopic and open resection or applied an external approach alone when sufficient resection was difficult to achieve endoscopically. The objective of this study was to evaluate the validity of our treatment strategy. METHODS: We assessed 30 patients with sinonasal mucosal melanoma who underwent definitive therapy between January 2002 and April 2021, and conducted a retrospective analysis. The median follow-up period was 2.2 years. The primary endpoint was overall survival. The Kaplan-Meier method was used for the calculation of survival rates, the cumulative incidence of distant metastasis, and local recurrence. RESULTS: Twenty-eight patients underwent surgery. The other two patients were treated by definitive proton beam therapy. Twenty-one of 28 (75%) patients underwent resection by endoscopic approach alone. Postoperative radiotherapy was performed for all 28 patients who underwent surgery. Twenty-one patients (70%) experienced recurrence during the observation period. Overall, distant metastasis was observed in 19 patients. Twelve patients died during the observation period, with 10 of the 12 patients (83%) dying of distant metastasis. The overall survival rate at 2 and 5 years was 70% and 46%, respectively. The cumulative incidence rate of distant metastasis at 2 years was 63%, while the 2-year cumulative incidence rate of local recurrence was 6.7%. CONCLUSION: The local disease was controlled by our treatment strategy. To improve treatment outcomes, control of the distant metastasis is needed.
• The superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is effective for metastatic lymph nodes in head and neck squamous cell carcinoma.
  Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Seijiro Hamada, Koichi Yasuda, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
  International journal of clinical oncology, 28, 9, 1121, 1128, 2023年06月08日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is a very promising treatment modality for locally advanced head and neck squamous cell carcinoma. However, there are some concerns regarding its potential for the control of neck lymph node metastasis. The objective of this study was to investigate whether RADPLAT provided inferior regional control compared to intravenous chemoradiotherapy (IV-CRT). METHODS: A total of 172 patients with neck lymph node metastases, 66 of whom underwent RADPLAT and 106 IV-CRT, were enrolled in this study. We retrospectively compared regional control rates between RADPLAT and IV-CRT. Furthermore, to adjust for differences in factors related to patient background between the groups, we conducted inverse probability weighting (IPW) analysis using the propensity score. RESULTS: A comparison between the two groups revealed that the regional control rates were almost equal under unadjusted conditions; however, after adjustment by IPW analysis, the RADPLAT group had a relatively better regional control rate than did the IV-CRT group (1 year regional control rate: 86.6% vs. 79.4%). In addition, the analysis of relative risk factors for regional control in the RADPLAT group showed that the absence of intra-arterial cisplatin infusion into metastatic lymph nodes was the only independent risk factor (Hazard ratio: 4.23, p = 0.04). CONCLUSION: This study showed that the regional control rate in patients treated with RADPLAT was noninferior to that for IV-CRT. Locally advanced head and neck cancers is a good indication for RADPLAT, even if the patients have neck lymph node metastases.
• 疼痛を伴わなかった悪性外耳道炎例
  佐藤 禄, 福田 篤, 森田 真也, 藤原 圭志, 中丸 裕爾, 本間 明宏
  耳鼻咽喉科臨床, 116, 6, 567, 572, 耳鼻咽喉科臨床学会, 2023年06月
  日本語
• 次世代シークエンサーによる鼻副鼻腔粘膜悪性黒色腫の遺伝子発現解析
  対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 安田 耕一, 清水 康, 田口 純, 本間 明宏
  頭頸部癌, 49, 2, 133, 133, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 頭頸部癌に対する化学放射線療法の効果予測マーカーとしてのSLFN11の有用性
  浜田 誠二郎, 加納 里志, 鈴木 崇祥, 対馬 那由多, 本間 明宏
  頭頸部癌, 49, 2, 187, 187, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• SlicerPIT 頭頸部アルミノックス治療の治療計画ソフトウェアの開発　　　　　　　　　　　　　　　
  鈴木 崇祥, 足利 雄一, 若林 侑輝, 勝俣 量平, 浜田 誠二郎, 井戸川 寛志, 対馬 那由多, 加納 里志, 本間 明宏
  頭頸部癌, 49, 2, 127, 127, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 頭頸部アルミノックス治療におけるニードルカテーテル穿刺のためのガイドプレートの製作について　　　　　　　　　　　　　　　
  足利 雄一, 鈴木 崇祥, 若林 侑輝, 格口 渉, 関口 珠希, 栗林 和代, 本間 明宏, 大廣 洋一
  頭頸部癌, 49, 2, 127, 127, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 高齢者の局所進行頭頸部扁平上皮癌患者におけるweeklyシスプラチン併用放射線治療の治療成績　　　　　　　　　　　　　　　
  打浪 雄介, 安田 耕一, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 田口 純, 清水 康, 坂下 智博, 本間 明宏
  頭頸部癌, 49, 2, 134, 134, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 当院で治療した頭頸部原発横紋筋肉腫症例の検討　　　　　　　　　　　　　　　
  勝俣 量平, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 清水 康, 田口 純, 安田 耕一, 打浪 雄介, 本間 明宏
  頭頸部癌, 49, 2, 161, 161, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 高齢者の頭頸部癌に対する放射線治療と化学療法併用の実態 日本頭頸部癌学会悪性腫瘍全国登録調査の解析　　　　　　　　　　　　　　　
  安田 耕一, 打浪 雄介, 加納 里志, 田口 純, 清水 康, 本間 明宏
  頭頸部癌, 49, 2, 171, 171, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 唾液腺癌の局所頸部制御における術後照射の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 安田 耕一, 打浪 雄介, 本間 明宏
  頭頸部癌, 49, 2, 192, 192, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 頭頸部アルミノックス治療におけるニードルカテーテル穿刺のためのガイドプレートの製作について　　　　　　　　　　　　　　　
  足利 雄一, 鈴木 崇祥, 若林 侑輝, 格口 渉, 関口 珠希, 栗林 和代, 本間 明宏, 大廣 洋一
  頭頸部癌, 49, 2, 127, 127, (一社)日本頭頸部癌学会, 2023年05月
  日本語
• 胸腔鏡+頸部アプローチで頸部から摘出した巨大縦隔内甲状腺腫の一例
  浜田 誠二郎, 加納 里志, 本間 明宏
  日本気管食道科学会会報, 74, 2, s1, s1, (NPO)日本気管食道科学会, 2023年04月
  日本語
• TRIM27の鼻副鼻腔粘膜悪性黒色腫におけるバイオマーカーとしての検討
  木村 将吾, 中丸 裕爾, 鈴木 正宣, 本間 あや, 中薗 彬, 加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 126, 4, 562, 562, (一社)日本耳鼻咽喉科頭頸部外科学会, 2023年04月
  日本語
• 頭頸部癌細胞株におけるSLFN11遺伝子発現と薬剤感受性の検討
  浜田 誠二郎, 加納 里志, 鈴木 崇祥, 対馬 那由多, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 126, 4, 600, 600, (一社)日本耳鼻咽喉科頭頸部外科学会, 2023年04月
  日本語
• 局所進行上顎洞癌に対する超選択的動注と放射線同時併用療法(JCOG1212試験) 有効性検証相(T4aN0M0)の結果　　　　　　　　　　　　　　　
  大越 明, 四宮 弘隆, 林 隆一, 齊藤 祐毅, 別府 慎太郎, 志賀 清人, 浅田 行紀, 上村 裕和, 上田 勉, 松浦 一登, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 126, 4, 630, 630, (一社)日本耳鼻咽喉科頭頸部外科学会, 2023年04月
  日本語
• TRIM27 expression is associated with poor prognosis in sinonasal mucosal melanoma.
  S Kimura, M Suzuki, Y Nakamaru, S Kano, M Watanabe, A Honma, A Nakazono, N Tsushima, S Hatakeyama, A Homma
  Rhinology, 2023年03月09日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Tripartite motif-containing 27 (TRIM27) has been implicated in the progression of various cancers. However, the role of TRIM27 in sinonasal mucosal melanoma (SNMM) remains poorly understood. MATERIALS & METHODS: We retrospectively examined 28 patients with SNMM treated with between 2003 and 2021. We undertook immunohistochemical analysis of TRIM27, Ki-67, and p-Akt1 expression in SNMM tissues. We also investigated the relationship between TRIM27 expression and clinical characteristics, prognosis, Ki-67 as a tumor growth potential marker, and p-Akt1 as one of the prognostic factors in mucosal melanoma. RESULTS: TRIM27 expression was significantly higher in T4 disease than in T3 disease and was higher in stage IV than in stage III. Patients with high-TRIM27 SNMM had a significantly poorer prognosis in terms of overall survival (OS) and disease-free survival.There was also a significantly higher rate of distant metastasis. Univariate analysis for OS revealed that TRIM27 and T classification were significant poor prognostic factors. In addition, the Ki-67 positive score and the p-Akt1 total staining score were significantly higher in the high-TRIM27 group than in the low-TRIM27 group. CONCLUSIONS: High TRIM27 expression in SNMM was associated with advanced T classification, poor prognosis and distant metastasis. We suggest that TRIM27 has potential as a novel biomarker for prognosis in SNMM.
• ボツリヌス毒素治療の極意 ワニの涙に対するボツリヌス毒素療法
  古田 康, 松村 道哉, 藤原 圭志, 本間 明宏
  Facial Nerve Research, 42, 30, 32, 日本顔面神経学会, 2023年03月
  日本語
• ANCA関連血管炎性中耳炎(OMAAV)における顔面神経麻痺症例の中耳術中所見
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 42, 203, 205, 日本顔面神経学会, 2023年03月
  日本語
• Nasal irrigation improving nasal obstruction and QoL of patients: two cases of HHT after nasal dermoplasty
  Hideaki Takeda, Masanobu Suzuki, Yuji Nakamaru, Shogo Kimura, Akira Nakazono, Aya Honma, Akihiro Homma
  JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY, 32, 3, 299, 303, Japan Society for Head and Neck Surgery, 2023年
  研究論文（学術雑誌）
• Mental workload during endoscopic sinus surgery is associated with surgeons' skill levels.
  Masanobu Suzuki, Kou Miyaji, Kotaro Matoba, Takashige Abe, Yuji Nakamaru, Ryosuke Watanabe, Takayoshi Suzuki, Akira Nakazono, Atsushi Konno, Dominik Hinder, A J Psaltis, P J Wormald, Akihiro Homma
  Frontiers in medicine, 10, 1090743, 1090743, 2023年, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Surgeons' mental workload during endoscopic sinus surgery (ESS) has not been fully evaluated. The assessment was challenging due to the great diversity of each patient's anatomy and the consequence variety of surgical difficulties. In this study, we examined the mental workload of surgeons with various surgical skill levels during ESS under the standardized condition provided by novel-designed 3D sinus models. MATERIALS AND METHODS: Forty-seven participants performed a high-fidelity ESS simulation with 3D-printed sinus models. Surgeons' mental workload was assessed with the national aeronautics and space administration-task load index (NASA-TLX). Associations between the total and subscales score of NASA-TLX and surgical skill index, including the board certification status, the number of experienced ESS cases, and the objective structured assessment of technical skills (OSATS), were analyzed. In addition, 10 registrars repeated the simulation surgery, and their NASA-TLX score was compared before and after the repetitive training. RESULTS: The total NASA-TLX score was significantly associated with OSATS score (p = 0.0001). Primary component analysis classified the surgeons' mental burden into three different categories: (1) the skill-level-dependent factors (temporal demand, effort, and performance), (2) the skill-level-independent factors (mental and physical demand), and (3) frustration. After the repetitive training, the skill-level-dependent factors were alleviated (temporal demand; z = -2.3664, p = 0.0091, effort; z = -2.1704, p = 0.0346, and performance; z = -2.5992, p = 0.0017), the independent factors were increased (mental demand; z = -2.5992, p = 0.0023 and physical demand; z = -2.2509, p = 0.0213), and frustration did not change (p = 0.3625). CONCLUSION: Some of the mental workload during ESS is associated with surgical skill level and alleviated with repetitive training. However, other aspects remain a burden or could worsen even when surgeons have gained surgical experience. Routine assessment of registrars' mental burdens would be necessary during surgical training to sustain their mental health.
• 腹臥位・人工気胸下での胸腔内剥離が有用であった巨大縦隔内甲状腺腫の1例　　　　　　　　　　　　　　　
  武藤 潤, 加納 里志, 山崎 雅久, 千葉 龍平, 野村 俊介, 藤原 晶, 氏家 秀樹, 樋田 泰浩, 加賀 基知三, 本間 明宏, 加藤 達哉
  日本臨床外科学会雑誌, 83, 12, 2119, 2119, 日本臨床外科学会, 2022年12月
  日本語
• Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy.
  Manami Otsuka, Koichi Yasuda, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Ryusuke Suzuki, Naoki Miyamoto, Hideki Minatogawa, Yasuhiro Dekura, Takashi Mori, Kentaro Nishioka, Jun Taguchi, Yasushi Shimizu, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
  Journal of medical imaging and radiation oncology, 67, 1, 98, 110, 2022年11月14日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Sequential boost intensity-modulated radiotherapy (SQB-IMRT) uses two different planning CTs (pCTs) and treatment plans. SQB-IMRT is a form of adaptive radiotherapy that allows for responses to changes in the shape of the tumour and organs at risk (OAR). On the other hand, dose accumulation with the two plans can be difficult to evaluate. The purpose of this study was to analyse patterns of loco-regional failure using deformable image registration (DIR) in hypopharyngeal cancer patients treated with SQB-IMRT. METHODS: Between 2013 and 2019, 102 patients with hypopharyngeal cancer were treated with definitive SQB-IMRT at our institution. Dose accumulation with the 1st and 2nd plans was performed, and the dose to the loco-regional recurrent tumour volume was calculated using the DIR workflow. Failure was classified as follows: (i) in-field (≥95% of the recurrent tumour volume received 95% of the prescribed dose); (ii) marginal (20-95%); or (iii) out-of-field (<20%). RESULTS: After a median follow-up period of 25 months, loco-regional failure occurred in 34 patients. Dose-volume histogram analysis showed that all loco-regional failures occurred in the field within 95% of the prescribed dose, with no marginal or out-of-field recurrences observed. CONCLUSION: The dosimetric analysis using DIR showed that all loco-regional failures were within the high-dose region. More aggressive treatment may be required for gross tumours.
• vHIT,VEMPを用いて手術による前庭機能改善を評価し得た小脳橋角部を占拠する錐体斜台部巨大軟骨肉腫の1例
  藤原 圭志, 山口 秀, 茂木 洋晃, 藤原 由有希, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 125, 11, 1593, 1598, (一社)日本耳鼻咽喉科頭頸部外科学会, 2022年11月
  日本語
• Pretreatment elevated mean corpuscular volume as an indicator for high risk esophageal second primary cancer in patients with head and neck cancer.
  Nayuta Tsushima, Satoshi Kano, Takayoshi Suzuki, Seijiro Hamada, Akihiro Homma
  Auris, nasus, larynx, 2022年10月10日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Esophageal cancer is the most common second primary cancer (SPC) in patients with head and neck cancer (HNC). Esophageal SPC has a negative impact on survival. Elevated mean corpuscular volume (MCV) is an accepted predictor of esophageal cancer risk. The aim of this study was to elucidate the usefulness of elevated MCV as an indicator of a high risk for esophageal SPC. METHODS: We retrospectively reviewed the medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal squamous cell carcinoma who underwent chemoradiotherapy between 2003 and 2012. We excluded patients younger than 20 years or who had received treatment for esophageal cancer and who had a histologically unproven lesion. Patients were divided into two groups according to their MCV. The cut-off for MCV was defined by receiver operating characteristics curve analysis. The primary endpoint was the cumulative incidence of esophageal SPC. RESULTS: A total of 295 patients were included. The median follow-up period for surviving patients was 7.4 years and the optimal cut-off point was 99.0 fL. One hundred ninety-five patients (66%) had an MCV < 99.0 fL and 100 (34%) had an MCV ≥ 99.0 fL. The 5-year cumulative incidence in patients with an MCV < 99.0 fL and ≥ 99.0 fL was 8.7% and 27%, respectively. In the multivariate analysis, an MCV ≥ 99.0 fL (HR=2.2; 95%CI, 1.1-4.2) was an independent risk factor. CONCLUSION: MCV ≥ 99.0 fL was found to be a risk factor for esophageal SPC. We, therefore, recommend that patients with an MCV ≥ 99.0 fL should undergo intensive monitoring.
• vHITを用いて前庭神経炎の慢性期を経過観察した一例
  赤松 明樹, 藤原 圭志, 本間 明宏
  Equilibrium Research, 81, 5, 425, 425, (一社)日本めまい平衡医学会, 2022年10月
  日本語
• video Head Impulse Testを用いた真珠腫性中耳炎半規管瘻孔症例における半規管機能評価
  藤原 圭志, 本間 明宏
  Equilibrium Research, 81, 5, 447, 447, (一社)日本めまい平衡医学会, 2022年10月
  日本語
• Utility of the deep learning technique for the diagnosis of orbital invasion on CT in patients with a nasal or sinonasal tumor.
  Junichi Nakagawa, Noriyuki Fujima, Kenji Hirata, Minghui Tang, Satonori Tsuneta, Jun Suzuki, Taisuke Harada, Yohei Ikebe, Akihiro Homma, Satoshi Kano, Kazuyuki Minowa, Kohsuke Kudo
  Cancer imaging : the official publication of the International Cancer Imaging Society, 22, 1, 52, 52, 2022年09月22日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: In nasal or sinonasal tumors, orbital invasion beyond periorbita by the tumor is one of the important criteria in the selection of the surgical procedure. We investigated the usefulness of the convolutional neural network (CNN)-based deep learning technique for the diagnosis of orbital invasion, using computed tomography (CT) images. METHODS: A total of 168 lesions with malignant nasal or sinonasal tumors were divided into a training dataset (n = 119) and a test dataset (n = 49). The final diagnosis (invasion-positive or -negative) was determined by experienced radiologists who carefully reviewed all of the CT images. In a CNN-based deep learning analysis, a slice of the square target region that included the orbital bone wall was extracted and fed into a deep-learning training session to create a diagnostic model using transfer learning with the Visual Geometry Group 16 (VGG16) model. The test dataset was subsequently tested in CNN-based diagnostic models and by two other radiologists who were not specialized in head and neck radiology. At approx. 2 months after the first reading session, two radiologists again reviewed all of the images in the test dataset, referring to the diagnoses provided by the trained CNN-based diagnostic model. RESULTS: The diagnostic accuracy was 0.92 by the CNN-based diagnostic models, whereas the diagnostic accuracies by the two radiologists at the first reading session were 0.49 and 0.45, respectively. In the second reading session by two radiologists (diagnosing with the assistance by the CNN-based diagnostic model), marked elevations of the diagnostic accuracy were observed (0.94 and 1.00, respectively). CONCLUSION: The CNN-based deep learning technique can be a useful support tool in assessing the presence of orbital invasion on CT images, especially for non-specialized radiologists.
• アブミ骨手術の術後成績の検討 とくにピストントリミングの有無との関連について
  小林 諒, 福田 篤, 森田 真也, 藤原 圭志, 中丸 裕爾, 本間 明宏
  耳鼻咽喉科臨床, 115, 9, 747, 752, 耳鼻咽喉科臨床学会, 2022年09月
  日本語
• Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma.
  Shinya Morita, Satoshi Kano, Kanako C Hatanaka, Yutaka Hatanaka, Takayoshi Suzuki, Atsushi Fukuda, Kimiko Hoshino, Keishi Fujiwara, Yuji Nakamaru, Akihiro Homma
  International journal of clinical oncology, 27, 9, 1394, 1403, 2022年09月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. METHODS: Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. RESULTS: Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). CONCLUSION: This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC.
• Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
  Yosuke Ota, Takeshi Kodaira, Hirofumi Fujii, Mototsugu Shimokawa, Tomoya Yokota, Torahiko Nakashima, Nobuya Monden, Akihiro Homma, Shinya Ueda, Tetsuo Akimoto
  International journal of clinical oncology, 27, 11, 1675, 1683, 2022年08月24日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Radiotherapy plus cetuximab (bioradiotherapy: BRT) is a standard option in the treatment of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Published data on its safety and efficacy in real-world settings is limited. Here, we conducted a prospective multi-institutional observational study to evaluate clinical outcomes of BRT in patients with LA-SCCHN. METHODS: We analyzed real-world data of all patients who underwent BRT from 2013 to 2016. The primary endpoint was 1-year progression-free survival (PFS). Secondary endpoints were 1-year locoregional PFS (LPFS), treatment completion rate (TCR), and adverse events (AEs). RESULTS: A total of 171 patients with a minimum 1-year follow-up were analyzed. Median age was 67 (36-85) years, and 37 patients (21.6%) were aged 75 years or older. 1-year PFS and LPFS were 51.5 and 56.1%, respectively. N stage (p = 0.049) was significantly associated with PFS. TCR was 77.2%. Cetuximab was definitively discontinued in 30 patients (17.5%), in 15 cases due to severe mucositis. N stage, T stage, and comorbidity were significantly associated with TCR. Major AEs of grade 3 or higher were pharyngeal mucositis (48.5%), radiation dermatitis (45.6%), and oral mucositis (40.4%). Pneumonitis was observed in 12 patients (7.0%); 6 cases (3.5%) were grades 3-4 and 2 (1.2%) were grade 5. CONCLUSION: As a result of the large number of elderly patients in clinical practice, toxicity reduced TCR. BRT-induced pneumonitis, which is sometimes fatal, was found to be more frequent than with chemotherapy plus cetuximab.
• Repetitive simulation training with novel 3D-printed sinus models for functional endoscopic sinus surgeries.
  Masanobu Suzuki, Kou Miyaji, Ryosuke Watanabe, Takayoshi Suzuki, Kotaro Matoba, Akira Nakazono, Yuji Nakamaru, Atsushi Konno, Alkis James Psaltis, Takashige Abe, Akihiro Homma, Peter-John Wormald
  Laryngoscope investigative otolaryngology, 7, 4, 943, 954, 2022年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: The purpose of this study was to find a utility of a newly developed 3D-printed sinus model and to evaluate the educational benefit of simulation training with the models for functional endoscopic sinus surgery (FESS). Material and methods: Forty-seven otolaryngologists were categorized as experts (board-certified physicians with ≥200 experiences of FESS, n = 9), intermediates (board-certified physicians with <200 experiences of FESS, n = 19), and novices (registrars, n = 19). They performed FESS simulation training on 3D-printed models manufactured from DICOM images of computed tomography (CT) scan of real patients. Their surgical performance was assessed with the objective structured assessment of technical skills (OSATS) score and dissection quality evaluated radiologically with a postdissection CT scan. First we evaluated the face, content, and constructive values. Second we evaluated the educational benefit of the training. Ten novices underwent training (training group) and their outcomes were compared to the remaining novices without training (control group). The training group performed cadaveric FESS surgeries before and after the repetitive training. Results: The feedback from experts revealed high face and content value of the 3D-printed models. Experts, intermediates, and novices demonstrated statistical differences in their OSATS scores (74.7 ± 3.6, 58.3 ± 10.1, and 43.1 ± 11.1, respectively, p < .001), and dissection quality (81.1 ± 13.1, 93.7 ± 15.1, and 126.4 ± 25.2, respectively, p < .001). The training group improved their OSATS score (41.1 ± 8.0 to 61.1 ± 6.9, p < .001) and dissection quality (122.1 ± 22.2 to 90.9 ± 10.3, p = .013), while the control group not. After training, 80% of novices with no prior FESS experiences completed surgeries on cadaver sinuses. Conclusion: Repeated training using the models revealed an initial learning curve in novices, which was confirmed in cadaveric mock FESS surgeries. Level of evidence: N/A.
• The utility of diffusion-weighted T2 mapping for the prediction of histological tumor grade in patients with head and neck squamous cell carcinoma.
  Noriyuki Fujima, Yukie Shimizu, Masami Yoneyama, Junichi Nakagawa, Hiroyuki Kameda, Taisuke Harada, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Kohsuke Kudo
  Quantitative imaging in medicine and surgery, 12, 8, 4024, 4032, 2022年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: In head and neck cancers, histopathological information is important for the determination of the tumor characteristics and for predicting the prognosis. The aim of this study was to assess the utility of diffusion-weighted T2 (DW-T2) mapping for the evaluation of tumor histological grade in patients with head and neck squamous cell carcinoma (SCC). Methods: The cases of 41 patients with head and neck SCC (21 well/moderately and 17 poorly differentiated SCC) were retrospectively analyzed. All patients received MR scanning using a 3-Tesla MR unit. The conventional T2 value, DW-T2 value, ratio of DW-T2 value to conventional T2 value, and apparent diffusion coefficient (ADC) were calculated using signal information from the DW-T2 mapping sequence with a manually placed region of interest (ROI). Results: ADC values in the poorly differentiated SCC group were significantly lower than those in the moderately/well differentiated SCC group (P<0.05). The ratio of DW-T2 value to conventional T2 value was also significantly different between poorly and moderately/well differentiated SCC groups (P<0.01). Receiver operating characteristic (ROC) curve analysis of ADC values showed a sensitivity of 0.76, specificity of 0.67, positive predictive value (PPV) of 0.62, negative predictive value (NPV) of 0.8, accuracy of 0.71 and area under the curve (AUC) of 0.73, whereas the ROC curve analysis of the ratio of DW-T2 value to conventional T2 value showed a sensitivity of 0.76, specificity of 0.83, PPV of 0.76, NPV of 0.83, accuracy of 0.8 and AUC of 0.82. Conclusions: DW-T2 mapping might be useful as supportive information for the determination of tumor histological grade in patients with head and neck SCC.
• Distribution pattern and pathologic analysis of metastatic sentinel and non-sentinel lymph nodes in lymphatic basin dissection for clinical T2/T3 oral cancer with clinical N0 status.
  Hitoshi Hirakawa, Takashi Matsuzuka, Hirokazu Uemura, Seiichi Yoshimoto, Kouki Miura, Akihiro Shiotani, Masashi Sugasawa, Akihiro Homma, Junkichi Yokoyama, Kiyoaki Tsukahara, Tomokazu Yoshizaki, Nobuhiro Hanai, Hidenori Suzuki, Mikio Suzuki, Yasuhisa Hasegawa
  Auris, nasus, larynx, 49, 4, 680, 689, 2022年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: The localization pattern of metastatic sentinel lymph node (SN) and non-SNs and pathologic analysis of metastatic lymph nodes in SN lymphatic basin dissection (SLBD) were investigated in patients with cT2/T3cN0 oral squamous cell carcinoma (OSCC). METHODS: This prospective multicenter trial involved 10 institutions nationwide in Japan. A total of 57 patients were enrolled. The lateral neck was divided into 5 lymphatic basins. The lymphatic basin containing SNs was defined as the SN lymphatic basin. All patients underwent SLBD with backup selective neck dissection (I-III) combined with primary tumor removal. When SNs were found outside of levels I-III, including in the contralateral neck, SLBD was performed by removing the compartments containing SNs separately. SN metastasis was classified as isolated tumor cells (ITCs), micrometastasis, or macrometastasis. ITCs are defined as a lesion no larger than 0.2 mm in largest dimension and are classified as pN0. RESULTS: SN metastasis was observed in 22 cases. All metastatic lymph nodes, including false-negative cases, were detected in the SN lymphatic basin. Isolated tumor cells in the SNs did not affect prognosis, whereas micrometastasis tended to have poor prognosis. After adjusting for other risk factors, a positive SN remained a significant predictor of poor 5-year overall survival in pT2-4 OSCC. CONCLUSION: SLBD for intraoperative SN biopsy is a sufficient therapeutic procedure and is valuable for determining pathologic nodal stage in OSCC. SN positivity was demonstrated to be an independent predictor of poor prognosis in patients with pT2-4 disease undergoing SLBD with backup selective neck dissection (I-III).
• Amide proton transfer imaging for the determination of human papillomavirus status in patients with oropharyngeal squamous cell carcinoma.
  Noriyuki Fujima, Yukie Shimizu, Masami Yoneyama, Junichi Nakagawa, Hiroyuki Kameda, Taisuke Harada, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Kohsuke Kudo
  Medicine, 101, 28, e29457, 2022年07月15日, ［国際誌］
  英語, 研究論文（学術雑誌）, The aim of this study was to investigate the utility of amide proton transfer (APT) imaging for the determination of human papillomavirus (HPV) status in patients with oropharyngeal squamous cell carcinoma (SCC). Thirty-one patients with oropharyngeal SCC were retrospectively evaluated. All patients underwent amide proton transfer imaging using a 3T magnetic resonance (MR) unit. Patients were divided into HPV-positive and -negative groups depending on the pathological findings in their primary tumor. In APT imaging, the primary tumor was delineated with a polygonal region of interest (ROI). Signal information in the ROI was used to calculate the mean, standard deviation (SD) and coefficient of variant (CV) of the APT signals (APT mean, APT SD, and APT CV, respectively). The value of APT CV in the HPV-positive group (0.43 ± 0.04) was significantly lower than that in the HPV-negative group (0.48 ± 0.04) (P = .01). There was no significant difference in APT mean (P = .82) or APT SD (P = .13) between the HPV-positive and -negative groups. Receiver operating characteristic (ROC) curve analysis of APT CV had a sensitivity of 0.75, specificity of 0.8, positive predictive value of 0.75, negative predictive value of 0.8, accuracy of 0.77 and area under the curve (AUC) of 0.8. The APT signal in the HPV-negative group was considered heterogeneous compared to the HPV-positive group. This information might be useful for the determination of HPV status in patients with oropharyngeal SCC.
• Evaluation of Semicircular Canal Function by Video Head Impulse Test in Patients With Labyrinthine Fistula Due to Cholesteatoma.
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Kimiko Hoshino, Yuji Nakamaru, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 43, 5, 587, 593, 2022年06月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: To evaluate semicircular canal function in patients with labyrinthine fistula (LF) due to cholesteatoma by the video Head Impulse Test (vHIT). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Ten patients with LF due to cholesteatoma and six without LF underwent vestibular examination. INTERVENTION: Diagnostic. MAIN OUTCOME MEASURES: The gain in vestibulo-ocular reflex (VOR) and the presence of catch-up saccade were examined for the semicircular canals in patients with LF. RESULTS: Seven of 10 cases (70.0%) in the fistula group were judged to have semicircular canal dysfunction based on preoperative evaluation. VOR gains in the patients with LF were significantly lower than those in the patients without LF. VOR gain decreased significantly in accordance with the severity of the LF. The postoperative VOR gain more than 6 months after surgery was significantly improved compared with the preoperative VOR gain. CONCLUSIONS: The vHIT is thought to be the most suitable method for evaluating semicircular canal function in patients with LF due to cholesteatoma as it is not influenced by middle ear pathology and can evaluate the function of the vertical canals. The vHIT could predict whether a LF is present or not before surgery, and the vHIT is essential for surgery for patients with LF.
• 内視鏡を用いたカダバー手術トレーニングにより喉頭全摘出術を咽頭側から理解する
  対馬 那由多, 加納 里志, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
  頭頸部癌, 48, 2, 192, 192, (一社)日本頭頸部癌学会, 2022年05月
  日本語
• ANCA関連血管炎性中耳炎(OMAAV)における顔面神経麻痺の検討
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 41, 81, 83, 日本顔面神経学会, 2022年05月
  日本語
• 咽喉頭癌に対するシスプラチン超選択的動注併用放射線治療(RADPLAT)による頸部制御の検討　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 吉田 大介, 打浪 雄介, 安田 耕一, 本間 明宏
  頭頸部癌, 48, 2, 151, 151, (一社)日本頭頸部癌学会, 2022年05月
  日本語
• 高齢の頭頸部悪性腫瘍に対する放射線治療の後ろ向き検討　　　　　　　　　　　　　　　
  安田 耕一, 打浪 雄介, 浜田 誠二郎, 鈴木 崇祥, 対馬 那由多, 田口 純, 清水 康, 加納 里志, 本間 明宏
  頭頸部癌, 48, 2, 200, 200, (一社)日本頭頸部癌学会, 2022年05月
  日本語
• Discrepancies in the caloric testing and video Head Impulse Test results in a case with bilateral lateral semicircular canal malformations.
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Kimiko Hoshino, Yuji Nakamaru, Akihiro Homma
  Auris, nasus, larynx, 2022年04月22日, ［国際誌］
  英語, Lateral semicircular canal (LSCC) malformations represent one of the most common types of inner ear malformation. As many cases of LSCC malformations are asymptomatic, detailed vestibular functions in such cases remain unclear. We present a case with bilateral LSCC malformations for whom the function of each vestibular organ was evaluated by caloric testing, video Head Impulse Test (vHIT) and vestibular evoked myogenic potentials (VEMP). Caloric testing showed canal paresis of the left side, whereas vHIT showed bilateral normal semicircular canal function. The results of VEMP indicated left saccular dysfunction. Discrepancies in caloric testing and vHIT results were observed and these discrepancies are thought to be due to endolymphatic hydrops rather than vestibular hypofunction, similar to that in Meniere disease.
• Systemic therapy for salivary gland malignancy: current status and future perspectives.
  Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Tomoya Yokota, Susumu Okano, Kaoru Tanaka, Takuma Onoe, Yosuke Ariizumi, Akihiro Homma
  Japanese journal of clinical oncology, 52, 4, 293, 302, 2022年04月06日, ［国際誌］
  英語, 研究論文（学術雑誌）, Salivary gland malignancies are rare neoplasms that have a broad histological spectrum and a variety of biologic behaviors. Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. This review summarizes the role of systemic therapy for salivary gland malignancies. To date, the advantage of adding concurrent chemotherapy has remained undefined for both postoperative and inoperable locally advanced salivary gland malignancy patients undergoing radiotherapy. For recurrent/metastatic disease, local and/or systemic treatment options should be discussed in a multidisciplinary setting with consideration to both patient needs and tumor factors. For symptomatic patients or those who may compromise organ function, palliative systemic therapy can be a reasonable option based on the results of phase II studies. Platinum combination regimens as first-line therapy have been widely accepted. Personalized therapies have become established options, particularly for androgen receptor-positive, HER2-positive and NTRK fusion-positive salivary gland malignancies (i.e. androgen receptor and HER2 in salivary duct carcinoma and NTRK3 in secretory carcinoma). For patients with adenoid cystic carcinoma, multi-targeted tyrosine kinase inhibitors have also been developed. Anti-PD1 checkpoint inhibitors have shown limited activity to date. Investigation of active systemic treatments for salivary gland malignancy remains a significant unmet need. Future directions might include a more comprehensive genomic screening approach (usually next-generation sequencing-based) and combination strategies using immune checkpoint inhibitors. These are rare malignancies that require ongoing effort in the conduct of high-quality clinical trials.
• Human papillomavirus-related oropharyngeal carcinoma.
  Yuki Saito, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Tomoya Yokota, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
  Japanese journal of clinical oncology, 52, 7, 692, 698, 2022年04月05日, ［国際誌］
  英語, 研究論文（学術雑誌）, It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.
• Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review.
  Antti A Mäkitie, Rasheed Omobolaji Alabi, Helena Orell, Omar Youssef, Alhadi Almangush, Akihiro Homma, Robert P Takes, Fernando López, Remco de Bree, Juan P Rodrigo, Alfio Ferlito
  Advances in therapy, 39, 4, 1502, 1523, 2022年04月, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Patients with head and neck cancer (HNC) are usually confronted with functional changes due to the malignancy itself or its treatment. These factors typically affect important structures involved in speech, breathing, chewing, swallowing, and saliva production. Consequently, the intake of food will be limited, which further contributes to loss of body weight and muscle mass, anorexia, malnutrition, fatigue, and anemia. This multifactorial condition can ultimately lead to cancer cachexia syndrome. This study aims to examine the treatment of cachexia in HNC patients. METHODS: We systematically searched OvidMedline, PubMed, Scopus, and Web of Science for articles examining the treatment of cachexia in HNC. RESULTS: A total of nine studies were found, and these suggested interventions including nutritional, pharmacologic, therapeutic exercise, and multimodal approaches. The nutritional intervention includes essential components such as dietary counseling, oral nutritional supplements, and medical nutritional support. Individualized nutritional interventions include oral, enteral (feeding tubes i.e., percutaneous endoscopic gastrostomy [PEG], nasogastric tube [NGT]) and parenteral nutrition. The pharmacologic interventions aim at increasing the appetite and weight of cachectic patients. Therapeutic exercise and increased physical activity can help to enhance the synthesis of muscle protein, reducing inflammation and the catabolic effects of cachexia syndrome. CONCLUSION: Owing to the multifactorial nature of this syndrome, it is expected that the management approach should be multi-interventional. Early implementation of these interventions may help to improve survival and quality of health and life of cachectic HNC patients.
• 内視鏡下頭蓋底手術を考慮した嗅神経芽細胞腫に対する新規病期分類の検討
  中薗 彬, 中丸 裕爾, 鈴木 正宣, 本間 あや, 木村 将吾, 本間 明宏
  日本耳鼻咽喉科頭頸部外科学会会報, 125, 4, 702, 702, (一社)日本耳鼻咽喉科頭頸部外科学会, 2022年04月
  日本語
• Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
  Naomi Kiyota, Makoto Tahara, Junki Mizusawa, Takeshi Kodaira, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Ichiro Ota, Kiyoto Shiga, Masashi Sugasawa, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Yasumasa Nishimura, Kenichi Nakamura, Ryuichi Hayashi
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40, 18, JCO2101293, 1990, 2022年03月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable efficacy with 3-weekly cisplatin in postoperative high-risk LA-SCCHN is unknown. PATIENTS AND METHODS: In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. The primary end point of phase II was the proportion of treatment completion, and that of phase III was overall survival. A noninferiority margin of hazard ratio was set at 1.32. RESULTS: Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided P for noninferiority = .0027 < .0043). Grade 3 or more neutropenia and infection were less frequent in the weekly arm (3-weekly v weekly, 49% v 35% and 12% v 7%, respectively), as were renal impairment and hearing impairment. No treatment-related death was reported in the 3-weekly arm, and two (1.6%) in the weekly arm. CONCLUSION: Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.
• postコロナ・withコロナの耳鼻咽喉科診療 頭頸部の診療　　　　　　　　　　　　　　　
  本間 明宏, 中丸 裕爾, 鈴木 正宣, 本間 あや
  日本耳鼻咽喉科免疫アレルギー感染症学会抄録集, 2回, 71, 71, 日本耳鼻咽喉科免疫アレルギー感染症学会, 2022年03月
  日本語
• 術前呼吸機能検査による鼻茸を伴う副鼻腔炎の予後推測　　　　　　　　　　　　　　　
  中丸 裕爾, 鈴木 正宣, 本間 あや, 中薗 彬, 木村 将吾, 本間 明宏
  日本耳鼻咽喉科免疫アレルギー感染症学会抄録集, 2回, 77, 77, 日本耳鼻咽喉科免疫アレルギー感染症学会, 2022年03月
  日本語
• 鼻粘膜上皮細胞での細菌・ウィルス結合受容体発現に対する自然免疫シグナルの影響　　　　　　　　　　　　　　　
  中薗 彬, 木村 将吾, 本間 あや, 鈴木 正宣, 中丸 裕爾, 本間 明宏
  日本耳鼻咽喉科免疫アレルギー感染症学会抄録集, 2回, 168, 168, 日本耳鼻咽喉科免疫アレルギー感染症学会, 2022年03月
  日本語
• 鼻粘膜上皮におけるMetallothionein-3発現解析　　　　　　　　　　　　　　　
  鈴木 正宣, 中丸 裕爾, 中薗 彬, 本間 あや, 木村 将吾, 本間 明宏
  日本耳鼻咽喉科免疫アレルギー感染症学会抄録集, 2回, 185, 185, 日本耳鼻咽喉科免疫アレルギー感染症学会, 2022年03月
  日本語
• The Quantification of Extracellular Trap Cell Death-Derived Products as Diagnostic Biomarkers for Otitis Media With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Eosinophilic Otitis Media.
  Shinya Morita, Yuji Nakamaru, Atsushi Fukuda, Keishi Fujiwara, Masanobu Suzuki, Kimiko Hoshino, Aya Honma, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 43, 3, e337-e343, 2022年03月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: This study aimed to quantify the cell-free deoxyribonucleic acid (DNA), citrullinated-histone H3 (cit-H3)-DNA complex, and myeloperoxidase (MPO)-DNA complex as extracellular trap cell death (ETosis)-derived products in the middle ear fluid, and to identify diagnostic biomarkers for the discrimination of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) from eosinophilic otitis media (EOM). STUDY DESIGN: Prospective study. SETTING: Tertiary referral center. PATIENTS: OMAAV patients were eligible for inclusion in this analysis. Patients with EOM were examined as controls. INTERVENTION: All samples were obtained from the middle ear fluid in patients with OMAAV or EOM. The fluid samples were aspirated from the middle ear through the anterior-inferior portion of the tympanic membrane using a 1-ml tuberculin syringe with a 24- or 26-gauge needle under a microscope. MAIN OUTCOME MEASURES: The levels of cell-free DNA, cit-H3-DNA complex and MPO-DNA complex in the fluid samples were quantified using an enzyme-linked immunosorbent assay. RESULTS: Patients with OMAAV showed significantly higher levels of MPO-DNA complex compared to patients with EOM, regardless of the serum ANCA status at the time of sampling (p < 0.001 and p < 0.001, respectively). Meanwhile, there were no significant differences in the values of cell-free DNA or cit-H3-DNA complex between the OMAAV and EOM patients. CONCLUSION: The findings of this study suggest that the detection and quantification of MPO-DNA complex in the otitis media fluid can be utilized to discriminate OMAAV, especially in cases of eosinophilic granulomatosis with polyangiitis, from EOM regardless of the serum ANCA status. It should be noted that it is possible for cell-free DNA and cit-H3-DNA complex in fluid samples to be derived from dead cells other than neutrophils that undergo ETosis.
• Management of elderly patients with head and neck cancer.
  Ryo Ishii, Akira Ohkoshi, Naomi Kiyota, Kazuto Matsuura, Koichi Yasuda, Yoshinori Imamura, Yuki Saito, Akihiro Homma
  Japanese journal of clinical oncology, 52, 4, 313, 321, 2022年02月15日, ［国際誌］
  英語, 研究論文（学術雑誌）, There are no established guidelines for managing older patients with head and neck cancer. Most clinical trials that define current standard therapy included few elderly patients. On the other hand, there is great variability in patients' comorbidities, physical functions, cognitive function, familial and financial background and values. The key point appears to be appropriate geriatric assessment, clarifying the patients' outcomes and a multidisciplinary team approach, including the treatment decision-making policy. Although these processes should be scientific in nature, the evidence for the treatment of elderly head and neck patients is very limited. This review summarizes the evidence available regarding the management of geriatric assessment, each treatment modality and the multidisciplinary team approach for older patients with head and neck cancers.
• 前頭開頭術後に生じた前頭蓋底粘液嚢胞の2例
  山田 真司, 鈴木 正宣, 中丸 裕爾, 本間 あや, 中薗 彬, 木村 将吾, 安川 真一郎, 蠣崎 文彦, 本間 明宏
  耳鼻咽喉科・頭頸部外科, 94, 2, 183, 187, 2022年02月
• Cystic Intracranial Recurrence of Olfactory Neuroblastoma without Accumulation on Fluorine-18-fluorodeoxyglucose Positron Emission Tomography.
  Yukitomo Ishi, Shigeru Yamaguchi, Kanako C Hatanaka, Emi Takakuwa, Hiroaki Motegi, Taishi Honda, Hiroyuki Kobayashi, Shunsuke Terasaka, Akihiro Homma, Miki Fujimura, Kiyohiro Houkin
  Acta medica Okayama, 76, 1, 93, 98, 2022年02月, ［国内誌］
  英語, A 66-year-old man underwent multimodal treatment for olfactory neuroblastoma (ONB). When he was 72 years old, a cystic intracranial lesion without accumulation on fluorine-18-fluorodeoxyglucose positron emission tomography was detected. Surgical resection was performed when the patient was 73 years old. The pathological examination revealed recurrence of ONB, and the patient underwent focal irradiation. At age 81, he presented with a second recurrence in the right occipital lobe with radiological and pathological findings similar to the prior recurrence. This case suggests that pathological confirmation should be considered in cases with atypical radiological findings following the treatment of ONB.
• Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
  Seijiro Hamada, Satoshi Kano, Junko Murai, Takayoshi Suzuki, Nayuta Tsushima, Takatsugu Mizumachi, Masanobu Suzuki, Tsuyoshi Takashima, Daiki Taniyama, Naoya Sakamoto, Yoichiro Fujioka, Yusuke Ohba, Akihiro Homma
  Frontiers in oncology, 12, 978875, 978875, 2022年, ［国際誌］
  英語, 研究論文（学術雑誌）, Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expression was associated with the therapeutic outcome of platinum-based CRT in head and neck squamous cell carcinoma (HNSCC). We performed immunohistochemical analyses for SLFN11 expression in 161 HNSCC tissues from patients who had been administered cisplatin-based CRT and examined the correlation between SLFN11 expression and progression-free survival (PFS). Additionally, SLFN11 expression was examined in 10 paired samples obtained before and after CRT in patients with local failure. Furthermore, in vitro experiments were performed using several HNSCC cell lines and isogenic SLFN11-knockout cells to assess the association between SLFN11 expression and drug sensitivity. PFS was found to be significantly better in the SLFN11-positive group than in the SLFN11-negative group among the 161 patients (5-year PFS: 78.8% vs. 52.8%, respectively, p < 0.001). Similar results were observed for the PFS at each primary site. The percentage of SLFN11 positivity was lower in tumor samples from patients with local failure after CRT than that in the corresponding primary tumors before CRT in 8 of 10 cases. Results of the in vitro assay demonstrated that SLFN11-knockout cells exhibited reduced sensitivity to DNA-damaging agents but not to the non-DNA-damaging agent docetaxel. Our findings suggest that SLFN11 may serve as a potential biomarker for predicting the response of HNSCC patients to platinum-based CRT.
• Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
  Ryuji Yasumatsu, Yasushi Shimizu, Nobuhiro Hanai, Shin Kariya, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Mizuo Ando, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Syuji Yonekura, Takahiro Asakage, Takahiro Nekado, Takayuki Yamada, Akihiro Homma
  International journal of clinical oncology, 27, 1, 95, 104, 2022年01月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: We have previously reported the effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) in real-world clinical practice in Japan. Here, we report long-term outcomes from this study in the overall population and subgroups stratified by subsequent chemotherapy. METHODS: In this multicenter, retrospective observational study, Japanese patients with recurrent or metastatic (R/M) HNC receiving nivolumab were followed up for 2 years. Effectiveness endpoints included overall survival (OS), OS rate, progression-free survival (PFS), and PFS rate. Safety endpoints included the incidence of immune-related adverse events (irAEs). RESULTS: Overall, 256 patients received a median of 6.0 doses (range: 1-52) of nivolumab over a median duration of 72.5 days (range: 1-736). Median OS was 9.5 months [95% confidence interval (CI) 8.2-12.0] and median PFS was 2.1 months (95% CI 1.8-2.7). A significant difference between 2-year survivors (n = 62) and non-2-year survivors was observed by median age (P = 0.0227) and ECOG PS (P = 0.0001). Of 95 patients who received subsequent chemotherapy, 54.7% received paclitaxel ± cetuximab. The median OS and PFS from the start of paclitaxel ± cetuximab were 6.9 months (95% CI 5.9-11.9) and 3.5 months (95% CI 2.3-5.5), respectively. IrAEs were reported in 17.2% of patients. Endocrine (7.0%) and lung (4.3%) disorders were the most common irAEs; kidney disorder (n = 1) was newly identified in this follow-up analysis. CONCLUSIONS: Results demonstrated the long-term effectiveness of nivolumab and potential effectiveness of subsequent chemotherapy in patients with R/M HNC in the real-world setting. Safety was consistent with that over the 1-year follow-up.
• Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma.
  Machiko Matsumoto-Sasaki, Kaoruko Simizu, Masanobu Suzuki, Masaru Suzuki, Hirokazu Kimura, Yuji Nakamaru, Yoichi M Ito, Akihiro Honma, Satoshi Konno
  Journal of asthma and allergy, 15, 187, 195, 2022年, ［国際誌］
  英語, 研究論文（学術雑誌）, Purpose: Biologics have been used increasingly for the treatment of severe asthma. However, established guidelines for the selection, switching, or discontinuation of biologics do not exist. We aimed to identify the clinical characteristics of patients with asthma who required switching biologics and the factors associated with switching biologics. Patients and Methods: This was a retrospective study of 42 patients with severe asthma treated with biologics at the Hokkaido University Hospital between 23rd June 2016 and 30th April 2021, when two biologics were available in Japan. We compared the characteristics of subjects who continued and switched biologics. The time to switch the biologics was assessed by type 2 inflammatory biomarkers, pulmonary function indices, and the presence of comorbidities, including the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) score and aspirin exacerbated respiratory diseases (AERD), using the Kaplan-Meier method and a multivariate Cox proportional hazards model. Results: Eight and five patients were treated by mepolizumab and benralizumab at baseline, respectively among the 31% (13/42) who switched the biologics. Subjects who required switching biologics were characterized by high blood eosinophil counts, younger age, JESREC scores of 11 points or higher, and AERD. The time taken to switch biologics was significantly shorter in the subgroups with high JESREC scores (≥11) or AERD, compared with their counterparts with low JESREC scores or without AERD (both, P < 0.05). JESREC scores of ≥11, but not the presence of AERD, were associated with time to switch biologics. Conclusion: The presence of eosinophilic chronic rhinosinusitis based on JESREC scores of ≥11 and younger age were factors associated with switching biologics in asthma.
• Reply to P. Kaul et al.
  Yasuhisa Hasegawa, Kiyoaki Tsukahara, Seiichi Yoshimoto, Kouki Miura, Junkichi Yokoyama, Shigeru Hirano, Hirokazu Uemura, Masashi Sugasawa, Tomokazu Yoshizaki, Akihiro Homma, Kazuaki Chikamatsu, Mikio Suzuki, Akihiro Shiotani, Takashi Matsuzuka, Naoyuki Kohno, Masakazu Miyazaki, Isao Oze, Keitaro Matsuo, Shigeru Kosuda, Yasushi Yatabe
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39, 31, 3518, 3519, 2021年11月01日, ［国際誌］
  英語
• Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
  Tomoya Yokota, Sadamoto Zenda, Ichiro Ota, Tomoko Yamazaki, Takuhiro Yamaguchi, Takenori Ogawa, Hiroyuki Tachibana, Takashi Toshiyasu, Akihiro Homma, Tempei Miyaji, Tomoe Mashiko, Satoshi Hamauchi, Kuniko Tominaga, Shinobu Ishii, Yui Otani, Noriko Orito, Yosuke Uchitomi
  International journal of radiation oncology, biology, physics, 111, 3, 794, 803, 2021年11月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Radiation dermatitis is one of the most common acute toxicities induced by chemoradiation therapy (CRT) for head and neck cancer (HNC). The benefit of topical steroids in the management of radiation dermatitis is still unclear. This phase 3, multi-institutional, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of topical steroids for radiation dermatitis in patients with locally advanced HNC receiving CRT. METHODS AND MATERIALS: Eligible patients were scheduled to receive bilateral neck irradiation (≥66 Gy) with concurrent cisplatin (≥200 mg/m2) as definitive or postoperative CRT. Patients were randomly assigned to receive either topical steroid or placebo when grade 1radiation dermatitis was observed or the total radiation dose reached 30 Gy. Basic skin care including gentle washing and moistening in the head and neck region was performed in both groups. The primary endpoint was the frequency of grade ≥2 radiation dermatitis, in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Grading of radiation dermatitis was performed by independent central review using photographs taken weekly. RESULTS: A total of 211 patients were enrolled (intention to treat: steroid 101 and placebo 102). The frequency of grade ≥2 radiation dermatitis was not significantly reduced with the steroid (73.3%; 95% confidence interval, 64.6%-81.9%) compared with the placebo (80.4%; 95% confidence interval, 72.7%-88.1%; P = .23), whereas the steroid significantly reduced the frequency of grade ≥3 radiation dermatitis (13.9% vs 25.5%; P = .034). No significant differences in adverse events, including local infection or compliance with CRT, were observed between the groups. CONCLUSIONS: Topical steroid may reduce the severity of radiation dermatitis in patients with HNC and thus may become an important therapeutic tool in the management of radiation dermatitis.
• video Head Impulse Testを用いたOMAAVにおける半規管障害の検討
  藤原 圭志, 柳 紘子, 本間 明宏
  Equilibrium Research, 80, 5, 459, 459, (一社)日本めまい平衡医学会, 2021年10月
  日本語
• 後天性中耳真珠腫におけるNotchシグナル関連分子発現についての検討　　　　　　　　　　　　　　　
  福田 篤, 森田 真也, 藤原 圭志, 干野 季美子, 中丸 裕爾, 本間 明宏
  日本耳科学会総会・学術講演会抄録集, 31回, 422, 422, (一社)日本耳科学会, 2021年10月
  日本語
• Remote Training of Functional Endoscopic Sinus Surgery With Advanced Manufactured 3D Sinus Models and a Telemedicine System
  Masanobu Suzuki, Erich Vyskocil, Kazuhiro Ogi, Kotaro Matoba, Yuji Nakamaru, Akihiro Homma, Peter J. Wormald, Alkis J. Psaltis
  Frontiers in Surgery, 8, Frontiers Media SA, 2021年10月01日
  研究論文（学術雑誌）, Objective: Traditionally, cadaveric courses have been an important tool in surgical education for Functional Endoscopic Sinus Surgery (FESS). The recent COVID-19 pandemic, however, has had a significant global impact on such courses due to its travel restrictions, social distancing regulations, and infection risk. Here, we report the world-first remote (Functional Endoscopic Sinus Surgery) FESS training course between Japan and Australia, utilizing novel 3D-printed sinus models. We examined the feasibility and educational effect of the course conducted entirely remotely with encrypted telemedicine software.
  
  Methods: Three otolaryngologists in Hokkaido, Japan, were trained to perform frontal sinus dissections on novel 3D sinus models of increasing difficulty, by two rhinologists located in Adelaide, South Australia. The advanced manufactured sinus models were 3D printed from the Computed tomography (CT) scans of patients with chronic rhinosinusitis. Using Zoom and the Quintree telemedicine platform, the surgeons in Adelaide first lectured the Japanese surgeons on the Building Block Concept for a three Dimensional understanding of the frontal recess. They in real time directly supervised the surgeons as they planned and then performed the frontal sinus dissections. The Japanese surgeons were asked to complete a questionnaire pertaining to their experience and the time taken to perform the frontal dissection was recorded. The course was streamed to over 200 otolaryngologists worldwide.
  
  Results: All dissectors completed five frontal sinusotomies. The time to identify the frontal sinus drainage pathway (FSDP) significantly reduced from 1,292 ± 672 to 321 ± 267 s (p = 0.02), despite an increase in the difficulty of the frontal recess anatomy. Image analysis revealed the volume of FSDP was improved (2.36 ± 0.00 to 9.70 ± 1.49 ml, p = 0.014). Questionnaires showed the course's general benefit was 95.47 ± 5.13 in dissectors and 89.24 ± 15.75 in audiences.
  
  Conclusion: The combination of telemedicine software, web-conferencing technology, standardized 3D sinus models, and expert supervision, provides excellent training outcomes for surgeons in circumstances when classical surgical workshops cannot be realized.
• Metallothionein-3 is a clinical biomarker for tissue zinc levels in nasal mucosa.
  Masanobu Suzuki, Mahnaz Ramezanpour, Clare Cooksley, Kazuhiro Ogi, Alkis J Psaltis, Yuji Nakamaru, Akihiro Homma, Peter-John Wormald, Sarah Vreugde
  Auris, nasus, larynx, 48, 5, 890, 897, 2021年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Recently, depleted tissue zinc levels were found in nasal mucosa from patients with chronic rhinosinusitis (CRS) in correlation with tissue eosinophilia, however, no clinical biomarkers for tissue zinc levels have been identified. Metallothionein-3 (MT3) is an intracellular zinc chelator and previous data showed MT3 mRNA levels to be reduced in CRS patients with nasal polyps (CRSwNP). In this study, we examined the correlation between MT3 expression and zinc levels in nasal mucosa and primary human nasal epithelial cells (HNECs) to investigate whether MT3 could be a clinical biomarker for tissue zinc levels. METHOD: Tissue was harvested from 36 patients and mounted on tissue micro-array (TMA) slides. MT3 expression and tissue zinc fluorescence intensity were measured at different areas within the mucosa (surface epithelium and lamina propria) and compared between controls, CRSwNP and CRS without nasal polyps (CRSsNP) patients. MT3 mRNA and protein expression were examined in zinc-depleted HNECs by qPCR and immunofluorescence microscopy. RESULTS: MT3 expression in CRSwNP was significantly decreased in both surface epithelium (p<0.001 to controls) and lamina propria (p = 0.0491 to controls). There was a significant positive correlation between tissue zinc levels and MT3 expression in nasal mucosa (r = 0.45, p = 0.007). In zinc-deplete HNECs, MT3 expression was significantly decreased at mRNA (p = 0.02) and protein level (p<0.01). There was a significant positive correlation between tissue zinc levels and MT3 expression within individual HNECs (r = 0.59, p<0.001). CONCLUSIONS: MT3 expression reflects intramucosal zinc levels in both nasal mucosa and HNECs indicating MT3 could be used as a clinical biomarker for monitoring intracellular zinc levels in the nasal mucosa.
• Notch Signaling in Acquired Middle Ear Cholesteatoma.
  Atsushi Fukuda, Satoshi Kano, Yuji Nakamaru, Shinya Morita, Kimiko Hoshino, Keishi Fujiwara, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 42, 9, e1389-e1395, 2021年10月01日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, HYPOTHESIS: We hypothesized that an anomalous change of Notch signaling might be involved in the pathophysiology of cholesteatoma. BACKGROUND: The Notch signaling pathway regulates integrated growth and differentiation control of keratinocytes. Its involvement in cholesteatoma proliferation has not been elucidated. METHODS: We obtained cholesteatoma and external auditory canal (EAC) skin samples from patients with middle ear cholesteatoma who underwent tympanomastoid surgery. We performed polymerase chain reaction using the RT2 Profiler™ PCR Array Human Notch Signaling Pathway (Qiagen) in the cholesteatoma and EAC skin samples (n = 6 each). This was followed by immunohistochemical staining of Notch1, enhancer of split-1 (HES1), and p53 in 41 and 8 cholesteatoma and EAC skin samples, respectively. RESULTS: The fold change of Notch1 gene expression was lowest in cholesteatoma, with a statistically significant difference (p = 0.0424). Moreover, the fold change of HES1 expression decreased (p = 0.272). The positive rates of Notch1 and HES1 protein expressions in the cholesteatoma (48.5 ± 32.4% and 44.9 ± 17.8%, respectively) were significantly lower than in the EAC skin (83.4 ± 17.5% and 55.7 ± 7.1%, respectively) (p < 0.001 and p < 0.01). In contrast, the positive rate of p53 expression in the cholesteatoma (8.5 ± 11.4%) was significantly higher than in the EAC skin (0.5 ± 0.7%) (p < 0.001). CONCLUSION: The decreases in Notch1 and HES1 protein expression might play an important role in the hyperproliferative character of the keratinizing squamous epithelium in cholesteatoma. An increase in p53 might reflect the reaction to cellular hyperproliferation.
• Sites of invasion of cancer of the external auditory canal predicting oncologic outcomes.
  Kiyoto Shiga, Ken-Ichi Nibu, Yasushi Fujimoto, Takahiro Asakage, Akihiro Homma, Hiroki Mitani, Takenori Ogawa, Kenji Okami, Shigeyuki Murono, Shigeru Hirano, Tsutomu Ueda, Nobuhiro Hanai, Kiyoaki Tsukahara, Ichiro Ota, Seiichi Yoshimoto, Takeshi Shinozaki, Shigemichi Iwae, Katsunori Katagiri, Daisuke Saito, Naomi Kiyota, Makoto Tahara, Fumiaki Takahashi, Ryuichi Hayashi
  Head & neck, 43, 10, 3097, 3105, 2021年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: This study aimed to reveal the influence of the invasion site of external auditory canal (EAC) cancer by analyzing the outcome of patients with advanced tumor. METHODS: A total of 111 patients with T4 EAC cancer were enrolled in this study. Of these patients, 79 underwent chemoradiotherapy and 32 underwent surgery under curative intent. Univariate and multivariate analyses and the Kaplan-Meier method were used to focus on the tumor invasion sites and overall survival of the patients. RESULTS: The 3-year overall survival rate of all patients was 55.0%. In multivariate analysis, the only significant invasion site for overall survival was the facial nerve, with the dura mater being the next most influential site. When Kaplan-Meier survival curve was calculated, facial nerve and dura mater were the significant factors resulting in poor patient outcomes. CONCLUSION: The facial nerve and dura mater are crucial sites of EAC cancer for patient outcomes.
• 鼻中隔前彎の客観的評価と適切な鼻中隔矯正術の術式選択　　　　　　　　　　　　　　　
  木村 将吾, 中丸 裕爾, 鈴木 正宣, 本間 あや, 中薗 彬, 本間 明宏
  日本鼻科学会会誌, 60, 3, 312, 312, (一社)日本鼻科学会, 2021年09月
  日本語
• 鼻粘膜上皮細胞におけるTLR3依存性自然免疫シグナル　　　　　　　　　　　　　　　
  鈴木 正宣, 中丸 裕爾, 中薗 彬, 本間 あや, 木村 将吾, Sarah Vreugde, Wormald PJ, 本間 明宏
  日本鼻科学会会誌, 60, 3, 352, 352, (一社)日本鼻科学会, 2021年09月
  日本語
• Prediction of the local treatment outcome in patients with oropharyngeal squamous cell carcinoma using deep learning analysis of pretreatment FDG-PET images.
  Noriyuki Fujima, V Carlota Andreu-Arasa, Sara K Meibom, Gustavo A Mercier, Minh Tam Truong, Kenji Hirata, Koichi Yasuda, Satoshi Kano, Akihiro Homma, Kohsuke Kudo, Osamu Sakai
  BMC cancer, 21, 1, 900, 900, 2021年08月06日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: This study aimed to assess the utility of deep learning analysis using pretreatment FDG-PET images to predict local treatment outcome in oropharyngeal squamous cell carcinoma (OPSCC) patients. METHODS: One hundred fifty-four OPSCC patients who received pretreatment FDG-PET were included and divided into training (n = 102) and test (n = 52) sets. The diagnosis of local failure and local progression-free survival (PFS) rates were obtained from patient medical records. In deep learning analyses, axial and coronal images were assessed by three different architectures (AlexNet, GoogLeNET, and ResNet). In the training set, FDG-PET images were analyzed after the data augmentation process for the diagnostic model creation. A multivariate clinical model was also created using a binomial logistic regression model from a patient's clinical characteristics. The test data set was subsequently analyzed for confirmation of diagnostic accuracy. Assessment of local PFS rates was also performed. RESULTS: Training sessions were successfully performed with an accuracy of 74-89%. ROC curve analyses revealed an AUC of 0.61-0.85 by the deep learning model in the test set, whereas it was 0.62 by T-stage, 0.59 by clinical stage, and 0.74 by a multivariate clinical model. The highest AUC (0.85) was obtained with deep learning analysis of ResNet architecture. Cox proportional hazards regression analysis revealed deep learning-based classification by a multivariate clinical model (P < .05), and ResNet (P < .001) was a significant predictor of the treatment outcome. In the Kaplan-Meier analysis, the deep learning-based classification divided the patient's local PFS rate better than the T-stage, clinical stage, and a multivariate clinical model. CONCLUSIONS: Deep learning-based diagnostic model with FDG-PET images indicated its possibility to predict local treatment outcomes in OPSCCs.
• Characteristics of and Prognosis for Facial Palsy in Patients With Otitis Media With ANCA-Associated Vasculitis (OMAAV).
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Hiroko Yanagi, Kimiko Hoshino, Yuji Nakamaru, Yasushi Furuta, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 42, 10, e1577-e1582, 2021年08月04日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The aim of the present study was to investigate the characteristics and prognosis of facial palsy in patients with otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Thirty-seven patients with OMAAV. MAIN OUTCOME MEASURES: The patients were divided into the facial palsy group and non-palsy group. The severity of and prognosis for facial palsy were evaluated using the House-Brackmann facial grading system (HB). Characteristics were compared between the facial palsy group and non-palsy group. RESULTS: Facial palsy was observed in eight patients. The last HB grade for all patients was either grade I or II after treatment with a combination of corticosteroids and immunosuppressant therapy. There were no cases in which palsy relapsed. Facial palsy in OMAAV was significantly more common in female patients, and patients with facial palsy demonstrated significantly higher rates of hypertrophic pachymeningitis than did those without facial palsy. CONCLUSIONS: Facial palsy in patients with OMAAV was detected in 21.6% and a good prognosis was obtained by use of the appropriate treatment. Facial palsy is one of the most important symptoms by which to diagnose OMAAV. When encountering the patients with intractable otitis media complicated with facial palsy, appropriate examination including ANCA titer should be performed.
• Predictors of the need for prophylactic percutaneous endoscopic gastrostomy in head and neck cancer patients treated with concurrent chemoradiotherapy.
  Satoshi Kano, Nayuta Tsushima, Takayoshi Suzuki, Seijiro Hamada, Taizo Yokokawa, Hiroshi Idogawa, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Hidefumi Aoyama, Akihiro Homma
  International journal of clinical oncology, 26, 7, 1179, 1187, 2021年07月, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: We investigated whether prophylactic percutaneous endoscopic gastrostomy (PEG) is used effectively for patients treated with definitive concurrent chemoradiotherapy (CCRT) and the predictors of the need for PEG. METHODS: 326 patients with laryngeal, oropharyngeal or hypopharyngeal cancers were retrospectively reviewed. RESULTS: The PEG tube use group had more favorable results than the total parenteral nutrition and nasogastric tube groups in terms of rate of serum albumin loss, incidence of severe fever and aspiration pneumonia, CCRT completion rate and hospitalization period. However, it was inferior to oral intake. Analysis of the relative risk of requiring enteral or parenteral nutrition revealed that performance status (PS) 2, primary site (supraglottis, oropharynx, or hypopharynx), N3 disease, and cisplatin were predictors of the need for nutritional support. CONCLUSIONS: Prophylactic PEG is effective for patients treated with definitive CCRT and is especially required for patients with PS2 or oropharyngeal cancer.
• Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
  Yasuhisa Hasegawa, Kiyoaki Tsukahara, Seiichi Yoshimoto, Kouki Miura, Junkichi Yokoyama, Shigeru Hirano, Hirokazu Uemura, Masashi Sugasawa, Tomokazu Yoshizaki, Akihiro Homma, Kazuaki Chikamatsu, Mikio Suzuki, Akihiro Shiotani, Takashi Matsuzuka, Naoyuki Kohno, Masakazu Miyazaki, Isao Oze, Keitaro Matsuo, Shigeru Kosuda, Yasushi Yatabe
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39, 18, 2025, 2036, 2021年06月20日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: This study aimed to compare patients with early oral cavity squamous cell carcinoma (OCSCC) (tumor category [T] 1-2, node-negative, and no distant metastasis) treated with traditional elective neck dissection (ND) with those managed by sentinel lymph node biopsy (SLNB) using survival and neck function and complications as end points. METHODS: Sixteen institutions in Japan participated in the study (trial registration number: UMIN000006510). Patients of age ≥ 18 years with histologically confirmed, previously untreated OCSCC (Union for International Cancer Control TNM Classification of Malignant Tumors 7th edition T1-2, node-negative no distant metastasis), with ≥ 4 mm (T1) depth of invasion, were randomly assigned to undergo standard selective ND (ND group; n = 137) or SLNB-navigated ND (SLNB group; n = 134). The primary end point was the 3-year overall survival rate, with a 12% noninferiority margin; secondary end points included postoperative neck functionality and complications and 3-year disease-free survival. Sentinel lymph nodes underwent intraoperative multislice frozen section analyses for the diagnosis. Patients with positive sentinel lymph nodes underwent either one-stage or second-look ND. RESULTS: Pathologic metastasis-positive nodes were observed in 24.8% (34 of 137) and 33.6% (46 of 134) of patients in the ND and SLNB groups, respectively (P = .190). The 3-year overall survival in the SLNB group (87.9%; lower limit of one-sided 95% CI, 82.4) was noninferior to that in the ND group (86.6%; lower limit 95% CI, 80.9; P for noninferiority < .001). The 3-year disease-free survival rate was 78.7% (lower limit 95% CI, 72.1) and 81.3% (75.0) in the SLNB and ND groups, respectively (P for noninferiority < .001). The scores of neck functionality in the SLNB group were significantly better than those in the ND group. CONCLUSION: SLNB-navigated ND may replace elective ND without a survival disadvantage and reduce postoperative neck disability in patients with early-stage OCSCC.
• 【上部消化管手術におけるトラブルシューティング-困難症例・偶発症への対策】頸部食道癌術後の永久気管孔の合併症予防とトラブルシューティング
  七戸 俊明, 村上 壮一, 倉島 庸, 海老原 裕磨, 平野 聡, 本間 明宏
  手術, 75, 7, 1147, 1152, 金原出版(株), 2021年06月
  日本語
• 当科で経験した頭蓋底骨髄炎の1例　　　　　　　　　　　　　　　
  佐藤 禄, 福田 篤, 藤原 圭志, 本間 明宏
  耳鼻咽喉科臨床 補冊, 補冊157, 58, 58, 耳鼻咽喉科臨床学会, 2021年06月
  日本語
• 当科におけるアブミ骨手術症例の検討　　　　　　　　　　　　　　　
  小林 諒, 福田 篤, 藤原 圭志, 中丸 裕爾, 本間 明宏
  耳鼻咽喉科臨床 補冊, 補冊157, 65, 65, 耳鼻咽喉科臨床学会, 2021年06月
  日本語
• Management of tracheostomy in COVID-19 patients: The Japanese experience.
  Taizo Yokokawa, Yosuke Ariizumi, Mariko Hiramatsu, Yujin Kato, Kazuhira Endo, Kazufumi Obata, Kayoko Kawashima, Toshifumi Sakata, Shigeru Hirano, Torahiko Nakashima, Tatsurou Sekine, Asanori Kiyuna, Saeko Uemura, Keisuke Okubo, Taro Sugimoto, Ichiro Tateya, Yasushi Fujimoto, Arata Horii, Yurika Kimura, Masamitsu Hyodo, Akihiro Homma
  Auris, nasus, larynx, 48, 3, 525, 529, 2021年06月, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Involvement in the tracheostomy procedure for COVID-19 patients can lead to a feeling of fear in medical staff. To address concerns over infection, we gathered and analyzed experiences with tracheostomy in the COVID-19 patient population from all over Japan. METHODS: The data for health-care workers involved in tracheostomies for COVID-19-infected patients were gathered from academic medical centers or their affiliated hospitals from all over Japan. RESULTS: Tracheostomies have been performed in 35 COVID-19 patients with a total of 91 surgeons, 49 anesthesiologists, and 49 surgical staff members involved. Twenty-eight (80%) patients underwent surgery more than 22 days after the development of COVID-19-related symptoms (11: 22-28 days and 17: ≥29 days). Thirty (85.7%) patients underwent surgery ≥ 15 days after intubation (14: 15-21 days, 6: 22-28 days, and 10: ≥29 days). Among the total of 189 health-care workers involved in the tracheostomy procedures, 25 used a powered air-purifying respirator (PAPR) and 164 used a N95 mask and eye protection. As a result, no transmission to staff occurred during the 2 weeks of follow-up after surgery. CONCLUSION: No one involved in tracheostomy procedures were found to have been infected with COVID-19 in this Japanese study. The reason is thought to be that the timing of the surgery was quite late after the infections, and the surgery was performed using appropriate PPE and surgical procedure. The indications for and timing of tracheostomy for severe COVID-19 patients should be decided through multidisciplinary discussion.
• Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting.
  Shin Kariya, Yasushi Shimizu, Nobuhiro Hanai, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Shuji Yonekura, Takahiro Asakage, Akinori Fujiwara, Takayuki Yamada, Akihiro Homma
  International journal of clinical oncology, 26, 6, 1049, 1056, 2021年06月, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: To examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer. METHODS: Data on the effectiveness of nivolumab were extracted from patient medical records. All patients were analyzed for effectiveness by prior cetuximab use. In the analyses for prior neck dissection, only patients with locally advanced disease were included. RESULTS: Of 256 patients analyzed, 155 had received prior cetuximab. Nineteen of 50 patients with local recurrence underwent neck dissection. The objective response rate was 14.7 vs 17.2% (p = 0.6116), median progression-free survival was 2.0 vs 3.1 months (p = 0.0261), and median overall survival was 8.4 vs 12 months (p = 0.0548) with vs without prior cetuximab use, respectively. The objective response rate was 23.1 vs 25.9% (p = 0.8455), median progression-free survival was 1.8 vs 3.0 months (p = 0.6650), and median overall survival was 9.1 vs 9.9 months (p = 0.5289) with vs without neck dissection, respectively. CONCLUSIONS: These findings support the use of nivolumab for patients with recurrent/metastatic head and neck cancer regardless of prior cetuximab use or neck dissection history. TRIAL REGISTRATION NUMBER: UMIN-CTR (UMIN000032600), Clinicaltrials.gov (NCT03569436).
• Standardization for oncologic head and neck surgery.
  Ohad Ronen, K Thomas Robbins, Remco de Bree, Orlando Guntinas-Lichius, Dana M Hartl, Akihiro Homma, Avi Khafif, Luiz P Kowalski, Fernando López, Antti A Mäkitie, Wai Tong Ng, Alessandra Rinaldo, Juan P Rodrigo, Alvaro Sanabria, Alfio Ferlito
  European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021年05月12日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The inherent variability in performing specific surgical procedures for head and neck cancer remains a barrier for accurately assessing treatment outcomes, particularly in clinical trials. While non-surgical modalities for cancer therapeutics have evolved to become far more uniform, there remains the challenge to standardize surgery. The purpose of this review is to identify the barriers in achieving uniformity and to highlight efforts by surgical groups to standardize selected operations and nomenclature. While further improvements in standardization will remain a challenge, we must encourage surgical groups to focus on strategies that provide such a level.
• Objective evaluation of caudal deviation of the nasal septum and selection of the appropriate septoplasty technique.
  Shogo Kimura, Masanobu Suzuki, Aya Honma, Akira Nakazono, Masayuki Osawa, Yuji Nakamaru, Akihiro Homma
  Auris, nasus, larynx, 49, 1, 67, 76, 2021年05月06日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Several methods have been reported to correct caudal deviation of the nasal septum, including open septorhinoplasty (OSR) and septoplasty with Killian incision (KI). In general, OSR is applied instead of KI for caudal deviation. However, there is little objective evidence own on the effects of OSR and KI for caudal deviation. In this study, we compared surgical outcomes between OSR and KI by quantifying nasal septum deviation using two simple and objective parameters on routine paranasal sinus CT scans. METHODS: We retrospectively analyzed 18 patients who underwent OSR and 11 patients who underwent septoplasty with KI between April 2006 and October 2019. Caudal deviation was defined on the basis of the "Anterior-posterior Position of the most deviated point of the nasal septum (AP)," which was measured on computerized tomography. The deformation rate (DR) of the nasal septum was also calculated. Nasal airway resistance and visual analogue scale (VAS) score for nasal obstruction were examined. RESULTS: The AP was significantly correlated with the VAS score (r=-0.58, p=0.017). The DR in patients with caudal septal deviation was significantly decreased by OSR (0.14±0.06 to 0.03±0.03, p=0.004), but not by KI (0.09±0.08 to 0.04±0.03, p=0.25). OSR also improved nasal airway resistance (1.10±0.44 to 0.42±0.15, p=0.02), and the VAS score (79.11±14.74 to 5.78±7.89, p=0.004). CONCLUSION: Nasal obstruction is more severe in patients with the caudal deviation. OSR corrects caudal deviation of the nasal septum more effectively than does KI. The AP could be useful for the evaluation of the deviation of the nasal septum and help in selecting the appropriate septoplastic technique.
• Psychological evaluation for patients with non-cured facial nerve palsy.
  Keishi Fujiwara, Atsushi Fukuda, Shinya Morita, Hiroko Yanagi, Kimiko Hoshino, Yuji Nakamaru, Yasushi Furuta, Akihiro Homma
  Auris, nasus, larynx, 49, 1, 53, 57, 2021年05月04日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: The aim of the present study was to evaluate the psychological condition of patients with non-cured facial nerve palsy and to investigate whether their psychological condition is correlated with the degree of facial nerve palsy, synkinesis or quality of life. METHODS: Thirty patients with non-cured facial nerve palsy were enrolled in this study. Psychological conditions were evaluated by questionnaires including State-Trait Anxiety Inventory and Self-rating Depression Scale. RESULTS: Of the thirty patients with non-cured facial nerve palsy, 17 (56.7%) and 15 patients (50.0%) felt anxiety and depression, respectively. Although there were no significant correlations between their psychological condition and the degree of facial nerve palsy or that of sequelae, significant correlations were observed between psychological condition and the degree of QOL, especially in terms of social function. CONCLUSIONS AND SIGNIFICANCE: Disabilities associated with facial nerve palsy may be overlooked when evaluation is performed by physician-graded instruments alone. To resolve this problem, patients with non-cured facial nerve palsy should be evaluated by not only physician-graded tools but also patient-based assessment tools.
• 早期舌癌治療のパラダイムシフトへ向けて-医科歯科病理の知の融合- Stage I/II舌癌に対する予防的頸部郭清省略の意義を検証するランダム化比較第III相試験(JCOG1601) RESPOND
  花井 信広, 朝蔭 孝宏, 本間 明宏, 林 隆一, 福島 啓文, 佐野 大佑, 向川 卓志, 上田 勉, 門田 伸也
  頭頸部癌, 47, 2, 140, 140, (一社)日本頭頸部癌学会, 2021年05月
  日本語
• 鼻腔粘膜上皮細胞における新型コロナウィルス細胞侵入因子の発現制御機構　　　　　　　　　　　　　　　
  中薗 彬, 鈴木 正宣, 木村 将吾, 本間 あや, 中丸 裕爾, Ramezanpour Mahnaz, Vreugde Sarah, Wormald P.J., 本間 明宏
  日本耳鼻咽喉科免疫アレルギー感染症学会抄録集, 1回, 127, 127, 日本耳鼻咽喉科免疫アレルギー感染症学会, 2021年05月
  日本語
• 咽喉頭扁平上皮癌IMRTの照射中における線量分布変化に関する解析　　　　　　　　　　　　　　　
  安田 耕一, 打浪 雄介, 湊川 英樹, 小泉 富基, 大塚 愛美, 藤田 祥博, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏
  頭頸部癌, 47, 2, 210, 210, (一社)日本頭頸部癌学会, 2021年05月
  日本語
• CCRTを施行した頭頸部癌患者に対する予防的胃瘻増設の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 浜田 誠二郎, 横川 泰三, 安田 耕一, 湊川 英樹, 打浪 雄介, 本間 明宏
  頭頸部癌, 47, 2, 211, 211, (一社)日本頭頸部癌学会, 2021年05月
  日本語
• Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study.
  Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Daiju Sakurai, Takahiro Asakage, Issei Doi, Takayuki Yamada, Akihiro Homma
  International journal of clinical oncology, 26, 5, 1005, 1006, 2021年05月, ［国内誌］
  英語
• Salvage surgery improves the treatment outcome of patients with residual/recurrent maxillary sinus cancer after superselective intra-arterial cisplatin infusion with concomitant radiation therapy.
  Nayuta Tsushima, Satoshi Kano, Takayoshi Suzuki, Hiroshi Idogawa, Daisuke Yoshida, Koichi Yasuda, Manami Otsuka, Hidefumi Aoyama, Akihiro Homma
  European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279, 2, 899, 905, 2021年04月18日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: We have performed superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT) for patients with maxillary sinus cancer. The promising treatment outcomes of this non-surgical treatment were reported in past studies. However, few clinical studies have been conducted to evaluate the outcome of salvage surgery following RADPLAT. The purpose of this study was to analyze the treatment outcomes of salvage surgery for patients with recurrent maxillary sinus cancer after RADPLAT. METHODS: We assessed 45 patients who had recurrence following RADPLAT between 1999 and 2017, and conducted a retrospective analysis. We excluded patients who did not complete RADPLAT. Patients were not considered to have completed RADPLAT if they underwent intra-arterial cisplatin less than three times or received a total radiation dose of less than 60 Gy. The primary endpoint was overall survival. The median follow-up period for surviving patients after recurrence was 5.1 years. RESULTS: Twenty-five of the 45 (56%) patients underwent salvage surgery. The 5-year overall survival rate was 68% in patients who underwent salvage surgery, while all patients who did not undergo salvage surgery died during the observation period. Fifteen of 24 (63%) patients with local recurrence underwent salvage surgery. Eight patients did not undergo salvage surgery because of unresectable disease; five of the eight patients had unresectable posterior extension. All nine patients with nodal recurrence underwent neck dissection. CONCLUSION: Treatment outcomes of salvage surgery following RADPLAT were favorable enough for it to be generally recommended. To reduce unresectable recurrence, the posterior section should be eradicated by RADPLAT.
• Usefulness of the Video Head Impulse Test for the Evaluation of Vestibular Function in Patients With Otitis Media With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Hiroko Yanagi, Kimiko Hoshino, Yuji Nakamaru, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 42, 4, e483-e488, 2021年04月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: To investigate usefulness of the video Head Impulse Test (vHIT) as a method for evaluating semicircular canal function in patients with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Fourteen patients with OMAAV underwent vestibular examination. MAIN OUTCOME MEASURES: The gain in vestibulo-ocular reflex (VOR) and the presence of catch-up saccade were examined for each semicircular canal. RESULTS: Seven (50.0%) of the 14 patients felt subjective symptoms of disequilibrium. Dysfunction in at least one semicircular canal was detected in all ears of the OMAAV patients evaluated by vHIT. Dysfunction in posterior semicircular canal was detected more frequently than that in the anterior or horizontal canal. There were no significant correlations between the gain in VOR and hearing loss. CONCLUSIONS: vHIT is thought to be the most suitable method for evaluating semicircular canal function in patients with OMAAV as vHIT is not influenced by middle ear pathology and was able to evaluate vertical canal function including the posterior canal.
• 新型コロナウイルス感染症患者に対する気管切開術 医療者感染リスクの全国調査
  有泉 陽介, 平松 真理子, 本間 明宏, 加藤 雄仁, 遠藤 一平, 小幡 和史, 川島 佳代子, 藤本 保志, 堀井 新, 木村 百合香, 兵頭 政光
  日本耳鼻咽喉科学会会報, 124, 4, 559, 559, (一社)日本耳鼻咽喉科頭頸部外科学会, 2021年04月
  日本語
• 新型コロナウイルス感染症患者に対する気管切開術 医療者感染リスクの全国調査　　　　　　　　　　　　　　　
  有泉 陽介, 平松 真理子, 本間 明宏, 加藤 雄仁, 遠藤 一平, 小幡 和史, 川島 佳代子, 藤本 保志, 堀井 新, 木村 百合香, 兵頭 政光
  日本耳鼻咽喉科学会会報, 124, 4, 559, 559, (一社)日本耳鼻咽喉科学会, 2021年04月
  日本語
• Role of intracellular zinc in molecular and cellular function in allergic inflammatory diseases.
  Masanobu Suzuki, Takayoshi Suzuki, Masashi Watanabe, Shigetsugu Hatakeyama, Shogo Kimura, Akira Nakazono, Aya Honma, Yuji Nakamaru, Sarah Vreugde, Akihiro Homma
  Allergology international : official journal of the Japanese Society of Allergology, 70, 2, 190, 200, 2021年04月, ［国際誌］
  英語, 研究論文（学術雑誌）, Zinc is an essential micronutrient in human body and a vital cofactor for the function of numerous proteins encoded by the human genome. Zinc has a critical role in maintaining many biochemical and physiological processes at the molecular, cellular, and multiple organ and systemic levels. The alteration of zinc homeostasis causes dysfunction of many organs and systems. In the immune system, zinc regulates the differentiation, proliferation and function of inflammatory cells, including T cells, eosinophils, and B cells, by modifying several signaling pathways such as NFκB signaling pathways and TCR signals. An adequate zinc level is essential for proper immune responses and decreased zinc levels were reported in many allergic inflammatory diseases, including atopic dermatitis, bronchial asthma, and chronic rhinosinusitis. Decreased zinc levels often enhance inflammatory activation. On the other hand, the inflammatory conditions alter the intracellular homeostasis of zinc, often decreasing zinc levels. These findings implied that there could be a vicious cycle between zinc deficiency and inflammatory conditions. In this review, we present recent evidence on the involvement of zinc in atopic dermatitis, bronchial asthma, and chronic rhinosinusitis, with insights into the involvement of zinc in the underlying molecular and cellular mechanisms related to these allergic inflammatory diseases.
• Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
  Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Seishin Takao, Masaya Tamura, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takatsugu Mizumachi, Takashi Mori, Kentaro Nishioka, Motoyasu Shido, Norio Katoh, Hiroshi Taguchi, Noriyuki Fujima, Rikiya Onimaru, Isao Yokota, Keiji Kobashi, Shinichi Shimizu, Akihiro Homma, Hiroki Shirato, Hidefumi Aoyama
  Journal of radiation research, 62, 2, 329, 337, 2021年03月10日, ［国際誌］
  英語, 研究論文（学術雑誌）, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.
• 顔面神経麻痺非治癒例の不安・うつ状態の評価
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 40, 127, 129, 日本顔面神経学会, 2021年03月
  日本語
• VZV再活性化例における好中球・リンパ球比の意義
  古田 康, 松村 道哉, 藤原 圭志, 本間 明宏
  Facial Nerve Research, 40, 149, 151, 日本顔面神経学会, 2021年03月
  日本語
• 顔面神経麻痺非治癒例の不安・うつ状態の評価
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 40, 127, 129, 日本顔面神経学会, 2021年03月
  日本語
• VZV再活性化例における好中球・リンパ球比の意義
  古田 康, 松村 道哉, 藤原 圭志, 本間 明宏
  Facial Nerve Research, 40, 149, 151, 日本顔面神経学会, 2021年03月
  日本語
• Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
  Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Daiju Sakurai, Takahiro Asakage, Issei Doi, Takayuki Yamada, Akihiro Homma
  International journal of clinical oncology, 26, 3, 494, 506, 2021年03月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: To fill the data gap between clinical trials and real-world settings, this study assessed the overall effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) during Japanese real-world clinical practice. METHODS: This was a multicenter, retrospective study in Japanese patients with recurrent or metastatic HNC who received nivolumab for the first time between July and December 2017. Data on the clinical use, effectiveness, and safety of nivolumab were extracted from patient medical records. RESULTS: Overall, 256 patients were enrolled in this study. The median duration of nivolumab treatment was 72.5 days, with patients receiving a median of 6.0 (range 1-27) doses. Median overall survival (OS) was 9.5 (95% confidence interval [CI] 8.2-12.0) months and the estimated 12-month OS rate was 43.2%. The objective response rate (ORR) was 15.7% overall and 21.1%, 7.1%, and 13.6% in patients with primary nasopharynx, maxillary sinus, and salivary gland tumors, respectively, who had been excluded from CheckMate 141. Grade ≥ 3 immune-related adverse events occurred in 5.9% of patients. No new safety signals were identified compared with adverse events noted in CheckMate 141. CONCLUSIONS: The effectiveness and safety of nivolumab in real-world clinical practice are consistent with data from the CheckMate 141 clinical trial. Therapeutic response was also observed in the groups of patients excluded from CheckMate 141. TRIAL REGISTRATION NUMBER: UMIN-CTR (UMIN000032600), Clinicaltrials.gov (NCT03569436).
• Multi‐institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan
  Kiyoto Shiga, Ken‐ichi Nibu, Yasushi Fujimoto, Takahiro Asakage, Akihiro Homma, Hiroki Mitani, Takenori Ogawa, Kenji Okami, Shigeyuki Murono, Shigeru Hirano, Tsutomu Ueda, Nobuhiro Hanai, Kiyoaki Tsukahara, Ichiro Ota, Seiichi Yoshimoto, Takeshi Shinozaki, Shigemichi Iwae, Katsunori Katagiri, Daisuke Saito, Naomi Kiyota, Makoto Tahara, Fumiaki Takahashi, Ryuichi Hayashi
  The Laryngoscope, 131, 3, E870, E874, Wiley, 2021年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Prognostic factors for duration of vertigo after stapes surgery via a time-to-event analysis.
  Atsushi Fukuda, Keishi Fujiwara, Shinya Morita, Kimiko Hoshino, Hiroko Yanagi, Yuji Nakamaru, Akihiro Homma
  Acta oto-laryngologica, 141, 3, 216, 221, 2021年03月, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Vertigo or dizziness after stapes surgery occurs sometimes, and it is generally temporary. However, while rare, it can be prolonged. AIMS/OBJECTIVES: To investigate the prognostic factors for duration of vertigo following stapedotomy using a time-to-event analysis. MATERIALS AND METHODS: The present study included a total of 35 primary ears (26 with otosclerosis and nine with congenital stapes fixation) from 31 patients. We assessed residual rates of nystagmus and complaints of subjective vestibular symptoms using Kaplan-Meier time-to-event methods. RESULTS: Postoperative spontaneous nystagmus was observed in 23 (65.7%) ears, and postoperative subjective vestibular symptoms were confirmed in 27 (77.1%) ears. The total mean duration of postoperative spontaneous nystagmus and subjective vestibular symptoms was 9.8 (range: 0-158) and 33.9 days (0-732), respectively. A history of stapes surgery in the opposite ear was a significant predictive factor for prolonged nystagmus and subjective vestibular symptoms (p = .0059 and p = .0146). CONCLUSIONS AND SIGNIFICANCE: For individuals with a history of stapes surgery in the opposite ear, spontaneous nystagmus and vertigo/dizziness sensations following stapedotomy may persist for a longer duration than in those without a history of stapes surgery in the opposite ear.
• Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
  Susumu Okano, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Tomoya Yokota, Yoshinori Imamura, Yosuke Ariizumi, Tetsuo Akimoto, Ryuichi Hayashi
  Japanese journal of clinical oncology, 51, 2, 173, 179, 2021年02月08日, ［国際誌］
  英語, 研究論文（学術雑誌）, In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.
• The role of endoscopic resection for selected patients with sinonasal squamous cell carcinoma.
  Yuji Nakamaru, Masanobu Suzuki, Satoshi Kano, Takatsugu Mizumachi, Nayuta Tsushima, Takayoshi Suzuki, Aya Honma, Akira Nakazono, Shogo Kimura, Rikiya Onimaru, Koichi Yasuda, Hiroki Shirato, Akihiro Homma
  Auris, nasus, larynx, 48, 1, 131, 137, 2021年02月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Despite of rapid advances in endoscopic surgery, the gold standard for sinonasal squamous cell carcinoma (SNSCC) surgery has remained the open approach with en-block resection due to the aggressive nature of SNSCC, including frequent recurrence and high mortality rate. For that reason, few studies have focused on SNSCC treated by endoscopic surgery alone. The objective of this study was to evaluate the usefulness of endoscopic surgery for patients with SNSCC. METHODS: A retrospective analysis was performed for 15 consecutive SNSCC patients who underwent endoscopic surgery without an open approach. We carefully selected patients whose tumor attachment sites could be fully visualized and completely resected through an endonasal approach. RESULTS: Of the fifteen patients, 4 patients (27%) were diagnosed with T1, 7 (47%) with T2, 4 (27%) with T3, and no patients with T4a or T4b disease. Four of the 15 (27%) patients showed positive surgical margins. The 5-yr overall survival, disease-specific survival, and local control rate was 72.4%, 79.6%, and 92.9%, respectively. The 5-yr disease-specific survival for T1, T2, and T3 disease was 100% and 75% and 75%, respectively. Patients with negative surgical margins had a better disease-specific survival rate than did those with positive surgical margins (p = 0.0253). CONCLUSION: Endoscopic surgery for patients with SNSCC appears to afford an effective method in selected cases. The achievement of negative surgical margins with a good view of the tumor attachment site was considered to be critical to the management of SNSCC.
• Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2).
  Tomoya Yokota, Yosuke Ota, Hirofumi Fujii, Takeshi Kodaira, Mototsugu Shimokawa, Torahiko Nakashima, Nobuya Monden, Akihiro Homma, Shinya Ueda, Tetsuo Akimoto
  International journal of clinical oncology, 26, 2, 316, 325, 2021年02月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The aims of this study are to evaluate the efficacy and safety of first-line treatment with chemotherapy plus cetuximab in real-world patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) and to identify prognostic factors for overall survival (OS). METHODS: This is a prospective observation study involving 20 oncology institutions in Japan. Patients with RM-SCCHN treated with a first-line therapy consisting of cetuximab plus any chemotherapy regimen between December 2013 and February 2017 were enrolled. The primary objective of the study was 1-year OS. Secondary objectives included response rate and adverse events. RESULTS: Of 120 patients recruited, 114 patients were analyzed. Median age was 64 years. Cetuximab in combination with platinum plus 5-FU (EXTREME regimen) was chosen in 86 patients (75.4%). The median OS was 12.4 months. A point estimate of the 1-year survival rate was 51.1%. Overall response rate was 26.3%. Grade 3 or worse adverse events included neutropenia (22.8%), hypokalemia (9.6%), acneiform rash (7.0%), pneumonitis (1.8%), and infusion-related reaction (0.9%). On multivariate analysis, regional lymph node metastasis, absence of intervention by dermatologists, lack of response to therapy, skin metastasis, and non-EXTREME regimen were identified as independent unfavorable prognostic factors for OS. CONCLUSION: The combination of cetuximab plus chemotherapy was tolerable and efficacious in patients with RM-SCCHN in a real-world setting. Clinical outcomes and prognostic factors extracted from this study provide a reference of the current clinical practice as well as for the future development of novel therapy in RM-SCCHN.
• Endonasal endoscopic surgery for sinonasal squamous cell carcinoma from an oncological perspective.
  Akihiro Homma, Yuji Nakamaru, Valerie J Lund, Ehab Y Hanna, Luiz Paulo Kowalski, Ronaldo Nunes Toledo, Antti A Mäkitie, Juan Pablo Rodrigo, Alessandra Rinaldo, Carl H Snyderman, Alfio Ferlito
  Auris, nasus, larynx, 48, 1, 41, 49, 2021年02月, ［査読有り］, ［筆頭著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Endonasal endoscopic surgery (EES) has been applied to the management of sinonasal (SN) tumors based on recent advances in endoscopic surgical techniques and technologies over the past three decades. EES has been mainly indicated for benign tumors and less aggressive malignant tumors. Notwithstanding this, EES has been gradually adopted for squamous cell carcinoma (SCC), which is the most common histology among SN malignancies. However, an analysis of the outcomes of EES for patients with SCC is difficult because most articles included SCC a wide range of different tumor histologies. Therefore, we herein review and clarify the current status of EES focusing on SCC from an oncological perspective. The oncologic outcomes and the ability to achieve a histologically complete resection are similar between endoscopic and open approaches in highly selected patients with SN-SCC. Surgical complications associated with EES are likely similar for SN-SCC compared to other sinonasal malignancies. The indications for a minimally invasive approach such as EES in the management of patients with SN-SCC should be stricter than those for less aggressive malignant tumors because of the aggressive nature of SCC. Also, it is important to achieve negative surgical margins with EES in patients with SCC. We believe that the indications for EES for SN-SCC are widening due to advances in diagnostic imaging, and endoscopic surgical techniques and technologies. However, while expanding the indications for EES for SN-SCC we must carefully confirm that the outcomes support this strategy.
• TLR Signals in Epithelial Cells in the Nasal Cavity and Paranasal Sinuses.
  Masanobu Suzuki, Clare Cooksley, Takayoshi Suzuki, Mahnaz Ramezanpour, Akira Nakazono, Yuji Nakamaru, Akihiro Homma, Sarah Vreugde
  Frontiers in allergy, 2, 780425, 780425, 2021年, ［国際誌］
  英語, 研究論文（学術雑誌）, The respiratory tract is constantly at risk of invasion by microorganisms such as bacteria, viruses, and fungi. In particular, the mucosal epithelium of the nasal cavity and paranasal sinuses is at the very forefront of the battles between the host and the invading pathogens. Recent studies have revealed that the epithelium not only constitutes a physical barrier but also takes an essential role in the activation of the immune system. One of the mechanisms equipped in the epithelium to fight against microorganisms is the Toll-like receptor (TLR) response. TLRs recognize common structural components of microorganisms and activate the innate immune system, resulting in the production of a plethora of cytokines and chemokines in the response against microbes. As the epithelia-derived cytokines are deeply involved in the pathogenesis of inflammatory conditions in the nasal cavity and paranasal sinuses, such as chronic rhinosinusitis (CRS) and allergic rhinitis (AR), the molecules involved in the TLR response may be utilized as therapeutic targets for these diseases. There are several differences in the TLR response between nasal and bronchial epithelial cells, and knowledge of the TLR signals in the upper airway is sparse compared to that in the lower airway. In this review, we provide recent evidence on TLR signaling in the upper airway, focusing on the expression, regulation, and responsiveness of TLRs in human nasal epithelial cells (HNECs). We also discuss how TLRs in the epithelium are involved in the pathogenesis of, and possible therapeutic targeting, for CRS and AR.
• Multiparametric Analysis of Tumor Morphological and Functional MR Parameters Potentially Predicts Local Failure in Pharynx Squamous Cell Carcinoma Patients.
  Noriyuki Fujima, Yukie Shimizu, Daisuke Yoshida, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Koichi Yasuda, Rikiya Onimaru, Osamu Sakai, Kohsuke Kudo, Hiroki Shirato
  The journal of medical investigation : JMI, 68, 3.4, 354, 361, 2021年, ［国内誌］
  英語, 研究論文（学術雑誌）, Purpose : To predict local control / failure by a multiparametric approach using magnetic resonance (MR)-derived tumor morphological and functional parameters in pharynx squamous cell carcinoma (SCC) patients. Materials and Methods : Twenty-eight patients with oropharyngeal and hypopharyngeal SCCs were included in this study. Quantitative morphological parameters and intratumoral characteristics on T2-weighted images, tumor blood flow from pseudo-continuous arterial spin labeling, and tumor diffusion parameters of three diffusion models from multi-b-value diffusion-weighted imaging as well as patients' characteristics were analyzed. The patients were divided into local control / failure groups. Univariate and multiparametric analysis were performed for the patient group division. Results : The value of morphological parameter of 'sphericity' and intratumoral characteristic of 'homogeneity' was revealed respectively significant for the prediction of the local control status in univariate analysis. Higher diagnostic performance was obtained with the sensitivity of 0.8, specificity of 0.75, positive predictive value of 0.89, negative predictive value of 0.6 and accuracy of 0.79 by multiparametric diagnostic model compared to results in the univariate analysis. Conclusion : A multiparametric analysis with MR-derived quantitative parameters may be useful to predict local control in pharynx SCC patients. J. Med. Invest. 68 : 354-361, August, 2021.
• Comparison of clinical characteristics of the nasal manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) and eosinophilic chronic rhinosinusitis (ECRS).
  Masanobu Suzuki, Akira Nakazono, Shinya Morita, Atsushi Fukuda, Aya Honma, Takayoshi Suzuki, Shogo Kimura, Yuji Nakamaru, Akihiro Homma
  Allergology international : official journal of the Japanese Society of Allergology, 70, 1, 143, 144, 2021年01月, ［国際誌］
  英語
• Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  Jun Taguchi, Yasushi Shimizu, Shin Ariga, Tomohiro Goda, Yoshihito Ohhara, Rio Honma, Takuro Noguchi, Satoshi Takeuchi, Ichiro Kinoshita, Toraji Amano, Takatsugu Mizumachi, Satoshi Kano, Miki Takahara, Takahisa Abe, Akihiro Homma, Hirotoshi Dosaka-Akita
  International journal of clinical oncology, 26, 1, 51, 58, 2021年01月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells.
  Akira Nakazono, Yuji Nakamaru, Mahnaz Ramezanpour, Takeshi Kondo, Masashi Watanabe, Shigetsugu Hatakeyama, Shogo Kimura, Aya Honma, P J Wormald, Sarah Vreugde, Masanobu Suzuki, Akihiro Homma
  Frontiers in cellular and infection microbiology, 11, 655666, 655666, 2021年, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: From the first detection in 2019, SARS-CoV-2 infections have spread rapidly worldwide and have been proven to cause an urgent and important health problem. SARS-CoV-2 cell entry depends on two proteins present on the surface of host cells, angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). The nasal cavity is thought to be one of the initial sites of infection and a possible reservoir for dissemination within and between individuals. However, it is not known how the expression of these genes is regulated in the nasal mucosa. Objective: In this study, we examined whether the expression of ACE2 and TMPRSS2 is affected by innate immune signals in the nasal mucosa. We also investigated how fluticasone propionate (FP), a corticosteroid used as an intranasal steroid spray, affects the gene expression. Methods: Primary human nasal epithelial cells (HNECs) were collected from the nasal mucosa and incubated with Toll-like receptor (TLR) agonists and/or fluticasone propionate (FP), followed by quantitative PCR, immunofluorescence, and immunoblot analyses. Results: Among the TLR agonists, the TLR3 agonist Poly(I:C) significantly increased ACE2 and TMPRSS2 mRNA expression in HNECs (ACE2 36.212±11.600-fold change, p<0.0001; TMPRSS2 5.598±2.434-fold change, p=0.031). The ACE2 protein level was also increased with Poly(I:C) stimulation (2.884±0.505-fold change, p=0.003). The Poly(I:C)-induced ACE2 expression was suppressed by co-incubation with FP (0.405±0.312-fold change, p=0.044). Conclusion: The activation of innate immune signals via TLR3 promotes the expression of genes related to SARS-CoV2 cell entry in the nasal mucosa, although this expression is suppressed in the presence of FP. Further studies are required to evaluate whether FP suppresses SARS-CoV-2 viral cell entry.
• Attempting to define sentinel node micrometastasis in oral squamous cell carcinoma.
  Takashi Matsuzuka, Hirokazu Uemura, Seiichi Yoshimoto, Kouki Miura, Akihiro Shiotani, Masashi Sugasawa, Akihiro Homma, Junkichi Yokoyama, Kiyoaki Tsukahara, Tomokazu Yoshizaki, Yasushi Yatabe, Takehiro Kobari, Shigeru Kosuda, Shigeyuki Murono, Yasuhisa Hasegawa
  Fukushima journal of medical science, 66, 3, 143, 147, 2020年12月10日, ［国内誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: The aim of this supplemental study of a sentinel node (SN) biopsy (SNB) trial for oral squamous cell carcinoma (OSCC) was to assess the effectiveness in identifying micrometastasis and determining whether elective neck dissection (END) is necessary. MATERIALS AND METHODS: Twenty-three patients with pathologically positive SNs were included. The sizes of the metastatic lesions in positive SNs (SMSNs) were classified and the rates of occult metastasis of non-SNs were compared. RESULTS: The patients were divided according to the SMSN:<0.2 mm (group A, n=3);0.2 mm to <2.0 mm (group B, n=7);and ≥2.0 mm (group C, n=13). The rates of occult metastasis in groups A, B, and C were 0% (0/3), 14% (1/7) and 23% (3/13), respectively. CONCLUSION: Rare cancer cell distribution to nodes other than SNs was observed in the patients with SN metastatic lesions of at least smaller than 0.2 mm in size, suggesting the possibility of defining SN micrometastasis in N0 OSCC.
• 北海道胆振東部地震における地震後めまい症候群の検討　　　　　　　　　　　　　　　
  藤原 圭志, 野村 泰之, 本間 明宏
  耳鼻咽喉科臨床 補冊, 補冊155, 158, 158, 耳鼻咽喉科臨床学会, 2020年12月
  日本語
• Pathological evaluation of the accuracy of a fluorescence spectroscopy system for detecting parathyroid glands
  Hiroshi Idogawa, Tomohiro Sakashita, Takeki Yagi, Keiko Segawa, Akihiro Homma
  European Archives of Oto-Rhino-Laryngology, 277, 11, 3145, 3147, Springer Science and Business Media Deutschland GmbH, 2020年11月01日
  英語, 研究論文（学術雑誌）
• 頭頸部癌患者におけるSLFN11発現とDNA障害型抗癌剤の効果に関する検討　　　　　　　　　　　　　　　
  浜田 誠二郎, 加納 里志, 鈴木 崇祥, 本間 明宏, 村井 純子
  日本癌学会総会記事, 79回, OJ15, 2, (一社)日本癌学会, 2020年10月
  英語
• 実臨床下での頭頸部癌患者に対するニボルマブの有効性と安全性、2年フォローアップ　　　　　　　　　　　　　　　
  大塚 倫之, 清水 康, 花井 信広, 假谷 伸, 安松 隆治, 横田 知哉, 塚原 清彰, 安藤 瑞生, 羽生 健司, 上田 勉, 平川 仁, 山田 智美, 山田 孝之, 本間 明宏
  日本癌治療学会学術集会抄録集, 58回, O1, 3, (一社)日本癌治療学会, 2020年10月
  英語
• video Head Impulse Testを用いたOMAAVにおける半規管障害の検討
  藤原 圭志, 柳 紘子, 本間 明宏
  Equilibrium Research, 79, 5, 466, 466, (一社)日本めまい平衡医学会, 2020年10月
  日本語
• Zinc-depletion associates with tissue eosinophilia and collagen depletion in chronic rhinosinusitis.
  M Suzuki, M Ramezanpour, C Cooksley, T J Lee, B Jeong, S Kao, T Suzuki, A J Psaltis, Y Nakamaru, A Homma, P J Wormald, S Vreugde
  Rhinology, 58, 5, 451, 459, 2020年10月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Zinc plays an important role in many biological processes. Reduced zinc levels have been found in chronic rhinosinusitis (CRS) patients, however, its role in the pathophysiology of this disease remains unknown. This study examined zinc levels in the serum, mucus and tissue from CRS patients in relation to collagen content and eosinophil infiltration. The effect of zinc depletion on inflammatory cytokine production and collagen synthesis was assessed in vitro. METHODOLOGY: Zinc levels were determined in serum, mucus and tissue from controls, CRS with (CRSwNP) and without nasal polyps (CRSsNP) patients. Tissue zinc levels, collagen and inflammatory cell infiltration was examined using zinquin assays, immunofluorescence and histology on Tissue Micro Arrays. Cytokine expression and collagen synthesis was evaluated in zinc depleted primary human nasal epithelial cells (HNECs) and primary fibroblasts. RESULTS: CRSwNP patients showed reduced tissue zinc levels in correlation with a reduction in collagen content, and increased eosinophil numbers. Zinc depletion of HNECs and fibroblasts induced the production of pro-inflammatory cytokines and MUC5AC and reduced collagen secretion. CONCLUSIONS: These results suggest mucosal zinc depletion associates with tissue eosinophilia and collagen depletion in CRSwNP and induces pro-inflammatory cytokine expression and reduction of collagen synthesis in vitro.
• 頭頸部癌放射線照射後遺残、異時性多発癌に対する内視鏡治療成績　　　　　　　　　　　　　　　
  井上 雅貴, 清水 勇一, 霜田 佳彦, 田中 一光, 木脇 佐代子, 石川 麻倫, 大野 正芳, 山本 桂子, 小野 尚子, 本間 明宏, 坂本 直哉
  Gastroenterological Endoscopy, 62, Suppl.2, 2127, 2127, (一社)日本消化器内視鏡学会, 2020年10月
  日本語
• video Head Impulse Testを用いたOMAAV症例の半規管機能評価
  藤原 圭志, 柳 紘子, 森田 真也, 干野 季美子, 福田 篤, 中丸 裕爾, 本間 明宏
  日本耳鼻咽喉科学会会報, 123, 4, 1142, 1142, (一社)日本耳鼻咽喉科頭頸部外科学会, 2020年09月
  日本語
• Immunotherapy for squamous cell carcinoma of the head and neck.
  Tomoya Yokota, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
  Japanese journal of clinical oncology, 50, 10, 1089, 1096, 2020年08月08日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.
• 北海道胆振東部地震における地震後めまい症候群に関するアンケート調査
  藤原 圭志, 野村 泰之, 柳 紘子, 本間 明宏
  Equilibrium Research, 79, 4, 251, 256, (一社)日本めまい平衡医学会, 2020年08月
  日本語
• Optimization of therapeutic strategy for p16‐positive oropharyngeal squamous cell carcinoma: Multi‐institutional observational study based on the national Head and Neck Cancer Registry of Japan
  Yuki Saito, Ryuichi Hayashi, Yoshiyuki Iida, Takatsugu Mizumachi, Takashi Fujii, Fumihiko Matsumoto, Takeshi Beppu, Masafumi Yoshida, Hirotaka Shinomiya, Ryosuke Kamiyama, Mutsukazu Kitano, Kazuhiko Yokoshima, Yasushi Fujimoto, Takanori Hama, Taku Yamashita, Kenji Okami, Kouki Miura, Takuo Fujisawa, Daisuke Sano, Hisayuki Kato, Shujiro Minami, Masashi Sugasawa, Muneyuki Masuda, Ichiro Ota, Shigemichi Iwae, Ryo Kawata, Nobuya Monden, Takayuki Imai, Takahiro Asakage, Masafumi Okada, Takanori Yoshikawa, Kensuke Tanioka, Megumi Kitayama, Mariko Doi, Satoshi Fujii, Masato Fujii, Nobuhiko Oridate, Munenaga Nakamizo, Seiichi Yoshimoto, Akihiro Homma, Ken‐ichi Nibu, Katsunari Yane
  Cancer, 126, 18, 4177, 4187, Wiley, 2020年07月10日, ［査読有り］
  研究論文（学術雑誌）
• Preoperative Pulmonary Function Testing to Predict Recurrence of Chronic Rhinosinusitis With Nasal Polyps
  Yuji Nakamaru, Masanobu Suzuki, Aya Honma, Akira Nakazono, Shogo Kimura, Keishi Fujiwara, Shinya Morita, Satoshi Konno, Akihiro Homma
  ALLERGY & RHINOLOGY, 11, 2020年07月
  英語, 研究論文（学術雑誌）
• 上・中・下咽頭癌に対する陽子線治療の初期経験　　　　　　　　　　　　　　　
  安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史
  頭頸部癌, 46, 2, 161, 161, (一社)日本頭頸部癌学会, 2020年07月
  日本語
• 休日による総治療期間延長に対して1回線量増加の方法を組み合わせて放射線治療を行った早期声門癌の検討　　　　　　　　　　　　　　　
  出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 本間 明宏, 青山 英史
  頭頸部癌, 46, 2, 179, 179, (一社)日本頭頸部癌学会, 2020年07月
  日本語
• 頭頸部粘膜悪性黒色腫に対する術後陽子線治療30GyE/5回の初期経験　　　　　　　　　　　　　　　
  湊川 英樹, 安田 耕一, 出倉 康裕, 鈴木 正宣, 中丸 裕爾, 中薗 彬, 鈴木 崇祥, 対馬 那由多, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史
  頭頸部癌, 46, 2, 188, 188, (一社)日本頭頸部癌学会, 2020年07月
  日本語
• Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus.
  Hisham Mehanna, John C Hardman, Jared A Shenson, Ahmad K Abou-Foul, Michael C Topf, Mohammad AlFalasi, Jason Y K Chan, Pankaj Chaturvedi, Velda Ling Yu Chow, Andreas Dietz, Johannes J Fagan, Christian Godballe, Wojciech Golusiński, Akihiro Homma, Sefik Hosal, N Gopalakrishna Iyer, Cyrus Kerawala, Yoon Woo Koh, Anna Konney, Luiz P Kowalski, Dennis Kraus, Moni A Kuriakose, Efthymios Kyrodimos, Stephen Y Lai, C Rene Leemans, Paul Lennon, Lisa Licitra, Pei-Jen Lou, Bernard Lyons, Haitham Mirghani, Anthonny C Nichols, Vinidh Paleri, Benedict J Panizza, Pablo Parente Arias, Mihir R Patel, Cesare Piazza, Danny Rischin, Alvaro Sanabria, Robert P Takes, David J Thomson, Ravindra Uppaluri, Yu Wang, Sue S Yom, Yi-Ming Zhu, Sandro V Porceddu, John R de Almeida, Chrisian Simon, F Christopher Holsinger
  The Lancet. Oncology, 21, 7, e350-e359, 2020年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of three rounds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology, representing 35 international professional societies and national clinical trial groups. Endorsed by 39 societies and professional bodies, these consensus practice recommendations aim to decrease inconsistency of practice, reduce uncertainty in care, and provide reassurance for clinicians worldwide for head and neck surgical oncology in the context of the COVID-19 pandemic and in the setting of acute severe resource constraint and high risk of infection to patients and staff.
• Evaluation of Semicircular Canal Function by Video Head Impulse Test in Patients With Facial Nerve Schwannoma.
  Keishi Fujiwara, Shinya Morita, Yasushi Furuta, Hiroko Yanagi, Kimiko Hoshino, Atsushi Fukuda, Yuji Nakamaru, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 41, 5, e615-e622, 2020年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The aim of the present study was to evaluate semicircular canal function by video Head Impulse Test (vHIT) in patients with facial nerve schwannoma (FNS). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Seven patients with FNS underwent vHIT examination. MAIN OUTCOME MEASURES: The gain in vestibulo-ocular reflex and the presence of catch-up saccade were examined for the semicircular canals including the vertical canals. RESULTS: Dysfunction of the semicircular canals was detected by vHIT in three of seven cases. Nystagmus beating toward the non-affected side was observed in all three cases with semicircular canal dysfunction. Dysfunction was observed in a case with no direct compression of the vestibular nerve or semicircular canals by FNS. CONCLUSIONS: Semicircular canal function in patients with FNS could be evaluated by vHIT. vHIT has two advantages for the evaluation of vestibular function in patients with FNS. First, vHIT could be used for the patients in whom a tumor exists in the external auditory canal or middle ear, unlike caloric testing. Second, as vHIT could evaluate all three canals, impaired vestibular nerves could be speculated from vHIT results when a tumor exists in internal auditory canal. vHIT should be performed in patients with FNS, especially before surgery, to evaluate vestibular function.
• A novel study for fluorescence patterns of the parathyroid glands during surgery using a fluorescence spectroscopy system
  Hiroshi Idogawa, Tomohiro Sakashita, Akihiro Homma
  European Archives of Oto-Rhino-Laryngology, 277, 5, 1525, 1529, Springer, 2020年05月01日
  英語, 研究論文（学術雑誌）
• Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
  Takashi Kitagataya, Goki Suda, Kazunori Nagashima, Takehiko Katsurada, Koji Yamamoto, Megumi Kimura, Osamu Maehara, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Shunsuke Ohnishi, Yoshito Komatsu, Hiroo Hata, Satoshi Takeuchi, Takashige Abe, Jun Sakakibara-Konishi, Takanori Teshima, Akihiro Homma, Naoya Sakamoto
  Journal of gastroenterology and hepatology, 35, 10, 1782, 1788, 2020年03月18日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
• video Head Impulse Testを用いた顔面神経鞘腫症例の半規管機能評価
  藤原 圭志, 古田 康, 本間 明宏
  Facial Nerve Research, 39, 121, 124, 日本顔面神経学会, 2020年03月
  日本語
• A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
  Tomohiro Enokida, Takenori Ogawa, Akihiro Homma, Kenji Okami, Shujiro Minami, Ayako Nakanome, Yasushi Shimizu, Daisuke Maki, Yuri Ueda, Takao Fujisawa, Atsushi Motegi, Akira Ohkoshi, Jun Taguchi, Koji Ebisumoto, Shogo Nomura, Susumu Okano, Makoto Tahara
  Cancer medicine, 9, 5, 1671, 1682, 2020年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Induction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) often compromises compliance with subsequent chemoradiotherapy (CRT), which negatively affects outcomes. Here, we assessed the combination of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN. METHODS: Induction chemotherapy consisted of weekly CBDCA area under the plasma concentration-time curve = 1.5, PTX 80 mg/m2 and Cmab with an initial dose of 400 mg/m2 followed by 250 mg/m2 for 8 weeks. Following IC, CDDP (20 mg/m2 , 4 days × 3 cycles) and concurrent radiotherapy (70 Gy/35 fr) were started. Primary endpoint was the proportion of CRT completion (%CRT completion). PCE was planned to be deemed effective if the Bayesian posterior probability (PP), defined as the probability that %CRT completion was larger than the threshold value of 65%, exceeded 84%. RESULTS: Thirty-five patients were enrolled. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all at Stage IV. Of 35 patients, 34 (97%) completed IC and 32 received CRT and met the criteria of full analysis set (FAS). In FAS, the %CRT completion was 96.9%, and PP was 99.9%, exceeding the prespecified boundary of 84%. Mean cumulative dose and relative to dose intensity of CDDP in CRT was 232.5 mg/m2 and 100%, respectively. Response rate was 88.6% by IC and 93.8% in the CRT phase. Three year overall survival was 83.5%. Main grade 3 toxicities included neutropenia (11.4%) and skin rash (5.7%) during IC; and oral mucositis (31.3%) and neutropenia (12.5%) during CRT. No grade 4 toxicity or treatment-related death was seen. CONCLUSIONS: PCE as IC was feasible, with promising efficacy and no effect on compliance with subsequent CRT in unresectable LA-SCCHN.
• Minimally invasive surgery for laryngopharyngeal cancer: Multicenter feasibility study of a combination strategy involving transoral surgery and real-time indocyanine green fluorescence-navigated sentinel node navigation surgery.
  Koji Araki, Masayuki Tomifuji, Akihiro Shiotani, Shigeru Hirano, Junkichi Yokoyama, Kiyoaki Tsukahara, Akihiro Homma, Seichi Yoshimoto, Yasuhisa Hasegawa
  Head & neck, 42, 2, 254, 261, 2020年02月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Sentinel node navigation surgery using indocyanine green (ICG-SNNS) can be performed in the operation room. The combination of minimally invasive transoral surgery (TOS) with ICG-SNNS can provide functional preservation options for both primary lesions and lymph node (LN) metastasis. This multicenter feasibility study of this strategy was conducted in Japan. METHODS: Patients with clinical T1 or T2, N0 oropharyngeal, hypopharyngeal, or supraglottic cancer were enrolled. The identification rate of sentinel nodes, delayed cervical LN metastasis in 2 years, and survival rate were assessed. RESULTS: Twenty-two patients (10 oropharynx, 8 hypopharynx, 4 supraglottic cancer) were enrolled. The identification rate was 100%. One case had delayed nodal metastasis. The accuracy was 95.5%, sensitivity was 75%, and specificity was 100%. The 5-year disease-specific survival was 100%, overall survival was 72.3%, and disease-free survival was 60.5%. CONCLUSIONS: The combination of TOS with ICG-SNNS is feasible as a minimally invasive strategy and has favorable oncological outcomes.
• Questionnaire survey to evaluate the features of Post Earthquake Dizziness Syndrome in Hokkaido
  Keishi Fujiwara, Yasuyuki Nomura, Hiroko Yanagi, Akihiro Homma
  Equilibrium Research, 79, 4, 251, 256, Japan Society for Equilibrium Research, 2020年
  日本語, 研究論文（学術雑誌）
• Analysis of semicircular canal function as evaluated by video Head Impulse Test in patients with vestibular schwannoma.
  Keishi Fujiwara, Shinya Morita, Atsushi Fukuda, Hiroki Akamatsu, Hiroko Yanagi, Kimiko Hoshino, Yuji Nakamaru, Satoshi Kano, Akihiro Homma
  Journal of vestibular research : equilibrium & orientation, 30, 2, 101, 108, 2020年, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: The aim of the present study was to investigate the factors influencing semicircular canal function as evaluated by video Head Impulse Test (vHIT) in patients with vestibular schwannoma. METHODS: Twenty-four patients with untreated vestibular schwannoma underwent vHIT examination. The correlations between semicircular canal function and factors including age, tumor size, disease duration and hearing loss were evaluated. RESULTS: The functions of all three semicircular canals on the affected side evaluated by vHIT were significantly lower than those on the unaffected side. Although there were no significant correlations between semicircular canal function and age, tumor size or disease duration, a negative significant correlation between vestibulo-ocular reflex (VOR) gain as evaluated by vHIT and hearing loss was observed. CONCLUSIONS: From the results of the relationship between hearing loss and VOR gain, the damage to the audio and vestibular systems in patients with VS may be correlated. As it has been suggested that tumor size was not a significant factor in the VOR gain evaluated by vHIT, multifactorial causes rather than the simple compression of the vestibular nerves alone may be related to the dysfunction of the semicircular canals in patients with vestibular schwannoma.
• Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma.
  Takayoshi Suzuki, Satoshi Kano, Masanobu Suzuki, Shinichiro Yasukawa, Takatsugu Mizumachi, Nayuta Tsushima, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Akihiro Homma
  Frontiers in oncology, 10, 603717, 603717, 2020年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Salivary duct carcinoma (SDC) is morphologically similar to breast cancer, with HER2-overexpression reported. With regard to the pattern of disease onset, SDC can arise from de novo or carcinoma ex-pleomorphic adenoma (Ca-ex-PA). Recently, multiple molecular profiles of SDC as well as breast cancer have been reported, with significant differences in HER2 expression between Ca-ex-PA and de novo. We assessed the differences in gene expression between onset classifications. We conducted immunohistochemical analysis and HER2-DISH for 23 patients and classified SDCs into three subtypes as follows: "HER2-positive" (HER2+/any AR), "Luminal-AR" (HER2-/AR+), and "Basal-like" (HER2-/AR-). We assessed the expression levels of 84 functional genes for 19 patients by using a qRT-PCR array. Ten cases were classified as HER2-positive, seven cases as Luminal-AR, and six cases as Basal-like. The gene expression pattern was generally consistent with the corresponding immunostaining classification. The expression levels of VEGFA, ERBB2(HER2), IGF1R, RB1, and XBP1 were higher, while those of SLIT2 and PTEN were lower in Ca-ex-PA than in de novo. The functions of those genes were concentrated in angiogenesis and AKT/PI3K signaling pathway (Fisher's test: p-value = 0.025 and 0.004, respectively). Multiple machine learning methods, OPLS-DA, LASSO, and RandomForest, also show that VEGFA can be a candidate for the characteristic differences between Ca-ex-PA and de novo. In conclusion, the AKT/PI3K signaling pathway leading to angiogenesis was hyper-activated in all SDCs, particularly in those classified into the Ca-ex-PAs. VEGFA was over-expressed significantly in the Ca-ex-PA, which can be a crucial factor in the malignant conversion to SDC.
• Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1)
  Yoshinori Imamura, Naomi Kiyota, Gakuto Ogawa, Tetsuo Akimoto, Masato Fujii, Nobuhiro Hanai, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Yusuke Onozawa, Ryuichi Hayashi, Makoto Tahara, Shujiro Minami, Hirofumi Fujii, Akihiro Homma, Junko Eba
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 49, 11, 1009, 1015, 2019年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CCRTを施行した進行頭頸部癌患者に対する予防的胃瘻増設の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 横川 泰三, 本間 明宏
  日本癌治療学会学術集会抄録集, 57回, P4, 4, (一社)日本癌治療学会, 2019年10月
  英語
• 北海道胆振東部地震における地震後めまい症候群に関するアンケート調査
  藤原 圭志, 野村 泰之, 柳 紘子, 矢島 諒人, 高野 賢一, 氷見 徹夫, 本間 明宏
  Equilibrium Research, 78, 5, 539, 539, (一社)日本めまい平衡医学会, 2019年10月
  日本語
• 地震後めまい症候群 「平成30年北海道胆振東部地震」における苫小牧での経験　　　　　　　　　　　　　　　
  野村 泰之, 志津木 健, 藤原 圭志, 本間 明宏, 矢島 諒人, 高野 賢一, 氷見 徹夫, 大島 猛史
  日本耳科学会総会・学術講演会抄録集, 29回, 350, 350, (一社)日本耳科学会, 2019年10月
  日本語
• 好酸球性中耳炎(EOM)と中耳炎を合併した好酸球性多発血管炎性肉芽腫症(EGPA)の比較　　　　　　　　　　　　　　　
  福田 篤, 森田 真也, 藤原 圭志, 干野 季美子, 中丸 裕爾, 本間 明宏
  日本耳科学会総会・学術講演会抄録集, 29回, 508, 508, (一社)日本耳科学会, 2019年10月
  日本語
• 当科における局所進行外耳道扁平上皮癌の治療成績の検討
  加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 対馬 那由多, 鈴木 崇祥, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
  頭頸部癌, 45, 3, 300, 304, (一社)日本頭頸部癌学会, 2019年10月
  日本語
• 日本人の頭頸部扁平上皮癌患者に対するCetuximab併用放射線治療の観察研究(JROSG12-2) 有害事象に関する中間評価
  太田 陽介, 古平 毅, 藤井 博文, 下川 元継, 中島 寅彦, 門田 伸也, 横田 知哉, 本間 明宏, 上田 眞也, 秋元 哲夫
  頭頸部癌, 45, 3, 330, 336, (一社)日本頭頸部癌学会, 2019年10月, ［査読有り］
  日本語
• 【二次出版】ANL Secondary Publication 急性感音難聴患者における抗ムンプスIgM抗体陽性率 北海道における後向き多施設共同研究
  福田 篤, 森田 真也, 中丸 裕爾, 干野 季美子, 藤原 圭志, 赤澤 茂, 坂下 智博, 小原 修幸, 本間 明宏
  日本耳鼻咽喉科学会会報, 122, 9, 1267, 1268, (一社)日本耳鼻咽喉科学会, 2019年09月
  日本語
• 当院における外鼻形成術および鼻中隔矯正術施行例の検討　　　　　　　　　　　　　　　
  木村 将吾, 中丸 裕爾, 鈴木 正宣, 本間 あや, 中薗 彬, 本間 明宏
  日本鼻科学会会誌, 58, 3, 632, 632, (一社)日本鼻科学会, 2019年09月
  日本語
• Differentiation Between Eosinophilic Otitis Media and Otitis Media Associated With Eosinophilic Granulomatosis With Polyangiitis.
  Atsushi Fukuda, Shinya Morita, Yuji Nakamaru, Kimiko Hoshino, Keishi Fujiwara, Akihiro Homma
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 40, 8, e796-e802, 2019年09月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: To perform comparisons and clarify differences in clinical manifestations between eosinophilic otitis media (EOM) and otitis media associated with eosinophilic granulomatosis with polyangiitis (EGPA). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Twenty-two ears of 11 patients exhibiting EOM (EOM group) and 20 ears of 12 patients exhibiting otitis media associated with EGPA (EGPA group). MAIN OUTCOME MEASURES: Otological manifestations, nasal and paranasal manifestations, incidence of asthma, positivity for serum antineutrophil cytoplasmic antibodies (ANCA), total serum immunoglobulin (Ig) E level, peripheral blood eosinophil fraction, and hearing outcomes. RESULTS: The incidence and age of onset of asthma and chronic rhinosinusitis were comparable between the EOM and EGPA groups. Moreover, otological findings and hearing outcomes at the initial visit were similar in both groups. Computed tomography images of the paranasal sinus showed predominant opacification of the ethmoid sinus in both groups. Although the total serum IgE level was not significantly different, the peripheral blood eosinophil fraction was significantly larger in the EGPA group than in the EOM group (p = 0.0035). Furthermore, the rate of myeloperoxidase-antineutrophil cytoplasmic antibodies (ANCA) positivity was significantly higher in the EGPA group than in the EOM group (p = 0.019). CONCLUSIONS: The findings of the present study suggest that the phenotypic characteristics of EOM closely resemble those of otitis media associated with EGPA in early stages before the appearance of vasculitis. Therefore, it is challenging to differentiate the two conditions purely on the basis of otorhinological examinations.
• Make-Up Therapy for Patients With Facial Nerve Palsy.
  Keishi Fujiwara, Yasushi Furuta, Wakae Aoki, Yuji Nakamaru, Shinya Morita, Kimiko Hoshino, Atsushi Fukuda, Akihiro Homma
  The Annals of otology, rhinology, and laryngology, 128, 8, 721, 727, 2019年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: To investigate the effectiveness of make-up therapy for patients with facial nerve palsy. METHODS: Seven female patients with facial nerve palsy who received specialist make-up therapy were enrolled. The objective of the make-up therapy was to obtain a symmetrical facial appearance. RESULTS: Overall score for the Facial Clinimetric Evaluation (FaCE) scale was significantly improved after make-up therapy. There was a tendency for symptoms of depression to be improved among patients after make-up therapy. CONCLUSION: Make-up therapy to improve the symmetry of facial appearance could afford a noninvasive and low-cost treatment for patients with facial nerve palsy, especially in terms of patient quality of life and psychological condition.
• Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
  Barbara Burtness, Robert Haddad, José Dinis, José Trigo, Tomoya Yokota, Luciano de Souza Viana, Ilya Romanov, Jan Vermorken, Jean Bourhis, Makoto Tahara, José Getulio Martins Segalla, Amanda Psyrri, Irina Vasilevskaya, Chaitali Singh Nangia, Manuel Chaves-Conde, Naomi Kiyota, Akihiro Homma, Petra Holeckova, Josep Maria Del Campo, Nirav Asarawala, Ulisses Ribaldo Nicolau, Daniel Rauch, Caroline Even, Bushi Wang, Neil Gibson, Eva Ehrnrooth, Kevin Harrington, Ezra E W Cohen
  JAMA oncology, 5, 8, 1170, 1180, 2019年08月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, Importance: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC. Objective: To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC. Design, Setting, and Participants: This multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 patients from November 2, 2011, to July 4, 2016. Patients who had complete response after CRT, comprising radiotherapy with cisplatin or carboplatin, with or without resection of residual disease, for locoregionally advanced high- or intermediate-risk HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx were included in the study. Data analysis was of the intention-to-treat population. Interventions: Patients were randomized (2:1) to treatment with afatinib (40 mg/d) or placebo, stratified by nodal status (N0-2a or N2b-3) and Eastern Cooperative Oncology Group performance status (0 or 1). Treatment continued for 18 months or until disease recurrence, unacceptable adverse events, or patient withdrawal. Main Outcomes and Measures: The primary end point was DFS, defined as time from the date of randomization to the date of tumor recurrence or secondary primary tumor or death from any cause. Secondary end points were DFS at 2 years, overall survival (defined as time from the date of randomization to death), and health-related quality of life. Results: A total of 617 patients were studied (mean [SD] age, 58 [8.4] years; 528 male [85.6%]). Recruitment was stopped after a preplanned interim futility analysis on July 4, 2016, on recommendation from an independent data monitoring committee. Treatment was discontinued. Median DFS was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57; stratified log-rank test P = .48). The most common grade 3 and 4 drug-related adverse effects were acneiform rash (61 [14.8%] of 411 patients in the afatinib group vs 1 [0.5%] of 206 patients in the placebo group), stomatitis (55 [13.4%] in the afatinib group vs 1 [0.5%] in the placebo group), and diarrhea (32 [7.8%] in the afatinib group vs 1 [0.5%] in the placebo group). Conclusions and Relevance: This study's findings indicate that treatment with afatinib after CRT did not improve DFS and was associated with more adverse events than placebo in patients with primary, unresected, clinically high- to intermediate-risk HNSCC. The use of adjuvant afatinib after CRT is not recommended. Trial Registration: ClinicalTrials.gov identifier: NCT01345669.
• Machine-Learning-Based Prediction of Treatment Outcomes Using MR Imaging-Derived Quantitative Tumor Information in Patients with Sinonasal Squamous Cell Carcinomas: A Preliminary Study.
  Fujima N, Shimizu Y, Yoshida D, Kano S, Mizumachi T, Homma A, Yasuda K, Onimaru R, Sakai O, Kudo K, Shirato H
  Cancers, 11, 6, 2019年06月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The purpose of this study was to determine the predictive power for treatment outcome of a machine-learning algorithm combining magnetic resonance imaging (MRI)-derived data in patients with sinonasal squamous cell carcinomas (SCCs). Thirty-six primary lesions in 36 patients were evaluated. Quantitative morphological parameters and intratumoral characteristics from T2-weighted images, tumor perfusion parameters from arterial spin labeling (ASL) and tumor diffusion parameters of five diffusion models from multi-b-value diffusion-weighted imaging (DWI) were obtained. Machine learning by a non-linear support vector machine (SVM) was used to construct the best diagnostic algorithm for the prediction of local control and failure. The diagnostic accuracy was evaluated using a 9-fold cross-validation scheme, dividing patients into training and validation sets. Classification criteria for the division of local control and failure in nine training sets could be constructed with a mean sensitivity of 0.98, specificity of 0.91, positive predictive value (PPV) of 0.94, negative predictive value (NPV) of 0.97, and accuracy of 0.96. The nine validation data sets showed a mean sensitivity of 1.0, specificity of 0.82, PPV of 0.86, NPV of 1.0, and accuracy of 0.92. In conclusion, a machine-learning algorithm using various MR imaging-derived data can be helpful for the prediction of treatment outcomes in patients with sinonasal SCCs.
• A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition).
  Head and, Neck Cancer, Study Group, HNCSG, Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N, Kodaira T, Zenda S, Fujii H, Tahara M, Yokota T, Akimoto T, Iwae S, Onitsuka T, Ogawa T, Okano S, Takahashi S, Shimizu Y, Yonezawa K, Hayashi R
  Japanese journal of clinical oncology, 49, 7, 589, 595, 2019年06月, ［査読有り］
  研究論文（学術雑誌）
• 扁平上皮癌におけるTripartite motif-containing protein 29(TRIM 29)の検討　　　　　　　　　　　　　　　
  柳 輝希, 秦 洋郎, 北村 真也, 清水 宏, 柳 紘子, 本間 明宏, 渡部 昌, 畠山 鎮次
  日本皮膚科学会雑誌, 129, 5, 1170, 1170, (公社)日本皮膚科学会, 2019年05月
  日本語
• 舌扁平上皮癌における改訂UICC TNM分類第8版の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 対馬 那由多, 水町 貴諭, 鈴木 崇祥, 浜田 誠二郎, 本間 明宏
  頭頸部癌, 45, 2, 157, 157, (一社)日本頭頸部癌学会, 2019年05月
  日本語
• 多形腺腫由来型唾液腺導管癌に特徴的な遺伝子発現の探索　　　　　　　　　　　　　　　
  鈴木 崇洋, 加納 里志, 浜田 誠二郎, 対馬 那由多, 水町 貴諭, 本間 明宏
  頭頸部癌, 45, 2, 221, 221, (一社)日本頭頸部癌学会, 2019年05月
  日本語
• Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
  Satoshi Hamauchi, Tomoya Yokota, Takatsugu Mizumachi, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuo Nishimura, Tetsuro Onitsuka, Hirofumi Yasui, Akihiro Homma
  International journal of clinical oncology, 24, 5, 468, 475, 2019年05月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is usually treated with cisplatin (CDDP)-based chemoradiotherapy, except when patients are elderly or have renal, cardiac, or neurogenic dysfunction. This study compared the safety and efficacy of concurrent carboplatin (CBDCA) to cetuximab (Cmab) plus radiotherapy (RT) in patients ineligible for CDDP treatment. METHODS: We retrospectively analyzed LASCCHN patients who received CBDCA plus RT (n = 29) or Cmab plus RT (n = 18) due to ineligibility for CDDP treatment at two Japanese institutions between August 2006 and December 2015. RESULTS: Patients characteristics for CBDCA plus RT and Cmab plus RT were: median age, 74 and 75 years; 0-1 performance status, 90% and 100%; main primary tumor site, hypopharynx 52% (n = 15) and oropharynx 39% (n = 7); and stage IV, 90% (n = 26) and 50% (n = 9), respectively. With a median follow-up time of 60.0 months for CBDCA plus RT and 53.6 months for Cmab plus RT, 3-year locoregional control rates were 56% versus 58%, and median progression-free survival was 42.7 versus 11.6 months. CBDCA plus RT was associated with more grade 3/4 hematologic toxicities, including neutropenia and thrombocytopenia, whereas Cmab plus RT was associated with more grade 3/4 oral mucositis and radiation dermatitis. CONCLUSIONS: CBDCA or Cmab as a concurrent systemic therapy with RT is a possible treatment option for LASCCHN patients ineligible for CDDP treatment, although attention to hematological toxicity should be paid.
• 強度変調X線治療および強度変調陽子線治療における皮膚炎と皮膚線量に関する検討　　　　　　　　　　　　　　　
  安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹
  頭頸部癌, 45, 2, 134, 134, (一社)日本頭頸部癌学会, 2019年05月
  日本語
• 外耳道癌における強度変調陽子線治療と強度変調X線治療との線量分布の比較　　　　　　　　　　　　　　　
  出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹
  頭頸部癌, 45, 2, 138, 138, (一社)日本頭頸部癌学会, 2019年05月
  日本語
• 頭頸部癌におけるがん免疫療法の進展
  田原 信, 清田 尚臣, 本間 明宏
  がん免疫療法, 3, 1, 12, 19, (株)メディカルレビュー社, 2019年05月
  日本語
• Desmoplastic small round cell tumor of the parotid gland-report of a rare case and a review of the literature.
  Hatanaka KC, Takakuwa E, Hatanaka Y, Suzuki A, IIzuka S, Tsushima N, Mitsuhashi T, Sugita S, Homma A, Morinaga S, Hashegawa T, Matsuno Y
  Diagnostic pathology, 14, 1, 43, 43, 2019年05月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare soft tissue tumor that generally involves the retroperitoneum, pelvis, omentum and mesentery in younger patients. However, extra-abdominal DSRCT is very rare. CASE PRESENTATION: A 49-year-old Japanese man noticed a mass in the right parotid gland. Ultrasound examination revealed a solid tumor about 2 cm in diameter. Computed tomography (CT) of the whole body revealed no other tumors or lymph node swelling. Superficial parotidectomy was performed. Histologically, the tumor was composed of various-sized tumor cell nests in an abundant fibromyxoid and collagenous background. The tumor cells were small to medium-sized. Immunohistochemistry showed that the tumor cells were immunoreactive for epithelial markers and desmin. They also showed strong nuclear staining with a Wilms tumor 1 (WT1) antibody detecting the C-terminal region (C-WT1), but not the N-terminal region (N-WT1). We also performed 3'/5' expression imbalance assay based on reverse transcription polymerase chain reaction (RT-PCR) to determine whether aberrant WT1 gene expression was present. This tumor was found to lack 5'-regional expression of the WT1 gene, as well as immunoreactivity with the N-WT1 antibody. Finally, fluorescence in situ hybridization (FISH) and RT-PCR analyses revealed the presence of a gene showing fusion between exon 7 of EWSR1 and exon 8 of WT1. The tumor was diagnosed as a DSRCT of the right parotid gland. The patient has been followed for 3 years without recurrence or metastasis. CONCLUSIONS: Although DSRCT in the salivary gland is extremely rare, it should be included in the differential diagnosis of poorly differentiated salivary gland neoplasms, especially with a fibromyxoid background. Pathologists should bear in mind that DSRCT may occur in major salivary glands and should perform immunohistochemistry with appropriate antibodies, not only those against keratin and desmin, but also one detecting the C-terminal region of WT-1. Furthermore, molecular detection of EWSR1-WT1 fusion gene conclusively confirmed the diagnosis of DSRCT in this uncommon location.
• 好酸球性中耳炎EOMと中耳炎を合併した好酸球性多発血管炎性肉芽腫症EGPAの比較
  福田 篤, 森田 真也, 藤原 圭志, 干野 季美子, 中丸 裕爾, 本間 明宏
  日本耳鼻咽喉科学会会報, 122, 4, 627, 627, (一社)日本耳鼻咽喉科学会, 2019年04月
  日本語
• video Head Impulse Testを用いた聴神経腫瘍患者の半規管機能評価
  藤原 圭志, 柳 紘子, 森田 真也, 干野 季美子, 福田 篤, 赤松 明樹, 中丸 裕爾, 本間 明宏
  日本耳鼻咽喉科学会会報, 122, 4, 704, 704, (一社)日本耳鼻咽喉科学会, 2019年04月
  日本語
• 切除不能局所進行頭頸部扁平上皮がんに対するPCE導入化学療法後の化学放射線療法の実施可能性検証試験
  南 修司郎, 榎田 智弘, 小川 武則, 本間 明宏, 大上 研二, 岩江 信法, 中目 亜矢子, 清水 康, 槇 大輔, 上田 百合, 藤澤 孝夫, 茂木 厚, 野村 尚吾, 岡野 晋, 田原 信
  日本耳鼻咽喉科学会会報, 122, 4, 711, 711, (一社)日本耳鼻咽喉科学会, 2019年04月
  日本語
• 頭頸部癌化学放射線療法におけるEPA高配合栄養機能食品(プロシュア)の有用性の検討
  水町 貴諭, 加納 里志, 本間 明宏, 赤澤 美樹子, 長谷川 千春, 城石 陽子, 岡本 千秋, 熊谷 聡美, 西村 雅勝, 高崎 裕代, 武田 宏司, 安田 耕一, 湊川 英樹, 出倉 康裕, 鬼丸 力也, 白土 博樹, 福田 諭
  癌と化学療法, 46, 4, 685, 689, (株)癌と化学療法社, 2019年04月
  日本語
• Controversies in relation to neck management in N0 early oral tongue cancer.
  Nobuhiro Hanai, Takahiro Asakage, Naomi Kiyota, Akihiro Homma, Ryuichi Hayashi
  Japanese journal of clinical oncology, 49, 4, 297, 305, 2019年04月01日, ［査読有り］, ［国際誌］
  英語, The standard local treatment for early-stage tongue cancer with no clinical lymph node metastases is partial glossectomy. The frequency of occult lymph node metastasis is ~20-30%. Thus, whether prophylactic neck dissection with glossectomy or glossectomy alone should be performed has been a controversial issue since the 1980s. Both treatments have advantages and disadvantages; however, especially in cases involving prophylactic neck dissection, surgical invasion and complications including the cosmetic disadvantage caused by neck skin incision, accessory nerve paralysis or facial nerve (mandibular marginal branch) paralysis, stiffness of the shoulder or neck and a feeling of neck tightness have been considered issues that could be solved by providing less-invasive treatment to the 70-80% of patients without occult lymph node metastasis. A more accurate preoperative diagnosis and strict follow-up are required to provide minimally invasive treatment while ensuring the therapeutic effect. It is also necessary to narrow down the target based on the risk-benefit balance. The depth of invasion should be considered in cases involving oral cavity malignancies. This was also taken into account in recent revisions of eighth edition of the TNM Classification of Malignant Tumors and it is an important factor for N0 neck management. This review article summarizes previous and recent reports on neck management, focusing on the risk-benefit and future perspectives of the diagnosis and treatment of early-stage oral tongue cancer. This effort is an attempt to establish treatment from the patient's point of view, with the patient's quality of life taken into account.
• Short-Term Hearing Prognosis of Ossiculoplasty in Pars Flaccida Cholesteatoma Using the EAONO/JOS Staging System.
  Fukuda A, Morita S, Nakamaru Y, Hoshino K, Fujiwara K, Homma A
  The journal of international advanced otology, 15, 1, 2, 7, 2019年04月, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The aim of the present study was to investigate the prognostic factors for short-term hearing outcomes of ossiculoplasty for primary pars flaccida cholesteatoma according to the European Academy of Otology and Neurotology/Japanese Otological Society (EAONO/JOS) and 2015 JOS staging systems. MATERIALS AND METHODS: A total of 34 patients with primary pars flaccida cholesteatoma who underwent one-stage tympanomastoidectomy with partial ossicular reconstruction using double cartilage block were included in the study. The postoperative pure-tone average air-bone gap (PTA-ABG) was calculated, and two criteria of successful hearing outcomes were defined as ≤10 and ≤20 dB. Patients were classified according to the EAONO/JOS and 2015 JOS staging systems. Cochran-Armitage test was used to statistically analyze staging, and Fisher's exact test was used to analyze other factors. RESULTS: Successful hearing outcome with postoperative PTA-ABG ≤10 and ≤20 dB occurred in 23.5% and 55.9% of cases, respectively. When postoperative PTA-ABG ≤20 dB was defined as successful, the success rate significantly decreased with increase in EAONO/JOS stage, and S0 pathological status of the stapes (no involvement) was a significantly favorable predictive factor. When postoperative PTA-ABG ≤10 dB was regarded as successful, the significantly favorable predictive factors were S0 pathological status of the stapes and development of mastoid cells with MC2-3 (better developed cells). CONCLUSION: Favorable prognostic factors for hearing outcomes of tympanomastoidectomy with partial ossicular reconstruction for primary pars flaccida cholesteatoma were low stage following the EAONO/JOS staging system and no stapes involvement and better development of mastoid cells following the 2015 JOS staging system.
• [A Nutritional Supplement with a High Blend Ratio of ω-3 Fatty Acids(Prosure®) Reduces Severe Oral Mucositis and Body Weight Loss for Head and Neck Cancer Patients Treated with Chemoradiotherapy].
  Mizumachi T, Kano S, Homma A, Akazawa M, Hasegawa C, Shiroishi Y, Okamoto C, Kumagai S, Nishimura M, Takasaki H, Takeda H, Yasuda K, Minatogawa H, Dekura Y, Onimaru R, Shirato H, Fukuda S
  Gan to kagaku ryoho. Cancer & chemotherapy, 46, 4, 685, 689, 2019年04月, ［査読有り］, ［国内誌］
  日本語, 研究論文（学術雑誌）, BACKGROUND: Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and the completion rate of chemoradiotherapy in patients with oropharyngeal and hypopharyngeal cancer. PATIENTS AND METHODS: The study group comprised patients with oropharyngeal and hypopharyngeal cancer who were treated with concomitant cisplatin and 70 Gy of radiotherapy. These patients received 2 packs of Prosure®per day during chemoradiotherapy. RESULTS: A total of 17 patients were included in this study. The reduction in body weight was significantly improved compared with that in the historical control group that did not receive Prosure®(7.3% vs 10.3%, p<0.01), and the rate of Grade 3-4 oral mucositis was significantly reduced for the patient groups that received Prosure®(CTCAE v3.0 GradeB3; 24% vs 58%, p<0.05). The completion rate of chemoradiotherapy was not significantly different between both groups(77% vs 60%, NS). CONCLUSIONS: A nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)had effects on oral mucositis and body weight loss in head and neck cancer patients treated with chemoradiotherapy.
• 顔面神経麻痺患者に対するメーキャップ治療の精神面に対する効果
  藤原 圭志, 古田 康, 青木 和香恵, 本間 明宏
  Facial Nerve Research, 38, 147, 149, 日本顔面神経学会, 2019年03月
  日本語
• 強度変調放射線治療中に皮下気腫をきたし,再検証を要した頭頸部癌患者の1例　　　　　　　　　　　　　　　
  湊川 英樹, 安田 耕一, 白土 博樹, 土屋 和彦, 鈴木 隆介, 宮本 直樹, 坂下 智博, 本間 明宏, 福田 諭
  Japanese Journal of Radiology, 37, Suppl., 4, 4, (公社)日本医学放射線学会, 2019年02月
  日本語
• Evaluation of Vertical Semicircular Canal Function in Patients With Vestibular Schwannoma.
  Fujiwara K, Yanagi H, Morita S, Hoshino K, Fukuda A, Nakamaru Y, Homma A
  The Annals of otology, rhinology, and laryngology, 128, 2, 113, 120, 2019年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES:: The aim of this study was to investigate vertical semicircular canal function in patients with vestibular schwannoma (VS) by video head impulse test (vHIT). METHODS:: Fifteen patients with VS who had not received any treatment, including surgery or stereotactic radiotherapy, before vHIT examination were enrolled. Vestibulo-ocular reflex gain and catch-up saccade in vHIT were evaluated. RESULTS:: Dysfunction of anterior and posterior semicircular canals was detected by vHIT in 26.7% and 60.0%, respectively. Six patients (40.0%) demonstrated abnormalities referable to both vestibular nerve divisions. Abnormalities referable to the superior vestibular nerve were identified in 3 patients (20.0%), while 3 patients (20.0%) demonstrated a pattern indicative of inferior vestibular nerve involvement. Anterior semicircular canal vHIT produced fewer abnormalities than did either horizontal or posterior semicircular canal vHIT. CONCLUSIONS:: Dysfunction of the semicircular canals, including the vertical canals, in patients with VS was detected by vHIT. The anterior semicircular canal was less frequently involved than the horizontal or posterior semicircular canal. The examination of the vertical canals by vHIT is useful in the evaluation of vestibular function in patients with VS.
• The Diagnostic and Clinical Utility of the Myeloperoxidase-DNA Complex as a Biomarker in Otitis Media With Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
  Morita S, Nakamaru Y, Nakazawa D, Suzuki M, Hoshino K, Fukuda A, Hattanda F, Kusunoki K, Tomaru U, Ishizu A, Homma A
  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 40, 2, e99, e106, 2019年02月, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: This prospective study aimed to evaluate the diagnostic and clinical utility of the myeloperoxidase (MPO)-DNA complex as a NETosis-derived product in the middle ear fluid of patients with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis (OMAAV). STUDY DESIGN: Prospective study. SETTING: Tertiary referral center. PATIENTS: Twenty-two patients diagnosed with OMAAV. INTERVENTION: Collection of the fluid samples from middle ear. MAIN OUTCOME MEASURE: The levels of the MPO-DNA complex in the fluid samples were quantified using an enzyme-linked immunosorbent assay. RESULTS: Patients with both systemic and localized forms of OMAAV showed significantly higher levels of the MPO-DNA complex compared to the controls (p < 0.001 and p = 0.002, respectively). In particular, they showed significantly higher levels of MPO-DNA complex compared to the controls, regardless of serum antineutrophil cytoplasmic antibody status (p < 0.001 and p < 0.001, respectively) or immunosuppressive therapy (p < 0.001 and p < 0.001, respectively) at the time of sampling. An optical density cutoff value of 0.16 at 405 nm according to the receiver operating characteristic curve showed a sensitivity of 86.4%, specificity of 95.5%, positive predictive value of 95.0% and negative predictive value of 87.5% for the diagnosis of OMAAV. Significant positive correlations were observed between the levels of MPO-DNA complex and the values for air conduction - (r = 0.49, p = 0.022) and bone conduction - pure tone average thresholds (r = 0.45, p = 0.035). CONCLUSIONS: The detection and quantification of the MPO-DNA complex in the otitis media fluid may aid in providing a definite diagnosis as well as predicting the activity and severity of OMAAV.
• The utility of MRI histogram and texture analysis for the prediction of histological diagnosis in head and neck malignancies.
  Fujima N, Homma A, Harada T, Shimizu Y, Tha KK, Kano S, Mizumachi T, Li R, Kudo K, Shirato H
  Cancer imaging : the official publication of the International Cancer Imaging Society, 19, 1, 5, 5, 2019年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• A prospective observation study of Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated by radiotherapy with cetuximab (JROSG12-2): Interim appraisal of the safety and treatment compliance:
  Yosuke Ota, Takeshi Kodaira, Hirofumi Fujii, Mototsugu Shimokawa, Torahiko Nakashima, Nobuya Monden, Tomoya Yokota, Akihiro Homma, Shinya Ueda, Tetsuo Akimoto
  Japanese Journal of Head and Neck Cancer, 45, 3, 330, 336, Japan Society for Head and Neck Cancer, 2019年
  日本語, 研究論文（学術雑誌）
• 扁平上皮におけるTripartite motif-containing protein 29(TRIM29)の機能解析　　　　　　　　　　　　　　　
  柳 輝希, 秦 洋郎, 北村 真也, 今福 恵輔, 清水 宏, 柳 紘子, 本間 明宏, 渡部 昌, 畠山 鎮次
  日本皮膚科学会雑誌, 129, 1, 45, 45, (公社)日本皮膚科学会, 2019年01月
  日本語
• Spontaneous Regression of Swollen Submandibular Glands in IgG4-Related Disease
  Masanobu Suzuki, Yuji Nakamaru, Dai Takagi, Aya Honma, Takayoshi Suzuki, Emi Takakuwa, Shinya Morita, Sarah Vreugde, Akihiro Homma
  Allergy & Rhinology, 10, 215265671881673, 215265671881673, SAGE Publications, 2019年01月
  研究論文（学術雑誌）, IgG4-related disease is a new clinical entity frequently associated with swelling of the submandibular glands (SMGs). The long-term outcome of SMG swelling without steroid therapy remains unknown.
  
  To examine whether swollen SMGs spontaneously regress without steroid therapy in the context of IgG4-related disease and to identify biomarkers that can predict the spontaneous regression of SMG swelling.
  
  The SMG volume of 49 patients diagnosed with IgG4-related disease was calculated by measuring the axial and coronal planes of computed tomography scans. The change in SMG volume over time was measured and examined by treatment regimen, clinical data, and serum complement level.
  
  We found 28 of 49 (57%) IgG4-related disease patients to have swollen SMGs, with 15 of 20 (75%) of the swollen SMGs regressing without steroid therapy. The time required for the SMGs swelling to regress was significantly shorter in the steroid therapy group than in the no-steroid therapy group. Serum complement components at the initial visit were significantly lower in the regressed SMG group than in the nonregressed SMG group.
  
  We observed 75% of swollen SMGs spontaneously regressed in patients with IgG4-related disease. The time required for the swollen SMGs to regress was longer in patients without steroid therapy than in those with steroid therapy. Serum complement level could be used as a predictor for the spontaneous regression of swollen SMGs in patients with IgG4-related disease.
  
  
• Treatment outcomes of local advanced external auditory canal squamous cell carcinomas
  Satoshi Kano, Shinya Morita, Yuji Nakamaru, Takatsugu Mizumachi, Nayuta Tsushima, Takayoshi Suzuki, Akira Nakazono, Atsushi Fukuda, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Akihiro Homma
  Japanese Journal of Head and Neck Cancer, 45, 3, 300, 304, 2019年, ［査読有り］, ［最終著者］
  研究論文（学術雑誌）
• 頭頸部癌患者の口腔支持療法と地域連携
  秦 浩信, 吉川 和人, 今待 賢治, 村井 知佳, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政
  頭頸部癌, 44, 4, 380, 386, (一社)日本頭頸部癌学会, 2018年12月
  日本語
• Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND).
  Kiyo Tanaka, Nobuhiro Hanai, Junko Eba, Junki Mizusawa, Takahiro Asakage, Akihiro Homma, Naomi Kiyota, Haruhiko Fukuda, Ryuichi Hayashi
  Japanese journal of clinical oncology, 48, 12, 1105, 1108, 2018年12月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, For stage I/II tongue cancer patients, it is controversial whether prophylactic neck dissection should be performed with partial glossectomy. Based on the evidence of the primary tumor's depth of invasion as a predictive factor of occult lymph node metastases and a prognostic factor of disease-free survival, randomized phase III trial was initiated in November 2017 to evaluate the omission value for prophylactic neck dissection for stage I/II tongue cancer with 3-10 mm of depth of invasion. In 5 years, 440 patients will be accrued from 28 institutions. The primary end point of the study is the overall survival, whereas the secondary end points are relapse-free survival, local relapse-free survival, proportion of unresectable relapse and of cervical lymph node relapse, post-operative function (paralysis of the accessory and facial nerves and subjective symptoms) and adverse events. This trial has been registered with the UMIN Clinical Trials Registry (registration number: UMIN000030098; http://www.umin.ac.jp/ctr/index.htm).
• Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients.
  N Fujima, K Hirata, T Shiga, R Li, K Yasuda, R Onimaru, K Tsuchiya, S Kano, T Mizumachi, A Homma, K Kudo, H Shirato
  Clinical radiology, 73, 12, 1059.e1-1059.e8, 2018年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIM: To assess potential prognostic factors in pharynx squamous cell carcinoma (SCC) patients by quantitative morphological and intratumoural characteristics obtained by 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (FDG-PET/CT). MATERIALS AND METHODS: The cases of 54 patients with pharynx SCC who underwent chemoradiation therapy were analysed retrospectively. Using their FDG-PET data, the quantitative morphological and intratumoural characteristics of 14 parameters were calculated. The progression-free survival (PFS) and overall survival (OS) information was obtained from patient medical records. Univariate and multivariate analyses were performed to assess the 14 quantitative parameters as well as the T-stage, N-stage, and tumour location data for their relation to PFS and OS. When an independent predictor was suggested in the multivariate analysis, the parameter was further assessed using the Kaplan-Meier method. RESULTS: In the assessment of PFS, the univariate and multivariate analyses indicated the following as independent predictors: the texture parameter of homogeneity and the morphological parameter of sphericity. In the Kaplan-Meier analysis, the PFS rate was significantly improved in the patients who had both a higher value of homogeneity (p=0.01) and a higher value of sphericity (p=0.002). With the combined use of homogeneity and sphericity, the patients with different PFS rates could be divided more clearly. CONCLUSION: The quantitative parameters of homogeneity and sphericity obtained by FDG-PET can be useful for the prediction of the PFS of pharynx SCC patients, especially when used in combination.
• Loss of TRIM29 alters keratin distribution to promote cell invasion in squamous cell carcinoma.
  Yanagi T, Watanabe M, Hata H, Kitamura S, Imafuku K, Yanagi H, Homma A, Wang L, Takahashi H, Shimizu H, Hatakeyama S
  Cancer research, 78, 24, 6795, 6806, 2018年11月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, : TRIM29 (tripartite motif-containing protein 29) is a TRIM family protein that has been implicated in breast, colorectal, and pancreatic cancers. However, its role in stratified squamous epithelial cells and tumors has not been elucidated. Here, we investigate the expression of TRIM29 in cutaneous head and neck squamous cell carcinomas (SCC) and its functions in the tumorigenesis of such cancers. TRIM29 expression was lower in malignant SCC lesions than in adjacent normal epithelial tissue or benign tumors. Lower expression of TRIM29 was associated with higher SCC invasiveness. Primary tumors of cutaneous SCC showed aberrant hypermethylation of TRIM29. Depletion of TRIM29 increased cancer cell migration and invasion; conversely, overexpression of TRIM29 suppressed these. Comprehensive proteomics and immunoprecipitation analyses identified keratins and keratin-interacting protein FAM83H as TRIM29 interactors. Knockdown of TRIM29 led to ectopic keratin localization of keratinocytes. In primary tumors, lower TRIM29 expression correlated with the altered expression of keratins. Our findings reveal an unexpected role for TRIM29 in regulating the distribution of keratins, as well as in the migration and invasion of SCC. They also suggest that the TRIM29-keratin axis could serve as a diagnostic and prognostic marker in stratified epithelial tumors and may provide a target for SCC therapeutics. SIGNIFICANCE: These findings identify TRIM29 as a novel diagnostic and prognostic marker in stratified epithelial tissues.
• 喉頭癌cT3の喉頭温存治療(CRT vs RADPLAT) 喉頭癌に対する超選択的動注と放射線同時併用療法
  本間 明宏, 加納 里志, 水町 貴諭, 中薗 彬, 鈴木 崇祥, 坂下 智博, 福田 諭, 鬼丸 力也, 安田 耕一, 湊川 英樹, 出倉 康裕, 土屋 和彦, 白土 博樹
  日本気管食道科学会会報, 69, 5, 319, 320, (NPO)日本気管食道科学会, 2018年10月
  日本語
• 聴神経腫瘍症例の半規管機能と関連する因子の検討
  藤原 圭志, 赤松 明樹, 本間 明宏
  Equilibrium Research, 77, 5, 499, 499, (一社)日本めまい平衡医学会, 2018年10月
  日本語
• Sirtuin-1 Controls Poly (I:C)-Dependent Matrix Metalloproteinase 9 Activation in Primary Human Nasal Epithelial Cells.
  Masanobu Suzuki, Mahnaz Ramezanpour, Clare Cooksley, Jian Li, Yuji Nakamaru, Akihiro Homma, Alkis Psaltis, Peter-John Wormald, Sarah Vreugde
  American journal of respiratory cell and molecular biology, 59, 4, 500, 510, 2018年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, Matrix metalloproteinase (MMP)-9 is thought to be involved in the etiopathogenesis of chronic rhinosinusitis (CRS) with nasal polyps and cleaves collagen IV, causing hyperpermeability of the basement membrane within mucosal tissue. It is known that MMP-9 expression is negatively affected by sirtuin (SIRT)-1 in human monocytotic cells, retinal endothelial cells, and epithelial carcinoma cells. However, it is unknown which factors affect MMP-9 expression and activity in human nasal epithelial cells (HNECs). To examine factors affecting MMP-9 expression and activity in HNECs, HNECs were stimulated with Toll-like receptor (TLR) agonists, followed by quantitative PCR, immunofluorescence, and zymography to examine MMP-9 expression and activity. MMP-9 expression was evaluated in sinonasal tissue of control subjects without CRS, and patients with CRS without nasal polyps and those with CRS with nasal polyps, in relation to the expression of SIRT1 using a tissue microarray. The effect of SIRT1 stimulation/inhibition on MMP-9 expression in HNECs was also tested. TLR3 agonists increased MMP-9 mRNA expression (473 fold, P = 0.0198) and activity (20.4-fold, P < 0.05). SIRT1 activation or inhibition reciprocally affected MMP-9 expression in the presence of TLR3 agonists. MMP-9 and SIRT1 expression within the epithelial layer of sinonasal tissue was inversely correlated only in patients with CRS but not in control subjects. TLR3 agonists increased MMP-9 expression and activity in HNECs, and the effect was abolished in the presence of SIRT1 activation. SIRT1 and MMP-9 expression was inversely correlated in CRS tissue, supporting SIRT1 as a possible therapeutic target for nasal polyp formation.
• Anti-mumps IgM antibody positive rate with sudden sensorineural hearing loss using second-generation enzyme immunoassay: A retrospective, multi-institutional investigation in Hokkaido, Japan
  Atsushi Fukuda, Shinya Morita, Yuji Nakamaru, Kimiko Hoshino, Keishi Fujiwara, Shigeru Akazawa, Tomohiro Sakashita, Nobuyuki Obara, Akihiro Homma
  Auris Nasus Larynx, 45, 5, 911, 915, Elsevier Ireland Ltd, 2018年10月01日, ［査読有り］, ［最終著者］
  英語, 研究論文（学術雑誌）
• EAONO/JOS中耳真珠腫進展度分類を用いた術後聴力予後因子の検討　　　　　　　　　　　　　　　
  福田 篤, 森田 真也, 干野 季美子, 藤原 圭志, 中丸 裕爾, 本間 明宏
  Otology Japan, 28, 4, 468, 468, (一社)日本耳科学会, 2018年09月
  日本語
• vHITを用いた聴神経腫瘍症例の垂直半規管機能評価　　　　　　　　　　　　　　　
  藤原 圭志, 森田 真也, 干野 季美子, 福田 篤, 中丸 裕爾, 本間 明宏
  Otology Japan, 28, 4, 637, 637, (一社)日本耳科学会, 2018年09月
  日本語
• 当院における嗅神経芽細胞腫の治療方針と成績　　　　　　　　　　　　　　　
  中薗 彬, 中丸 裕爾, 鈴木 正宣, 水町 貴諭, 高木 大, 本間 明宏
  日本鼻科学会会誌, 57, 3, 429, 429, (一社)日本鼻科学会, 2018年09月
  日本語
• 篩骨動脈を茎とする鼻中隔粘膜弁を用いた鼻中隔穿孔閉鎖術の1例　　　　　　　　　　　　　　　
  勝俣 量平, 鈴木 正宣, 中薗 彬, 中丸 裕爾, 本間 明宏
  日本鼻科学会会誌, 57, 3, 504, 504, (一社)日本鼻科学会, 2018年09月
  日本語
• Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using F-18-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma
  Fujima Noriyuki, Hirata Kenji, Shiga Tohru, Yasuda Koichi, Onimaru Rikiya, Tsuchiya Kazuhiko, Kano Satoshi, Mizumachi Takatsugu, Homma Akihiro, Kudo Kohsuke, Shirato Hiroki
  QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 8, 8, 788, 795, 2018年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 【ちょっと気になる頭頸部癌化学療法】 動注療法 上顎洞　　　　　　　　　　　　　　　
  本間 明宏
  JOHNS, 34, 8, 975, 977, (株)東京医学社, 2018年08月, ［責任著者］
  日本語
• Early prediction of lenvatinib treatment efficacy by using ¹⁸F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observatio
  Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, Gouda T, Ohhara Y, Homma R, Shimizu Y, Kinoshita I, Tsuji Y, Homma A, Iijima H, Tamaki N, Dosaka-Akita H
  BMJ open, 8, 8, e021001, 2018年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Lenvatinib, an oral molecular targeted drug, is used to treat patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment. Effective methods for evaluating molecular targeted drugs are a critical unmet need owing to their expensive costs and unique adverse events. The aim of this study is to determine whether 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT at 1 week after commencing lenvatinib can predict treatment outcomes. DESIGN AND METHODS: This study is planned as a non-randomised single-arm multicentre study; patients with pathologically confirmed differentiated thyroid carcinoma (DTC) with lesions that are refractory to radioiodine treatment are eligible. The main exclusion criteria are medullary or anaplastic carcinoma, prior treatment with chemotherapy, poor general condition and thromboembolism-requiring treatment. Patients to be included in the study will be treated with lenvatinib and undergo FDG-PET/CT examination twice: before and 1 week after the initiation of treatment. Contrast-enhanced CT, the gold standard for evaluation, will be performed at least 4 weeks after the initiation of treatment. The primary objective is to evaluate the ability of the lesion maximum standard uptake value for FDG PET/CT performed 1 week after the initiation of treatment to predict outcomes compared with the response evaluation obtained via contrast-enhanced CT performed at least 4 weeks after the initiation of treatment. ETHICS AND DISSEMINATION: This study is conducted in accordance with the Declaration of Helsinki and has received ethical approval from the institutional review board of the Hokkaido University Hospital (approval number: 015-402). The results of this study will be disseminated through a presentation at a conference and the publication of the data in a peer-reviewed journal. The study will be implemented and reported in line with the SPIRIT statement. TRIAL REGISTRATION NUMBER: UMIN000022592.
• Intra-arterial Chemoradiation Therapy as an Option for Maxillary Sinus Cancers
  Akihiro Homma, Rikiya Onimaru
  International Journal of Radiation Oncology Biology Physics, 101, 4, 763, 2018年07月15日, ［筆頭著者］
• Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
  Mizushima T, Ohnishi S, Shimizu Y, Hatanaka Y, Hatanaka KC, Kuriki Y, Kamiya M, Homma A, Yamamoto K, Ono S, Urano Y, Sakamoto N
  Head & neck, 40, 7, 1466, 1475, 2018年07月, ［査読有り］
• Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer.
  Morita S, Mizumachi T, Nakamaru Y, Sakashita T, Kano S, Hoshino K, Fukuda A, Fujiwara K, Homma A
  International journal of clinical oncology, 23, 6, 1029, 1037, 2018年07月, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The purpose was to compare survival differences between patients with external auditory canal (EAC) cancer treated according to the University of Pittsburgh modified TNM staging system and those treated in accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging manual on the TNM staging system for cutaneous cancers of the head and neck. METHODS: We performed a retrospective, single-institution review of 60 patients with EAC cancer treated with curative intent between September 2002 and March 2018. Survival outcomes were measured on the basis of the two staging systems. RESULTS: The C-index values for the overall survival (OS) rate revealed that the University of Pittsburgh staging system had higher prognostic accuracy than the 8th edition of the AJCC staging system. Univariable and multivariable analysis showed that T classification according to the University of Pittsburgh staging system was an independent predictor of the OS rate (hazard ratio 5.25; 95% confidence interval 1.38-24.9; P = 0.015). Meanwhile, the AJCC staging system could not differentiate T2 from T3-4 cancers. CONCLUSION: The University of Pittsburgh staging system for patients with EAC cancer is a valuable tool for use in clinical decision-making and predicting survival outcome.
• 喉頭癌に対する超選択的動注と放射線同時併用療法　　　　　　　　　　　　　　　
  本間 明宏
  耳鼻咽喉科展望, 61, 3, 142, 149, 耳鼻咽喉科展望会, 2018年06月, ［筆頭著者］
  日本語
• Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing
  Shinichiro Yasukawa, Satoshi Kano, Hiromitsu Hatakeyama, Yuji Nakamaru, Dai Takagi, Takatsugu Mizumachi, Masanobu Suzuki, Takayoshi Suzuki, Akira Nakazono, Shinya Tanaka, Hiroshi Nishihara, Akihiro Homma
  International Journal of Clinical Oncology, 1, 9, Springer Tokyo, 2018年05月19日, ［査読有り］, ［最終著者］
  英語, 研究論文（学術雑誌）
• 慢性肉芽腫症に対する骨髄移植後に発生した小児甲状腺乳頭癌の1例　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 対馬 那由多, 川浪 康太郎, 福田 諭
  北海道医学雑誌, 93, 1, 70, 70, 北海道医学会, 2018年05月
  日本語
• 切除不能局所進行頭頸部扁平上皮がんに対するPCE導入化学療法後の化学放射線療法の実施可能性検証試験　　　　　　　　　　　　　　　
  岡野 晋, 榎田 智弘, 小川 武則, 本間 明宏, 大上 研二, 南 修司郎, 岩江 信法, 中目 亜矢子, 清水 康, 槇 大輔, 上田 百合, 藤澤 孝夫, 茂木 厚, 野村 尚吾, 田原 信
  頭頸部癌, 44, 2, 148, 148, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• 次世代シーケンサーを用いたHPV陽性およびHPV陰性中咽頭癌の遺伝子解析 頭頸部癌基礎研究会報告　　　　　　　　　　　　　　　
  家根 旦有, 藤井 正人, 太田 一郎, 菅澤 正, 本間 明宏, 水田 啓介, 倉富 勇一郎, 丹生 健一, 加藤 久幸, 大上 研二, 北村 守正, 辻 裕之, 安松 隆治, 永澤 昌
  頭頸部癌, 44, 2, 125, 125, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• 放射線治療による頭頸部がん治療成績改善の取り組みと展望 動注化学放射線療法　　　　　　　　　　　　　　　
  水町 貴諭, 松浦 一登, 鬼丸 力也, 林 隆一, 本間 明宏
  頭頸部癌, 44, 2, 97, 97, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• 当科における局所進行外耳道扁平上皮癌の治療成績の検討　　　　　　　　　　　　　　　
  加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
  頭頸部癌, 44, 2, 181, 181, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• Quality of Survivalを考慮した頭頸部癌支持療法 頭頸部がん患者の口腔支持療法と地域連携　　　　　　　　　　　　　　　
  秦 浩信, 吉川 和人, 今待 賢治, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政
  頭頸部癌, 44, 2, 115, 115, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• 次世代シーケンサーを用いたHPV陽性およびHPV陰性中咽頭癌の遺伝子解析 頭頸部癌基礎研究会報告　　　　　　　　　　　　　　　
  家根 旦有, 藤井 正人, 太田 一郎, 菅澤 正, 本間 明宏, 水田 啓介, 倉富 勇一郎, 丹生 健一, 加藤 久幸, 大上 研二, 北村 守正, 辻 裕之, 安松 隆治, 永澤 昌
  頭頸部癌, 44, 2, 125, 125, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• Quality of Survivalを考慮した頭頸部癌支持療法 頭頸部がん患者の口腔支持療法と地域連携　　　　　　　　　　　　　　　
  秦 浩信, 吉川 和人, 今待 賢治, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政
  頭頸部癌, 44, 2, 115, 115, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• 当科における局所進行外耳道扁平上皮癌の治療成績の検討　　　　　　　　　　　　　　　
  加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏
  頭頸部癌, 44, 2, 181, 181, (一社)日本頭頸部癌学会, 2018年05月
  日本語
• Validation of the 8th edition of the AJCC/UICC TNM staging system for tongue squamous cell carcinoma
  Satoshi Kano, Tomohiro Sakashita, Nayuta Tsushima, Takatsugu Mizumachi, Akira Nakazono, Takayoshi Suzuki, Shinichiro Yasukawa, Akihiro Homma
  International Journal of Clinical Oncology, 1, 7, Springer Tokyo, 2018年04月19日, ［査読有り］, ［最終著者］
  英語, 研究論文（学術雑誌）
• 舌扁平上皮癌における新しいTNM分類の有用性の検討
  加納 里志, 水町 貴諭, 対馬 那由多, 鈴木 崇祥, 中薗 彬, 安川 真一郎, 本間 明宏
  日本耳鼻咽喉科学会会報, 121, 4, 578, 578, (一社)日本耳鼻咽喉科学会, 2018年04月
  日本語
• AMED研究:頭頸部癌領域 進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究　　　　　　　　　　　　　　　
  本間 明宏, 松浦 一登, 鬼丸 力也, 林 隆一
  日本耳鼻咽喉科学会会報, 121, 4, 383, 384, (一社)日本耳鼻咽喉科学会, 2018年04月
  日本語
• 両側半規管麻痺を呈した大動脈炎症候群の1例
  藤原 圭志, 本間 明宏
  Equilibrium Research, 77, 2, 64, 68, (一社)日本めまい平衡医学会, 2018年04月, ［査読有り］, ［最終著者］
  日本語
• Elevated Level of Myeloperoxidase-Deoxyribonucleic Acid Complex in the Middle Ear Fluid Obtained from Patients with Otitis Media Associated with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
  Shinya Morita, Yuji Nakamaru, Daigo Nakazawa, Fumihiko Hattanda, Haruki Shida, Yoshihiro Kusunoki, Kanako Watanabe, Sakiko Masuda, Dai Takagi, Masanobu Suzuki, Kimiko Hoshino, Atsushi Fukuda, Utano Tomaru, Akihiro Homma, Akihiro Ishizu
  Otology and Neurotology, 39, 4, e257, e262, Lippincott Williams and Wilkins, 2018年04月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• A case of aortitis syndrome with bilateral canal paresis
  Keishi Fujiwara, Akihiro Homma
  Equilibrium Research, 77, 2, 64, 68, Japan Society for Equilibrium Research, 2018年04月01日, ［査読有り］, ［最終著者］
  日本語, 研究論文（学術雑誌）
• Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
  Makoto Tahara, N. Kiyota, T. Yokota, Y. Hasegawa, K. Muro, S. Takahashi, T. Onoe, A. Homma, J. Taguchi, M. Suzuki, K. Minato, K. Yane, S. Ueda, H. Hara, K. Saijo, T. Yamanaka
  Annals of Oncology, 29, 4, 1004, 1009, Oxford University Press, 2018年04月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• AMED研究:頭頸部癌領域 進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究　　　　　　　　　　　　　　　
  本間 明宏, 松浦 一登, 鬼丸 力也, 林 隆一
  日本耳鼻咽喉科学会会報, 121, 4, 383, 384, (一社)日本耳鼻咽喉科学会, 2018年04月, ［査読有り］, ［筆頭著者］
  日本語
• The surgical outcome of minimally invasive pharyngo-laryngo-oesophagectomy in prone position.
  Ogino M, Ebihara Y, Homma A, Tanaka K, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S
  Journal of minimal access surgery, 15, 2, 98, 102, 2018年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Pharyngo-laryngo-oesophagectomy (PLE) which is mainly indicated for cervical oesophageal cancer or synchronous double cancer of the thoracic oesophagus and the pharynx or larynx, is extremely invasive. Since minimally invasive oesophagectomy (MIE) using video-assisted thoracic surgery has become popular recently, the procedure can be adopted to PLE. Moreover, the use of the prone position (PP) in MIEs has been increasing recently because technical advantages and fewer post-operative complications were reported. To assess the validity of PP, this study compared surgical outcomes of minimally invasive PLE (MIPLE) in PP with that in the left lateral decubitus position (LLDP). PATIENTS AND METHODS: This study enrolled consecutive 15 patients that underwent MIPLE with LLDP (n = 7) or PP (n = 8) between January 1996 and October 2016. The patients' background characteristics, operative findings and post-operative complications were examined. RESULTS: Eligible diseases are 5 cases of cervical oesophageal cancer, 9 cases of synchronous double cancer of the thoracic oesophagus and head and neck and 1 case of cervical oesophageal recurrence of the head-and-neck cancer. The patients' background characteristics were not significantly different. During surgery, thoracic blood loss was significantly lower in PP than in LLDP (P = 0.0487). Other operative findings and post-operative complications were not significantly different between the two groups. CONCLUSIONS: In MIPLE, the PP could reduce blood loss due to the two-lung ventilation under artificial pneumothorax and was associated with lower surgical stress than LLDP.
• Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase
  Akihiro Homma, Rikiya Onimaru, Kazuto Matsuura, Hirotaka Shinomiya, Tomohiro Sakashita, Kiyoto Shiga, Hiroyuki Tachibana, Kenichi Nakamura, Junki Mizusawa, Hideaki Kitahara, Junko Eba, Haruhiko Fukuda, Masato Fujii, Ryuichi Hayashi
  Head and Neck, 40, 3, 475, 484, 2018年03月, ［査読有り］, ［筆頭著者］
  研究論文（学術雑誌）
• 同時期に異所性に発生した悪性腫瘍に対して、二部位同時にIMRTを施行した症例　　　　　　　　　　　　　　　
  湊川 英樹, 安田 耕一, 白土 博樹, 土屋 和彦, 原田 八重, 水町 貴諭, 坂下 智博, 本間 明宏, 福田 諭, 石嶋 漢, 宮本 直樹, 高尾 聖心, 鈴木 隆介, 松浦 妙子, 牧永 綾乃, 田村 昌也
  Japanese Journal of Radiology, 36, Suppl., 6, 6, (公社)日本医学放射線学会, 2018年02月
  日本語
• 咽喉頭直達鏡固定システムの試作　　　　　　　　　　　　　　　
  本間 明宏, 清水 勇一, 畠山 博充, 溝口 兼司, 水町 貴諭, 加納 里志, 坂下 智博, 福田 諭
  耳鼻咽喉科展望, 61, 1, 66, 67, 耳鼻咽喉科展望会, 2018年02月, ［査読有り］, ［筆頭著者］
  日本語
• 頭頸部癌に対する超選択的動注化学療法の適応と実際
  本間 明宏
  日本耳鼻咽喉科学会会報, 121, 2, 150, 151, (一社)日本耳鼻咽喉科学会, 2018年02月, ［筆頭著者］
  日本語
• Clinical Characteristics and Treatment Outcomes for Patients with External Auditory Canal Cholesteatoma
  Shinya Morita, Yuji Nakamaru, Atsushi Fukuda, Keishi Fujiwara, Kimiko Hoshino, Akihiro Homma
  Otology and Neurotology, 39, 2, 189, 195, Lippincott Williams and Wilkins, 2018年02月01日, ［査読有り］, ［最終著者］
  英語, 研究論文（学術雑誌）
• Utility of a Hybrid IVIM-DKI Model to Predict the Development of Distant Metastasis in Head and Neck Squamous Cell Carcinoma Patients.
  Noriyuki Fujima, Tomohiro Sakashita, Akihiro Homma, Daisuke Yoshida, Kohsuke Kudo, Hiroki Shirato
  Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 17, 1, 21, 27, 2018年01月10日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To evaluate the diagnostic power of hybrid intravoxel incoherent motion (IVIM)-diffusion kurtosis imaging (DKI) model parameters in pretreatment for the prediction of future distant metastasis in head and neck squamous cell carcinoma (HNSCC) patients. MATERIALS AND METHODS: We retrospectively evaluated 49 HNSCC patients who underwent curative chemoradiation therapy. Diffusion-weighted image (DWI) acquired by single-shot spin-echo echo-planar imaging with 12 b-values (0-2000) was performed in all patients before any treatment. We calculated the IVIM-DKI parameters and the conventional apparent diffusion coefficient (ADC) in the ROI placed on the primary lesion. The presence of future distant metastasis was determined by histological findings or clinical follow-up. RESULTS: A univariate analysis revealed significant differences between the patients with distant metastasis and those without in slow diffusion coefficient (D) and kurtosis value (K). Highest diagnostic accuracy was obtained by the D value. In addition, a multivariate analysis revealed that the D value was an independent predictor of future distant metastasis. CONCLUSION: The D and K values obtained by this hybrid IVIM-DKI model can be one of the diagnostic tools for the prediction of future distant metastasis in HNSCC patients.
• Regional dental cooperation and oral supportive care for head and neck cancer patients
  Hironobu Hata, Kazuhito Yoshikawa, Kenji Imamachi, Chika Murai, Michihiro Ueda, Tatsumi Nagahashi, Noriaki Nishiyama, Kouichi Yasuda, Akihiro Honma, Yoshimasa Kitagawa
  Japanese Journal of Head and Neck Cancer, 44, 4, 380, 386, 2018年
  研究論文（学術雑誌）
• 内転型痙攣性発声障害話者の同音異義語弁別について
  柳田 早織, 西澤 典子, 溝口 兼司, 畠山 博充, 本間 明宏, 福田 諭
  音声言語医学, 59, 1, 16, 21, 日本音声言語医学会, 2018年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Oncocytoma of the Parotid Gland with Facial Nerve Paralysis.
  Seijiro Hamada, Keishi Fujiwara, Hiromitsu Hatakeyama, Akihiro Homma
  Case reports in otolaryngology, 2018, 7687951, 7687951, 2018年, ［査読有り］, ［最終著者］, ［国際誌］
  英語, Parotid gland tumor with facial nerve paralysis is strongly suggestive of a malignant tumor. However, several case reports have documented benign tumors of the parotid gland with facial nerve paralysis. Here, we report a case of oncocytoma of the parotid gland with facial nerve paralysis. A 61-year-old male presented with pain in his right parotid gland. Physical examination demonstrated the presence of a right parotid gland tumor and ipsilateral facial nerve paralysis of House-Brackmann (HB) grade III. Due to the facial nerve paralysis, a malignant tumor of the parotid gland was suspected and right parotidectomy was performed. Oncocytoma was confirmed histopathologically. The facial nerve paralysis was resolved 2 months after surgery. During the follow-up period (one and a half years), no recurrence was observed. As the tumor showed a distinctive dumbbell shape and increased somewhat due to inflammation (i.e., infection), the facial nerve was pinched by the enlarged tumor. Ischemia and strangulation of the nerve were considered to be the cause of the facial nerve paralysis associated with the benign tumor in this case.
• Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting DPP-IV
  Ohnishi Shunsuke, Mizushima Takeshi, Shimizu Yuichi, Hatanaka Yutaka, Hatanaka Kanako, Yamamoto Keiko, Homma Akihiro, Kuriki Yugo, Kamiya Mako, Urano Yasuteru, Sakamoto Naoya
  CANCER SCIENCE, 109, 730, 2018年01月, ［査読有り］
• 【どこが変わった頭頸部がんTNM分類】 鼻副鼻腔がん　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏
  耳鼻咽喉科・頭頸部外科, 89, 13, 1068, 1073, (株)医学書院, 2017年12月, ［最終著者］
  日本語
• Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy
  Shigemichi Iwae, Masato Fujii, Ryuichi Hayashi, Yasuhisa Hasegawa, Takashi Fujii, Kenji Okami, Akihiro Homma, Tetsuro Onitsuka, Takakuni Kato, Takenori Ogawa, Kyoichi Terao, Nobuya Monden, Naoki Otsuki, Hiroshi Nishino, Ichiro Ota, Yasushi Fujimoto, Kazuto Matsuura, Kazuyoshi Kawabata, Hidetoshi Matsui, Koichiro Yonezawa, Ken-ichi Nibu
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 6, 1001, 1008, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Value of T1-weighted magnetic resonance imaging in cholesteatoma detection
  Atsushi Fukuda, Shinya Morita, Taisuke Harada, Keishi Fujiwara, Kimiko Hoshino, Yuji Nakamaru, Akihiro Homma
  Otology and Neurotology, 38, 10, 1440, 1444, Lippincott Williams and Wilkins, 2017年12月01日, ［査読有り］, ［最終著者］
  英語
• 舌扁平上皮癌における新しいTNM分類の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 中薗 彬, 水町 貴諭, 本間 明宏
  日本癌治療学会学術集会抄録集, 55回, P157, 4, (一社)日本癌治療学会, 2017年10月
  日本語
• 舌扁平上皮癌における新しいTNM分類の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 中薗 彬, 水町 貴諭, 本間 明宏
  日本癌治療学会学術集会抄録集, 55回, P157, 4, (一社)日本癌治療学会, 2017年10月
  日本語
• 根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析　　　　　　　　　　　　　　　
  松塚 崇, 清田 尚臣, 水澤 純基, 秋元 哲夫, 長谷川 泰久, 岩江 信法, 門田 伸也, 松浦 一登, 小野澤 祐輔, 本間 明宏, 藤井 博文, 福田 治彦, 林 隆一, 田原 信
  日本癌治療学会学術集会抄録集, 55回, P108, 3, (一社)日本癌治療学会, 2017年10月
  日本語
• 抗好中球細胞質抗体関連血管炎症候群に伴う難治性中耳炎における好中球細胞外トラップの発現　　　　　　　　　　　　　　　
  森田 真也, 中丸 裕爾, 干野 季美子, 福田 篤, 本間 明宏
  Otology Japan, 27, 4, 429, 429, (一社)日本耳科学会, 2017年10月
  日本語
• 外耳・中耳病変を有する症例の半規管機能評価 video Head Impulse Testを用いて
  藤原 圭志, 本間 明宏
  Equilibrium Research, 76, 5, 490, 490, (一社)日本めまい平衡医学会, 2017年10月
  日本語
• 急性感音難聴患者におけるムンプスIgM抗体陽性率の検討(第2報)
  福田 篤, 森田 真也, 干野 季美子, 藤原 圭志, 赤澤 茂, 中丸 裕爾, 本間 明宏
  Otology Japan, 27, 4, 568, 568, (一社)日本耳科学会, 2017年10月
  日本語
• 根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析　　　　　　　　　　　　　　　
  松塚 崇, 清田 尚臣, 水澤 純基, 秋元 哲夫, 長谷川 泰久, 岩江 信法, 門田 伸也, 松浦 一登, 小野澤 祐輔, 本間 明宏, 藤井 博文, 福田 治彦, 林 隆一, 田原 信
  日本癌治療学会学術集会抄録集, 55回, P108, 3, (一社)日本癌治療学会, 2017年10月
  日本語
• Atypical adenoma of the thyroid diagnosed as anaplastic cancer by cytopathology
  Hiromitsu Hatakeyama, Kimiko Hoshino, Kenji Mizoguchi, Takayoshi Suzuki, Kanako C. Hatanaka, Yukie Yamaya, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma
  DIAGNOSTIC CYTOPATHOLOGY, 45, 10, 928, 933, 2017年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 鼻粘膜上皮細胞での自然免疫シグナルによるMMP9の発現誘導　　　　　　　　　　　　　　　
  鈴木 正宣, 中丸 裕爾, 高木 大, 本間 あや, Vreugde Sarah, Wormald Peter-John, 本間 明宏
  日本鼻科学会会誌, 56, 3, 429, 429, (一社)日本鼻科学会, 2017年09月
  日本語
• Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出　　　　　　　　　　　　　　　
  大西 俊介, 水島 健, 清水 勇一, 畑中 豊, 畑中 佳奈子, 山本 桂子, 本間 明宏, 栗木 優五, 神谷 真子, 浦野 泰照, 坂本 直哉
  日本癌学会総会記事, 76回, P, 2320, 日本癌学会, 2017年09月
  英語
• 日本の多施設共同研究によるHPV関連中咽頭癌の遺伝子解析　　　　　　　　　　　　　　　
  家根 旦有, 澤西 和恵, 西尾 和人, 坂井 和子, 藤井 正人, 本間 明宏, 菅澤 正, 大上 研二, 太田 一郎
  日本癌学会総会記事, 76回, P, 1030, 日本癌学会, 2017年09月
  英語
• 鼻粘膜上皮細胞での自然免疫シグナルによるMMP9の発現誘導　　　　　　　　　　　　　　　
  鈴木 正宣, 中丸 裕爾, 高木 大, 本間 あや, Vreugde Sarah, Wormald Peter-John, 本間 明宏
  日本鼻科学会会誌, 56, 3, 429, 429, (一社)日本鼻科学会, 2017年09月
  日本語
• Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出　　　　　　　　　　　　　　　
  大西 俊介, 水島 健, 清水 勇一, 畑中 豊, 畑中 佳奈子, 山本 桂子, 本間 明宏, 栗木 優五, 神谷 真子, 浦野 泰照, 坂本 直哉
  日本癌学会総会記事, 76回, P, 2320, 日本癌学会, 2017年09月
  英語
• 日本の多施設共同研究によるHPV関連中咽頭癌の遺伝子解析　　　　　　　　　　　　　　　
  家根 旦有, 澤西 和恵, 西尾 和人, 坂井 和子, 藤井 正人, 本間 明宏, 菅澤 正, 大上 研二, 太田 一郎
  日本癌学会総会記事, 76回, P, 1030, 日本癌学会, 2017年09月
  英語
• 【頭頸部悪性腫瘍の疑問に答える】 治療後の対応 咽頭癌、喉頭癌に対して化学放射線療法を行いCRとなった場合の経過観察について教えてください　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏
  JOHNS, 33, 9, 1325, 1327, (株)東京医学社, 2017年09月
  日本語
• 【頭頸部悪性腫瘍の疑問に答える】 治療選択 全身合併症がある場合の治療選択について教えてください　　　　　　　　　　　　　　　
  本間 明宏
  JOHNS, 33, 9, 1254, 1256, (株)東京医学社, 2017年09月
  日本語
• 舌扁平上皮癌における新しいTNM分類の有用性の検討　　　　　　　　　　　　　　　
  加納 里志, 坂下 智博, 水町 貴諭, 本間 明宏
  口腔・咽頭科, 30, 3, 429, 429, 日本口腔・咽頭科学会, 2017年08月
  日本語
• Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
  Takatsugu Mizumachi, Akihiro Homma, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 4, 682, 689, 2017年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Japanese Clinical Practice Guideline for Head and Neck Cancer
  Ken-ichi Nibu, Ryuichi Hayashi, Takahiro Asakage, Hiroya Ojiri, Yoshihiro Kimata, Takeshi Kodaira, Toshitaka Nagao, Torahiko Nakashima, Takashi Fujii, Hirofumi Fujii, Akihiro Homma, Kazuto Matsuura, Nobuya Monden, Takeshi Beppu, Nobuhiro Hanai, Tadaaki Kirita, Yuzuru Kamei, Naoki Otsuki, Naomi Kiyota, Sadamoto Zenda, Ken Omura, Koichi Omori, Tetsuo Akimoto, Kazuyoshi Kawabata, Seiji Kishimoto, Hiroya Kitano, Iwai Tohnai, Takashi Nakatsuka
  AURIS NASUS LARYNX, 44, 4, 375, 380, 2017年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Reliability and Validity of Speech Evaluation in Adductor Spasmodic Dysphonia.
  Yanagida S, Nishizawa N, Hashimoto R, Mizoguchi K, Hatakeyama H, Homma A, Fukuda S
  Journal of voice : official journal of the Voice Foundation, 32, 5, 585, 591, 2017年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The aim of this study was to evaluate speech in patients with adductor spasmodic dysphonia (ADSD) by perceptual evaluations and acoustic measures, and to examine the reliability and validity of these measures. METHODS: Twenty-four patients with ADSD and 24 healthy volunteers were included in the study. Speech materials consisted of three sentences constructed from serial voiced syllables to elicit abductor voice breaks. Three otolaryngologists rated the degree of voice symptoms using a visual analog scale (VAS). VAS sheets with five 100-mm horizontal lines were given to each rater. The ends of the lines were labeled normal vs severe, and the five lines were labeled as overall severity of each of the four speech symptoms (strangulation, interruption, tremor and strained speech). Nine words were selected for acoustic analysis, and abnormal acoustic events were classified into one of the three categories. To evaluate the intra- and inter-rater and intermeasurer reliabilities of the VAS scores or acoustic measures, Pearson r correlations were calculated. To examine the validity of perceptual evaluations and acoustic measures, the sensitivity and the specificity were calculated. RESULTS: Pearson r correlation coefficients for overall severity showed the highest intra- and inter-rater reliabilities. For acoustic events, the intrameasurer reliabilities were r = .645 (frequency shifts), r = .969 (aperiodic segments), and r = 1.0 (phonation breaks), and the intermeasurer reliability ranged from r = .102 to r = 1.0. Perceptual evaluation showed high sensitivity (91.7%) and specificity (100%), whereas acoustic analysis showed low sensitivity (70.8%) and high specificity (100%). CONCLUSION: Both perceptual evaluation and acoustic measures alone were found likely to overlook patients with true ADSD.
• Osteoradionecrosis of the hyoid bone after intra-arterial chemoradiotherapy for oropharyngeal cancer: MR imaging findings
  Hiromitsu Hatakeyama, Noriyuki Fujima, Kazuhiko Tsuchiya, Kenji Mizoguchi, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
  CANCER IMAGING, 17, 2017年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 化学放射線療法
  本間 明宏
  日本耳鼻咽喉科学会会報, 120, 7, 962, 965, (一社)日本耳鼻咽喉科学会, 2017年07月
  日本語
• Osteoradionecrosis of the hyoid bone after intra-arterial chemoradiotherapy for oropharyngeal cancer: MR imaging findings.
  Hatakeyama H, Fujima N, Tsuchiya K, Mizoguchi K, Mizumachi T, Sakashita T, Kano S, Homma A, Fukuda S
  Cancer imaging : the official publication of the International Cancer Imaging Society, 17, 1, 22, 22, 2017年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Osteoradionecrosis (ORN) of the hyoid bone sometimes induces severe front neck infection and can cause laryngeal stenosis and carotid rupture. Although ORN of the hyoid bone is known to be a complication of chemoradiotherapy for head and neck cancer, there has been no basis for its evaluation. Our purpose is to present the clinical and MR imaging features of ORN of the hyoid bone. METHODS: The study group comprised patients with advanced oropharyngeal cancer treated with targeted intra-arterial cisplatin infusion with concomitant radiotherapy. ORN of the hyoid bone was identified on the basis of decreased signal intensity of the bone marrow on T1WI images. Signal intensity on T2WI images was used to distinguish between inflammation and fibrosis. RESULTS: A total of 39 pre-treatment MR images and follow-up MR images were reviewed. ORN of the hyoid bone were detected in 30% of patients after treatment, with 23% of them showing inflammation and 7.7% fibrosis. Two patients developed severe neck infection and received antibiotics and underwent surgical intervention by tracheostomy and resection of the hyoid bone. CONCLUSION: Our MR imaging study showed that ORN of the hyoid bone is not particularly rare in patients with oropharyngeal cancer treated with chemoradiotherapy. Clinicians should evaluate images carefully to prevent the development of severe complication due to infection associated with ORN of the hyoid bone.
• Role of microRNA-296-3p in the malignant transformation of sinonasal inverted papilloma
  Tomohiko Kakizaki, Hiromitsu Hatakeyama, Yuji Nakamaru, Dai Takagi, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
  ONCOLOGY LETTERS, 14, 1, 987, 992, 2017年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 北海道大学病院における舌癌治療の現況・選択的動注化学療法の意義　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 畠山 博充, 加納 里志, 水町 貴諭, 蠣崎 文彦, 対馬 那由多, 福田 諭
  耳鼻咽喉科展望, 60, 補冊1, 50, 51, 耳鼻咽喉科展望会, 2017年06月
  日本語
• 北海道大学病院における喉頭癌治療の現況　　　　　　　　　　　　　　　
  中薗 彬, 水町 貴諭, 本間 明宏, 畠山 博充, 加納 里志, 古沢 純, 坂下 智博, 鈴木 章之, 福田 諭
  耳鼻咽喉科展望, 60, 補冊1, 8, 9, 耳鼻咽喉科展望会, 2017年06月
  日本語
• 放射線動注化学療法後の救済手術 上顎全摘術について
  坂下 智博, 本間 明宏
  頭頸部癌Frontier, 5, 1, 51, 55, (株)メディカルレビュー社, 2017年06月
  日本語
• Sentinel node biopsy for oral cancer: A prospective multicenter Phase II trial
  Kouki Miura, Hitoshi Hirakawa, Hirokazu Uemura, Seiichi Yoshimot, Akihiro Shiotani, Masashi Sugasawa, Akihiro Homma, Junkichi Yokoyama, Kiyoaki Tsukahara, Tomokazu Yoshizaki, Yasushi Yatabe, Keitaro Matsuo, Yasuo Ohkura, Shigeru Kosuda, Yasuhisa Hasegawa
  AURIS NASUS LARYNX, 44, 3, 319, 326, 2017年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 甲状腺癌分化癌の骨転移に対するIMRTを含めた外照射の治療成績　　　　　　　　　　　　　　　
  安田 耕一, 加藤 徳雄, 岡本 祥三, 木下 留美子, 志賀 哲, 水町 貴諭, 畠山 博充, 本間 明宏, 田口 純, 清水 康, 森 崇, 土屋 和彦, 白土 博樹
  頭頸部癌, 43, 2, 221, 221, (一社)日本頭頸部癌学会, 2017年05月
  日本語
• 舌扁平上皮癌における腫瘍免疫チェックポイントの解析　　　　　　　　　　　　　　　
  加納 里志, 鈴木 崇祥, 倉本 倫之介, 坂下 智博, 水町 貴諭, 畠山 博充, 本間 明宏, 福田 諭
  頭頸部癌, 43, 2, 207, 207, (一社)日本頭頸部癌学会, 2017年05月
  日本語
• 個別化治療を目指した頭頸部癌診療ガイドライン　　　　　　　　　　　　　　　
  本間 明宏, 丹生 健一, 中溝 宗永, 水町 貴諭, 林 隆一
  頭頸部癌, 43, 2, 143, 143, (一社)日本頭頸部癌学会, 2017年05月
  日本語
• Rapid Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting Dipeptidylpeptidase-Iv
  Shunsuke Ohnishi, Takeshi Mizushima, Yuichi Shimizu, Yutaka Hatanaka, Kanako Hatanaka, Keiko Yamamoto, Akihiro Homma, Yugo Kuriki, Mako Kamiya, Yasuteru Urano, Naoya Sakamoto
  GASTROINTESTINAL ENDOSCOPY, 85, 5, AB530, AB530, 2017年05月, ［査読有り］
  英語
• Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia
  Kenji Mizoguchi, Hiromitsu Hatakeyama, Saori Yanagida, Noriko Nishizawa, Nobuhiko Oridate, Satoshi Fukuda, Akihiro Homma
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 274, 5, 2215, 2223, 2017年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Non-invasive prediction of the tumor growth rate using advanced diffusion models in head and neck squamous cell carcinoma patients
  Noriyuki Fujima, Tomohiro Sakashita, Akihiro Homma, Taisuke Harada, Yukie Shimizu, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
  ONCOTARGET, 8, 20, 33631, 33643, 2017年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Residual tumour detection in post-treatment granulation tissue by using advanced diffusion models in head and neck squamous cell carcinoma patients
  Noriyuki Fujima, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Kohsuke Kudo, Hiroki Shirato
  EUROPEAN JOURNAL OF RADIOLOGY, 90, 14, 19, 2017年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• HPV関連中咽頭癌症例におけるTNM分類改訂に伴う病期分類と生存率の検討
  水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 福田 諭
  日本耳鼻咽喉科学会会報, 120, 4, 611, 611, (一社)日本耳鼻咽喉科学会, 2017年04月
  日本語
• 外耳道癌組織における免疫組織化学的手法に基づく発現分子解析　　　　　　　　　　　　　　　
  森田 真也, 本間 明宏, 中丸 裕爾, 安川 真一郎, 福田 篤, 福田 諭
  日本耳鼻咽喉科学会会報, 120, 4, 566, 566, (一社)日本耳鼻咽喉科学会, 2017年04月
  日本語
• 外耳道癌組織における免疫組織化学的手法に基づく発現分子解析　　　　　　　　　　　　　　　
  森田 真也, 本間 明宏, 中丸 裕爾, 安川 真一郎, 福田 篤, 福田 諭
  日本耳鼻咽喉科学会会報, 120, 4, 566, 566, (一社)日本耳鼻咽喉科学会, 2017年04月
  日本語
• 頭頸部癌に対する化学放射線療法と有害事象対策
  本間 明宏
  日本耳鼻咽喉科学会会報, 120, 3, 248, 251, (一社)日本耳鼻咽喉科学会, 2017年03月
  日本語
• 上顎洞癌に対するシスプラチンの超選択的動注と放射線治療の同時併用療法
  本間 明宏, 坂下 智博, 吉田 大介, 鬼丸 力也
  耳鼻咽喉科臨床, 110, 3, 160, 161, 耳鼻咽喉科臨床学会, 2017年03月
  日本語
• Prediction of the treatment outcome using intravoxel incoherent motion and diffusional kurtosis imaging in nasal or sinonasal squamous cell carcinoma patients
  Noriyuki Fujima, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Akiko Tsukahara, Yukie Shimizu, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
  EUROPEAN RADIOLOGY, 27, 3, 956, 965, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 顔面神経麻痺をきたした耳下腺oncocytomaの1例
  浜田 誠二郎, 藤原 圭志, 畠山 博充, 本間 明宏, 福田 諭
  Facial Nerve Research, 36, 191, 193, 日本顔面神経学会, 2017年02月
  日本語
• 顔面神経麻痺をきたした耳下腺oncocytomaの1例　　　　　　　　　　　　　　　
  浜田 誠二郎, 藤原 圭志, 畠山 博充, 本間 明宏, 福田 諭
  Facial Nerve Research, 36, 191, 193, 日本顔面神経学会, 2017年02月
  日本語
• 【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌臨床研究の動向 多施設での中咽頭癌の治療成績(手術、放射線)　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏
  日本臨床, 75, 増刊2 頭頸部癌学, 184, 189, (株)日本臨床社, 2017年02月
  日本語
• 【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌の治療 頭頸部癌の外科治療 頭頸部癌の外科治療(低侵襲・機能温存) 口腔癌 超選択的動注化学療法併用放射線治療　　　　　　　　　　　　　　　
  本間 明宏
  日本臨床, 75, 増刊2 頭頸部癌学, 324, 328, (株)日本臨床社, 2017年02月
  日本語
• 【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌臨床研究の動向 多施設での上顎洞癌の治療成績　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏
  日本臨床, 75, 増刊2 頭頸部癌学, 179, 183, (株)日本臨床社, 2017年02月
  日本語
• Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma
  Shinya Morita, Yuji Nakamaru, Akihiro Homma, Shinichiro Yasukawa, Hiromitsu Hatakeyama, Tomohiro Sakashita, Satoshi Kano, Atsushi Fukuda, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 1, 181, 189, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer
  Satoshi Kano, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Tomohiro Sakashita, Tomohiko Kakizaki, Satoshi Fukuda
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 39, 2, 247, 253, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Advanced diffusion models in head and neck squamous cell carcinoma patients: Goodness of fit, relationships among diffusion parameters and comparison with dynamic contrast-enhanced perfusion
  Noriyuki Fujima, Tomohiro Sakashita, Akihiro Homma, Yukie Shimizu, Atsushi Yoshida, Taisuke Harada, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
  MAGNETIC RESONANCE IMAGING, 36, 16, 23, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 内転型痙攣性発声障害話者の同音異義語弁別について
  柳田 早織, 西澤 典子, 溝口 兼司, 畠山 博充, 本間 明宏, 福田 諭
  音声言語医学, 58, 1, 77, 77, 日本音声言語医学会, 2017年01月
  日本語
• 甲状軟骨形成術II型の周術期合併症についての検討
  溝口 兼司, 畠山 博充, 柳田 早織, 西澤 典子, 本間 明宏, 福田 諭
  音声言語医学, 58, 1, 76, 76, 日本音声言語医学会, 2017年01月
  日本語
• HPV陽性中咽頭癌とHPV陽性鼻腔癌の同時性重複例
  井戸川 寛志, 水町 貴諭, 本間 明宏, 福田 諭
  日本耳鼻咽喉科学会会報, 120, 6, 841, 846, (一社)日本耳鼻咽喉科学会, 2017年
  日本語, 研究論文（学術雑誌）
• Evaluation of Vestibular Functions in Patients with Vogt-Koyanagi-Harada Disease
  Keishi Fujiwara, Shinya Morita, Kimiko Hoshino, Atsushi Fukuda, Yuji Nakamaru, Akihiro Homma
  AUDIOLOGY AND NEURO-OTOLOGY, 22, 3, 190, 195, 2017年, ［査読有り］
  英語, 研究論文（学術雑誌）
• 当院におけるバイオバンクシステム構築の取り組み
  鈴木 崇祥, 畠山 博充, 安川 真一郎, 本間 明宏, 西原 広史, 松野 吉宏, 福田 諭
  耳鼻咽喉科展望, 59, 6, 371, 376, 耳鼻咽喉科展望会, 2016年12月
  日本語
• 用語解説 胸骨上隙(suprasternal space)　　　　　　　　　　　　　　　
  本間 明宏
  日本気管食道科学会会報, 67, 6, 439, 440, (NPO)日本気管食道科学会, 2016年12月
  日本語
• Reduction of blood eosinophil counts in eosinophilic chronic rhinosinusitis after surgery
  A. Honma, D. Takagi, Y. Nakamaru, A. Homma, M. Suzuki, S. Fukuda
  JOURNAL OF LARYNGOLOGY AND OTOLOGY, 130, 12, 1147, 1152, 2016年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The role of prophylactic neck dissection and tumor thickness evaluation for patients with cN0 tongue squamous cell carcinoma
  Nayuta Tsushima, Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Tomohiko Kakizaki, Takayoshi Suzuki, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273, 11, 3987, 3992, 2016年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Glucose Metabolism and Its Complicated Relationship with Tumor Growth and Perfusion in Head and Neck Squamous Cell Carcinoma
  Noriyuki Fujima, Tomohiro Sakashita, Akihiro Homma, Kenji Hirata, Tohru Shiga, Kohsuke Kudo, Hiroki Shirato
  PLOS ONE, 11, 11, e0166236, 2016年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 頭頸・口腔 頭頸部がんの集学的治療 表在性頭頸部扁平上皮癌のGGT活性化標的薬を用いた蛍光イメージング(Fluorescent imaging of superficial head and neck squamous cell carcinoma using a GGT-Activated targeting agent)　　　　　　　　　　　　　　　
  大西 俊介, 水島 健, 清水 勇一, 畑中 豊, 畑中 佳奈子, 本間 明宏, 浦野 泰照, 坂本 直哉
  日本癌治療学会学術集会抄録集, 54回, WS81, 6, (一社)日本癌治療学会, 2016年10月
  英語
• 頭頸・口腔 頭頸部がんに対する治療戦略 局所進行上顎洞癌に対するCDDP超選択的動注と放射線併用療法(JCOG1212)用量探索の結果　　　　　　　　　　　　　　　
  四宮 弘隆, 本間 明宏, 鬼丸 力也, 松浦 一登, 林 隆一, 志賀 清人, 立花 弘之, 中村 健一, 水澤 純基, 藤井 正人
  日本癌治療学会学術集会抄録集, 54回, WS80, 5, (一社)日本癌治療学会, 2016年10月
  日本語
• 頭頸・口腔 頭頸部がんに対する治療戦略 再発・転移頭頸部癌に対するPaclitaxel+Carboplatin+Cetuximab療法の第II相試験　　　　　　　　　　　　　　　
  清田 尚臣, 横田 知哉, 長谷川 泰久, 室 圭, 高橋 俊二, 尾上 琢磨, 本間 明宏, 鈴木 政美, 家根 旦有, 原 浩樹, 西條 憲, 山中 竹春, 田原 信
  日本癌治療学会学術集会抄録集, 54回, WS80, 1, (一社)日本癌治療学会, 2016年10月
  日本語
• Effectiveness of superselective intra-arterial chemoradiotherapy targeting retropharyngeal lymph node metastasis
  Takayoshi Suzuki, Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Fumiyuki Suzuki, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 273, 10, 3331, 3336, 2016年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Association of impaired renal function and poor prognosis in oropharyngeal squamous cell carcinoma
  Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Takashi Fujii, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38, 10, 1495, 1500, 2016年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The Outcomes of Surgery and Chemoradiotherapy for Temporal Bone Cancer
  Shinya Morita, Akihiro Homma, Yuji Nakamaru, Tomohiro Sakashita, Hiromitsu Hatakeyama, Satoshi Kano, Atsushi Fukuda, Satoshi Fukuda
  OTOLOGY & NEUROTOLOGY, 37, 8, 1174, 1182, 2016年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 舌癌N0症例における予防的頸部郭清術の役割と潜在的頸部転移陽性率に関する検討　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 対馬 那由多, 福田 諭
  口腔・咽頭科, 29, 3, 401, 401, 日本口腔・咽頭科学会, 2016年08月
  日本語
• TORS 米国におけるTransoral Robotic Surgery(TORS)の現況 2nd International TransOral Robotic Surgery(TORS)Conferenceに参加して　　　　　　　　　　　　　　　
  本間 明宏, 水町 貴諭, 花井 信広, 西川 大輔
  日本気管食道科学会会報, 67, 4, 319, 319, (NPO)日本気管食道科学会, 2016年08月
  日本語
• A Retrospective Study of G-Tube Use in Japanese Patients Treated with Concurrent Chemoradiotherapy for Hypopharyngeal Cancer
  Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Rinnosuke Kuramoto, Yuji Nakamaru, Rikiya Onimaru, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  PLOS ONE, 11, 8, e0161734, 2016年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 骨固定型ピックアップから導出した直接骨導音の音響特性
  前田 秀彦, 西澤 典子, 武市 紀人, 本間 明宏, 前田 昌紀, 玉重 詠子, 米本 清
  音声言語医学, 57, 3, 294, 304, 日本音声言語医学会, 2016年07月
  日本語
• Fluorescent imaging of superficial head and neck squamous cell carcinoma using a γ-glutamyltranspeptidase-activated targeting agent: a pilot study.
  Mizushima T, Ohnishi S, Shimizu Y, Hatanaka Y, Hatanaka KC, Hosono H, Kubota Y, Natsuizaka M, Kamiya M, Ono S, Homma A, Kato M, Sakamoto N, Urano Y
  BMC cancer, 16, 411, 2016年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 頭頸部癌症例 あなたならどうする? 鼻副鼻腔
  本間 明宏
  日本耳鼻咽喉科学会会報, 119, 6, 903, 904, (一社)日本耳鼻咽喉科学会, 2016年06月
  日本語
• 下咽頭癌に対するCisplatin週1回放射線化学療法と導入化学療法の有用性と治療完遂率に関する検討
  坂下 智博, 対馬 那由多, 本間 明宏, 水町 貴諭, 福田 諭
  口腔・咽頭科, 29, 2, 169, 174, 日本口腔・咽頭科学会, 2016年06月
  日本語
• 中咽頭扁平上皮癌に対する化学放射線療法施行症例の臨床的検討　　　　　　　　　　　　　　　
  水町 貴諭, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭
  頭頸部癌, 42, 2, 181, 181, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 化学放射線治療を行った頭頸部扁平上皮癌患者における治療前血中炎症細胞と予後に関する検討　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
  頭頸部癌, 42, 2, 183, 183, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 再発・転移頭頸部扁平上皮癌に対するPCE併用療法の第II相試験(CSPOR-HN02)　　　　　　　　　　　　　　　
  福田 裕次郎, 長谷川 泰久, 鬼塚 哲郎, 丹生 健一, 川端 一嘉, 岩江 信法, 本間 明宏, 鈴木 政美, 家根 且有, 山中 竹春, 田原 信
  頭頸部癌, 42, 2, 194, 194, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 日本人の頭頸部癌患者におけるCetuximabを含む治療の観察研究(JROSG12-2) BRT有害事象に関する中間評価　　　　　　　　　　　　　　　
  太田 陽介, 古平 毅, 藤井 博文, 下川 元継, 中島 寅彦, 門田 伸也, 横田 知哉, 本間 明宏, 上田 眞也, 秋元 哲夫
  頭頸部癌, 42, 2, 195, 195, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 下咽頭癌に対する化学放射線療法後の嚥下障害 欧米の報告との比較　　　　　　　　　　　　　　　
  本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 坂下 智博, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭
  頭頸部癌, 42, 2, 214, 214, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 次世代遺伝子シークエンサーを用いた、鼻副鼻腔内反性乳頭腫の悪性転化に関与する変異遺伝子の解析　　　　　　　　　　　　　　　
  安川 真一郎, 畠山 博充, 鈴木 崇祥, 水町 貴諭, 中丸 裕爾, 本間 明宏, 福田 諭
  頭頸部癌, 42, 2, 220, 220, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• 頭頸部癌における免疫チェックポイント分子と増殖・刺激因子シグナル伝達経路　　　　　　　　　　　　　　　
  畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 本間 明宏, 福田 諭
  頭頸部癌, 42, 2, 220, 220, (一社)日本頭頸部癌学会, 2016年05月
  日本語
• Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
  Makoto Tahara, Naomi Kiyota, Tomoya Yokota, Yasuhisa Hasegawa, Kei Muro, Shunji Takahashi, Takuma Onoe, Akihiro Homma, Jun Taguchi, Masami Suzuki, Koichi Minato, Katsunari Yane, Shinya Ueda, Hiroki Hara, Ken Saijo, Takeharu Yamanaka
  JOURNAL OF CLINICAL ONCOLOGY, 34, 15, 2016年05月
  英語
• 喉頭腫瘍におけるHPV感染の検討　　　　　　　　　　　　　　　
  水町 貴諭, 中薗 彬, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
  日本気管食道科学会会報, 67, 2, s61, s61, (NPO)日本気管食道科学会, 2016年04月
  日本語
• 気管切開術後の輪状軟骨壊死に対して喉頭全摘術を施行した1例
  浜田 誠二郎, 溝口 兼司, 畠山 博充, 本間 明宏, 福田 諭
  日本気管食道科学会会報, 67, 2, s66, s66, (NPO)日本気管食道科学会, 2016年04月
  日本語
• 【耳鼻咽喉科処方マニュアル】 頭頸部がん 副鼻腔がん　　　　　　　　　　　　　　　
  本間 明宏, 清水 康
  耳鼻咽喉科・頭頸部外科, 88, 5, 292, 295, (株)医学書院, 2016年04月
  日本語
• Comparison of hearing outcomes after treatment for early-stage external auditory canal cancer
  Shinya Morita, Yuji Nakamaru, Akihiro Homma, Tomohiro Sakashita, Hiromitsu Hatakeyama, Masayori Masuya, Satoshi Fukuda
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38, E1110, E1116, 2016年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Sonographic findings of immunoglobulin G4-related sclerosing sialadenitis
  Satomi Omotehara, Mutsumi Nishida, Megumi Satoh, Mamiko Inoue, Yusuke Kudoh, Tatsunori Horie, Akihiro Homma, Yuji Nakamaru, Kanako C. Hatanaka, Chikara Shimizu
  JOURNAL OF MEDICAL ULTRASONICS, 43, 2, 257, 262, 2016年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 【中咽頭癌-HPVの視点からみた大きな変化】 治療 中咽頭癌の予後因子は?　　　　　　　　　　　　　　　
  水町 貴諭, 本間 明宏
  JOHNS, 32, 3, 323, 325, (株)東京医学社, 2016年03月
  日本語
• 手術手技 私が愛用する手術器具 上顎全摘術の骨切りに使う器械 ギグリ線鋸と田川式彎曲ノミ　　　　　　　　　　　　　　　
  本間 明宏
  JOHNS, 32, 2, 255, 257, (株)東京医学社, 2016年02月
  日本語
• Usefulness of pseudocontinuous arterial spin-labeling for the assessment of patients with head and neck squamous cell carcinoma by measuring tumor blood flow in the pretreatment and early treatment period
  N. Fujima, D. Yoshida, T. Sakashita, A. Homma, A. Tsukahara, K. K. Tha, K. K. Tha, K. Kudo, H. Shirato, H. Shirato
  American Journal of Neuroradiology, 37, 2, 342, 348, 2016年02月01日, ［国際誌］
  英語, 研究論文（学術雑誌）
• 頭頸部癌に対する化学療法の新展開
  本間 明宏
  日本気管食道科学会会報, 67, 2, 177, 177, 特定非営利活動法人 日本気管食道科学会, 2016年
  日本語
• 北海道における痙攣性発声障害の実態調査
  柳田 早織, 西澤 典子, 畠山 博充, 溝口 兼司, 本間 明宏, 福田 諭
  音声言語医学, 57, 4, 391, 397, 日本音声言語医学会, 2016年
  日本語, 研究論文（学術雑誌）
• Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer
  Jun Furusawa, Akihiro Homma, Rikiya Onimaru, Tomohiro Sakashita, Daisuke Yoshida, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  Journal of Otolaryngology of Japan, 119, 5, 782, 783, 一般社団法人 日本耳鼻咽喉科学会, 2016年01月01日
  日本語
• Intra-arterial chemoradiotherapy for head and neck cancer
  Akihiro Homma, Rikiya Onimaru, Kazuto Matsuura, K. Thomas Robbins, Masato Fujii
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 46, 1, 4, 12, 2016年01月, ［査読有り］
  英語
• Otologic and Rhinologic Manifestations of Eosinophilic Granulomatosis with Polyangiitis.
  Yuji Nakamaru, Dai Takagi, Masanobu Suzuki, Aya Homma, Shinya Morita, Akihiro Homma, Satoshi Fukuda
  Audiology & neuro-otology, 21, 1, 45, 53, 2016年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• The Short- and Long-Term Outcome of Intratympanic Steroid Therapy as a Salvage Treatment for Acute Low-Tone Sensorineural Hearing Loss without Episodes of Vertigo
  Shinya Morita, Yuji Nakamaru, Keishi Fujiwara, Keiji Iizuka, Masayori Masuya, Akihiro Homma, Atsushi Fukuda, Satoshi Fukuda
  AUDIOLOGY AND NEURO-OTOLOGY, 21, 3, 132, 140, 2016年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical outcomes of weekly cisplatin chemoradiotherapy for patients with pyriform sinus cancer
  Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 6, 1081, 1085, 2015年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer
  Jun Furusawa, Akihiro Homma, Rikiya Onimaru, Tomohiro Sakashita, Daisuke Yoshida, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  AURIS NASUS LARYNX, 42, 6, 443, 448, 2015年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 唾液腺導管癌におけるHER2下流シグナルの解析　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 鈴木 崇祥, 福田 諭
  日本唾液腺学会誌, 56, 34, 34, 日本唾液腺学会, 2015年11月
  日本語
• Induction chemotherapy in locally advanced head and neck cancer
  Yasushi Shimizu, Jun Taguchi, Ichiro Kinoshita, Kazuhiko Tsuchiya, Hiroki Shirato, Akihiro Homma, Satoshi Fukuda, Hirotoshi Akita
  ANNALS OF ONCOLOGY, 26, 33, 33, 2015年11月
  英語
• Locally advanced head and neck squamous cell carcinomas treated with TPF(docetaxel, cisplatin, 5-FU) induction chemotherapy
  Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita, Rio Honma, Satoshi Takeuchi, Kazuhiko Tsuchiya, Hiroki Shirato, Akihiro Homma, Satoshi Fukuda, Hirotoshi Akita
  ANNALS OF ONCOLOGY, 26, 90, 90, 2015年11月
  英語
• Early and long-term morbidity after minimally invasive total laryngo-pharyngo-esophagectomy with gastric pull-up reconstruction via thoracoscopy, laparoscopy and cervical incision
  Akihiro Homma, Yuji Nakamaru, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Tomohiro Sakashita, Toshiaki Shichinohe, Yuma Ebihara, Satoshi Hirano, Hiroshi Furukawa, Toshihiko Hayashi, Yuhei Yamamoto, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 272, 11, 3551, 3556, 2015年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Diagnostic value of tumor blood flow and its histogram analysis obtained with pCASL to differentiate sinonasal malignant lymphoma from squamous cell carcinoma
  Noriyuki Fujima, Hiroyuki Kameda, Akiko Tsukahara, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
  EUROPEAN JOURNAL OF RADIOLOGY, 84, 11, 2187, 2193, 2015年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 人工血管置換・大胸筋皮弁再建によっても救命しえなかった気管腕頭動脈瘻の1例
  浜田 誠二郎, 坂下 智博, 本間 明宏, 溝口 兼司, 福田 諭
  頭頸部外科, 25, 2, 241, 245, (NPO)日本頭頸部外科学会, 2015年10月
  日本語
• γ-Glutamyltranspeptidaseにより蛍光を発するprobeによる早期頭頸部がんの検出　　　　　　　　　　　　　　　
  大西 俊介, 清水 勇一, 水島 健, 畑中 豊, 畑中 佳奈子, 久保田 良政, 夏井坂 光輝, 神谷 真子, 本間 明宏, 加藤 元嗣, 浦野 泰照, 坂本 直哉
  日本癌学会総会記事, 74回, P, 3308, 日本癌学会, 2015年10月
  英語
• Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience
  Akihiro Homma, Yuji Nakamaru, Tomohiro Sakashita, Rikiya Onimaru, Shunsuke Terasaka, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiromitsu Hatakeyama, Jun Furusawa, Takatsugu Mizumachi, Satoshi Kano, Hiroki Shirato, Satoshi Fukuda
  AURIS NASUS LARYNX, 42, 5, 377, 381, 2015年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 【耳鼻咽喉科薬物療法2015】 耳鼻咽喉科の疾患・症候別薬物療法 頭頸部扁平上皮癌の動注化学療法
  本間 明宏
  JOHNS, 31, 9, 1356, 1357, (株)東京医学社, 2015年09月
  日本語
• 耳下腺原発唾液腺導管癌の検討
  蠣崎 文彦, 加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
  耳鼻咽喉科展望, 58, 補冊1, 12, 13, 耳鼻咽喉科展望会, 2015年09月
  日本語
• 北海道大学における原発不明頸部リンパ節転移癌の解析
  加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 古沢 純, 坂下 智博, 福田 諭
  耳鼻咽喉科展望, 58, 補冊1, 52, 53, 耳鼻咽喉科展望会, 2015年09月
  日本語
• 頭頸部・口腔がん治療の未来を展望する 頭頸部癌ゲノム・プロテオーム解析からの個別化分子標的治療へ　　　　　　　　　　　　　　　
  畠山 博充, 本間 明宏, 坂下 智博, 水町 貴諭, 加納 里志, 蠣崎 文彦, 福田 諭
  日本癌治療学会誌, 50, 3, 323, 323, (一社)日本癌治療学会, 2015年09月
  日本語
• 頭頸部扁平上皮癌患者における治療前血中炎症細胞と予後に関する検討　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
  日本癌治療学会誌, 50, 3, 2350, 2350, (一社)日本癌治療学会, 2015年09月
  日本語
• 腎機能は中咽頭癌の予後因子である　　　　　　　　　　　　　　　
  本間 明宏, 林 隆一, 川端 一喜, 藤井 隆, 岩江 信法, 長谷川 泰久, 丹生 健一, 加藤 孝邦, 志賀 清人, 松浦 一登, 門田 伸也, 藤井 正人
  日本癌治療学会誌, 50, 3, 2352, 2352, (一社)日本癌治療学会, 2015年09月
  日本語
• 北日本12施設における耳下腺多形腺腫由来癌の治療成績　　　　　　　　　　　　　　　
  鈴木 政博, 松塚 崇, 近藤 敦, 西條 聡, 大森 孝一, 高原 幹, 小川 武則, 片桐 克則, 福井 奈緒子, 石田 晃弘, 山田 和之, 舘田 勝, 阿部 尚央, 本間 明宏, 松浦 一登
  日本癌治療学会誌, 50, 3, 2358, 2358, (一社)日本癌治療学会, 2015年09月
  日本語
• 梨状陥凹原発扁平上皮癌に対するシスプラチン週一回投与併用放射線化学療法の検討　　　　　　　　　　　　　　　
  対馬 那由多, 坂下 智博, 本間 明宏, 水町 貴諭, 福田 諭
  口腔・咽頭科, 28, 3, 367, 367, 日本口腔・咽頭科学会, 2015年08月
  日本語
• Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan
  Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  ACTA OTO-LARYNGOLOGICA, 135, 8, 853, 858, 2015年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 顎下腺内顔面動脈瘤の1例　　　　　　　　　　　　　　　
  井戸川 寛志, 本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊142, 173, 173, 耳鼻咽喉科臨床学会, 2015年06月
  日本語
• Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).
  Tahara M, Kiyota N, Mizusawa J, Nakamura K, Hayashi R, Akimoto T, Hasegawa Y, Iwae S, Monden N, Matsuura K, Fujii H, Onozawa Y, Homma A, Kubota A, Fukuda H, Fujii M
  Cancer science, 106, 6, 726, 733, 2015年06月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, We conducted a phase II study to evaluate the efficacy and safety of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Chemotherapy consisted of S-1 twice daily on days 1-14 at 60 mg/m(2) /day and cisplatin at 20 mg/m(2) /day on days 8-11, repeated twice at a 5-week interval. Single daily radiation of 70 Gy in 35 fractions was given concurrently starting on day 1. For patients achieving an objective response after chemoradiotherapy, two additional cycles of chemotherapy were administered. Of the 45 enrolled patients, the percentage of clinical complete remission, the primary endpoint, was 64.4% (8 complete response, 21 good partial response) on central review. After a median follow-up of 3.52 years, 3-year local progression-free survival was 62.2%, with 3-year progression-free survival of 60.0%, 3-year overall survival of 64.4%, and 3-year time to treatment failure of 48.9%. Grade 3 or 4 toxicity included pharyngeal mucositis (46.7%), oral mucositis (44.4%), dysphagia (46.7%), anorexia (42.2%), radiation dermatitis (26.7%), neutropenia (26.7%), and febrile neutropenia (4.4%). No treatment-related deaths were observed. This combination showed promising efficacy with acceptable toxicities.
• Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
  Takatsugu Mizumachi, Akihiro Homma, Tomohiko Kakizaki, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Kazuhiko Tsuchiya, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita, Hirotoshi Akita, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 20, 3, 431, 437, 2015年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 日本人の頭頸部癌患者におけるCetuximabを含む治療の観察研究(JROSG12-2) 急性期有害事象の中間評価　　　　　　　　　　　　　　　
  太田 陽介, 古平 毅, 藤井 博文, 下川 元継, 中島 寅彦, 門田 伸也, 横田 知哉, 本間 明宏, 上田 眞也, 秋元 哲夫
  頭頸部癌, 41, 2, 189, 189, (一社)日本頭頸部癌学会, 2015年05月
  日本語
• 当院における下咽頭癌に対する強度変調放射線治療(IMRT)の初期臨床成績　　　　　　　　　　　　　　　
  土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊
  頭頸部癌, 41, 2, 254, 254, (一社)日本頭頸部癌学会, 2015年05月
  日本語
• 唾液腺癌を対象としたHER2タンパク過剰発現および遺伝子増幅検査法の臨床的バリデーションに関する検討　　　　　　　　　　　　　　　
  加納 里志, 畑中 豊, 松野 吉宏, 本間 明宏, 秋田 弘俊, 福田 諭
  頭頸部癌, 41, 2, 257, 257, (一社)日本頭頸部癌学会, 2015年05月
  日本語
• 喉頭癌T1症例の臨床的検討
  水町 貴諭, 中薗 彬, 溝口 兼司, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
  日本耳鼻咽喉科学会会報, 118, 4, 504, 504, (一社)日本耳鼻咽喉科学会, 2015年04月
  日本語
• 頭頸部癌化学放射線療法におけるEPA高配合栄養機能食品(プロシュア)の有用性の検討　　　　　　　　　　　　　　　
  水町 貴諭, 中薗 彬, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
  日本気管食道科学会会報, 66, 2, s20, s20, (NPO)日本気管食道科学会, 2015年04月
  日本語
• 喉頭に生じたInflammatory Myofibroblastic Tumorの一例　　　　　　　　　　　　　　　
  横川 泰三, 加納 里志, 溝口 兼司, 畠山 博充, 本間 明宏, 福田 諭
  日本気管食道科学会会報, 66, 2, s64, s64, (NPO)日本気管食道科学会, 2015年04月
  日本語
• Multi-institutional retrospective study for the evaluation of ocular function-preservation rates in maxillary sinus squamous cell carcinomas with orbital invasion
  Tomohiro Sakashita, Ryuichi Hayashi, Akihiro Homma, Kazuto Matsuura, Kengo Kato, Kazuyoshi Kawabata, Nobuya Monden, Yasuhisa Hasegawa, Tetsuro Onitsuka, Yasushi Fujimoto, Shigemichi Iwae, Kenji Okami, Takashi Matsuzuka, Kunitoshi Yoshino, Masato Fujii
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 37, 4, 537, 542, 2015年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Measurement of Tumor Blood Flow in Head and Neck Squamous Cell Carcinoma by Pseudo-Continuous Arterial Spin Labeling: Comparison With Dynamic Contrast-Enhanced MRI
  Noriyuki Fujima, Kohsuke Kudo, Akiko Tsukahara, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Khin Khin Tha, Hiroki Shirato
  JOURNAL OF MAGNETIC RESONANCE IMAGING, 41, 4, 983, +, 2015年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Measurement of tumor blood flow in head and neck squamous cell carcinoma by pseudo-continuous arterial spin labeling: comparison with dynamic contrast-enhanced MRI.
  Noriyuki Fujima, Kohsuke Kudo, Akiko Tsukahara, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Khin Khin Tha, Hiroki Shirato
  Journal of magnetic resonance imaging : JMRI, 41, 4, 983, 91, 2015年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: To investigate the feasibility of tumor blood flow (TBF) measurement in head and neck squamous cell carcinoma (HNSCC) using pseudo-continuous arterial spin labeling (pCASL) in a comparison with dynamic contrast-enhanced (DCE) perfusion. MATERIALS AND METHODS: We prospectively scanned 18 patients with HNSCC using 3T magnetic resonance imaging (MRI) with both pCASL and DCE perfusion. Quantitative TBF value in the whole-tumor region of interest (ROI), and regional TBF in the ROIs of the central and peripheral areas in the tumor were respectively measured. Relative TBF value in the whole-tumor ROI was also calculated. We determined the correlation and agreement between each measured TBF by pCASL and DCE perfusion using Pearson's correlation coefficients, intraclass correlation coefficients (ICC), and Bland-Altman analysis. RESULTS: In the whole-tumor ROIs, significant correlation was observed between the absolute TBF values (r = 0.72, P < 0.01), with an ICC of 0.72; moreover, higher correlation was observed in the relative TBF (r = 0.79). The correlation was higher in the peripheral ROI (r = 0.70) than the central ROI (r = 0.65), with an ICC of 0.62 and 0.54, respectively. Bland-Altman plots revealed the underestimation of TBF by pCASL in central ROIs. CONCLUSION: TBF measurement by pCASL was feasible in patients with HNSCC. J. Magn. Reson. Imaging 2015;41:1-1. © 2014 Wiley Periodicals, Inc.
• Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography
  Takashi Mori, Rikiya Onimaru, Shunsuke Onodera, Kazuhiko Tsuchiya, Koichi Yasuda, Hiromitsu Hatakeyama, Hiroyuki Kobayashi, Shunsuke Terasaka, Akihiro Homma, Hiroki Shirato
  RADIATION ONCOLOGY, 10, 88, 2015年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 第８７群 鼻副鼻腔癌
  座長:西野 宏, 本間 明宏
  日本耳鼻咽喉科学会会報, 118, 4, 593, 594, The Oto-Rhino-Laryngological Society of Japan, Inc., 2015年
  日本語
• Lymph node metastasis in the suprasternal space from thyroid papillary cancer
  Homma Akihiro, Hatakeyama Hiromitsu, Mizumachi Takatsugu, Furusawa Jun, Kano Satoshi, Sakashita Tomohiro, Fukuda Satoshi
  International Cancer Conference Journal, 4, 1, 57, 60, Springer, 2015年01月
  英語, The suprasternal space is a narrow space between the superficial and deep layers of the investing layers of the deep cervical fascia above the manubrium of the sternum. The suprasternal space has been paid littleattention as a space with the potential for lymph nodemetastasis from both thyroid cancer and head and neckcancer. We experienced 2 patients who were found to have a lymph node in the suprasternal space preoperatively. Both of them had well-differentiated thyroid papillary carcinomas and level III and IV lymph node metastases as well as metastasis in the suprasternal space. We have not previously dissected the suprasternal space prophylactically in other patients with thyroid papillary cancer, but no patient has developed metastasis in this space to date. Thesuprasternal space is not usually dissected in atients with thyroid cancer. However, suprasternal space metastasis has been reported to occur occasionally in patients with lymph node metastases in levels III and IV. We consider that dissection of the suprasternal space, which is not routinely performed, should be done when preoperative examination suggests lymph node metastasis in the suprasternal space as dissection of this space is less invasive, easy to achieve, and is not time consuming. Greater attention should be paidto the suprasternal space as an area with the otential for lymph node metastasis from thyroid cancer.
• Differentiation of squamous cell carcinoma and inverted papilloma using non-invasive MR perfusion imaging
  N. Fujima, Y. Nakamaru, T. Sakashita, A. Homma, A. Tsukahara, K. Kudo, H. Shirato, H. Shirato
  Dentomaxillofacial Radiology, 44, 9, 20150074, 20150074, 2015年01月01日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Dose-finding and efficacy confirmation trial of superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for patients with locally advanced maxillary sinus cancer (JCOG1212, RADPLAT-MSC)
  Akihiro Homma, Kenichi Nakamura, Kazuto Matsuura, Junki Mizusawa, Rikiya Onimaru, Haruhiko Fukuda, Masato Fujii
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45, 1, 119, 122, 2015年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Oxidative Stress Regulates IL-4 Gene Expression in Mast Cells through the Reduction of Histone Deacetylase
  Yuji Nakamaru, Dai Takagi, Akihiro Homma, Shigetsugu Hatakeyama, Satoshi Fukuda
  OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 152, 1, 48, 52, 2015年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Hangeshashinto Improves the Completion Rate of Chemoradiotherapy and the Nutritional Status in Patients with Head and Neck Cancer
  Hiromitsu Hatakeyama, Hiroki Takahashi, Nobuhiko Oridate, Rinnosuke Kuramoto, Keishi Fujiwara, Akihiro Homma, Hiroshi Takeda, Satoshi Fukuda
  ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, 77, 2, 100, 108, 2015年, ［査読有り］
  英語, 研究論文（学術雑誌）
• The efficacy of superselective intra-arterial infusion with concomitant radiotherapy for adenoid cystic carcinoma of the head and neck
  Akihiro Homma, Tomohiro Sakashita, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Yuji Nakamaru, Daisuke Yoshida, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  ACTA OTO-LARYNGOLOGICA, 135, 9, 950, 954, 2015年, ［査読有り］
  英語, 研究論文（学術雑誌）
• 魚骨異物に対し頸部外切開施行時の術中3D-CTの有用性
  高橋 紘樹, 坂下 智博, 佐藤 宏紀, 藤原 由有希, 水町 貴諭, 本間 明宏, 福田 諭
  耳鼻咽喉科展望, 57, 6, 349, 349, 耳鼻咽喉科展望会, 2014年12月
  日本語
• 頸部腫瘤摘出・生検後に中咽頭癌と診断された症例の検討
  水町 貴諭, 加納 里志, 坂下 智博, 畠山 博充, 本間 明宏, 福田 諭
  日本耳鼻咽喉科学会会報, 117, 12, 1463, 1470, (一社)日本耳鼻咽喉科学会, 2014年12月01日
  日本語, 研究論文（学術雑誌）
• Intravoxel incoherent motion diffusion-weighted imaging in head and neck squamous cell carcinoma: Assessment of perfusion-related parameters compared to dynamic contrast-enhanced MRI
  Noriyuki Fujima, Daisuke Yoshida, Tomohiro Sakashita, Akihiro Homma, Akiko Tsukahara, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
  MAGNETIC RESONANCE IMAGING, 32, 10, 1206, 1213, 2014年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Epithelial-mesenchymal transition in human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma
  Hiromitsu Hatakeyama, Takatsugu Mizumachi, Tomohiro Sakashita, Satoshi Kano, Akihiro Homma, Satoshi Fukuda
  ONCOLOGY REPORTS, 32, 6, 2673, 2679, 2014年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A clinical study of cases diagnosed as being oropharyngeal carcinoma after cervical mass extirpation/biopsy
  Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Hiromitsu Hatakeyama, Akihiro Homma, Satoshi Fukuda
  Journal of Otolaryngology of Japan, 117, 12, 1463, 1470, Oto-Rhino-Laryngological Society of Japan Inc., 2014年12月01日, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Effect of local extension sites on survival in locally advanced maxillary sinus cancer
  Satoshi Kano, Ryuichi Hayashi, Akihiro Homma, Kazuto Matsuura, Kengo Kato, Kazuyoshi Kawabata, Nobuya Monden, Yasuhisa Hasegawa, Tetsuro Onitsuka, Yasushi Fujimoto, Shigemichi Iwae, Kenji Okami, Takashi Matsuzuka, Kunitoshi Yoshino, Masato Fujii
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 36, 11, 1567, 1572, 2014年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 原発不明頸部リンパ節転移におけるヒト乳頭腫ウイルスの解析
  加納 里志, 本間 明宏, 鈴木 清護, 畠山 博充, 古沢 純, 水町 貴諭, 坂下 智博, 折舘 伸彦, 福田 諭
  頭頸部癌, 40, 3, 344, 348, (一社)日本頭頸部癌学会, 2014年10月31日
  日本語, 研究論文（学術雑誌）
• 初診時メラノーシスと診断され2年以上経過したあとに悪性黒色腫と診断された1例　　　　　　　　　　　　　　　
  木村 将吾, 水町 貴諭, 干野 季美子, 本間 明宏, 福田 諭
  耳鼻咽喉科・頭頸部外科, 86, 11, 931, 935, (株)医学書院, 2014年10月
  日本語
• The incidence of late neck recurrence in N0 maxillary sinus squamous cell carcinomas after superselective intra-arterial chemoradiotherapy without prophylactic neck irradiation
  Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Jun Furusawa, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 271, 10, 2767, 2770, 2014年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Arterial Spin Labeling to Determine Tumor Viability in Head and Neck Cancer Before and After Treatment
  Noriyuki Fujima, Kohsuke Kudo, Daisuke Yoshida, Akihiro Homma, Tomohiro Sakashita, Akiko Tsukahara, Khin Khin Tha, Yuri Zaitsu, Satoshi Terae, Hiroki Shirato
  JOURNAL OF MAGNETIC RESONANCE IMAGING, 40, 4, 920, 928, 2014年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 術前細胞診にて悪性が確定しなかった甲状腺結節におけるエコー陽性所見の数と悪性リスクの関係について　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 古沢 純, 飯塚 さとし, 干野 季美子, 畑中 佳奈子, 福田 諭
  日本内分泌・甲状腺外科学会雑誌, 31, Suppl.2, S234, S234, 日本内分泌外科学会・日本甲状腺外科学会, 2014年09月
  日本語
• 頸部転移を有する中咽頭扁平上皮癌における初回頸部郭清術の意義　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 林 隆一, 岩江 信法, 藤井 正人
  口腔・咽頭科, 27, 3, 329, 329, 日本口腔・咽頭科学会, 2014年08月
  日本語
• 頭頸部がんの化学療法 臨床試験から日常臨床へ
  本間 明宏
  口腔・咽頭科, 27, 3, 267, 267, 日本口腔・咽頭科学会, 2014年08月
  日本語
• Japanese Board Certification System for head and neck surgeons
  Seiichi Yoshimoto, Torahiko Nakashima, Takashi Fujii, Kazuto Matsuura, Naoki Otsuki, Takahiro Asakage, Yasushi Fujimoto, Nobuhiro Hanai, Akihiro Homma, Nobuya Monden, Kenji Okami, Masashi Sugasawa, Yasuhisa Hasegawa, Ken-ichi Nibu, Shin-etsu Kamata, Seiji Kishimoto, Naoyuki Kohno, Satoshi Fukuda, Yasuo Hisa
  AURIS NASUS LARYNX, 41, 4, 327, 330, 2014年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The role of initial neck dissection for patients with node-positive oropharyngeal squamous cell carcinomas
  Tomohiro Sakashita, Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
  ORAL ONCOLOGY, 50, 7, 657, 661, 2014年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 上顎洞原発扁平上皮癌T4症例の頸部転移について 多施設後ろ向き観察研究　　　　　　　　　　　　　　　
  本間 明宏, 林 隆一, 松浦 一登, 加藤 健吾, 川端 一嘉, 門田 伸也, 長谷川 泰久, 鬼塚 哲郎, 藤本 保志, 加藤 孝邦, 丹生 健一, 西野 宏, 朝蔭 孝宏, 池淵 嘉一郎, 藤井 正人
  日本癌治療学会誌, 49, 3, 1053, 1053, (一社)日本癌治療学会, 2014年06月
  日本語
• 喉頭軟骨肉腫の2症例　　　　　　　　　　　　　　　
  藤原 由有希, 水町 貴諭, 本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊139, 104, 104, 耳鼻咽喉科臨床学会, 2014年06月
  日本語
• 頸部外切開を要した魚骨異物の3例
  高橋 紘樹, 坂下 智博, 本間 明宏, 福田 諭
  口腔・咽頭科, 27, 2, 143, 146, 日本口腔・咽頭科学会, 2014年06月
  日本語
• 癌予測に有用なエコー所見に関する検討 術前細胞診で癌が確定しなかった症例を対象に
  坂下 智博, 本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 古沢 純, 飯塚 さとし, 畑中 佳奈子, 福田 諭
  日本内分泌・甲状腺外科学会雑誌, 31, 2, 130, 133, 日本内分泌外科学会・日本甲状腺外科学会, 2014年06月
  日本語
• 当院における下咽頭癌に対する強度変調放射線治療(IMRT)の初期経験　　　　　　　　　　　　　　　
  土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊
  頭頸部癌, 40, 2, 257, 257, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 下咽頭癌化学放射線療法後再発症例における救済治療と予後の検討 多施設による観察研究　　　　　　　　　　　　　　　
  米澤 宏一郎, 林 隆一, 鬼塚 哲郎, 長谷川 泰久, 大上 研二, 本間 明宏, 岩江 信法, 加藤 孝邦, 丹生 健一, 加藤 健吾, 藤井 正人
  頭頸部癌, 40, 2, 199, 199, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 下咽頭癌に対するRADPLATとweekly CDDP併用化学放射線治療の比較検討　　　　　　　　　　　　　　　
  古沢 純, 本間 明宏, 坂下 智博, 畠山 博充, 加納 里志, 水町 貴諭, 土屋 和彦, 吉田 大介, 安田 耕一, 白土 博樹, 福田 諭
  頭頸部癌, 40, 2, 198, 198, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 唾液腺導管癌におけるHER2下流シグナルの解析　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 畠山 博充, 古沢 純, 水町 貴諭, 坂下 智博, 福田 諭
  頭頸部癌, 40, 2, 191, 191, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• セツキシマブ投与におけるEGFRリガンド発現変化と効果　　　　　　　　　　　　　　　
  畠山 博充, 坂下 智博, 水町 貴諭, 加納 里志, 本間 明宏, 福田 諭, 古沢 純
  頭頸部癌, 40, 2, 187, 187, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 局所進行頭頸部癌に対する導入化学療法後のweekly CDDP併用化学放射線療法の安全性と有用性の検討　　　　　　　　　　　　　　　
  水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 清水 康, 秋田 弘俊, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭
  頭頸部癌, 40, 2, 177, 177, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 眼窩骨壁浸潤を伴う進行上顎洞癌における治療別生存率比較 眼窩内容温存全摘術の妥当性について　　　　　　　　　　　　　　　
  坂下 智博, 林 隆一, 本間 明宏, 松浦 一登, 加藤 健吾, 川端 一嘉, 松塚 崇, 岩江 信法, 大上 研二, 藤井 正人
  頭頸部癌, 40, 2, 172, 172, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• 腹腔鏡下遊離空腸採取に伴う問題点と対策　　　　　　　　　　　　　　　
  村尾 尚規, 古川 洋志, 林 利彦, 山本 有平, 本間 明宏, 七戸 俊明
  頭頸部癌, 40, 2, 165, 165, (一社)日本頭頸部癌学会, 2014年05月
  日本語
• Lymph Node Metastasis in T4 Maxillary Sinus Squamous Cell Carcinoma: Incidence and Treatment Outcome
  Akihiro Homma, Ryuichi Hayashi, Kazuto Matsuura, Kengo Kato, Kazuyoshi Kawabata, Nobuya Monden, Yasuhisa Hasegawa, Tetsuro Onitsuka, Yasushi Fujimoto, Shigemichi Iwae, Kenji Okami, Takashi Matsuzuka, Kunitoshi Yoshino, Ken-ichi Nibu, Takakuni Kato, Hiroshi Nishino, Takahiro Asakage, Ichiro Ota, Morimasa Kitamura, Akira Kubota, Tsutomu Ueda, Kaichiro Ikebuchi, Akihito Watanabe, Masato Fujii
  ANNALS OF SURGICAL ONCOLOGY, 21, 5, 1706, 1710, 2014年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Burns spaceに転移を来した甲状腺乳頭癌の2例　　　　　　　　　　　　　　　
  本間 明宏, 畠山 博充, 水町 貴諭, 古沢 純, 加納 里志, 坂下 智博, 福田 諭
  日本耳鼻咽喉科学会会報, 117, 4, 605, 605, (一社)日本耳鼻咽喉科学会, 2014年04月
  日本語
• 早期外耳道癌症例に対する治療前後の聴力に関する検討
  森田 真也, 中丸 裕爾, 本間 明宏, 坂下 智博, 桝谷 将偉, 福田 諭
  日本耳鼻咽喉科学会会報, 117, 4, 565, 565, (一社)日本耳鼻咽喉科学会, 2014年04月
  日本語
• 口腔癌に対するセンチネルリンパ節ナビゲーション頸部郭清術の研究
  上村 裕和, 平川 仁, 三浦 弘規, 吉本 世一, 塩谷 彰浩, 菅澤 正, 小須田 茂, 本間 明宏, 横山 純吉, 吉崎 智一, 塚原 清彰, 長谷川 泰久
  日本耳鼻咽喉科学会会報, 117, 4, 455, 455, (一社)日本耳鼻咽喉科学会, 2014年04月
  日本語
• 【画像診断パーフェクトガイド 読影のポイントとピットフォール】 部位別診断法 鼻・副鼻腔 鼻・副鼻腔癌
  藤間 憲幸, 本間 明宏
  耳鼻咽喉科・頭頸部外科, 86, 5, 149, 155, (株)医学書院, 2014年04月
  日本語
• Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy
  Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Jun Furusawa, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Fumiyuki Suzuki, Satoshi Fukuda
  BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 52, 4, 323, 328, 2014年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Synchronous HPV-Positive Squamous Cell Carcinoma of the Bilateral Base of the Tongue　　　　　　　　　　　　　　　
  Takatsugu Mizumachi, Tomohiro Sakashita, Yusuke Hishimura, Tomohiko Kakizaki, Akihiro Homma, Tomoko Mitsuhashi, Satoshi Fukuda
  Otolaryngology, 4, 2, 2014年03月, ［査読有り］
  英語
• Secondary voice prosthesis placement using a curved rigid esophagoscope　　　　　　　　　　　　　　　
  Takatsugu Mizumachi, Akihiro Homma, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Seigo Suzuki, Nobuhiko Oridate, Satoshi Fukuda
  Oto-Rhino-Laryngology Tokyo, 56, 5, 334, 337, 2014年
  日本語, 研究論文（学術雑誌）
• 中咽頭扁平上皮癌症例に対するWeekly CDDP併用化学放射線療法の臨床的検討
  水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭
  頭頸部癌, 40, 1, 66, 70, (一社)日本頭頸部癌学会, 2014年
  日本語, 研究論文（学術雑誌）
• Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy
  Sakashita T, Homma A, Hatakeyama H, Kano S, Mizumachi T, Furusawa J, Yoshida D, Fujima N, Onimaru R, Tsuchiya K, Yasuda K, Shirato H, Suzuki F, Fukuda S
  Br J Oral Maxillofac Surg, 52, 4, 323, 8, 2014年, ［査読有り］
• The potential diagnostic role of the number of ultrasonographic characteristics for patients with thyroid nodules evaluated as bethesda I-v.
  Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Satoshi Iizuka, Kimiko Hoshino, Kanako C Hatanaka, Koji Oba, Satoshi Fukuda
  Frontiers in oncology, 4, 261, 261, 2014年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Fine-needle aspiration cytology (FNAC) is considered to be the most reliable method of examination for thyroid nodules. However, when thyroid nodules are evaluated as Bethesda I-V, the role of ultrasonography is considered to be enhanced. We investigated the association between a number of ultrasonographic (US) characteristics and the risk of thyroid malignancy, and assessed the optimal compromise on the number of US characteristics for predicting thyroid malignancy. METHODS: Seventy-three patients, whose thyroid nodules were evaluated as Bethesda I-V by FNAC prior to surgery, were treated surgically. A number of US characteristics, such as microcalcification, irregular margins, hypoechogenicity, a taller-than-wide shape, and the absence of halo sign, were assessed before surgery. The optimal compromise on the number of US characteristics was analyzed using a receiver operating characteristics (ROC) curve. The area under the ROC curve (AUC) represents the overall discriminatory ability of a test. RESULTS: The risk of malignancy was 11.8% in patients without any US characteristics, 44.4% in those with one characteristic, 61.5% in those with two characteristics, 75% in those with three characteristics, 90% in those with four characteristics, and 100% in those with five characteristics. The AUC was favorable (0.81599). At least two US characteristics were revealed to be the optimal compromise on the number of US characteristics based on the ROC curve. CONCLUSION: We proved the role of the number of US characteristics in predicting thyroid malignancy. It was thought that a surgical approach should be considered for patients with at least two US characteristics.
• Hearing Preservation after Lateral Temporal Bone Resection for Early-Stage External Auditory Canal Carcinoma
  Shinya Morita, Yuji Nakamaru, Akihiro Homma, Tomohiro Sakashita, Masayori Masuya, Satoshi Fukuda
  AUDIOLOGY AND NEURO-OTOLOGY, 19, 6, 351, 357, 2014年, ［査読有り］
  英語, 研究論文（学術雑誌）
• LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS TREATED WITH DCF (DOCETAXEL, CISPLATIN, 5-FU) INDUCTION CHEMOTHERAPY
  J. Taguchi, T. Amano, I. Kinoshita, R. Honma, Y. Shimizu, K. Tsuchiya, H. Shirato, A. Homma, S. Fukuda, H. Akita
  ANNALS OF ONCOLOGY, 24, 2013年11月
  英語
• 中咽頭扁平上皮癌症例におけるHPV感染とp16の発現に関する検討
  水町 貴諭, 畠山 博充, 加納 里志, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 39, 3, 334, 338, (一社)日本頭頸部癌学会, 2013年10月28日
  日本語, 研究論文（学術雑誌）
• 上顎洞原発扁平上皮癌T4症例の多施設による後ろ向き観察研究
  本間 明宏, 林 隆一, 松浦 一登, 加藤 健吾, 川端 一喜, 門田 伸也, 長谷川 泰久, 鬼塚 哲郎, 藤本 保志, 岩江 信法, 大上 研二, 松塚 崇, 吉野 邦俊, 藤井 正人
  頭頸部癌, 39, 3, 310, 316, (一社)日本頭頸部癌学会, 2013年10月28日
  日本語, 研究論文（学術雑誌）
• 当科における二期的気管食道瘻形成術 彎曲型食道直達鏡の試作
  水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 鈴木 清護, 折舘 伸彦, 福田 諭
  耳鼻咽喉科展望, 56, 5, 334, 337, 耳鼻咽喉科展望会, 2013年10月
  日本語
• Salvage surgery for recurrent oropharyngeal cancer after chemoradiotherapy
  Satoshi Kano, Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18, 5, 817, 823, 2013年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma
  Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Hiromitsu Hatakeyama, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18, 5, 824, 828, 2013年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 進行喉頭癌に対する喉頭温存療法の後ろ向き多施設共同研究　　　　　　　　　　　　　　　
  藤井 正人, 本間 明宏, 藤本 保志, 太田 一郎, 林 隆一, 田原 信, 大上 研二, 岩江 信法, 大月 直樹, 清田 尚臣, 西野 宏, 鬼塚 哲郎
  日本癌治療学会誌, 48, 3, 2164, 2164, (一社)日本癌治療学会, 2013年09月
  日本語
• 進行下咽頭癌に対する根治的化学放射線療法の治療成績 多施設共同による後ろ向き研究　　　　　　　　　　　　　　　
  岩江 信法, 林 隆一, 大上 研二, 本間 明宏, 米澤 宏一郎, 鬼塚 哲郎, 長谷川 泰久, 加藤 健吾, 加藤 孝邦, 太田 一郎, 田原 信, 藤井 正人
  日本癌治療学会誌, 48, 3, 1250, 1250, (一社)日本癌治療学会, 2013年09月
  日本語
• 中咽頭癌に対する放射線化学療法の検討 多施設による後方視的観察研究　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 林 隆一, 川端 一喜, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 丹生 健一, 加藤 孝邦, 志賀 清人, 松浦 一登, 門田 伸也, 藤井 正人
  日本癌治療学会誌, 48, 3, 1248, 1248, (一社)日本癌治療学会, 2013年09月
  日本語
• Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas
  Tomohiro Sakashita, Akihiro Homma, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Nobuhiko Oridate, Satoshi Fukuda
  ACTA OTO-LARYNGOLOGICA, 133, 9, 984, 991, 2013年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 頸部外切開を要した魚骨異物の3例　　　　　　　　　　　　　　　
  高橋 紘樹, 坂下 智博, 本間 明宏, 福田 諭
  口腔・咽頭科, 26, 3, 317, 317, 日本口腔・咽頭科学会, 2013年08月
  日本語
• リンパ節および肺転移をきたしたprimary mucinous carcinoma of the skinの1例　　　　　　　　　　　　　　　
  本間 英里奈, 青柳 哲, 濱出 洋平, 西村 慶子, 保科 大地, 秦 洋郎, 清水 宏, 坂下 智博, 本間 明宏, 加賀 基知三
  日本皮膚科学会雑誌, 123, 8, 1547, 1547, (公社)日本皮膚科学会, 2013年07月
  日本語
• 頭頸部癌 超選択的動注化学療法　　　　　　　　　　　　　　　
  本間 明宏
  癌と化学療法, 40, 7, 857, 860, (株)癌と化学療法社, 2013年07月
  日本語
• 中咽頭癌症例におけるHPV感染と転移リンパ節の検討
  水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
  口腔・咽頭科, 26, 2, 161, 166, 日本口腔・咽頭科学会, 2013年06月
  日本語
• 甲状腺未分化癌・低分化癌症例における分化機構についての免疫組織学的検討　　　　　　　　　　　　　　　
  干野 季美子, 畠山 博充, 坂下 智博, 加納 里志, 水町 貴諭, 本間 明宏, 畑中 佳奈子, 福田 諭
  頭頸部癌, 39, 2, 244, 244, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• 両側に生じたHPV陽性舌根癌症例　　　　　　　　　　　　　　　
  水町 貴諭, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 福田 諭
  頭頸部癌, 39, 2, 228, 228, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• II-IV期上咽頭癌に対する化学放射線同時併用療法 併用化学療法に関する後ろ向き比較検討　　　　　　　　　　　　　　　
  土屋 和彦, 安田 耕一, 木下 留美子, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊
  頭頸部癌, 39, 2, 218, 218, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• 上顎洞扁平上皮癌に対する超選択的動注併用放射線治療後の救済手術に関する検討　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 鈴木 章之, 畠山 博充, 加納 里志, 水町 貴諭, 古沢 純, 福田 諭
  頭頸部癌, 39, 2, 202, 202, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• 上顎洞原発扁平上皮癌T4症例の進展部位別予後解析 多施設後ろ向き観察研究　　　　　　　　　　　　　　　
  加納 里志, 林 隆一, 本間 明宏, 松浦 一登, 加藤 健吾, 川端 一喜, 松塚 崇, 大上 研二, 岩江 信法, 藤井 正人
  頭頸部癌, 39, 2, 201, 201, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• HPV陽・陰性中咽頭扁平上皮癌の上皮間葉移行における特性　　　　　　　　　　　　　　　
  畠山 博充, 水町 貴諭, 坂下 智博, 加納 里志, 本間 明宏, 福田 諭
  頭頸部癌, 39, 2, 188, 188, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• HPV陽性中咽頭癌に対するweekly CDDP併用化学放射線治療の臨床的検討　　　　　　　　　　　　　　　
  水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 福田 諭
  頭頸部癌, 39, 2, 139, 139, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• 化学放射線療法の現状と役割 動注化学療法による化学放射線療法 上顎洞癌を中心に　　　　　　　　　　　　　　　
  本間 明宏, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 藤井 正人, 福田 諭
  頭頸部癌, 39, 2, 134, 134, (一社)日本頭頸部癌学会, 2013年05月
  日本語
• 北海道大学病院における上咽頭癌の治療 10年間(2000〜2010)のまとめ
  土屋 和彦, 安田 耕一, 西川 由記子, 木下 留美子, 鬼丸 力也, 原田 慶一, 井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 西岡 健, 鈴木 恵士郎, 田口 大志, 長谷川 雅一, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭, 竹内 啓, 田口 純
  耳鼻咽喉科展望, 56, 補冊2, 174, 175, 耳鼻咽喉科展望会, 2013年05月
  日本語
• 北海道大学病院における鼻副鼻腔癌の治療成績 上顎洞原発扁平上皮癌を中心に
  本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 古沢 純, 水町 貴諭, 坂下 智博, 鈴木 章之, 瀧 重成, 稲村 直哉, 福田 諭
  耳鼻咽喉科展望, 56, 補冊2, 130, 131, 耳鼻咽喉科展望会, 2013年05月
  日本語
• Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of a phase II trial
  Takayuki Yoshino, Yasuhisa Hasegawa, Shunji Takahashi, Nobuya Monden, Akihiro Homma, Kenji Okami, Yusuke Onozawa, Masato Fujii, Takahide Taguchi, Barbara de Blas, Frank Beier, Makoto Tahara
  Japanese Journal of Clinical Oncology, 43, 5, 524, 531, 2013年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 当科における導入化学療法後の放射線化学療法例の検討　　　　　　　　　　　　　　　
  蠣崎 文彦, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭
  日本耳鼻咽喉科学会会報, 116, 4, 524, 524, (一社)日本耳鼻咽喉科学会, 2013年04月
  日本語
• 眼窩骨壁浸潤を認める進行上顎洞癌における治療別視機能温存率についての検討
  坂下 智博, 林 隆一, 本間 明宏, 松浦 一登, 加藤 健吾, 川端 一嘉, 松塚 崇, 岩江 信法, 大上 研二, 藤井 正人
  日本耳鼻咽喉科学会会報, 116, 4, 440, 440, (一社)日本耳鼻咽喉科学会, 2013年04月
  日本語
• 頭頸部癌化学放射線療法における小野寺栄養指数の意義　　　　　　　　　　　　　　　
  折舘 伸彦, 倉本 倫之介, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 蠣崎 文彦, 福田 諭
  日本気管食道科学会会報, 64, 2, s55, s55, (NPO)日本気管食道科学会, 2013年04月
  日本語
• Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas
  Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  AURIS NASUS LARYNX, 40, 2, 211, 215, 2013年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 喉頭癌T3症例の治療成績の検討
  水町 貴諭, 折舘 伸彦, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 鈴木 清護, 福田 諭
  頭頸部外科, 22, 3, 317, 321, (NPO)日本頭頸部外科学会, 2013年02月
  日本語
• 当科で放射線治療を施行した頭頸部原発小細胞癌症例の検討　　　　　　　　　　　　　　　
  西川 由記子, 安田 耕一, 土屋 和彦, 鬼丸 力也, 白土 博樹, 本間 明宏, 竹内 啓, 田口 純
  Japanese Journal of Radiology, 31, Suppl.I, 12, 12, (公社)日本医学放射線学会, 2013年02月
  日本語
• 中咽頭癌に対する治療の現状 多施設による後ろ向き観察研究
  本間 明宏, 林 隆一, 川端 一喜, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 加納 里志, 丹生 健一, 加藤 孝邦, 志賀 清人, 松浦 一登, 門田 伸也, 藤井 正人
  頭頸部癌, 39, 4, 449, 455, (一社)日本頭頸部癌学会, 2013年
  日本語, 研究論文（学術雑誌）
• Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer
  Homma A, Sakashita T, Yoshida D, Onimaru R, Tsuchiya K, Suzuki F, Yasuda K, Hatakeyama H, Furusawa J, Mizumachi T, Kano S, Inamura N, Taki S, Shirato H, Fukuda S
  Br J Cancer, 109, 12, 2980, 6, Nature publishing group, 2013年, ［査読有り］
  英語, Background: The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS). Methods: Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100-120mgm(-2) per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n-5), brain necrosis (n-1), and ocular/ visual problems (n = 14) were observed as late adverse reactions. Conclusion: We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.
• Matched-Pair Analysis in Patients with Advanced Oropharyngeal Cancer: Surgery versus Concurrent Chemoradiotherapy
  Satoshi Kano, Akihiro Homma, Ryuichi Hayashi, Kazuyoshi Kawabata, Kunitoshi Yoshino, Shigemichi Iwae, Yasuhisa Hasegawa, Kenichi Nibu, Takakuni Kato, Kiyoto Shiga, Kazuto Matsuura, Nobuya Monden, Masato Fujii
  ONCOLOGY, 84, 5, 290, 298, 2013年, ［査読有り］
  英語, 研究論文（学術雑誌）
• 切除可能T3、T4上顎洞扁平上皮癌における手術の位置付け 当院における治療戦略
  本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭
  耳鼻と臨床, 58, Suppl.1, S52, S56, 耳鼻と臨床会, 2012年11月
  日本語
• 口腔癌における超選択的シスプラチン動注化学療法後のセンチネルリンパ節内プラチナ濃度測定
  坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 吉田 大介, 藤間 憲幸, 福田 諭
  北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 6, 261, 261, 2012年11月01日
  日本語
• An analysis of sentinel lymph node distribution for ealry tongue cancer　　　　　　　　　　　　　　　
  Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Satoshi Fukuda
  Oto-Rhino-Laryngology Tokyo, 55, 5, 100, 104, 2012年10月
  日本語, 研究論文（学術雑誌）
• Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for squamous cell carcinoma of the nasal vestibule: a report of two cases
  Homma Akihiro, Suzuki Fumiyuki, Hatakeyama Hiromitsu, Sakashita Tomohiro, Yoshida Daisuke, Tsuchiya Kazuhiko, Onimaru Rikiya, Oridate Nobuhiko, Shirato Hiroki, Fukuda Satoshi
  International Cancer Conference Journal, 1, 4, 215, 219, Springer, 2012年10月
  英語, Squamous cell carcinoma of the nasal vestibule (SCC-NV) is rare among head and neck malignancies. It behaves differently from cancers arising in the nasal cavity and paranasal sinuses, and skin cancer of the external nose. Prognosis is more favorable than nasal cavity tumors and less favorable than skin cancers. We experienced two cases of SCC-NV who were treated with rapid superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT). A 56-year-old male and a 68-year-old female with SCC-NV, classified as T4aN0M0 according to UICC and T2 according to Wang classification, were given superselective intra-arterial infusions of cisplatin, with simultaneous intravenous infusions of thiosulfate to neutralizecisplatin toxicity, together with conventionalradiotherapy. In both cases, the internal maxillary artery and the facial artery were considered to be feeders of the tumor. No serious adverse events have been observed in either patient to date during follow-up of 7.3 and 5.3 years, respectively. Both patients are alive without disease and show excellent cosmetic results. RADPLAT is considered to be useful for the treatment of patients with SCC of the nasal vestibule.
• 早期舌癌におけるセンチネルリンパ節の領域分布に関する検討
  坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
  耳鼻咽喉科展望, 55, 5, 364, 368, 耳鼻咽喉科展望会, 2012年10月
  日本語
• 当科で導入化学療法を施行した頭頸部局所進行扁平上皮癌症例の治療成績　　　　　　　　　　　　　　　
  天野 虎次, 田口 純, 木下 一郎, 合田 智宏, 本間 理央, 竹内 啓, 清水 康, 安田 耕一, 土屋 和彦, 白土 博樹, 本間 明宏, 福田 諭, 秋田 弘俊
  日本癌治療学会誌, 47, 3, 2112, 2112, (一社)日本癌治療学会, 2012年10月
  日本語
• 再発/転移性頭頸部扁平上皮癌患者対象の化学療法併用によるcetuximabの第II相臨床試験　　　　　　　　　　　　　　　
  長谷川 泰久, 吉野 孝之, 高橋 俊二, 門田 伸也, 小野澤 祐輔, 本間 明宏, 大上 研二, 藤井 正人, 田口 享秀, 太田 雅貴, 田原 信
  日本癌治療学会誌, 47, 3, 1378, 1378, (一社)日本癌治療学会, 2012年10月
  日本語
• 頭頸部癌化学放射線療法における経管栄養の役割に関する検討
  倉本 倫之介, 折舘 伸彦, 本間 明宏, 及川 敬太, 藤田 香, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭
  嚥下医学, 1, 2, 359, 363, 日本嚥下医学会, 2012年10月
  日本語
• Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy
  Shigenari Taki, Akihiro Homma, Fumiyuki Suzuki, Nobuhiko Oridate, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Tomohiro Sakashita, Naoya Inamura, Daisuke Yoshida, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 17, 5, 441, 446, 2012年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Platinum concentration in sentinel lymph nodes after preoperative intra-arterial cisplatin chemotherapy targeting primary tongue cancer
  Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Daisuke Yoshida, Noriyuki Fujima, Satoshi Fukuda
  ACTA OTO-LARYNGOLOGICA, 132, 10, 1121, 1125, 2012年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• HPV陽性中咽頭癌の転移リンパ節の臨床像　　　　　　　　　　　　　　　
  水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
  口腔・咽頭科, 25, 3, 295, 295, 日本口腔・咽頭科学会, 2012年08月
  日本語
• 【頭頸部扁平上皮癌の最新情報】 頭頸部扁平上皮癌に対する新しい治療戦略 化学療法 同時放射線治療と超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏
  JOHNS, 28, 8, 1181, 1184, (株)東京医学社, 2012年08月
  日本語
• 舌根癌における放射線同時併用超選択的動注化学療法
  加納 里志, 本間 明宏, 折舘 伸彦, 鈴木 章之, 畠山 博充, 水町 貴諭, 古沢 純, 坂下 智博, 吉田 大介, 鬼丸 力也, 白戸 博樹, 福田 諭
  北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 4, 208, 208, 2012年08月01日
  日本語
• PET-CT検査にてはじめて原因が特定しえた喉頭麻痺の2症例　　　　　　　　　　　　　　　
  折舘 伸彦, 溝口 兼司, 加納 里志, 本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊133, 110, 110, 耳鼻咽喉科臨床学会, 2012年07月
  日本語
• 大量シスプラチンの超選択的動注療法と照射の同時併用療法の現状
  本間 明宏
  頭頸部外科, 22, 1, 29, 31, (NPO)日本頭頸部外科学会, 2012年06月
  日本語
• Evaluation of nodal response after intra-arterial chemoradiation for node-positive head and neck cancer
  Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 269, 6, 1671, 1676, 2012年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 進行上顎洞癌症例の多施設による後ろ向き観察研究　　　　　　　　　　　　　　　
  本間 明宏, 林 隆一, 松浦 一登, 加藤 健吾, 川端 一嘉, 門田 伸也, 長谷川 泰久, 鬼塚 哲郎, 藤本 保志, 藤井 正人
  頭頸部癌, 38, 2, 245, 245, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• 頭頸部癌化学放射線療法における経管栄養の役割に関する検討　　　　　　　　　　　　　　　
  折舘 伸彦, 倉本 倫之介, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 及川 敬太, 福田 諭
  頭頸部癌, 38, 2, 210, 210, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• 中咽頭癌に対する治療の現状(第2報) 多施設による後ろ向き観察研究　　　　　　　　　　　　　　　
  林 隆一, 川端 一嘉, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 加納 里志, 丹生 健一, 加藤 孝邦, 志賀 清人, 本間 明宏, 藤井 正人
  頭頸部癌, 38, 2, 205, 205, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• 頭頸部扁平上皮癌根治切除症例の切除断端における免疫組織学的予後因子の検討　　　　　　　　　　　　　　　
  坂下 智博, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
  頭頸部癌, 38, 2, 182, 182, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• 原発不明頸部リンパ節転移におけるp16とヒト乳頭腫ウイルスの解析　　　　　　　　　　　　　　　
  加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
  頭頸部癌, 38, 2, 162, 162, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• 中咽頭扁平上皮癌症例におけるHPV感染とp16の発現に関する検討　　　　　　　　　　　　　　　
  水町 貴諭, 鈴木 清護, 畠山 博充, 加納 里志, 坂下 智博, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 38, 2, 161, 161, (一社)日本頭頸部癌学会, 2012年05月
  日本語
• Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706
  Makoto Tahara, Naomi Kiyota, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi, Tetsuo Akimoto, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Hirofumi Fujii, Yusuke Onozawa, Akihiro Homma, Akira Kubota, Haruhiko Fukuda, Masato Fujii
  JOURNAL OF CLINICAL ONCOLOGY, 30, 15, 2012年05月
  英語
• Weekly CDDP同時併用放射線療法後の頸部郭清・頸部制御率
  坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
  日本耳鼻咽喉科学会会報, 115, 4, 519, 519, (一社)日本耳鼻咽喉科学会, 2012年04月
  日本語
• 女性喉頭癌症例におけるHPV感染の検討
  水町 貴諭, 加納 里志, 畠山 博充, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  日本耳鼻咽喉科学会会報, 115, 4, 466, 466, (一社)日本耳鼻咽喉科学会, 2012年04月
  日本語
• 中咽頭癌に対する治療の現状 多施設による後ろ向き観察研究
  本間 明宏, 林 隆一, 川端 一喜, 吉野 邦俊, 岩江 信法, 長谷川 泰久, 丹生 健一, 加藤 孝邦, 志賀 清人, 松浦 一登, 門田 信也, 藤井 正人
  日本耳鼻咽喉科学会会報, 115, 4, 458, 458, (一社)日本耳鼻咽喉科学会, 2012年04月
  日本語
• 【最新の診療NAVI 日常診療必携】 腫瘍性疾患診療NAVI 鼻副鼻腔腫瘍　　　　　　　　　　　　　　　
  本間 明宏
  耳鼻咽喉科・頭頸部外科, 84, 5, 249, 253, (株)医学書院, 2012年04月
  日本語
• 上咽頭癌再発症例に対する再照射例の検討　　　　　　　　　　　　　　　
  鬼丸 力也, 安田 耕一, 西川 昇, 米山 理奈, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭
  Japanese Journal of Radiology, 30, Suppl.I, 5, 5, (公社)日本医学放射線学会, 2012年02月
  日本語
• 舌根部癌に対する喉頭機能温存治療 中咽頭前壁原発扁平上皮癌に対する超選択的動注化学療法と照射の同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 坂下 智博, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 福田 諭
  日本気管食道科学会会報, 63, 1, 77, 78, (NPO)日本気管食道科学会, 2012年02月
  日本語
• オピオイドによる難治性の嘔気とめまいに対してヒスタミンH₁受容体拮抗薬とペロスピロンの併用が有効であった2症例
  長田 貴之, 坂下 智博, 折舘 伸彦, 本間 明宏, 福田 諭, 菅原 満, 井関 健, 柴山 良彦, 熊井 正貴, 山田 武宏, 笠師 久美子, 倉本 倫之介, 洲崎 真吾, 赤澤 茂, 真栄田 浩行
  医療薬学, 38, 1, 51, 55, 一般社団法人日本医療薬学会, 2012年
  日本語
• 骨固定型ピックアップを用いた食道発声支援装置用骨伝導マイクロホンの開発 非経皮的骨導音導出に関する予備的検討　　　　　　　　　　　　　　　
  前田 秀彦, 西澤 典子, 武市 紀人, 本間 明宏, 玉重 詠子, 目須田 康, 葛西 聡子, 折舘 伸彦, 福田 諭
  音声言語医学, 53, 1, 84, 85, 日本音声言語医学会, 2012年01月
  日本語
• 当院で施行した頭頚部局所進行扁平上皮癌に対するDCF(docetaxel,cisplatin,5‐FU)導入化学療法の検討
  田口純, 天野虎次, 木下一郎, 合田智宏, 本間理央, 竹内啓, 清水康, 安田耕一, 土屋和彦, 鬼丸力也, 本間明宏, 福田諭, 秋田弘俊
  日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 179, 180, 2012年
  日本語
• Otolaryngologic Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
  Yuji Nakamaru, Dai Takagi, Nobuhiko Oridate, Akihiro Homma, Satoshi Fukuda
  OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 146, 1, 119, 121, 2012年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• [Hearing loss of aging].
  Homma A, Takeichi N, Tsubuku T, Obara N
  [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 87, 1, 7, 9, 2012年01月, ［査読有り］
  日本語
• Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy
  Sadamoto Zenda, Kazuto Matsuura, Hiroyuki Tachibana, Akihiro Homma, Tadaaki Kirita, Nobuya Monden, Shigemichi Iwae, Yojiro Ota, Tetsuo Akimoto, Hiroshi Otsuru, Makoto Tahara, Kengo Kato, Masao Asai
  RADIOTHERAPY AND ONCOLOGY, 101, 3, 410, 414, 2011年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Transoral surgery of the larynx and pharynx using Weerda-type videolaryngoscope　　　　　　　　　　　　　　　
  Nobuhiko Oridate, Akihiro Homma, Yuji Nakamaru, Seigo Suzuki, Satoshi Fukuda
  Oto-Rhino-Laryngology Tokyo, 54, 5, 355, 359, 2011年10月15日
  日本語, 研究論文（学術雑誌）
• 頭頸部がん治療update 頭頸部癌治療における超選択的動注の役割　　　　　　　　　　　　　　　
  福田 諭, 本間 明宏
  日本医学会総会会誌, 28回, I, 298, 298, 日本医学会, 2011年10月
  日本語
• WEERDA型拡張式ビデオ喉頭鏡を用いた経口的喉頭・咽頭手術
  折舘 伸彦, 本間 明宏, 中丸 裕爾, 鈴木 清護, 福田 諭
  耳鼻咽喉科展望, 54, 5, 355, 359, 耳鼻咽喉科展望会, 2011年10月
  日本語
• 唾液導管癌におけるHER2の発現解析
  鈴木 崇祥, 加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 水町 貴諭, 古沢 純, 坂下 智博, 福田 諭
  頭頸部外科, 21, 2, 195, 201, (NPO)日本頭頸部外科学会, 2011年10月
  日本語
• 放射線療法の進歩と将来展望 放射線治療におけるPositron emission tomography(PET)検査の利用
  鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 岡本 祥三, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 37, 3, 376, 380, (一社)日本頭頸部癌学会, 2011年10月
  日本語
• 骨固定型ピックアップによる非経皮的骨導音の検出 : 周波数特性に関する予備的検討
  前田 秀彦, 西澤 典子, 武市 紀人, 本間 明宏, 玉重 詠子, 葛西 聡子, 前田 昌紀, 中津 政典, 大橋 正實, 福田 諭
  Audiology Japan, 54, 5, 615, 616, 日本聴覚医学会, 2011年09月30日
  日本語
• HPV感染による中咽頭癌治療の層別化戦略　　　　　　　　　　　　　　　
  水町 貴諭, 加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
  口腔・咽頭科, 24, 3, 353, 353, 日本口腔・咽頭科学会, 2011年08月
  日本語
• 機能温存をめざした下咽頭癌の治療 下咽頭癌に対する超選択的動注化学療法と照射の同時併用療法の有用性
  本間 明宏, 加納 里志, 水町 貴諭, 福田 諭
  口腔・咽頭科, 24, 3, 229, 229, 日本口腔・咽頭科学会, 2011年08月
  日本語
• Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer
  Akihiro Homma, Naoya Inamura, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Rikiya Onimaru, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 8, 980, 986, 2011年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 【頭頸部癌診療の今】 化学療法 超選択的動注療法　　　　　　　　　　　　　　　
  福田 諭, 本間 明宏
  Pharma Medica, 29, 7, 35, 38, (株)メディカルレビュー社, 2011年07月
  日本語
• Superselective arterial cisplatin infusion with concomitant radiation therapy for base of tongue cancer
  Satoshi Kano, Akihiro Homma, Nobuhiko Oridate, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Jun Furusawa, Tomohiro Sakashita, Daisuke Yoshida, Rikiya Onimaru, Hiroki Shirato, Satoshi Fukuda
  ORAL ONCOLOGY, 47, 7, 665, 670, 2011年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 私たちが行っている化学放射線療法後の救済手術における皮膚切開デザインの工夫
  本間 明宏, 折舘 伸彦, 鈴木 章之, 鈴木 清護, 原 敏浩, 真栄田 裕行, 水町 貴諭, 稲村 直哉, 福田 諭
  頭頸部外科, 21, 1, 103, 106, (NPO)日本頭頸部外科学会, 2011年06月
  日本語
• 高齢、併存疾患と頭頸部癌治療
  本間 明宏
  耳鼻咽喉科臨床, 104, 6, 460, 461, 耳鼻咽喉科臨床学会, 2011年06月
  日本語
• 【頭頸部悪性腫瘍の初期症状とその対応】 嗄声・呼吸困難・誤嚥　　　　　　　　　　　　　　　
  本間 明宏, 鈴木 崇祥
  ENTONI, 128, 8, 13, (株)全日本病院出版会, 2011年06月
  日本語
• 唾液腺悪性腫瘍におけるEGFR、HER2、c-KITの発現解析　　　　　　　　　　　　　　　
  加納 里志, 鈴木 清護, 折舘 伸彦, 本間 明宏, 畠山 博充, 水町 貴諭, 坂下 智博, 福田 諭
  頭頸部癌, 37, 2, 270, 270, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 頭頸部進行癌に対する集学的治療 "導入化学療法→化学放射線同時併用療法"　　　　　　　　　　　　　　　
  本間 明宏, 清水 康, 折舘 伸彦, 鬼丸 力也, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 安田 耕一, 秋田 弘俊, 白土 博樹, 福田 諭
  頭頸部癌, 37, 2, 233, 233, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 頭頸部扁平上皮癌N+症例における放射線動注化学療法後の頸部評価 Wait and See Policyは成立するか　　　　　　　　　　　　　　　
  坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹
  頭頸部癌, 37, 2, 231, 231, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 頭頸部癌におけるNF-kBパスウエイの活性化とセツキシマブ耐性　　　　　　　　　　　　　　　
  畠山 博充, 鈴木 清護, 坂下 智博, 加納 里志, 水町 貴諭, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 37, 2, 230, 230, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 個別化を目指す薬物療法 HPV陽性中咽頭癌に対する個別化治療戦略　　　　　　　　　　　　　　　
  水町 貴諭, 畠山 博充, 加納 里志, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 37, 2, 191, 191, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 放射線治療の進歩と将来展望 放射線治療におけるPETの利用　　　　　　　　　　　　　　　
  鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 37, 2, 185, 185, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 頭頸部癌患者を支えるチーム医療 大学病院での頭頸部がん治療における口腔ケアの取り組みについて　　　　　　　　　　　　　　　
  秦 浩信, 山崎 裕, 佐藤 淳, 村田 翼, 村井 知佳, 今待 賢治, 本間 明宏, 北川 善政
  頭頸部癌, 37, 2, 181, 181, (一社)日本頭頸部癌学会, 2011年05月
  日本語
• 鼻副鼻腔腫瘍治療戦略の新しい可能性を探る 鼻副鼻腔悪性腫瘍に対する超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏, 水町 貴諭, 原 敏浩, 福田 諭
  日本鼻科学会会誌, 50, 1, 92, 94, (一社)日本鼻科学会, 2011年04月
  日本語
• 喉頭癌T1症例の検討　　　　　　　　　　　　　　　
  中薗 彬, 折舘 伸彦, 本間 明宏, 坂下 智博, 鬼丸 力也, 福田 諭
  日本気管食道科学会会報, 62, 2, 261, 262, (NPO)日本気管食道科学会, 2011年04月
  日本語
• 頭頸部癌セツキシマブ耐性獲得におけるEGFRリガンドの発現とmicroRNA制御　　　　　　　　　　　　　　　
  畠山 博充, 本間 明宏, 折舘 伸彦, 福田 諭
  日本耳鼻咽喉科学会会報, 114, 4, 356, 356, (一社)日本耳鼻咽喉科学会, 2011年04月
  日本語
• 【ここまで変わった頸部郭清術】 外科的治療以外で頸部リンパ節はどこまで制御できるか 超選択的動注化学療法　　　　　　　　　　　　　　　
  本間 明宏, 坂下 智博, 福田 諭
  JOHNS, 27, 2, 229, 233, (株)東京医学社, 2011年02月
  日本語
• 喉頭摘出後の音声リハビリテーションに関する実態調査 医療現場と喉摘者福祉団体との比較
  前田 秀彦, 西澤 典子, 目須田 康, 苅安 誠, 本間 明宏, 折舘 伸彦, 葛西 聡子, 大橋 正實, 福田 諭
  音声言語医学, 52, 1, 79, 79, 日本音声言語医学会, 2011年01月
  日本語
• 顎下腺悪性腫瘍1次症例の検討
  北尾 恭子, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 加納 里志, 水町 貴諭, 瀧 重成, 稲村 直哉, 福田 諭
  日本耳鼻咽喉科学会会報, 114, 3, 126, 132, (一社)日本耳鼻咽喉科学会, 2011年
  日本語, 研究論文（学術雑誌）
• 化学放射線療法を行う頭頸部がん患者を対象とするクリニカルパスを用いた疼痛管理法有効性/安全性評価試験
  加藤 健吾, 松浦 一登, 全田 貞幹, 立花 弘之, 本間 明宏, 桐田 忠昭, 門田 伸也, 大田 洋二郎, 岩江 信法, 大鶴 洋, 秋元 哲夫, 田原 信, 浅井 昌大
  頭頸部癌, 37, 1, 153, 157, (一社)日本頭頸部癌学会, 2011年
  日本語, 研究論文（学術雑誌）
• 個別化を目指す薬物療法 HPV陽性中咽頭癌に対する個別化治療戦略
  水町 貴諭, 畠山 博充, 加納 里志, 坂下 智博, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 37, 3, 394, 397, (一社)日本頭頸部癌学会, 2011年
  日本語, 研究論文（学術雑誌）
• 頭頸部癌患者を支えるチーム医療 北海道大学病院の頭頸部がん患者に対する口腔ケアの取り組み
  秦 浩信, 山崎 裕, 今待 賢治, 村井 知佳, 佐藤 淳, 水町 貴諭, 加納 里志, 本間 明宏, 福田 諭, 北川 善政
  頭頸部癌, 37, 4, 486, 493, (一社)日本頭頸部癌学会, 2011年
  日本語, 研究論文（学術雑誌）
• Human Papillomavirus Frequency in Oropharyngeal Squamous Cell Carcinoma in Japan
  Takatsugu Mizumachi, Satoshi Kano, Naoya Inamura, Toshihiro Hara, Fumiyuki Suzuki, Seigo Suzuki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
  RECENT ADVANCES IN TONSILS AND MUCOSAL BARRIERS OF THE UPPER AIRWAYS, 72, 208, 208, 2011年
  英語
• Radiotherapy for glottic T1N0 carcinoma with slight hypofractionation and standard overall treatment time: importance of overall treatment time.
  Onimaru R, Hasegawa M, Yasuda K, Homma A, Oridate N, Fukuda S, Shirato H
  Jpn J Clin Oncol, 41, 1, 103, 9, 2011年, ［査読有り］
• Concomitant weekly cisplatin and radiotherapy for head and neck cancer.
  Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, Kano S, Sakashita T, Onimaru R, Yasuda K, Shirato H, Fukuda S
  Jpn J Clin Oncol, 41, 8, 980, 6, 2011年, ［査読有り］
• Radiotherapy for Glottic T1N0 Carcinoma with Slight Hypofractionation and Standard Overall Treatment Time: Importance of Overall Treatment Time
  Rikiya Onimaru, Masakazu Hasegawa, Kouichi Yasuda, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda, Hiroki Shirato
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 1, 103, 109, 2011年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical analysis of malignant submandibular tumor
  Kyoko Kitao, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Fumiyuki Suzuki, Toshihiro Hara, Satoshi Káno, Takatsugu Mizumachi, Shigenari Taki, Naoya Inamura, Satoshi Fukud
  Journal of Otolaryngology of Japan, 114, 3, 126, 132, Oto-Rhino-Laryngological Society of Japan Inc., 2011年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 術後感染予防に対するレボフロキサシン(クラビット)の術前単回投与の有用性について
  対馬 那由多, 本間 明宏, 福田 諭
  耳鼻と臨床, 56, 6, 254, 258, 耳鼻と臨床会, 2010年11月
  日本語
• 下咽頭癌 喉頭機能温存治療 超選択的動注療法
  本間 明宏, 折舘 伸彦, 鈴木 章之, 原 敏浩, 真栄田 栄行, 加納 里志, 水町 貴諭, 瀧 重成, 稲村 直哉, 古沢 純, 福田 諭
  耳鼻と臨床, 56, Suppl.1, S66, S70, 耳鼻と臨床会, 2010年11月
  日本語
• Salvage surgery for local recurrence after chemoradiotherapy or radiotherapy in hypopharyngeal cancer patients
  Shigenari Taki, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Fumiyuki Suzuki, Tomohiro Sakashita, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 267, 11, 1765, 1769, 2010年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 頭頸部癌に対する化学放射線療法での体重減少率の検討　　　　　　　　　　　　　　　
  松浦 一登, 全田 貞幹, 立花 弘之, 本間 明宏, 桐田 忠昭, 門田 伸也, 田原 信, 加藤 健吾, 浅井 昌大
  日本癌治療学会誌, 45, 2, 666, 666, (一社)日本癌治療学会, 2010年09月
  日本語
• 化学放射線療法を行う頭頸部がん患者を対象とするクリニカルパスを用いた疼痛管理法　　　　　　　　　　　　　　　
  全田 貞幹, 松浦 一登, 立花 弘之, 本間 明宏, 桐田 忠和, 門田 伸也, 岩江 信法, 大田 洋二郎, 秋元 哲夫, 大鶴 洋, 浅井 昌大
  日本癌治療学会誌, 45, 2, 502, 502, (一社)日本癌治療学会, 2010年09月
  日本語
• 中咽頭側壁・前壁癌に対する放射線化学療法の検討　　　　　　　　　　　　　　　
  加納 里志, 本間 明宏, 折舘 伸彦, 福田 諭
  口腔・咽頭科, 23, 3, 373, 373, 日本口腔・咽頭科学会, 2010年08月
  日本語
• Screening examination for superficial carcinoma of the head and neck following endoscopic resection for esophageal carcinoma.
  Shimizu Y, Yoshida T, Kato M, Ono S, Homma A, Oridate N, Asaka M
  Endoscopy, 42, 8, 686, 687, 2010年08月, ［査読有り］
• 鼻副鼻腔腫瘍治療戦略の新しい可能性を探る 鼻副鼻腔悪性腫瘍に対する超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏, 水町 貴諭, 原 敏浩, 福田 諭
  日本鼻科学会会誌, 49, 3, 326, 326, (一社)日本鼻科学会, 2010年07月
  日本語
• 鼻腔・副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法　　　　　　　　　　　　　　　
  長谷川 雅一, 安田 耕一, 吉田 大介, 加藤 徳雄, 鬼丸 力也, 浅野 剛, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭, 石川 正純, Bengua Gerard, Sutherland Kenneth, 宮本 直樹, 鈴木 隆介
  Japanese Journal of Radiology, 28, Suppl.I, 7, 7, (公社)日本医学放射線学会, 2010年07月
  日本語
• Cesium Implant for Tongue Carcinoma with a Thickness of 1.5 cm or More: Cases Successfully Treated with a Modified Manchester System
  Takeshi Nishioka, Masaharu Fujino, Akihiro Homma, Tetsuro Yamashita, Akira Sato, Keiichi Ohmori, Kenichi Obinata, Hiroki Shirato, Kenichi Notani, Masamichi Nishio
  YONSEI MEDICAL JOURNAL, 51, 4, 557, 561, 2010年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 耳下腺癌切除後のネットワーク型再建による顔面神経の即時再建　　　　　　　　　　　　　　　
  古川 洋志, 七戸 龍司, 大澤 昌之, 斎藤 亮, 山本 有平, 本間 明宏, 福田 諭, 古田 康, 関堂 充
  日本マイクロサージャリー学会会誌, 23, 2, 206, 206, (一社)日本マイクロサージャリー学会, 2010年06月
  日本語
• 北海道大学における中咽頭癌症例の検討
  加納 里志, 折舘 伸彦, 本間 明宏, 鈴木 清護, 鈴木 章之, 原 敏浩, 水町 貴諭, 稲村 直哉, 福田 諭
  耳鼻咽喉科展望, 53, 補冊1, 6, 7, 耳鼻咽喉科展望会, 2010年06月
  日本語
• 内視鏡下に摘出し得た鼻腔神経鞘腫の1例　　　　　　　　　　　　　　　
  洲崎 真吾, 本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊128, 82, 82, 耳鼻咽喉科臨床学会, 2010年06月
  日本語
• 超選択的動注化学療法と放射線の同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊128, 47, 47, 耳鼻咽喉科臨床学会, 2010年06月
  日本語
• 化学放射線療法 下咽頭がんに対する超選択的動注化学療法　　　　　　　　　　　　　　　
  本間 明宏
  日本気管食道科学会会報, 61, 3, 338, 338, (NPO)日本気管食道科学会, 2010年06月
  日本語
• 化学放射線療法を行う頭頸部がん患者を対象とするクリニカルパスを用いた疼痛管理法 有効性/安全性評価試験　　　　　　　　　　　　　　　
  立花 弘之, 全田 貞幹, 松浦 一登, 本間 明宏, 桐田 忠昭, 門田 伸也, 大田 洋二郎, 岩江 信法, 大鶴 洋, 秋元 哲夫, 浅井 昌大
  頭頸部癌, 36, 2, 212, 212, (一社)日本頭頸部癌学会, 2010年05月
  日本語
• 頭頸部癌に対するweekly cisplatinと放射線同時併用療法の検討　　　　　　　　　　　　　　　
  稲村 直哉, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 真栄田 裕行, 加納 里志, 水町 貴諭, 福田 諭, 鬼丸 力也, 長谷川 雅一, 安田 耕一, 白土 博樹
  頭頸部癌, 36, 2, 206, 206, (一社)日本頭頸部癌学会, 2010年05月
  日本語
• 中咽頭扁平上皮癌におけるHPV感染と治療成績の検討　　　　　　　　　　　　　　　
  水町 貴諭, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 36, 2, 205, 205, (一社)日本頭頸部癌学会, 2010年05月
  日本語
• 化学放射線治療後の頸部郭清の必要性について　　　　　　　　　　　　　　　
  本間 明宏, 折舘 伸彦, 鈴木 章之, 鈴木 清護, 原 敏浩, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹
  頭頸部癌, 36, 2, 191, 191, (一社)日本頭頸部癌学会, 2010年05月
  日本語
• Phase I/II Study of S-1 plus Cisplatin Combination Chemotherapy in Patients with Advanced/Recurrent Head and Neck Cancer
  Masato Fujii, Kitinobu Tomita, Wataru Nishijima, Mamoru Tsukuda, Yasuhisa Hasegawa, Junichi Ishitoya, Hideo Yamane, Akihiro Homma, Toshiki Tomita
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 40, 3, 214, 221, 2010年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• IMPORTANCE OF COMORBIDITY IN HYPOPHARYNGEAL CANCER
  Akihiro Homma, Tomohiro Sakashita, Nobuhiko Oridate, Fumiyuki Suzuki, Seigo Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Shigenari Taki, Satoshi Fukuda
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 32, 2, 148, 153, 2010年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 化学放射線療法後の喉頭全摘出術におけるpharyngeal interposition graftを用いた創合併症の予防
  古田 康, 松村 道哉, 大谷 文雄, 鈴木 正宣, 佐藤 宏紀, 森田 真也, 本間 明宏, 折舘 伸彦, 福田 諭
  日本耳鼻咽喉科学会会報, 113, 1, 9, 14, (一社)日本耳鼻咽喉科学会, 2010年
  日本語, 研究論文（学術雑誌）
• 中咽頭扁平上皮癌におけるHPV感染と治療成績の検討
  水町 貴諭, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 36, 4, 498, 501, (一社)日本頭頸部癌学会, 2010年
  英語, 研究論文（学術雑誌）
• 喉頭癌T1症例の検討
  中薗彬, 折舘伸彦, 本間明宏, 坂下智博, 鬼丸力也, 福田諭
  日本気管食道科学会総会ならびに学術講演会プログラム・予稿集, 62nd, 116, 2010年
  日本語
• Prevention of wound complications after salvage total laryngectomy following chemoradiotherapy with a pectoralis major muscle interposition flap
  Yasushi Furuta, Michiya Matsumura, Fumio Ohtani, Masanobu Suzuki, Hiroki Satoh, Shinya Morita, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda
  Journal of Otolaryngology of Japan, 113, 1, 9, 14, Oto-Rhino-Laryngological Society of Japan Inc., 2010年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 【頭頸部腫瘍診療における論点 耳鼻口腔咽頭編】 舌癌T1-3症例の原発部位に対する治療法の選択は? 超選択的動注療法の立場から
  本間 明宏, 鈴木 章之, 福田 諭
  JOHNS, 25, 10, 1503, 1506, (株)東京医学社, 2009年10月
  日本語
• Superselective High-Dose Cisplatin Infusion With Concomitant Radiotherapy in Patients With Advanced Cancer of the Nasal Cavity and Paranasal Sinuses A Single Institution Experience
  Akihiro Homma, Nobuhiko Oridate, Fumiyuki Suzuki, Shigenari Taki, Takeshi Asano, Daisuke Yoshida, Rikiya Onimaru, Takeshi Nishioka, Hiroki Shirato, Satoshi Fukuda
  CANCER, 115, 20, 4705, 4714, 2009年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 当科における顎下腺悪性腫瘍1次症例の検討　　　　　　　　　　　　　　　
  北尾 恭子, 本間 明宏, 福田 諭
  口腔・咽頭科, 22, 3, 355, 355, 日本口腔・咽頭科学会, 2009年08月
  日本語
• 【新・静脈栄養・経腸栄養ガイド NSTに必須の知識と実践のすべて】 周術期の栄養管理の実際 頭頸部手術　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  Medical Practice, 26, 臨増, 354, 358, (株)文光堂, 2009年07月
  日本語
• Value of fluorodeoxyglucose positron emission tomography before radiotherapy for head and neck cancer: does the standardized uptake value predict treatment outcome?
  Keishiro Suzuki, Takeshi Nishioka, Akihiro Homma, Kazuhiko Tsuchiya, Motoaki Yasuda, Hidefumi Aoyama, Rikiya Onimaru, Nagara Tamaki, Hiroki Shirato
  JAPANESE JOURNAL OF RADIOLOGY, 27, 6, 237, 242, 2009年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 当科における耳下腺悪性腫瘍症例の検討
  稲村 直哉, 本間 明宏, 福田 諭
  口腔・咽頭科, 22, 2, 167, 172, 日本口腔・咽頭科学会, 2009年06月
  日本語
• 【機能温存をめざした頭頸部癌治療update】 超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏
  ENTONI, 103, 7, 13, (株)全日本病院出版会, 2009年06月
  日本語
• 頭頸部がん治療における多職種医療普及のためのサテライト講演会 その成果と課題　　　　　　　　　　　　　　　
  全田 貞幹, 大田 洋二郎, 本間 明宏, 丹生 健一, 神田 亨, 妻木 浩美, 清田 尚臣, 浅井 昌大
  頭頸部癌, 35, 2, 173, 173, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 喉頭癌に対する超選択動注併用放射線療法の治療成績　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 水町 貴諭, 福田 諭, 鬼丸 力也, 長谷川 雅一, 白土 博樹
  頭頸部癌, 35, 2, 116, 116, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 上咽頭癌に対するCDDP、5-FUを用いた放射線化学療法の治療成績　　　　　　　　　　　　　　　
  木下 留美子, 長谷川 雅一, 安田 耕一, 田口 大志, 鬼丸 力也, 土屋 和彦, 西岡 健, 本間 明宏, 折舘 伸彦, 福田 諭, 白土 博樹
  頭頸部癌, 35, 2, 93, 93, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 頭頸部癌治療における口腔ケアの実際 頭頸部進行癌に対する再建手術の合併症減少に口腔ケアは寄与するか　　　　　　　　　　　　　　　
  秦 浩信, 山崎 裕, 佐藤 淳, 村井 知佳, 中村 裕介, 今待 賢治, 北川 善政, 本間 明宏, 瀧 重成, 折舘 伸彦, 福田 諭, 斉藤 亮, 古川 洋志, 山本 有平, 関堂 充
  頭頸部癌, 35, 2, 71, 71, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 臨床パネル「頭頸部癌とヒト乳頭腫ウイルス(HPV)」 頭頸部癌におけるヒト乳頭腫ウイルスによる発癌のメカニズムと検出について　　　　　　　　　　　　　　　
  水町 貴諭, 瀧 重成, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭, 古田 康
  頭頸部癌, 35, 2, 68, 68, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 強度変調放射線治療(IMRT)の中長期成績 北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績　　　　　　　　　　　　　　　
  鬼丸 力也, 長谷川 雅一, 安田 耕一, 木下 留美子, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 35, 2, 65, 65, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 化学放射線療法後の救済手術 問題点とその対策 喉頭下咽頭癌に対する化学放射線療法後の救済手術　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 折舘 伸彦, 鈴木 清護, 水町 貴諭, 加納 里志, 瀧 重成, 稲村 直哉, 鬼丸 力也, 長谷川 雅一, 白土 博樹, 古田 康, 福田 諭
  頭頸部癌, 35, 2, 61, 61, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 耳下腺癌切除後の顔面神経即時再建 我々の手技と工夫 Network型再建による耳下腺癌切除後の顔面神経即時再建　　　　　　　　　　　　　　　
  古川 洋志, 齋藤 亮, 山本 有平, 本間 明宏, 福田 諭, 古田 康, 関堂 充
  頭頸部癌, 35, 2, 54, 54, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• 耳下腺癌切除後の顔面神経即時再建 我々の手技と工夫 耳下腺癌切除後の顔面神経即時再建の適応と現状、術後の評価について　　　　　　　　　　　　　　　
  古田 康, 大谷 文雄, 稲村 直哉, 鈴木 章之, 本間 明宏, 折舘 伸彦, 山本 有平, 福田 諭
  頭頸部癌, 35, 2, 51, 51, (一社)日本頭頸部癌学会, 2009年05月
  日本語
• Long-term outcome after endoscopic resection in patients with hypopharyngeal carcinoma invading the subepithelium: a case series.
  Shimizu Y, Yoshida T, Kato M, Ono S, Nakagawa M, Homma A, Oridate N, Asaka M
  Endoscopy, 41, 4, 374, 376, 2009年04月, ［査読有り］
• Voice-Related Quality of Life After Treatment of Laryngeal Cancer
  Nobuhiko Oridate, Akihiro Homma, Seigo Suzuki, Yuji Nakamaru, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Shigenari Taki, Tomohiro Sakashita, Noriko Nishizawa, Yasushi Furuta, Satoshi Fukuda
  ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 135, 4, 363, 368, 2009年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• マイクロデブリッダーが有用であった成人型多発性喉頭乳頭腫の1症例
  鈴木 正宣, 折舘 伸彦, 本間 明宏, 中丸 裕爾, 畠山 博充, 目須田 康, 古田 康, 福田 諭
  耳鼻咽喉科・頭頸部外科, 81, 3, 219, 221, (株)医学書院, 2009年03月
  日本語
• Complications of Skull Base Surgery: An Analysis of 30 Cases
  Tomohiro Sakashita, Nobuhiko Oridate, Akihiro Homma, Yuji Nakamaru, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Shigenari Taki, Yutaka Sawamura, Yuhei Yamamoto, Yasushi Furuta, Satoshi Fukuda
  SKULL BASE-AN INTERDISCIPLINARY APPROACH, 19, 2, 127, 132, 2009年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• レボフロキサシンの術後感染予防への使用　　　　　　　　　　　　　　　
  飯塚 さとし, 本間 明宏, 福田 諭
  頭頸部外科, 18, 3, 273, 277, (NPO)日本頭頸部外科学会, 2009年02月
  日本語
• 高Ca血症をきたさなかった巨大上皮小体癌の1例　　　　　　　　　　　　　　　
  蠣崎 文彦, 本間 明宏, 畠山 博充, 前田 昌紀, 福田 諭
  耳鼻咽喉科・頭頸部外科, 81, 2, 133, 136, (株)医学書院, 2009年02月
  日本語
• p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma
  Nobuhiko Oridate, Akihiro Homma, Eisaku Higuchi, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Jun Furusawa, Shigenari Taki, Yasushi Furuta, Satoshi Fukuda
  AURIS NASUS LARYNX, 36, 1, 57, 63, 2009年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 強度変調放射線治療(IMRT)の中長期成績 北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績
  鬼丸 力也, 長谷川 雅一, 安田 耕一, 木下 留美子, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部癌, 35, 3, 245, 249, (一社)日本頭頸部癌学会, 2009年
  日本語, 研究論文（学術雑誌）
• 耳下腺癌切除後の顔面神経即時再建 我々の手技と工夫 ネットワーク型再建による耳下腺癌切除後の顔面神経即時再建
  古川 洋志, 齋藤 亮, 林 利彦, 山本 有平, 本間 明宏, 福田 諭, 古田 康, 関堂 充
  頭頸部癌, 35, 3, 217, 222, (一社)日本頭頸部癌学会, 2009年
  英語, 研究論文（学術雑誌）
• 耳下腺癌切除後の顔面神経即時再建 我々の手技と工夫 耳下腺癌切除後の顔面神経再建の現状および術後評価
  古田 康, 大谷 文雄, 稲村 直哉, 鈴木 章之, 本間 明宏, 折舘 伸彦, 山本 有平, 福田 諭
  頭頸部癌, 35, 3, 213, 216, (一社)日本頭頸部癌学会, 2009年
  英語, 研究論文（学術雑誌）
• 頭頸部癌とヒト乳頭腫ウイルス(HPV) 頭頸部癌におけるヒト乳頭腫ウイルスによる発癌のメカニズムと検出について
  水町 貴諭, 瀧 重成, 加納 里志, 原 敏浩, 鈴木 章之, 鈴木 清護, 本間 明宏, 折舘 伸彦, 福田 諭, 古田 康
  頭頸部癌, 35, 4, 356, 359, (一社)日本頭頸部癌学会, 2009年
  英語, 研究論文（学術雑誌）
• 化学放射線療法後の救済手術 問題点とその対策 喉頭・下咽頭癌に対する化学放射線療法後の救済手術
  鈴木 章之, 本間 明宏, 折舘 伸彦, 鈴木 清護, 水町 貴諭, 加納 里志, 瀧 重成, 稲村 直哉, 鬼丸 力也, 長谷川 雅一, 白土 博樹, 古田 康, 福田 諭
  頭頸部癌, 35, 4, 344, 349, (一社)日本頭頸部癌学会, 2009年
  日本語, 研究論文（学術雑誌）
• Novel Function of Transcription Factor ATF5: Blockade of p53-dependent Apoptosis Induced by Ionizing Irradiation
  Takeshi Nishioka, Yusuke Miyai, Hisashi Haga, Kazushige Kawabata, Hiroki Shirato, Akihiro Homma, Kenichiro Shibata, Motoaki Yasuda
  CELL STRUCTURE AND FUNCTION, 34, 1, 17, 22, 2009年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Computer image-guided surgery for total maxillectomy
  Akihiro Homma, Masahiko Saheki, Fumiyuki Suzuki, Satoshi Fukuda
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 265, 12, 1521, 1526, 2008年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Surgical complications of salvage total laryngectomy following concurrent chemoradiotherapy
  Yasushi Furuta, Akihiro Homma, Nobuhiko Oridate, Fumiyuki Suzuki, Hiromitsu Hatakeyama, Keishiro Suzuki, Takeshi Nishioka, Hiroki Shirato, Satoshi Fukuda
  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 13, 6, 521, 527, 2008年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 化学放射線療法後の手術治療 化学放射線療法後のsalvage手術法の選択 喉頭癌の場合
  古田 康, 本間 明宏, 折舘 伸彦, 愛宕 義浩, 鈴木 清護, 鈴木 章之, 福田 諭
  耳鼻と臨床, 54, Suppl.1, S61, S66, 耳鼻と臨床会, 2008年11月
  日本語
• 舌進行癌手術症例における術前超選択的動注化学療法　　　　　　　　　　　　　　　
  鈴木 章之, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 瀧 重成, 坂下 智博, 福田 諭
  日本癌治療学会誌, 43, 2, 528, 528, (一社)日本癌治療学会, 2008年10月
  日本語
• 頭頸部癌における集学的治療 頭頸部癌に対する超選択的動注療法・照射同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 水町 貴諭, 加納 里志, 瀧 重成, 浅野 剛, 吉田 大介, 西岡 健, 鬼丸 力也, 長谷川 雅一, 白土 博樹, 福田 諭
  日本癌治療学会誌, 43, 2, 284, 284, (一社)日本癌治療学会, 2008年10月
  日本語
• Intra-arterial chemotherapy for head and neck cancer: Experiences from three continents
  K. Thomas Robbins, Akihiro Homma
  SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 17, 4, 919, +, 2008年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 鼻腔/副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法の治療成績
  長谷川雅一, 安田耕一, 吉田大介, 加藤徳雄, 鬼丸力也, 浅野剛, 白土博樹, 本間明宏, 折館伸彦, 福田諭
  日本放射線腫よう学会誌, 20, Supplement 1, 223, 2008年09月22日
  日本語
• 当科における耳下腺悪性腫瘍症例の検討
  稲村 直哉, 本間 明宏, 福田 諭
  口腔・咽頭科, 21, 1, 87, 87, 日本口腔・咽頭科学会, 2008年08月
  日本語
• 領域別に見る64列MDCTの検査と診断 心・大血管領域 心・大血管領域における造影64列MDCTの有用性　　　　　　　　　　　　　　　
  藤田 安彦, 大川 智彦, 太田 淑子, 永野 尚登, 本間 明宏, 宗像 雅則, 中埜 信太郎, 香川 昇
  INNERVISION, 23, 9, 88, 92, (株)インナービジョン, 2008年08月
  日本語
• 喉頭癌治療後の音声に関するQOLの検討　　　　　　　　　　　　　　　
  折舘 伸彦, 本間 明宏, 福田 諭
  耳鼻咽喉科・頭頸部外科, 80, 9, 597, 603, (株)医学書院, 2008年08月
  日本語
• Initial CT findings in early tongue and oral floor cancer as predictors of late neck metastasis
  Jun Furusawa, Nobuhiko Oridate, Fumiyuki Suzuki, Akihiro Homma, Yasushi Furuta, Satoshi Fukuda
  ORAL ONCOLOGY, 44, 8, 793, 797, 2008年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 鼻前庭原発扁平上皮癌に対する超選択的動注療法と照射の同時併用療法の経験　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊121, 134, 134, 耳鼻咽喉科臨床学会, 2008年06月
  日本語
• 大学病院における頭頸部がん治療への歯科的口腔ケア介入　　　　　　　　　　　　　　　
  村井 知佳, 秦 浩信, 山崎 裕, 本間 明宏, 北川 善政
  頭頸部癌, 34, 2, 231, 231, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 北海道大学病院における口腔底癌の治療成績　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 加納 里志, 水町 貴諭, 古田 康, 福田 諭
  頭頸部癌, 34, 2, 229, 229, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 超選択的動注と放射線の同時併用療法を施行した外側咽頭後リンパ節転移症例の検討　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 瀧 重成, 水町 貴諭, 鈴木 清護, 折舘 伸彦, 福田 諭
  頭頸部癌, 34, 2, 184, 184, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 機能面を考慮した口腔・中咽頭再建 舌根1/2以上を合併切除した口腔中咽頭がんに対する機能再建　　　　　　　　　　　　　　　
  関堂 充, 山本 有平, 本間 明宏, 鈴木 章之, 福田 諭, 古田 康
  頭頸部癌, 34, 2, 135, 135, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 頭頸部vascular malformationに対する治療戦略 頭頸部vascular malformationに対する治療戦略　　　　　　　　　　　　　　　
  古川 洋志, 佐々木 了, 堤田 新, 関堂 充, 山本 有平, 浅野 剛, 鈴木 章之, 本間 明宏
  頭頸部癌, 34, 2, 126, 126, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 選択的動注化学療法の現状と将来展望 頭頸部進行癌新鮮例に対する超選択的動注療法の現状と今後の展望　　　　　　　　　　　　　　　
  本間 明宏, 折舘 伸彦, 鈴木 章之, 瀧 重成, 坂下 智博, 浅野 剛, 吉田 大介, 鬼丸 力也, 長谷川 雅一, 西岡 健, 白土 博樹, 福田 諭
  頭頸部癌, 34, 2, 110, 110, (一社)日本頭頸部癌学会, 2008年05月
  日本語
• 下咽頭癌におけるcomorbidity(併存疾患)の予後への影響について　　　　　　　　　　　　　　　
  本間 明宏, 坂下 智博, 折舘 伸彦, 鈴木 章之, 鈴木 清護, 畠山 博充, 水町 貴諭, 瀧 重成, 福田 諭
  日本耳鼻咽喉科学会会報, 111, 4, 392, 392, (一社)日本耳鼻咽喉科学会, 2008年04月
  日本語
• 巨大上皮体癌の1例　　　　　　　　　　　　　　　
  蠣崎 文彦, 本間 明宏, 前田 昌紀, 畠山 博充, 福田 諭
  日本気管食道科学会会報, 59, 2, 287, 287, (NPO)日本気管食道科学会, 2008年04月
  日本語
• 下咽頭進行癌に対する超選択的動注と放射線の同時併用療法 治療成績とその適応　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 折舘 伸彦, 畠山 博充, 古沢 純, 古田 康, 福田 諭
  日本気管食道科学会会報, 59, 2, 246, 246, (NPO)日本気管食道科学会, 2008年04月
  日本語
• 頸動脈小体腫瘍症例における術前栄養血管塞栓術および術後合併症の検討
  森田 真也, 古田 康, 本間 明宏, 鈴木 章之, 藤田 香, 福田 諭
  日本耳鼻咽喉科学会会報, 111, 3, 96, 101, (一社)日本耳鼻咽喉科学会, 2008年
  日本語, 研究論文（学術雑誌）
• 喉頭癌治療後の音声・嚥下機能評価 放射線治療を受けた喉頭癌患者の治療後音声に関するQOLの検討
  折舘 伸彦, 古田 康, 西澤 典子, 本間 明宏, 鈴木 清護, 目須田 康, 福田 諭
  喉頭, 19, 2, 59, 64, 日本喉頭科学会, 2007年12月
  日本語
• 頭頸部癌に対する超選択的抗癌剤動注化学療法　　　　　　　　　　　　　　　
  吉田 大介, 浅野 剛, 白土 博樹, 本間 明宏, 鈴木 章之, 福田 諭
  IVR: Interventional Radiology, 22, 4, 502, 502, (一社)日本インターベンショナルラジオロジー学会, 2007年10月
  日本語
• Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy
  Eisaku Higuchl, Nobuhiko Oridate, Akihiro Homma, Fumiyuki Suzuki, Yoshihiro Atago, Tatsumi Nagahashi, Yasushi Furuta, Satoshi Fukuda
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 29, 10, 940, 947, 2007年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 頭頸部癌再発・転移症例に対するS-1の有用性の検討　　　　　　　　　　　　　　　
  本間 明宏, 折舘 伸彦, 鈴木 章之, 福田 諭, 古田 康
  日本癌治療学会誌, 42, 2, 480, 480, (一社)日本癌治療学会, 2007年09月
  日本語
• 気管内挿管チューブの側孔を利用したvoice prosthesis二期的挿入術
  古田 康, 本間 明宏, 折舘 伸彦, 目須田 康, 西澤 典子, 福田 諭
  日本気管食道科学会会報, 58, 4, 417, 421, (NPO)日本気管食道科学会, 2007年08月
  日本語
• 【医療におけるトラブルをめぐって 予期せぬ出来事への対応】 頭頸部癌領域 癌化学療法の合併症　　　　　　　　　　　　　　　
  福田 諭, 本間 明宏
  JOHNS, 23, 8, 1138, 1142, (株)東京医学社, 2007年08月
  日本語
• 頭頸部癌 動注化学療法と放射線治療併用療法　　　　　　　　　　　　　　　
  本間 明宏
  癌と化学療法, 34, 7, 1027, 1030, (株)癌と化学療法社, 2007年07月
  日本語
• [Head and neck: intra-arterial chemotherapy and combined radiotherapy].
  Homma A
  Gan to kagaku ryoho. Cancer & chemotherapy, 34, 7, 1027, 1030, 2007年07月, ［査読有り］
• Development of a radiation detector made of a cubic boron nitride polycrystal
  J. H. Kaneko, T. Taniguchi, S. Kawamura, K. Satou, F. Fujita, A. Homma, M. Furusaka
  NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT, 576, 2-3, 417, 421, 2007年06月
  英語, 研究論文（学術雑誌）
• 下咽頭癌症例における咽頭後リンパ節転移についての検討　　　　　　　　　　　　　　　
  坂下 智博, 古田 康, 折舘 伸彦, 本間 明宏, 永橋 立望, 鈴木 章之, 畠山 博充, 古沢 純, 瀧 重成, 福田 諭
  頭頸部癌, 33, 2, 206, 206, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• 喉頭癌治療後の音声に関するQOLの検討　　　　　　　　　　　　　　　
  折舘 伸彦, 古田 康, 本間 明宏, 鈴木 清護, 中丸 裕爾, 鈴木 章之, 畠山 博充, 瀧 重成, 坂下 智博, 西澤 典子, 目須田 康, 福田 諭
  頭頸部癌, 33, 2, 178, 178, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• 化学療法と放射線治療の同時併用療法(CRT)後の頸部郭清術における郭清範囲の縮小について　　　　　　　　　　　　　　　
  本間 明宏, 折舘 伸彦, 鈴木 章之, 古田 康, 畠山 博充, 古沢 純, 瀧 重成, 坂下 智博, 福田 諭
  頭頸部癌, 33, 2, 164, 164, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• 下咽頭癌における(化学)放射線療法後の救済手術の治療成績　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 古田 康, 折舘 伸彦, 鈴木 章之, 古沢 純, 坂下 智博, 木下 留美子, 白戸 博樹, 福田 諭
  頭頸部癌, 33, 2, 163, 163, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• 中咽頭前壁(舌根)癌に対する超選択的動注と放射線の同時併用療法　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 古沢 純, 浅野 剛, 坂下 智博, 瀧 重成, 畠山 博充, 折舘 伸彦, 古田 康, 福田 諭
  頭頸部癌, 33, 2, 149, 149, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• Salvage手術 切除範囲と合併症 喉頭癌に対する化学放射線同時併用療法後salvage手術の合併症　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 折舘 伸彦, 鈴木 章之, 畠山 博充, 瀧 重成, 坂下 智博, 西岡 健, 鈴木 恵士郎, 白土 博樹, 福田 諭
  頭頸部癌, 33, 2, 97, 97, (一社)日本頭頸部癌学会, 2007年05月
  日本語
• 遊離皮弁術による再建手術における術前治療の影響　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 古田 康, 鈴木 章之, 折舘 伸彦, 坂下 智博, 関堂 充, 山本 有平, 福田 諭
  日本耳鼻咽喉科学会会報, 110, 4, 365, 365, (一社)日本耳鼻咽喉科学会, 2007年04月
  日本語
• GERD 咽喉頭酸逆流症患者における酸抑制治療による典型的胃食道逆流症状と咽喉頭症状の改善の差異
  折舘 伸彦, 目須田 康, 西澤 典子, 森 美果, 本間 明宏, 古田 康, 福田 諭
  日本気管食道科学会会報, 58, 2, 187, 188, (NPO)日本気管食道科学会, 2007年04月
  日本語
• Evidenceに基づく下咽頭進行癌の治療戦略 超選択的動注療法
  本間 明宏, 古田 康, 鈴木 章之, 古沢 純, 折舘 伸彦, 愛宕 義浩, 樋口 栄作, 福田 諭
  日本気管食道科学会会報, 58, 2, 130, 130, (NPO)日本気管食道科学会, 2007年04月
  日本語
• 【口腔癌にどう対応するか 症例から学ぶ】 上歯肉癌、硬口蓋癌 T3・T4症例の化学療法・放射線治療
  本間 明宏
  JOHNS, 23, 4, 599, 602, (株)東京医学社, 2007年04月
  日本語
• 64-MDCTによる冠動脈の評価 CAGとの比較(Evaluation of Coronary Arteries with 64-MDCT: Comparison with CAG)　　　　　　　　　　　　　　　
  藤田 安彦, 大川 智彦, 太田 淑子, 永野 尚登, 本間 明宏, 宗像 雅則, 中埜 信太郎, 香川 昇
  日本医学放射線学会学術集会抄録集, 66回, S165, S165, (公社)日本医学放射線学会, 2007年02月
  日本語
• 超選択的動注療法+照射の同時併用療法におけるリンパ節転移への効果
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 古沢 純, 折舘 伸彦, 畠山 博充, 永橋 立望, 鈴木 恵士郎, 西岡 健, 白土 博樹, 福田 諭
  頭頸部癌, 33, 1, 39, 42, (一社)日本頭頸部癌学会, 2007年
  英語, 研究論文（学術雑誌）
• 喉頭癌に対する化学放射線同時併用療法後salvage手術の合併症
  古田 康, 本間 明宏, 折舘 伸彦, 鈴木 章之, 畠山 博充, 瀧 重成, 坂下 智博, 西岡 健, 鈴木 恵士郎, 白土 博樹, 関堂 充, 山本 有平, 福田 諭
  頭頸部癌, 33, 3, 356, 360, (一社)日本頭頸部癌学会, 2007年
  英語, 研究論文（学術雑誌）
• 喉頭癌治療後の音声に関するQOLの検討
  折舘 伸彦, 古田 康, 本間 明宏, 鈴木 清護, 鈴木 章之, 畠山 博充, 瀧 重成, 坂下 智博, 福田 諭
  頭頸部癌, 33, 4, 465, 469, (一社)日本頭頸部癌学会, 2007年
  英語, 研究論文（学術雑誌）
• A novel approach to advanced carcinoma of the tongue: Cases successfully treated with combination of superselective intra-arterial chemotherapy and external/high-dose-rate interstitial radiotherapy
  Takeshi Nishioka, Akihiro Homma, Yasushi Furuta, Hidefumi Aoyama, Fumiyuki Suzuki, Keiichi Ohmori, Takeshi Asano, Daisuke Yoshida, Hiroki Shirato, Satoshi Fukuda
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 36, 12, 822, 826, 2006年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• "Watch-and-see" policy for the clinically positive neck in head and neck cancer treated with chemoradiotherapy
  Akihiro Homma, Yasushi Furuta, Nobuhiko Oridate, Fumiyuki Suzuki, Eisaku Higuchi, Takeshi Nishioka, Hiroki Shirato, Tatsumi Nagahashi, Katsunori Yagi, Satoshi Fukuda
  International Journal of Clinical Oncology, 11, 6, 441, 448, 2006年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 上咽頭癌放射線治療後に晩期嚥下障害を発症した3例
  目須田 康, 本間 明宏, 西澤 典子, 折舘 伸彦, 堂坂 善弘, 古田 康, 福田 諭
  耳鼻と臨床, 52, Suppl.4, S286, S290, 耳鼻と臨床会, 2006年11月
  日本語
• 【小児の耳鼻咽喉頭・頭頸部疾患 診断と治療】 頭頸部良性腫瘍　　　　　　　　　　　　　　　
  福田 諭, 古田 康, 本間 明宏
  小児外科, 38, 11, 1366, 1371, (株)東京医学社, 2006年11月
  日本語
• Total maxillectomy using image-guided navigation system　　　　　　　　　　　　　　　
  Akihiro Homma, Eisaku Higuchi, Fumiyuki Suzuki, Masahiko Saheki, Satoshi Fukuda
  Oto-Rhino-Laryngology Tokyo, 49, 5, 96, 98, 2006年10月
  日本語, 研究論文（学術雑誌）
• 上顎全摘術におけるナビゲーションシステムの有用性について　　　　　　　　　　　　　　　
  本間 明宏, 樋口 榮作, 鈴木 章之, 佐伯 昌彦, 福田 諭
  耳鼻咽喉科展望, 49, 5, 310, 312, 耳鼻咽喉科展望会, 2006年10月
  日本語
• 術前に超選択的動注療法を施行した頬部有棘細胞癌の1例
  柳 輝希, 青柳 哲, 芝木 晃彦, 本間 明宏, 坪田 晶子, 清水 宏
  Skin Cancer, 21, 2, 184, 188, (一社)日本皮膚悪性腫瘍学会, 2006年10月
  日本語
• 副鼻腔癌の治療方針
  橋本 省, 本間 明宏, 兵藤 伊久夫, 石原 明子
  耳鼻と臨床, 52, Suppl.3, S232, S242, 耳鼻と臨床会, 2006年09月
  日本語
• 鼻副鼻腔癌に対する超選択的動注療法+照射の同時併用療法
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 吉田 大介, 西岡 健, 鈴木 恵士郎, 白土 博樹, 福田 諭
  耳鼻と臨床, 52, Suppl.3, S213, S219, 耳鼻と臨床会, 2006年09月
  日本語
• 頭頸部癌におけるchemoradiationの有用性と限界 超選択的動注によるchemoradiationの有用性と限界　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 鈴木 章之, 古沢 純, 折舘 伸彦, 浅野 剛, 吉田 大介, 西岡 健, 鈴木 恵士郎, 白土 博樹, 福田 諭
  日本癌治療学会誌, 41, 2, 323, 323, (一社)日本癌治療学会, 2006年09月
  日本語
• 【頭頸部がん患者診療のポイント】 化学療法の実際とポイント 超選択的動注化学療法
  鈴木 章之, 本間 明宏, 福田 諭
  臨床腫瘍プラクティス, 2, 3, 280, 285, (株)ヴァンメディカル, 2006年08月
  日本語
• 【頭頸部がん患者診療のポイント】 放射線療法の適応 手術+放射線療法
  折舘 伸彦, 本間 明宏, 西岡 健
  臨床腫瘍プラクティス, 2, 3, 268, 270, (株)ヴァンメディカル, 2006年08月
  日本語
• 【頭頸部がん患者診療のポイント】 頭頸部がんの検査とそのポイント
  樋口 榮作, 本間 明宏, 福田 諭
  臨床腫瘍プラクティス, 2, 3, 235, 241, (株)ヴァンメディカル, 2006年08月
  日本語
• 下咽頭癌に対する超選択的動注療法と放射線同時併用療法の検討
  古沢 純, 本間 明宏, 福田 諭
  口腔・咽頭科, 18, 3, 407, 413, 日本口腔・咽頭科学会, 2006年06月
  日本語
• 外来で行うがん化学療法 頭頸部癌再発例に対するTS-1の有用性について　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊118, 38, 38, 耳鼻咽喉科臨床学会, 2006年06月
  日本語
• 咽喉頭酸逆流症状に対する酸抑制治療の効果とHelicobacter pylori感染との関連
  折舘 伸彦, 目須田 康, 西澤 典子, 森 美果, 中丸 裕爾, 本間 明宏, 古田 康, 福田 諭
  日本気管食道科学会会報, 57, 3, 262, 267, (NPO)日本気管食道科学会, 2006年06月
  日本語
• 口腔癌T1-2N0症例における後発頸部転移に関する免疫組織学的検討　　　　　　　　　　　　　　　
  折舘 伸彦, 鈴木 章之, 鈴木 清護, 本間 明宏, 水町 貴諭, 古田 康, 福田 諭
  頭頸部癌, 32, 2, 181, 181, (一社)日本頭頸部癌学会, 2006年05月
  日本語
• 超選択的動注療法+照射の同時併用療法のリンパ節転移への効果　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 古沢 純, 折舘 伸彦, 樋口 栄作, 永橋 立望, 鈴木 恵士郎, 西岡 健, 白土 博樹, 福田 諭
  頭頸部癌, 32, 2, 177, 177, (一社)日本頭頸部癌学会, 2006年05月
  日本語
• 舌進行癌手術症例における術前超選択的動注化学療法　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 古沢 純, 浅野 剛, 折舘 伸彦, 樋口 栄作, 鈴木 清護, 古田 康, 福田 諭
  頭頸部癌, 32, 2, 176, 176, (一社)日本頭頸部癌学会, 2006年05月
  日本語
• 鼻副鼻腔乳頭腫T3症例に対する内視鏡下手術の検討　　　　　　　　　　　　　　　
  及川 敬太, 古田 康, 中丸 裕爾, 本間 明宏, 折舘 伸彦, 福田 諭
  日本耳鼻咽喉科学会会報, 109, 4, 410, 410, (一社)日本耳鼻咽喉科学会, 2006年04月
  日本語
• 鼻副鼻腔進行癌に対する超選択的動注と放射線の同時併用療法　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 古沢 純, 折舘 伸彦, 古田 康, 樋口 栄作, 福田 諭
  日本耳鼻咽喉科学会会報, 109, 4, 408, 408, (一社)日本耳鼻咽喉科学会, 2006年04月
  日本語
• 北海道大学における声門癌T2N0症例の検討　　　　　　　　　　　　　　　
  愛宕 義浩, 古田 康, 本間 明宏, 折舘 伸彦, 樋口 栄作, 鈴木 章之, 福田 諭, 永橋 立望
  日本気管食道科学会会報, 57, 2, 224, 225, (NPO)日本気管食道科学会, 2006年04月
  日本語
• 気管内挿管チューブを用いたグロニンゲン・ボイスボタン二期的挿入法　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 折舘 伸彦, 樋口 栄作, 鈴木 章之, 目須田 康, 西澤 典子, 福田 諭
  日本気管食道科学会会報, 57, 2, 216, 216, (NPO)日本気管食道科学会, 2006年04月
  日本語
• 鼻副鼻腔内反性乳頭腫の術式選択におけるstaging systemの問題点
  古田 康, 及川 敬太, 中丸 裕爾, 本間 明宏, 折舘 伸彦, 福田 諭
  頭頸部外科, 15, 3, 195, 201, (NPO)日本頭頸部外科学会, 2006年02月
  日本語
• Marked and restricted cutaneous pigmentation induced by selective intra-arterial cisplatin infusion
  T Yanagi, M Akiyama, S Aoyagi, A Shibaki, A Homma
  JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 54, 2, 362, 363, 2006年02月, ［査読有り］
  英語
• PPI投与にて改善した機能性発声障害の3例　　　　　　　　　　　　　　　
  目須田 康, 折舘 伸彦, 西澤 典子, 森 美果, 本間 明宏, 古田 康, 堂坂 善弘, 福田 諭
  音声言語医学, 47, 1, 93, 94, 日本音声言語医学会, 2006年01月
  日本語
• 嗅神経芽細胞腫のMRI所見
  飯尾 光博, 本間 明宏, 古田 康, 福田 諭
  日本耳鼻咽喉科学会会報, 109, 3, 142, 148, (一社)日本耳鼻咽喉科学会, 2006年
  日本語, 研究論文（学術雑誌）
• 北海道大学病院における超選択的動注療法+照射の同時併用療法の治療成績
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 永橋 立望, 古沢 純, 畠山 博充, 鈴木 恵士郎, 西岡 健, 白土 博樹, 福田 諭
  頭頸部癌, 32, 1, 87, 92, (一社)日本頭頸部癌学会, 2006年
  英語, 研究論文（学術雑誌）
• 当科における嗅神経芽細胞腫の治療経験
  加納 里志, 古田 康, 本間 明宏, 折舘 伸彦, 樋口 榮作, 鈴木 章之, 永橋 立望, 澤村 豊, 福田 諭
  日本耳鼻咽喉科学会会報, 109, 5, 433, 439, (一社)日本耳鼻咽喉科学会, 2006年
  日本語, 研究論文（学術雑誌）
• Magnetic resonance imaging of olfactory neuroblastoma
  Mitsuhiro Iio, Akihiro Homma, Yasushi Furuta, Satoshi Fukuda
  Journal of Otolaryngology of Japan, 109, 3, 142, 148, Oto-Rhino-Laryngological Society of Japan Inc., 2006年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Olfactory neuroblastoma: The Hokkaido University experience
  Satoshi Kano, Yasushi Furuta, Akihiro Homma, Nobuhiko Oridate, Eisaku Higuchi, Fumiyuki Suzuki, Tatsumi Nagahashi, Yutaka Sawamura, Satoshi Fukuda
  Journal of Otolaryngology of Japan, 109, 5, 433, 439, Oto-Rhino-Laryngological Society of Japan Inc., 2006年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity
  F Suzuki, N Oridate, A Homma, Y Nakamaru, T Nagahashi, K Yagi, S Yamaguchi, Y Furuta, S Fukuda
  ONCOLOGY REPORTS, 14, 6, 1493, 1498, 2005年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 上顎全摘術におけるナビゲーションシステムの使用経験
  本間 明宏, 鈴木 章之, 佐伯 昌彦, 福田 諭
  頭頸部外科, 15, 2, 153, 157, (NPO)日本頭頸部外科学会, 2005年10月
  日本語
• Laryngeal zoster mimicking a laryngeal cancer
  E Higuchi, Y Nakamaru, R Ohwatari, T Sakashita, Y Mesuda, A Homma, Y Furuta, S Fukuda
  OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 133, 4, 647, 647, 2005年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 口腔癌の最新治療 舌癌に対する超選択的動注療法と高線量率組織内照射の併用療法　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 吉田 大介, 西岡 健, 鈴木 恵士郎, 白土 博樹, 福田 諭
  日本癌治療学会誌, 40, 2, 236, 236, (一社)日本癌治療学会, 2005年09月
  日本語
• 【耳鼻咽喉科領域における難治性疾患】 若年性血管線維腫　　　　　　　　　　　　　　　
  福田 諭, 本間 明宏
  JOHNS, 21, 9, 1309, 1313, (株)東京医学社, 2005年09月
  日本語
• Voice restoration by primary insertion of indwelling voice prosthesis following circumferential pharyngolaryngectomy with free jejunal graft
  Y Furuta, A Homma, T Nagahashi, N Oridate, Y Mesuda, N Nishizawa, M Sekido, Y Yamamoto, S Okushiba, S Fukuda
  AURIS NASUS LARYNX, 32, 3, 269, 274, 2005年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 下咽頭癌に対する超選択的動注療法と放射線同時併用療法の検討
  古沢 純, 本間 明宏, 福田 諭
  口腔・咽頭科, 18, 1, 66, 66, 日本口腔・咽頭科学会, 2005年08月
  日本語
• 頸部外切開で魚骨異物の摘出を必要とした3症例　　　　　　　　　　　　　　　
  佐伯 昌彦, 本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊116, 62, 62, 耳鼻咽喉科臨床学会, 2005年07月
  日本語
• 舌進行癌に対する超選択的動注療法と高線量率組織内照射による治療
  本間 明宏, 福田 諭
  口腔・咽頭科, 17, 3, 379, 384, 日本口腔・咽頭科学会, 2005年06月
  日本語
• 気道上皮細胞におけるS100A2発現抑制による遺伝子発現変化の検討　　　　　　　　　　　　　　　
  折舘 伸彦, 水町 貴諭, 鈴木 章之, 本間 明宏, 古田 康, 福田 諭
  頭頸部癌, 31, 2, 269, 269, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 北海道大学病院における超選択的動注療法+放射線の同時併用療法の治療成績　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 鈴木 章之, 浅野 剛, 永橋 立望, 折舘 伸彦, 古沢 純, 畠山 博充, 鈴木 恵士郎, 西岡 健, 白土 博樹, 福田 諭
  頭頸部癌, 31, 2, 242, 242, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• ドセタキセル・放射線同時併用療法におけるp53過剰発現と392セリン残基リン酸化の予後因子としての検討　　　　　　　　　　　　　　　
  樋口 榮作, 折舘 伸彦, 本間 明宏, 永橋 立望, 古田 康, 鈴木 章之, 西岡 健, 鈴木 恵士郎, 滝沢 昌彦, 白土 博樹, 福田 諭
  頭頸部癌, 31, 2, 227, 227, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 頭頸部癌超選択的動注化学療法症例における癌関連遺伝子産物の免疫組織学的検討　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 折舘 伸彦, 樋口 栄作, 古田 康, 福田 諭
  頭頸部癌, 31, 2, 227, 227, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 化学放射線同時併用療法後の喉頭全摘術における合併症の検討　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 折舘 伸彦, 樋口 栄作, 鈴木 章之, 西岡 健, 青山 英史, 鈴木 恵士郎, 白土 博樹, 福田 諭
  頭頸部癌, 31, 2, 220, 220, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 舌癌後発頸部リンパ節転移症例での治療前CTによるリンパ節評価　　　　　　　　　　　　　　　
  古沢 純, 鈴木 章之, 折舘 伸彦, 本間 明宏, 古田 康, 福田 諭
  頭頸部癌, 31, 2, 214, 214, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 抗癌剤の耐性と感受性 ドセタキセル耐性ヒト扁平上皮癌細胞株の樹立および遺伝子発現の検討　　　　　　　　　　　　　　　
  水町 貴諭, 折舘 伸彦, 樋口 榮作, 鈴木 章之, 本間 明宏, 古田 康, 福田 諭
  頭頸部癌, 31, 2, 204, 204, (一社)日本頭頸部癌学会, 2005年05月
  日本語
• 北大病院における嚥下機能改善術及び誤嚥防止手術の現況について　　　　　　　　　　　　　　　
  目須田 康, 西澤 典子, 森 美果, 折舘 伸彦, 本間 明宏, 永橋 立望, 柏村 正明, 古田 康, 堂坂 善弘, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 497, 497, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 北海道大学病院における喉頭癌T1,T2症例の検討　　　　　　　　　　　　　　　
  愛宕 義浩, 古田 康, 本間 明宏, 折舘 伸彦, 樋口 栄作, 鈴木 章之, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 467, 467, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 鼻副鼻腔癌に対する超選択的動注化学療法における予後予測分子指標の同定　　　　　　　　　　　　　　　
  折舘 伸彦, 本間 明宏, 鈴木 章之, 水町 貴諭, 樋口 栄作, 古田 康, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 458, 458, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 当科における嗅神経芽細胞腫の治療経験　　　　　　　　　　　　　　　
  加納 里志, 古田 康, 本間 明宏, 折舘 伸彦, 樋口 榮作, 鈴木 章之, 永橋 立望, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 457, 457, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 鼻副鼻腔内反性乳頭腫におけるstage別治療成績の検討　　　　　　　　　　　　　　　
  及川 敬太, 古田 康, 本間 明宏, 折舘 伸彦, 中丸 裕爾, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 457, 457, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 頭頸部癌に対するドセタキセル・放射線同時併用療法における予後予測因子としてのcyclin D1とp16　　　　　　　　　　　　　　　
  樋口 榮作, 本間 明宏, 折舘 伸彦, 古田 康, 鈴木 章之, 川浪 貢, 滝沢 昌彦, 福田 諭
  日本耳鼻咽喉科学会会報, 108, 4, 442, 442, (一社)日本耳鼻咽喉科学会, 2005年04月
  日本語
• 化学放射線同時併用療法後の喉頭全摘・一期的T-Eシャント作成ボイスボタン挿入の問題点　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 西澤 典子, 樋口 栄作, 鈴木 章之, 折舘 伸彦, 目須田 康, 福田 諭
  日本気管食道科学会会報, 56, 2, 242, 242, (NPO)日本気管食道科学会, 2005年04月
  日本語
• 【MRI症例ファイル】 副鼻腔良性腫瘍　　　　　　　　　　　　　　　
  福田 諭, 古田 康, 本間 明宏
  JOHNS, 21, 3, 401, 407, (株)東京医学社, 2005年03月
  日本語
• Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery.
  Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K
  Cancer journal (Sudbury, Mass.), 11, 152, 156, 2, 2005年03月, ［査読有り］
• 声帯麻痺 片側声帯麻痺に対する甲状軟骨形成術I型・側筋牽引術併用例の音声機能　　　　　　　　　　　　　　　
  目須田 康, 本間 明宏, 西澤 典子, 福田 諭, 堂坂 善弘
  音声言語医学, 46, 1, 47, 47, 日本音声言語医学会, 2005年01月
  日本語
• アジスロマイシンの術後感染予防への使用
  本間 明宏, 福田 諭
  耳鼻咽喉科臨床, 98, 9, 735, 739, 耳鼻咽喉科臨床学会, 2005年
  日本語, 研究論文（学術雑誌）
• 気道上皮細胞におけるS100A2発現抑制による遺伝子発現変化の検討
  折舘 伸彦, 水町 貴諭, 鈴木 章之, 本間 明宏, 古田 康, 福田 諭
  頭頸部癌, 31, 4, 481, 486, (一社)日本頭頸部癌学会, 2005年
  英語, 研究論文（学術雑誌）
• Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
  Suzuki F, Nakamaru Y, Oridate N, Homma A, Nagahashi T, Yamaguchi S, Nishihira J, Furuta Y, Fukuda S
  Oncology reports, 13, 1, 59, 64, 1, 2005年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The macrophage migration inhibitory factor (MIF) is known to be a proinflammatory cytokine as well as a tumor growth regulator. Although the positive and negative effects of the MIF on tumor cell growth have been reported, the exact role of the MIF in tumorigenesis remains ambiguous. We examined the expression of the MIF protein in tumor specimens obtained from 50 head and neck squamous cell carcinoma (HNSCC) patients treated with concurrent chemoradiotherapy (carboplatin, 100 mg/m2), 4-7 times every week; a total radiation therapy dose of 65-75 Gy over 6.5-7.5 weeks, and determined whether the MIF level is related to clinical outcomes of these patients. Immunostaining with an MIF specific antibody was performed in formalin-fixed, paraffin-embedded specimens. The MIF protein was expressed to various extent in the tumor tissue specimens from the HNSCC patients. Prognostic analysis using the Kaplan-Meier method with regard to the MIF expression revealed that the patients with the MIF-negative tumors had a worse prognosis when compared to those with the MIF expression. The results of this study suggest that the intratumoral MIF expression has a prognostic value in HNSCC patients administered concurrent chemoradiotherapy.
• Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer
  A Homma, Y Furuta, F Suzuki, N Oridate, H Hatakeyama, T Nagahashi, S Ushikoshi, T Asano, T Nishioka, H Shirato, S Fukuda
  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 27, 1, 65, 71, 2005年01月
  英語, 研究論文（学術雑誌）
• 鼻副鼻腔進行癌に対する超選択的動注療法と照射の同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊115, 6, 7, 耳鼻咽喉科臨床学会, 2004年11月
  日本語
• Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
  Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H
  International journal of radiation oncology, biology, physics, 60, 3, 847, 852, 3, 2004年11月, ［査読有り］
• 鼻咽腔血管線維腫に対するナビゲーションガイド下鼻内内視鏡による摘出の経験
  本間 明宏, 中丸 裕爾, 佐伯 昌彦, 福田 諭
  頭頸部外科, 14, 2, 109, 113, (NPO)日本頭頸部外科学会, 2004年10月
  日本語
• 【悪性リンパ腫 診断・治療マニュアル】 最近の悪性リンパ腫の取り扱い その現状と展望　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭
  ENTONI, 41, 1, 8, (株)全日本病院出版会, 2004年09月
  日本語
• 頭頸部癌治療における最近の進歩と今後の臨床展開 治療の個別化に向けて 鼻副鼻腔進行癌に対する超選択的動注療法+放射線同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 永橋 立望, 白土 博樹, 福田 諭
  日本癌治療学会誌, 39, 2, 271, 271, (一社)日本癌治療学会, 2004年09月
  日本語
• Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck
  A Homma, H Shirato, Y Furuta, T Nishioka, N Oridate, K Tsuchiya, T Nagahashi, H Aoyama, Y Inuyama, S Fukuda
  CANCER JOURNAL, 10, 5, 326, 332, 2004年09月
  英語, 研究論文（学術雑誌）
• Preliminary results on development of a thin GSO scintillator for neutron science
  J. H. Kaneko, N. Susa, S. Tsuchida, M. Watanabe, S. Miura, T. Mizuno, Y. Yamauchi, M. Hashiba, T. Oku, A. Homma, F. Fujita, T. Ino, M. Furusaka, T. Sawamura, H. M. Shimizu, Y. Kiyanagi
  Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 529, 1-3, 307, 309, 2004年08月21日, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• 舌進行癌に対する超選択的動注療法と高線量率組織内照射による治療
  本間 明宏, 福田 諭
  口腔・咽頭科, 17, 1, 108, 108, 日本口腔・咽頭科学会, 2004年08月
  日本語
• 頭頸部,上部消化管再発癌における微小血管吻合を用いた再建に関する検討　　　　　　　　　　　　　　　
  関堂 充, 山本 有平, 佐々木 了, 古川 洋志, 杉原 平樹, 本間 明宏, 永橋 立望, 古田 康, 福田 諭, 矢島 和宜, 野平 久仁彦, 新冨 芳尚, 八木 克憲, 上田 倫弘, 山下 徹郎
  頭頸部腫瘍, 30, 2, 286, 286, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 化学療法併用放射線療法後に喉頭全摘術後の瘻孔発生率は高まるか? 過去10年間の喉頭全摘症例の検討　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 永橋 立望, 樋口 栄作, 鈴木 章之, 折舘 伸彦, 福田 諭, 西岡 健, 青山 英史, 白土 博樹
  頭頸部腫瘍, 30, 2, 270, 270, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 気道上皮細胞における潜在的癌抑制遺伝子S100A2発現抑制による形質変化
  折舘 伸彦, 鈴木 章之, 水町 貴諭, 本間 明宏, 古田 康, 福田 諭
  頭頸部腫瘍, 30, 2, 249, 249, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 口腔癌T1T2N0症例におけるS100A2発現消失と後発頸部リンパ節転移との関連　　　　　　　　　　　　　　　
  鈴木 章之, 折舘 伸彦, 本間 明宏, 永橋 立望, 古田 康, 福田 諭
  頭頸部腫瘍, 30, 2, 206, 206, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 頬粘膜腫瘍の放射線治療成績　　　　　　　　　　　　　　　
  大森 桂一, 中村 博行, 山崎 裕, 小野 貢伸, 青山 英史, 土屋 和彦, 西岡 健, 白土 博樹, 本間 明宏, 古田 康, 中村 太保
  頭頸部腫瘍, 30, 2, 195, 195, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 頭頸部癌に対するDocetaxelと放射線同時併用療法の有用性の検討　　　　　　　　　　　　　　　
  樋口 榮作, 本間 明宏, 永橋 立望, 折舘 伸彦, 古田 康, 鈴木 章之, 西岡 健, 土屋 和彦, 青山 英史, 滝沢 昌彦, 白土 博樹, 福田 諭
  頭頸部腫瘍, 30, 2, 194, 194, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 頭頸部がん治療におけるチーム医療 理想的なチーム医療を行うために 北海道大学病院の実際　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 折舘 伸彦, 永橋 立望, 鈴木 章之, 樋口 栄作, 福田 諭
  頭頸部腫瘍, 30, 2, 155, 155, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 下咽頭・食道の再建 下咽頭・食道の再建 難治性皮膚瘻孔
  山本 有平, 関堂 充, 堤田 新, 矢島 和宜, 杉原 平樹, 古田 康, 本間 明宏, 永橋 立望, 福田 論, 奥芝 俊一, 八木 克憲
  頭頸部腫瘍, 30, 2, 128, 128, (一社)日本頭頸部癌学会, 2004年05月
  日本語
• 長期留置型voice prosthesisを用いた喉頭摘出後の音声再建症例の検討　　　　　　　　　　　　　　　
  古田 康, 西澤 典子, 目須田 康, 永橋 立望, 本間 明宏, 福田 諭
  日本気管食道科学会会報, 55, 2, 171, 171, (NPO)日本気管食道科学会, 2004年04月
  日本語
• 頭頸部癌再発症例,肺転移症例に対する外来化学療法としてのTS-1使用効果
  永橋 立望, 鈴木 章之, 樋口 栄作, 本間 明宏, 古田 康, 福田 諭
  頭頸部腫瘍, 30, 1, 111, 115, (一社)日本頭頸部癌学会, 2004年04月
  日本語
• 目でみる耳鼻咽喉科 Superolateral thyrotomyにて摘出した喉頭神経鞘腫の1例　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 山田 和之, 福田 諭
  耳鼻咽喉科・頭頸部外科, 76, 4, 246, 247, (株)医学書院, 2004年04月
  日本語
• 選択的動注療法における抗癌剤投与量決定の考察 腫瘍容積より算出法　　　　　　　　　　　　　　　
  横山 純吉, 西條 茂, 本間 明宏, 吉崎 智一
  日本耳鼻咽喉科学会会報, 107, 4, 467, 467, (一社)日本耳鼻咽喉科学会, 2004年04月
  日本語
• 頭頸部癌に対するDocetaxelと放射線同時併用療法の有用性の検討　　　　　　　　　　　　　　　
  樋口 榮作, 本間 明宏, 永橋 立望, 折舘 伸彦, 古田 康, 鈴木 章之, 川浪 貢, 滝沢 昌彦, 福田 諭
  日本耳鼻咽喉科学会会報, 107, 4, 465, 465, (一社)日本耳鼻咽喉科学会, 2004年04月
  日本語
• 頸部リンパ節転移を初発症状とした甲状腺オカルト癌症例の検討　　　　　　　　　　　　　　　
  水町 貴諭, 折舘 伸彦, 古田 康, 本間 明宏, 永橋 立望, 福田 諭
  日本耳鼻咽喉科学会会報, 107, 4, 431, 431, (一社)日本耳鼻咽喉科学会, 2004年04月
  日本語
• 鼻副鼻腔乳頭腫の術式選択におけるstaging systemの検討　　　　　　　　　　　　　　　
  及川 敬太, 古田 康, 永橋 立望, 本間 明宏, 折舘 伸彦, 中丸 裕爾, 福田 諭
  日本耳鼻咽喉科学会会報, 107, 4, 399, 399, (一社)日本耳鼻咽喉科学会, 2004年04月
  日本語
• 【頭頸癌におけるTumor dormancy therapy/低用量化学療法】 頭頸部癌におけるTumor dormancy therapy　　　　　　　　　　　　　　　
  永橋 立望, 本間 明宏, 福田 諭
  頭頸部外科, 13, 3, 107, 111, (NPO)日本頭頸部外科学会, 2004年03月
  日本語
• 【副咽頭間隙腫瘍の治療】 副咽頭間隙腫瘍摘出後のFirst Bite Syndrome　　　　　　　　　　　　　　　
  古田 康, 本間 明宏, 永橋 立望, 高木 大, 鈴木 章之, 目須田 康, 折舘 伸彦, 福田 諭
  頭頸部外科, 13, 3, 73, 78, (NPO)日本頭頸部外科学会, 2004年03月
  日本語
• Groningen Voice Prosthesis挿入後合併症の検討
  古田 康, 目須田 康, 永橋 立望, 本間 明宏, 折舘 伸彦, 西澤 典子, 福田 諭
  日本気管食道科学会会報, 55, 1, 16, 21, (NPO)日本気管食道科学会, 2004年02月
  日本語
• 喉頭摘出後の音声リハビリテーション 周術期音声指導の試み　　　　　　　　　　　　　　　
  西澤 典子, 吉田 康, 葛西 聡子, 目須田 康, 永橋 立望, 本間 明宏, 鈴木 章之, 福田 諭
  音声言語医学, 45, 1, 66, 67, 日本音声言語医学会, 2004年01月
  日本語
• 頸部リンパ節転移を初発症状とした甲状腺癌症例の検討
  水町 貴諭, 折舘 伸彦, 本間 明宏, 永橋 立望, 古田 康, 福田 諭
  日本耳鼻咽喉科学会会報, 107, 8, 750, 755, (一社)日本耳鼻咽喉科学会, 2004年
  日本語, 研究論文（学術雑誌）
• 理想的なチーム医療を行うために チーム医療における看護師の関与
  本間 明宏, 古田 康, 折舘 伸彦, 永橋 立望, 鈴木 章之, 樋口 栄作, 福田 諭
  頭頸部癌, 30, 3, 391, 394, (一社)日本頭頸部癌学会, 2004年
  英語, 研究論文（学術雑誌）
• 気道上皮細胞における潜在的癌抑制遺伝子S100A2発現抑制による形質変化
  折舘 伸彦, 鈴木 章之, 水町 貴諭, 本間 明宏, 古田 康, 福田 諭
  頭頸部癌, 30, 4, 651, 656, (一社)日本頭頸部癌学会, 2004年
  英語, 研究論文（学術雑誌）
• 放射線化学同時併用
  福田 諭, 藤井 博文, 本間 明宏, 山本 智矢, 藤井 正人
  耳鼻と臨床, 49, Suppl.3, S188, S190, 耳鼻と臨床会, 2003年11月
  日本語
• 少量白金製剤併用放射線化学療法と超選択的動注療法
  本間 明宏, 古田 康, 永橋 立望, 八木 克憲, 鈴木 章之, 牛越 聡, 浅野 剛, 白土 博樹, 西岡 健, 犬山 征夫, 福田 諭
  耳鼻と臨床, 49, Suppl.3, S167, S174, 耳鼻と臨床会, 2003年11月
  日本語
• 【癌転移】 癌転移に対する各種治療法の進歩 頭頸部癌リンパ節転移への放射線・化学療法
  本間 明宏, 古田 康, 永橋 立望, 福田 諭
  日本臨床, 61, 増刊8 癌転移, 612, 616, (株)日本臨床社, 2003年11月
  日本語
• Preoperative staging of sinonasal inverted papilloma by magnetic resonance imaging
  K Oikawa, Y Furuta, N Oridate, T Nagahashi, A Homma, T Ryu, S Fukuda
  LARYNGOSCOPE, 113, 11, 1983, 1987, 2003年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 当科における原発不明頸部転移癌の臨床的検討
  及川 敬太, 本間 明宏, 鈴木 章之, 永橋 立望, 古田 康, 福田 諭
  耳鼻咽喉科展望, 46, 補冊2, 74, 81, 耳鼻咽喉科展望会, 2003年10月
  日本語
• 頭頸部がんに対する急速動注療法 頭頸部進行癌に対する超選択的動注療法と放射線の同時併用療法
  本間 明宏, 古田 康, 牛越 聡, 鈴木 章之, 永橋 立望, 畠山 博充, 浅野 剛, 西岡 健, 白土 博樹, 福田 諭
  頭頸部腫瘍, 29, 3, 450, 456, (一社)日本頭頸部癌学会, 2003年09月
  日本語
• 頭頸部癌放射線・化学療法施行例における頸部リンパ節転移への対応　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 永橋 立望, 白土 博樹, 西岡 健, 八木 克憲, 犬山 征夫, 福田 諭
  日本癌治療学会誌, 38, 2, 352, 352, (一社)日本癌治療学会, 2003年09月
  日本語
• 喉頭全摘に至った喉頭帯状疱疹の一例　　　　　　　　　　　　　　　
  樋口 榮作, 中丸 裕爾, 大渡 隆一郎, 坂下 智博, 目須田 康, 本間 明宏, 古田 康, 福田 諭
  耳鼻咽喉科免疫アレルギー, 21, 2, 80, 82, 日本耳鼻咽喉科免疫アレルギー学会, 2003年06月
  日本語
• 頭頸部がんに対する急速動注療法 頭頸部進行癌に対する超選択的動注療法と放射線の同時併用療法
  本間 明宏, 古田 康, 牛越 聡, 鈴木 章之, 永橋 立望, 畠山 博充, 浅野 剛, 西岡 健, 白土 博樹, 福田 諭
  頭頸部腫瘍, 29, 2, 265, 265, (一社)日本頭頸部癌学会, 2003年05月
  日本語
• 頭頸部扁平上皮癌の放射線化学療法施行例におけるマクロファージ遊走阻止因子の発現の検討　　　　　　　　　　　　　　　
  鈴木 章之, 中丸 裕爾, 本間 明宏, 永橋 立望, 折館 伸彦, 古田 康, 福田 諭
  頭頸部腫瘍, 29, 2, 363, 363, (一社)日本頭頸部癌学会, 2003年05月
  日本語
• 頭頸部癌再発症例に対するTS-1使用効果 肺転移症例を中心として　　　　　　　　　　　　　　　
  永橋 立望, 鈴木 章之, 樋口 栄作, 本間 明宏, 古田 康, 福田 諭
  頭頸部腫瘍, 29, 2, 321, 321, (一社)日本頭頸部癌学会, 2003年05月
  日本語
• コンソーシアム形式でのオリゴDNAマイクロアレイの作成と頭頸部癌における発現解析　　　　　　　　　　　　　　　
  古田 康, 山崎 健一, 樋口 栄作, 折舘 伸彦, 畠山 博允, 本間 明宏, 永橋 立望, 福田 諭
  頭頸部腫瘍, 29, 2, 298, 298, (一社)日本頭頸部癌学会, 2003年05月
  日本語
• 超選択的動注と放射線の同時併用療法
  本間 明宏, 鈴木 章之, 犬山 征夫, 福田 諭
  耳鼻咽喉科臨床, 96, 5, 449, 454, 耳鼻咽喉科臨床学会, 2003年05月
  日本語
• 上部消化管再建後壊死症例のsalvage手術　　　　　　　　　　　　　　　
  関堂 充, 山本 有平, 佐々木 了, 杉原 平樹, 矢島 和宜, 野平 久仁彦, 新冨 芳尚, 皆川 英彦, 古川 洋志, 本間 明宏, 永橋 立望, 古田 康, 福田 諭, 八木 克憲
  頭頸部腫瘍, 29, 2, 335, 335, (一社)日本頭頸部癌学会, 2003年05月
  日本語
• 喉頭癌に対する放射線化学療法施行例の検討　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 永橋 立望, 八木 克憲, 鈴木 章之, 犬山 征夫, 福田 諭
  日本耳鼻咽喉科学会会報, 106, 4, 428, 428, (一社)日本耳鼻咽喉科学会, 2003年04月
  日本語
• 鼻副鼻腔inverted papilloma再発例の検討　　　　　　　　　　　　　　　
  及川 敬太, 古田 康, 永橋 立望, 本間 明宏, 折舘 伸彦, 中丸 裕爾, 福田 諭
  日本耳鼻咽喉科学会会報, 106, 4, 393, 393, (一社)日本耳鼻咽喉科学会, 2003年04月
  日本語
• 難治性気管狭窄に対するステントとしてのTチューブの有用性　　　　　　　　　　　　　　　
  目須田 康, 永橋 立望, 古田 康, 本間 明宏, 瀧 重成, 福田 諭, 森川 利昭
  日本気管食道科学会会報, 54, 2, 163, 164, (NPO)日本気管食道科学会, 2003年04月
  日本語
• Groningen voice prosthesis挿入後合併症の検討　　　　　　　　　　　　　　　
  古田 康, 目須田 康, 永橋 立望, 本間 明宏, 西澤 典子, 福田 諭
  日本気管食道科学会会報, 54, 2, 137, 138, (NPO)日本気管食道科学会, 2003年04月
  日本語
• 喉頭神経鞘腫の1例　　　　　　　　　　　　　　　
  瀧 重成, 本間 明宏, 目須田 康, 福田 諭
  日本気管食道科学会会報, 54, 2, 132, 132, (NPO)日本気管食道科学会, 2003年04月
  日本語
• 遊離空腸再建症例におけるvoice prosthesis一期的挿入による音声再建
  古田 康, 永橋 立望, 本間 明宏, 折舘 伸彦, 目須田 康, 西澤 典子, 関堂 充, 山本 有平, 奥芝 俊一, 福田 論
  頭頸部腫瘍, 29, 1, 81, 85, (一社)日本頭頸部癌学会, 2003年03月
  日本語
• 術前動注併用放射線治療を行った進行舌癌の2例　　　　　　　　　　　　　　　
  守屋 信吾, 佐藤 明, 大森 桂一, 山崎 裕, 佐藤 千晴, 西岡 健, 本間 明宏, 野谷 健一, 福田 博
  日本口腔外科学会雑誌, 49, 2, 139, 139, (公社)日本口腔外科学会, 2003年02月
  日本語
• 鼻中隔に発生した修復性巨細胞肉芽腫の1例　　　　　　　　　　　　　　　
  古沢 純, 古田 康, 本間 明宏, 前田 昌紀, 福田 諭
  耳鼻咽喉科・頭頸部外科, 75, 2, 117, 119, (株)医学書院, 2003年02月
  日本語
• 頭系部癌リンパ筋転移への放射線・化学療法　　　　　　　　　　　　　　　
  日本臨床, 61, 8, 612, 616, 2003年
• 頭頸部進行癌に対する超選択的動注療法と放射線の同時併用療法
  本間明宏, 古田康, 牛越聡, 鈴木章之, 永橋立望, 畠山博充, 浅野剛, 西岡健, 白土博樹
  頭系部腫瘍, 29, 3, 450, 456, Japan Society for Head and Neck Cancer, 2003年
  日本語, Robbins の原法にほぼ準じて大量シスプラチン (100～120mg/m²) の超選択的動注療法と照射の同時併用療法を切除不能, 手術拒否の進行癌新鮮例44例に対して行った。原発巣のCRが38.6%, PRが56.8%, 奏効率は95.4%で, 原発巣の progression free survival (2年) は全体で66.9%, 新しいUICC分類のT4b例でも57%が得られた。しかし粗生存率 (2年) は全体で52.4%であった。有害事象は, 脳神経麻痺, 菌血症などの合併症が出現する場合はあったが, 粘膜炎を含めて概ね許容範囲のものと考えられた。局所に集中的に大量のシスプラチンを投与できる超選択的動注療法は非常に効果の高い治療法であり, 切除不能例でも治癒を期待できる方法であるが, 今後は長期の治療成績, 晩期の合併症を明らかにし, 適応を確立していくことが必要である。
• 頭頸部進行癌に対するシスプラチンの超選択的動注と放射線の同時併用療法　　　　　　　　　　　　　　　
  本間 明宏, 鈴木 章之, 犬山 征夫, 福田 諭
  耳鼻咽喉科臨床 補冊, 補冊108, 64, 65, 耳鼻咽喉科臨床学会, 2002年11月
  日本語
• 頭頸部癌リンパ節転移陽性例に対する放射線化学療法の検討　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 永橋 立望, 白土 博樹, 西岡 健, 八木 克憲, 影井 兼司, 犬山 征夫, 福田 諭
  日本癌治療学会誌, 37, 2, 383, 383, (一社)日本癌治療学会, 2002年09月
  日本語
• TS-1の投与により消失し,長期CRが得られた中咽頭扁平上皮癌の1例
  本間 明宏, 鈴木 章之, 折舘 伸彦, 古田 康, 犬山 征夫, 福田 諭
  癌と化学療法, 29, 8, 1475, 1478, (株)癌と化学療法社, 2002年08月
  日本語
• [Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma].
  Homma A, Suzuki F, Oridate N, Furuta Y, Inuyama Y, Fukuda S
  Gan to kagaku ryoho. Cancer & chemotherapy, 29, 8, 1475, 1478, 2002年08月, ［査読有り］, ［国内誌］
  日本語, 研究論文（学術雑誌）, A 60-year-old man had a recurrence of squamous cell carcinoma at the right side of the tongue base. Chemotherapy with TS-1 (100 mg/day) was begun. Each course of chemotherapy consisted of 4 weeks of TS-1, followed by 2 weeks of no treatment. After the completion of two courses, macroscopic examination revealed a complete response. From the third course of TS-1 treatment, the dose was increased to 120 mg/day. The complete response persisted on macroscopic examination. A biopsy done during the ninth course of TS-1 treatment confirmed the complete response histologically, with no evidence of malignancy. After 12 courses of TS-1 treatment, the drug was switched to 600 mg/day of UFT. Although there were no signs or symptoms of recurrence, the patient died of cancer of the pancreas. There was no recurrence of the oropharyngeal cancer, even at the time of death.
• T2N0声門癌の治療方針 放射線化学同時併用療法
  永橋 立望, 福田 諭, 本間 明宏, 犬山 征夫, 白土 博樹
  耳鼻と臨床, 48, Suppl.1, S41, S45, 耳鼻と臨床会, 2002年07月
  日本語
• 放射線治療と化学療法の同時併用の効果予測 免疫組織化学からcDNAマイクロアレイへ
  古田 康, 本間 明宏, 樋口 栄作, 折舘 伸彦, 永橋 立望, 福田 諭
  耳鼻咽喉科免疫アレルギー, 20, 2, 42, 43, 日本耳鼻咽喉科免疫アレルギー学会, 2002年06月
  日本語
• Duplex scan(超音波パルスドップラー法)を用いた微小血管吻合後の血流モニタリング
  関堂 充, 山本 有平, 杉原 平樹, 横山 朋子, 古川 洋志, 矢島 和宜, 本間 明宏, 永橋 立望, 折舘 伸彦, 古田 康, 福田 諭
  頭頸部腫瘍, 28, 2, 442, 442, (一社)日本頭頸部癌学会, 2002年05月
  日本語
• 遊離空腸再建症例におけるvoice prosthesis一期的挿入による音声再建　　　　　　　　　　　　　　　
  古田 康, 永橋 立望, 本間 明宏, 折舘 伸彦, 目須田 康, 西澤 典子, 福田 諭, 関堂 充, 山本 有平, 奥芝 俊一
  頭頸部腫瘍, 28, 2, 420, 420, (一社)日本頭頸部癌学会, 2002年05月
  日本語
• 頭頸部癌切除可能例に対するCDDP+RT vs CBDCA+RTの無作為化比較試験の検討　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭, 永橋 立望, 古田 康, 八木 克憲, 犬山 征夫, 白土 博樹, 西岡 健, 影井 兼司
  頭頸部腫瘍, 28, 2, 380, 380, (一社)日本頭頸部癌学会, 2002年05月
  日本語
• 超選択的動注化学療法を施行した中・下咽頭癌症例における治療後の嚥下状態の検討　　　　　　　　　　　　　　　
  鈴木 章之, 本間 明宏, 古田 康, 折館 伸彦, 永橋 立望, 畠山 博充, 福田 諭, 牛越 聡, 浅野 剛, 西岡 健, 白土 博樹
  頭頸部腫瘍, 28, 2, 376, 376, (一社)日本頭頸部癌学会, 2002年05月
  日本語
• 下咽頭扁平上皮癌における頸部郭清術　　　　　　　　　　　　　　　
  山田 和之, 本間 明宏, 永橋 立望, 八木 克憲, 古田 康, 福田 諭
  頭頸部腫瘍, 28, 2, 374, 374, (一社)日本頭頸部癌学会, 2002年05月
  日本語
• 鼻副鼻腔乳頭腫のstaging MRIの術前評価　　　　　　　　　　　　　　　
  及川 敬太, 古田 康, 劉 澤周, 八木 克憲, 栢村 正明, 折舘 伸彦, 永橋 立望, 本間 明宏, 福田 諭
  日本耳鼻咽喉科学会会報, 105, 4, 474, 474, (一社)日本耳鼻咽喉科学会, 2002年04月
  日本語
• 頭頸部腫瘍におけるC-11 L-methionine PETの役割　　　　　　　　　　　　　　　
  永橋 立望, 本間 明宏, 折館 伸彦, 古田 康, 福田 諭
  日本耳鼻咽喉科学会会報, 105, 4, 482, 482, (一社)日本耳鼻咽喉科学会, 2002年04月
  日本語
• cDNAマイクロアレイを用いた鼻副鼻腔癌及び前癌病変における遺伝子発現の検討
  畠山 博充, 古田 康, 本間 明宏, 折舘 伸彦, 鈴木 清護, 永橋 立望, 八木 克憲, 犬山 征夫, 福田 諭, 山崎 健一, 楠崎 幸作
  頭頸部腫瘍, 28, 1, 269, 274, (一社)日本頭頸部癌学会, 2002年03月
  日本語
• 頬粘膜癌に対する放射線治療成績　　　　　　　　　　　　　　　
  大森 桂一, 小日向 謙一, 金子 正範, 中村 太保, 鄭 漢忠, 戸塚 靖則, 野谷 健一, 福田 博, 西岡 健, 本間 明宏
  日本口腔科学会雑誌, 51, 1, 91, 91, (NPO)日本口腔科学会, 2002年01月
  日本語
• 嚥下障害をきたした喉頭麻痺に対する透視CT下経皮的声帯内注入術の経験　　　　　　　　　　　　　　　
  目須田 康, 本間 明宏, 西澤 典子, 福田 諭, 高木 大, 須藤 敏, 犬山 征夫
  日本耳鼻咽喉科学会会報, 105, 1増刊, 94, 95, (一社)日本耳鼻咽喉科学会, 2002年01月
  日本語
• 頭頸部腫瘍に対するCDDP+RT vs CBDCA+RTの無作為化比較試験　　　　　　　　　　　　　　　
  本間 明宏, 福田 諭, 八木 克憲, 古田 康, 犬山 征夫, 白土 博樹, 西岡 健, 影井 兼司
  日本癌治療学会誌, 36, 2, 594, 594, (一社)日本癌治療学会, 2001年10月
  日本語
• 舌癌に対する化学療法 術前・術後化学療法 放射線と化学療法の同時併用療法(chemoradiation)と治療ガイドライン
  福田 諭, 本間 明宏, 永橋 立望, 八木 克憲, 犬山 征夫
  耳鼻と臨床, 47, Suppl.1, S11, S15, 耳鼻と臨床会, 2001年09月
  日本語
• cDNA microarrayを用いた鼻副鼻腔癌及び前癌病変における遺伝子発現の解析　　　　　　　　　　　　　　　
  畠山 博充, 古田 康, 本間 明宏, 折舘 伸彦, 鈴木 清護, 永橋 立望, 八木 克憲, 福田 諭, 犬山 征夫, 楠崎 幸作, 山崎 健一
  頭頸部腫瘍, 27, 2, 407, 407, (一社)日本頭頸部癌学会, 2001年05月
  日本語
• cDNA microarrayを用いたシスプラチン耐性関連遺伝子の解析　　　　　　　　　　　　　　　
  古田 康, 畠山 博充, 樋口 栄作, 鈴木 清護, 折舘 伸彦, 本間 明宏, 永橋 立望, 八木 克憲, 福田 諭, 犬山 征夫, 楠崎 幸作, 山崎 健一
  頭頸部腫瘍, 27, 2, 406, 406, (一社)日本頭頸部癌学会, 2001年05月
  日本語
• 頭頸部進行癌に対するシスプラチンの超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏, 畠山 博充, 永橋 立望, 折舘 伸彦, 八木 克憲, 古田 康, 福田 諭, 犬山 征夫, 浅野 剛, 牛越 聡, 西岡 健, 白土 博樹, 宮坂 和男
  頭頸部腫瘍, 27, 2, 356, 356, (一社)日本頭頸部癌学会, 2001年05月
  日本語
• 側頭骨外科,頭蓋底外科 頭蓋底外科の適応疾患,合併症,現在の動向 多施設トライアルの結果を中心として
  福田 諭, 本間 明宏, 永橋 立望, 八木 克憲, 古田 康, 犬山 征夫, 山本 有平, 澤村 豊
  頭頸部腫瘍, 27, 2, 281, 281, (一社)日本頭頸部癌学会, 2001年05月
  日本語
• 当科におけるシスプラチンの超選択的動注療法　　　　　　　　　　　　　　　
  本間 明宏, 畠山 博充, 加納 里志, 永橋 立望, 八木 克憲, 古田 康, 福田 諭, 犬山 征夫
  日本耳鼻咽喉科学会会報, 104, 5増刊, 640, 641, (一社)日本耳鼻咽喉科学会, 2001年05月
  日本語
• 【静脈・経腸栄養】 各種疾患における静脈・経腸栄養の実際 耳鼻咽喉科領域における静脈・経腸栄養　　　　　　　　　　　　　　　
  本間 明宏, 犬山 征夫
  日本臨床, 59, 増刊5 静脈・経腸栄養, 714, 717, (株)日本臨床社, 2001年05月
  日本語
• Concurrent chemotherapy and radiotherapy as initial treatment for stage II supraglottic squamous cell carcinoma
  T Nagahashi, S Fukuda, A Homma, K Yagi, Y Furuta, Y Inuyama
  AURIS NASUS LARYNX, 28, S95, S98, 2001年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A clinical study on the cervical lymph node metastasis of maxillary sinus carcinoma
  K Yagi, S Fukuda, Y Furuta, N Oridate, A Homma, T Nagahashi, Y Inuyama
  AURIS NASUS LARYNX, 28, S77, S81, 2001年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical study of adenoid cystic carcinoma of the head and neck
  D Takagi, S Fukuda, Y Furuta, K Yagi, A Homma, T Nagahashi, Y Inuyama
  AURIS NASUS LARYNX, 28, S99, S102, 2001年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A study of piriform sinus fistula cases
  H Hatakeyama, A Homma, T Nagahashi, N Oridate, K Yagi, S Fukuda, Y Inuyama
  AURIS NASUS LARYNX, 28, S139, S143, 2001年05月
  英語
• Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy
  A Homma, Y Furuta, N Oridate, Y Nakano, K Yagi, T Nagahashi, S Fukuda, Y Inuyama
  AURIS NASUS LARYNX, 28, suppl, S87, S94, 2001年05月
  英語, 研究論文（学術雑誌）
• 声門上癌における放射線・化学同時併用療法の役割　　　　　　　　　　　　　　　
  永橋 立望, 福田 諭, 本間 明宏, 八木 克憲, 古田 康, 犬山 征夫
  日本耳鼻咽喉科学会会報, 104, 4, 357, 357, (一社)日本耳鼻咽喉科学会, 2001年04月
  日本語
• 頭頸部腺様嚢胞癌39例における放射線治療の検討
  大森 桂一, 西岡 健, 本間 明宏, 鄭 漢忠, 山下 徹郎, 小日向 謙一, 細川 洋一郎, 中村 太保
  日本口腔科学会雑誌, 50, 1, 53, 57, (NPO)日本口腔科学会, 2001年01月
  日本語
• 鼻中隔に発生したgiant cell reparative granulomaの1例　　　　　　　　　　　　　　　
  古沢 純, 古田 康, 本間 明宏, 前田 昌紀, 犬山 征夫
  日本耳鼻咽喉科学会会報, 104, 1増刊, 79, 80, (一社)日本耳鼻咽喉科学会, 2001年01月
  日本語
• 下咽頭癌における放射線・化学同時併用療法
  永橋 立望, 福田 諭, 本間 明宏, 八木 克憲, 古田 康, 犬山 征夫, 西岡 健, 白土 博樹
  頭頸部腫瘍, 26, 3, 476, 482, (一社)日本頭頸部癌学会, 2000年11月
  日本語
• 肋軟骨弁付き腹直筋皮弁による上顎再建 One buttress:zygomaticomaxillary buttress再建について
  山本 有平, 関堂 充, 古川 洋志, 杉原 平樹, 福田 諭, 古田 康, 八木 克憲, 永橋 立望, 本間 明宏, 犬山 征夫
  頭頸部腫瘍, 26, 3, 436, 440, (一社)日本頭頸部癌学会, 2000年11月
  日本語
• 下咽頭・頸部食道癌 治療成績・QOL向上の工夫 北大における下咽頭癌の治療成績 放射線・化学同時併用療法を中心として　　　　　　　　　　　　　　　
  永橋 立望, 福田 諭, 本間 明宏, 八木 克憲, 古田 康, 犬山 征夫, 西岡 健, 白土 博樹
  頭頸部腫瘍, 26, 2, 204, 204, (一社)日本頭頸部癌学会, 2000年05月
  日本語
• 形態機能を温存するための上顎下顎再建 肋軟骨弁付き腹直筋皮弁による上顎再建 One buttress:zygomaticomaxillary buttress再建について
  山本 有平, 皆川 英彦, 川嶋 邦裕, 関堂 充, 古川 洋志, 杉原 平樹, 福田 諭, 古田 康, 八木 克憲, 永橋 立望, 本間 明宏, 犬山 征夫
  頭頸部腫瘍, 26, 2, 182, 182, (一社)日本頭頸部癌学会, 2000年05月
  日本語
• 頸部原発脂肪肉腫の1症例　　　　　　　　　　　　　　　
  加納 里志, 飯尾 光博, 本間 明宏, 八木 克憲, 福田 諭, 犬山 征夫
  日本耳鼻咽喉科学会会報, 103, 5増刊, 699, 699, (一社)日本耳鼻咽喉科学会, 2000年05月
  日本語
• 下咽頭癌放射線治療症例の検討　　　　　　　　　　　　　　　
  八木 克憲, 福田 諭, 永橋 立望, 本間 明宏, 古田 康, 犬山 征夫
  日本耳鼻咽喉科学会会報, 103, 4, 425, 425, (一社)日本耳鼻咽喉科学会, 2000年04月
  日本語
• 頭頸部癌に対する遊離空腸による再建 49症例の術後合併症と摂食状況について
  山田 和之, 福田 諭, 八木 克憲, 目須田 康, 横浜 優樹, 本間 明宏, 永橋 立望, 古田 康, 佐藤 信清, 犬山 征夫, 山本 有平, 大野 耕一, 奥芝 俊一
  日本耳鼻咽喉科学会会報, 102, 12, 1279, 1286, (一社)日本耳鼻咽喉科学会, 1999年12月
  日本語
• 頭頸部再建における形成再建手技の進歩
  山本 有平, 佐々木 了, 関堂 充, 古川 洋志, 杉原 平樹, 福田 諭, 古田 康, 八木 克憲, 永橋 立望, 本間 明宏, 犬山 征夫, 奥芝 俊一, 吉田 哲憲, 野平 久仁彦, 渡邉 昭仁, 山下 徹郎
  頭頸部腫瘍, 25, 3, 471, 475, (一社)日本頭頸部癌学会, 1999年11月
  日本語
• 下咽頭癌の化学療法 放射線同時併用療法
  福田 諭, 永橋 立望, 本間 明宏, 犬山 征夫, 白土 博樹
  耳鼻と臨床, 45, Suppl.3, 706, 709, 耳鼻と臨床会, 1999年11月
  日本語
• 篩骨洞悪性腫瘍の臨床的検討　　　　　　　　　　　　　　　
  八木 克憲, 福田 諭, 本間 明宏, 永橋 立望, 古田 康, 犬山 征夫
  頭頸部腫瘍, 25, 2, 369, 369, (一社)日本頭頸部癌学会, 1999年05月
  日本語
• 鼻・副鼻腔inverted papilloma癌化例に対する診断治療の検討　　　　　　　　　　　　　　　
  古田 康, 八木 克憲, 劉 沢周, 本間 明宏, 永橋 立望, 福田 諭, 犬山 征夫
  頭頸部腫瘍, 25, 2, 247, 247, (一社)日本頭頸部癌学会, 1999年05月
  日本語
• 当科における中咽頭扁平上皮癌の頸部リンパ節転移の治療　　　　　　　　　　　　　　　
  本間 明宏, 八木 克憲, 永橋 立望, 古田 康, 福田 諭, 犬山 征夫, 白土 博樹, 西岡 健, 影井 兼司
  頭頸部腫瘍, 25, 2, 314, 314, (一社)日本頭頸部癌学会, 1999年05月
  日本語
• 当科における聴器癌治療成績の検討　　　　　　　　　　　　　　　
  永橋 立望, 八木 克憲, 本間 明宏, 古田 康, 福田 諭, 犬山 征夫
  頭頸部腫瘍, 25, 2, 317, 317, (一社)日本頭頸部癌学会, 1999年05月
  日本語
• 再度遊離空腸移植術を必要とした下咽頭頸部食道再建例の検討　　　　　　　　　　　　　　　
  古川 洋志, 山本 有平, 関堂 充, 杉原 平樹, 福田 諭, 佐藤 信清, 古田 康, 八木 克憲, 永橋 立望, 本間 明宏
  頭頸部腫瘍, 25, 2, 284, 284, (一社)日本頭頸部癌学会, 1999年05月
  日本語
• 上顎洞悪性腫瘍における眼窩浸潤症例の検討　　　　　　　　　　　　　　　
  八木 克憲, 福田 諭, 本間 明宏, 永橋 立望, 古田 康, 犬山 征夫
  日本耳鼻咽喉科学会会報, 102, 4, 587, 587, (一社)日本耳鼻咽喉科学会, 1999年04月
  日本語
• Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy
  A Homma, Y Furuta, N Oridate, Y Nakano, G Kohashi, K Yagi, T Nagahashi, S Fukuda, K Inoue, Y Inuyama
  CLINICAL CANCER RESEARCH, 5, 4, 801, 806, 1999年04月
  英語, 研究論文（学術雑誌）
• 中咽頭癌に対する根治的放射線治療
  影井 兼司, 清水 伸一, 橋本 井子, 西岡 健, 白土 博樹, 本間 明宏, 金子 正範, 大森 圭一, 宮坂 和男
  頭頸部腫瘍, 25, 1, 30, 35, (一社)日本頭頸部癌学会, 1999年03月
  日本語
• 悪性転化したと考えられる副咽頭間隙腫瘍の1症例　　　　　　　　　　　　　　　
  祢津 宏昭, 間口 四郎, 後藤田 裕之, 寺山 吉彦, 本間 明宏, 八木 克憲, 犬山 征夫
  日本耳鼻咽喉科学会会報, 102, 1増刊, 104, 104, (一社)日本耳鼻咽喉科学会, 1999年01月
  日本語
• 上咽頭に発生したlow-grade papillary adenocarcinomaの1症例　　　　　　　　　　　　　　　
  川原 弘匡, 本間 明宏, 古田 康, 犬山 征夫, 大谷 文雄, 藤岡 保範
  日本耳鼻咽喉科学会会報, 102, 1増刊, 105, 105, (一社)日本耳鼻咽喉科学会, 1999年01月
  日本語
• 当科における重複癌の検討　　　　　　　　　　　　　　　
  津布久 崇, 八木 克憲, 永橋 立望, 本間 明宏, 福田 諭, 犬山 征夫
  日本耳鼻咽喉科学会会報, 102, 1増刊, 104, 104, (一社)日本耳鼻咽喉科学会, 1999年01月
  日本語
• 【頭頸部癌 私の治療方針と成績】 声帯癌T3症例の保存的治療 北海道大学病院の場合　　　　　　　　　　　　　　　
  犬山 征夫, 福田 諭, 古田 康, 本間 明宏, 白土 博樹
  耳鼻咽喉科・頭頸部外科, 70, 12, 799, 804, (株)医学書院, 1998年11月
  日本語
• 咽頭癌治療の最前線 中咽頭・口腔癌に対するChemoradiation　　　　　　　　　　　　　　　
  福田 諭, 本間 明宏, 犬山 征夫
  癌の臨床, 44, 11, 1253, 1260, (株)篠原出版新社, 1998年10月
  日本語
• 中咽頭癌に対する根治的放射線治療　　　　　　　　　　　　　　　
  影井 兼司, 清水 伸一, 橋本 井子, 西岡 健, 白土 博樹, 金子 正範, 大森 圭一, 本間 明宏, 宮坂 和男
  頭頸部腫瘍, 24, 2, 148, 148, (一社)日本頭頸部癌学会, 1998年05月
  日本語
• CBDCA・放射線同時併用療法を行った喉頭癌症例におけるp53,bcl-2,bax,MIB-1発現と予後との関連　　　　　　　　　　　　　　　
  本間 明宏, 古田 康, 折舘 伸彦, 永橋 立望, 八木 克憲, 福田 諭, 犬山 征夫
  頭頸部腫瘍, 24, 2, 193, 193, (一社)日本頭頸部癌学会, 1998年05月
  日本語
• 重複癌の現況とその対策 頭頸部癌の立場から 現況・診断・予防
  福田 諭, 本間 明宏, 折舘 伸彦
  日本気管食道科学会会報, 49, 2, 146, 150, (NPO)日本気管食道科学会, 1998年04月
  日本語
• The management of olfactory neuroblastoma: outcome of 8 cases
  S Fukuda, A Homma, T Nagahashi, Y Furuta, Y Inuyama
  1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 643, 646, 1998年, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• 舌癌における頸部リンパ節転移
  八木 克憲, 福田 諭, 永橋 立望, 本間 明宏, 古田 康, 佐藤 信清, 犬山 征夫
  頭頸部外科, 7, 3, 147, 151, (NPO)日本頭頸部外科学会, 1997年12月
  日本語
• 頸部食道癌におけるリンパ節転移の検討
  八木 克憲, 福田 論, 永橋 立望, 本間 明宏, 古田 康, 佐藤 信清, 犬山 征夫, 奥芝 俊一, 本原 敏司
  頭頸部腫瘍, 23, 1, 189, 194, (一社)日本頭頸部癌学会, 1997年03月
  日本語
• 当科における中咽頭扁平上皮癌症例の検討　　　　　　　　　　　　　　　
  本間 明宏
  頭頸部腫瘍, 22, 2, 360, 360, (一社)日本頭頸部癌学会, 1996年06月
  日本語
• 100 当科での中咽頭癌における重複癌症例の検討
  福田 諭, 本間 明宏, 八木 克憲, 犬山 征夫
  口腔・咽頭科, 9, 1, 134, 134, 日本口腔・咽頭科学会, 1996年
  日本語
• 急速増大する甲状腺腫瘍　　　　　　　　　　　　　　　
  米川 博之, 本間 明宏, 樋口 栄作
  市立釧路総合病院医学雑誌, 7, 1, 45, 51, 市立釧路総合病院, 1995年03月
  日本語
• 反回神経麻痺を生じた甲状腺腫瘍手術症例の検討
  本間 明宏, 飯塚 桂司, 米川 博之
  耳鼻咽喉科・頭頸部外科, 67, 1, 61, 64, (株)医学書院, 1995年01月
  日本語
• 当科における副鼻腔悪性腫瘍の治療
  米川 博之, 本間 明宏, 飯塚 桂司
  耳鼻咽喉科臨床, 88, 12, 1605, 1611, 耳鼻咽喉科臨床学会, 1995年
  英語, 研究論文（学術雑誌）
• 反回神経麻痺を生じた甲状腺手術症例の検討　　　　　　　　　　　　　　　
  耳鼻咽喉科・頭頚部外科, 67, 1, 61, 64, 1995年
• 頭頸部癌の化学療法
  本間 明宏, 米川 博之, 飯塚 桂司
  市立釧路総合病院医学雑誌, 6, 1, 9, 21, 市立釧路総合病院, 1994年03月
  日本語
• 頭頸部癌に対するCBDCA,5-FU,UFT併用療法の検討　　　　　　　　　　　　　　　
  癌と化学療法, 21, 5, 627, 631, 1994年
• 頭頚部癌の化学療法　　　　　　　　　　　　　　　
  市立釧路総合病院雑誌, 6, 1, 9, 21, 1994年
• 当科における鼻骨骨折症例の検討　　　　　　　　　　　　　　　
  中丸 裕爾, 本間 明宏, 飯塚 桂司
  耳鼻咽喉科・頭頸部外科, 65, 9, 745, 748, (株)医学書院, 1993年09月
  日本語
• Interavascular papillary endothelial hyperplasia例
  中丸 裕爾, 飯塚 桂司, 本間 明宏
  耳鼻咽喉科臨床, 86, 12, 1747, 1751, 耳鼻咽喉科臨床学会, 1993年
  英語, 研究論文（学術雑誌）
• 当科における甲状腺結節性病変の診断-Decision makingについて-　　　　　　　　　　　　　　　
  市立釧路総合病院雑誌, 5, 1, 39, 45, 1993年
• 小児の喉頭に原発した悪性リンパ腫症例
  酒井 昇, 本間 明宏, 犬山 征夫
  日本気管食道科学会会報, 42, 3, 255, 258, (NPO)日本気管食道科学会, 1991年06月
  日本語
• 当科におけるOlfactory neuroblastoma症例の検討　　　　　　　　　　　　　　　
  本間 明宏
  日本鼻科学会会誌, 29, 1, 57, 57, (一社)日本鼻科学会, 1990年09月
  日本語